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Executve summary
This report presents the findings of the major research project 'benzodiazepine and pharmaceutical 
opioid misuse and their relationship to crime', and is an examination of illicit prescription drug 
markets in Melbourne.
Background and ratonale
The National Drug Law Enforcement Research Fund (NDLERF) sought tenders in 2002 for research 
to enhance law enforcement sector understanding of the structure and functioning of illicit drug 
markets in Australia. The request for tender (RFT 04/02) for which the current study was developed 
called for a focus on the impact of benzodiazepine and pharmaceutical opioid misuse on crime 
in Victoria, Tasmania and the Northern Territory. Available evidence at that time from sources such 
as the Illicit Drug Reporting System (IDRS) suggested that existing illicit prescription drug markets 
were consolidating in some major cities (e.g. Hobart and Darwin) and emerging in other cities (e.g. 
Melbourne) facilitated at least in part by the reduction in heroin supply which peaked between late 
2000 – early 2001 (Topp et al. 2002). In fulfilment of its aim of performing a monitoring and early 
warning function, the IDRS was able to identify key issues with respect to benzodiazepine and 
pharmaceutical opioid diversion and misuse that require further investigation.
One important area of investigation that is indicated relates to the possible law enforcement 
implications of benzodiazepine and pharmaceutical opioid diversion and illicit use. There 
have been few Australian studies that have sought to investigate the nexus between prescribed 
pharmaceutical misuse and crime. While the precise nature of this relationship remains to be 
clarified, some indications exist from previous research into the illicit drugs-crime nexus that has 
suggested the following: people who misuse illicit drugs are more likely to have an arrest record 
or to report property crime than those who do not (Blumstein et al. 1986); frequency of property 
offending is positively correlated with extent of illicit drug use (Blumstein et al. 1986; Salmelainen 
1995; Stevenson & Forsythe 1998); and violence and violent crime is typically employed by 
illicit drug manufacturers and distributors as a tool to support attempts to manipulate the market 
(Kleiman 1992). At this point the extent to which the broader illicit drugs and crime literature may 
assist in understanding prescription drugs and crime links is undetermined.
A second important area of investigation indicated relates to the health implications of 
benzodiazepine and pharmaceutical opioid diversion and use through injection. A large 
international literature exists on the public health implications of prescription pharmaceutical 
diversion and injecting, with reports from a number of countries concerning associations between 
misuse, significant health harms and dependence (Darke & Ross 2000). To date the literature 
has focused largely on health issues associated with benzodiazepine and pharmaceutical opioid 
diversion and use in illicit drug market settings. There is much less available data concerning the 
dimensions and characteristics of such illicit markets (for licit substances) or how law enforcement 
and public health concerns may intersect in these settings.
Evidence shows that illicit drug markets and patterns of illicit drug use may vary markedly 
between and within jurisdictions (Darke, Hall & Topp 2001; Fitzgerald, Hope & Dare 1999). It 
is reasonable, therefore, to predict that patterns of prescription pharmaceutical diversion and 
injection may also differ across settings. This needs to be better understood. A necessary step in 
devising appropriate responses around issues such as benzodiazepine and pharmaceutical opioid 
diversion and injection is to gather reliable local evidence regarding the nature and extent of the 
problem.
Acknowledgements
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Stakeholder perspectives are also of core importance when the responses may necessitate 
incorporation of regulatory interventions. In this regard the current lack of understanding of a 
number of key issues of relevance to benzodiazepine and pharmaceutical opioid diversion and 
crime links reduces the capacity for developing informed interventions. 
A comprehensive literature review was conducted in order to examine the following key issues of 
relevance to benzodiazepine and pharmaceutical opioid use and crime.
Drugs and crime nexus – literature on illicit drug markets and interpretive utility for the case of 
illicit markets for prescribed pharmaceuticals.
Drug trends in Australia – evidence, dimensions, monitoring statistics (e.g. use trends, prescribing 
trends, crime/police activity, health, drug market characteristics and pharmaceutical use).
Benzodiazepine and pharmaceutical opioid misuse and crime – types of crime, evidence, reasons, 
extent, etc. (e.g. robbery, prescription fraud, on-selling prescriptions, crimes committed under the 
influence).
Supply reduction and law enforcement impact – evidence of impact for users and for law 
enforcement and other frontline workers.
Appropriate interventions – responding to law enforcement and health impacts of the illicit 
benzodiazepine and pharmaceutical opioid markets and misuse.
One of the main aims of the Illicit Drug Reporting System has been to highlight issues that require 
further investigation through follow up specialist research in order to inform law enforcement and 
health sector policy and program responses to illicit drug use. Thus, the aim of this current research 
was to fulfil this second aim of the IDRS, by following up the identified emerging trend in illicit 
prescription drug use, and how that may impact on both criminal activity and health outcomes by 
examining the nexus between illicit prescription drug use, illicit prescription drug markets, crime 
and health harms. Clearly, there has been a deficit in such Australian research to date. 
The increase in pharmaceutical-related crime has the potential to impact on the law enforcement 
sector through increased levels of theft from pharmacies and other suppliers, other methods of 
diversion of the drugs to the black market, crime committed whilst under the influence of the drugs 
or whilst withdrawing from them, and also the disinhibition ('Rambo effect') that is associated with 
benzodiazepine intoxication that may lead to violent behaviour and other types of crime. 
Study purpose and ams
The purpose of this study was to contribute to law enforcement sector understanding of the 
relationship between benzodiazepine and pharmaceutical opioid misuse and crime in three select 
Australian jurisdictions (Victoria, Tasmania, Northern Territory) where there is evidence of illicit 
prescription pharmaceutical markets. This report focuses on the Victorian aspect of the study, and 
the broader findings are presented in the National Overview Report (Fry, Smith, Bruno, O’Keefe 
& Miller, in press). While the primary focus of the study remains on law enforcement interests 
in relation to licit and illicit benzodiazepine and pharmaceutical opioid markets, these are 
discussed in relation to the broader public health implications of supply reduction efforts in a harm 
minimisation framework.
x
The primary aims of the study therefore were to:
1. Gain a greater understanding of illicit benzodiazepine and pharmaceutical opioid market-
place dimensions and characteristics.
2. Investigate the hypothesised relationship between benzodiazepine and pharmaceutical opioid 
misuse and crime.
3. Explore the implications for police and other frontline workers (e.g. accident and emergency 
staff, ambulance officers and health/youth workers) of emergent illicit markets for 
benzodiazepine and pharmaceutical opioids.
4. Consider appropriate interventions to address both the law enforcement and health impacts of 
benzodiazepine and pharmaceutical opioid misuse.
A secondary and broader aim of the research was to examine the nexus between prescribed 
pharmaceutical misuse, illicit prescription pharmaceutical markets, crime and health harms. An 
extensive set of research questions was developed by NDLERF and specified in the RFT 04/02 
tender specifications under the four key themes of: market characteristics; diversion; links to crime; 
implications for police and other frontline workers; and interventions (these appear in Appendix 
A). 
Methodology
The design for this study was based on that of the IDRS, and comprised a triangulation of 
methodologies: interviews with key informants (KI) recruited from law enforcement and health 
providers; interviews with people who inject drugs (PWID); and analysis of secondary data 
indicators relevant to prescription drugs use. The combination of methods of data collection was 
designed to maximise access to relevant information. 
The study comprised four stages. The first stage was a comprehensive literature search and 
literature review, as well as surveys of 13 Victorian law enforcement KI, who provided their 
perspectives on the impacts of illicit prescription drug use on policing. Stage two was a survey 
of 102 PWID in five locations across the Melbourne metropolitan area, and Stage three was 
the collation and analysis of secondary data related to prescription drug use and crime in order 
to provide contextual information relevant to prescription drug use and crime statistics. Stage 
four consisted of a second survey of 50 Melbourne PWID, designed to serve a monitoring 
and confirmatory purpose, following the findings of Stage two. In-depth interviews with law 
enforcement and health KI were also designed to follow up on information collected in Stage one, 
and gather more qualitative, in-depth law enforcement and health-related perspectives. 
Summary of Vctoran findngs
Man findngs (Stage one, Law Enforcement Key Informant Intervews)
Market characteristics 
Thirteen KI participated. Most KI believed that heroin and methamphetamines were much 
more likely to be associated with crime than pharmaceutical opioids or benzodiazepines, 
with one informant linking both to burglaries and robberies.
Most informants indicated they believed pharmaceutical drug use was dependent on heroin 
trends.
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Diversion
It is believed that prescription drugs are diverted to the black market via burglaries and 
pharmacy thefts, prescription forgeries, doctor-shopping and on-selling by users.
Links to crime
llicit use of prescriptions drugs such as opioids and benzodiazepines is difficult to police, as 
the drugs themselves are legal when prescribed.
Implications for police and other frontline workers
Policing issues were identified as drug driving, care of children, and management of 
intoxicated people.
Interventions
It was reported that the drug diversion desk of the Major Drug Investigation Division was 
implementing a notification scheme in partnership with the Health Insurance Commission 
(HIC).
Man findngs (Stage two, Survey of 102 people who nject drugs)
Over two-thirds of the sample (71%) was male, and the mean age was 32 years (range 18 - 50). 
More than half the participants lived in their own accommodation or with their parents, most 
of the remainder lived in boarding houses, shelters or hostels, while 8% had no fixed address. 
The sample had on average 9.6 years of education, and less than half (44%) had post-school 
qualifications. Most (92%) were unemployed, with 77% reporting their main source of income 
to be government benefits, and 15% reporting it was the proceeds of crime. More than half 
the sample (55%) was not in current drug treatment, while 21% were undertaking methadone 
maintenance treatment and 22% were in the buprenorphine program. Almost two-thirds (64%) had 
been imprisoned at some time in the past. The sample was similar in demographic characteristics 
and drug use history patterns to the most recent IDRS sample, with the main exception that a 
higher proportion of the current sample had injected benzodiazepines in the six months prior to 
the interview. 
Market characteristics
All participants had used benzodiazepines in the six months prior to the survey, and 
45% reported they had injected the drugs, mainly temazepam (but also alprazolam and 
diazepam) in that time. Temazepam gel capsules were reportedly readily available in some 
areas of Melbourne, selling for between $5 and $30 each depending on size. The majority 
of participants believed that suppliers of benzodiazepines were users selling their own 
drugs or small-time dealers, but many reported that dealers sold other drugs such as heroin, 
methamphetamine, morphine and cannabis.
Almost all participants had used opioids within the same time frame, and 85% had injected 
them. A large proportion (37%) had been in buprenorphine treatment and 29% had 
undergone methadone maintenance treatment in the previous six months. 
Most (78%) had used morphine, and 77% had injected it, with the most frequently used 
brands being Kapanol and MSContin . Morphine was preferred as it most closely approximates 
the effects of heroin, and is injected by boiling down and filtering the tablets/capsules. 
Morphine, in particular Kapanol capsules and MS Contin tablets, was reportedly readily 
available in most surveyed areas of Melbourne, selling for between $10 and $100 each 
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depending on size. The majority of participants believed that suppliers of morphine were users 
selling their own drugs or small-time dealers, but many reported that dealers sold other drugs 
such as methamphetamine and cannabis.
Forty-one percent of the sample had also injected buprenorphine, and 32% of the sample had 
used illicit buprenorphine. Buprenorphine was reportedly readily available on the street in 
most surveyed areas of Melbourne for around $5 a dose. The majority of participants believed 
that suppliers of the drug were users sharing their own doses, but many reported that dealers 
sold other drugs such as methamphetamine and cannabis.
Nine percent of the sample had injected methadone syrup, and 20% of the sample had used 
illicit methadone. Three percent said they had bought it a from dealer (for about one dollar 
per ml). Many reported that dealers sold other drugs such as heroin, methamphetamine and 
cannabis.
Fifteen percent of the sample had injected other opioids (such as oxycodone, Panadeine forte 
and tramadol), with 20% of the sample reporting they had used illicitly acquired drugs, and 
one-quarter reporting they had been prescribed the drugs.
The sample were predominantly poly drug users, whose drug of choice was heroin.
There was a significant relationship between both heroin and methamphetamine use and 
illicit benzodiazepine injecting in the previous six months. Substantial proportions of 
participants who reported injecting benzodiazepines had also injected illicit buprenorphine, 
methadone and morphine in the same time period, and almost one-quarter of heroin users 
indicated that if heroin were not available they would substitute benzodiazepines for it.
There was also a significant relationship between both heroin and methamphetamine use and 
illicit morphine injecting in the previous six months.
Substantial proportions of participants who reported injecting morphine had also injected 
illicit buprenorphine, methadone and benzodiazepines in the same time period, and six 
heroin users indicated that if heroin were not available they would substitute morphine for it.
Diversion
Eighty percent of participants had received the drugs via prescription, with 13% reporting they 
had faked symptoms to obtain them, and 85% of the sample reported visiting a number of 
doctors (up to 20) to acquire a prescription. Almost all participants (91%) had also acquired 
the drug illicitly, mostly as a 'gift' from a friend or other user, although almost one-third each 
had bought them from a dealer or a friend. Almost 10% had recently stolen benzodiazepines, 
and six percent had forged prescriptions (in both cases temazepam was the drug most likely to 
be the target, but alprazolam and diazepam were also nominated). 
Most respondents reporting opioids use reported it was obtained licitly (60% of the sample), 
with six percent reporting they had feigned symptoms to receive opioids. However, 61% 
reported they received opioids as a gift from a friend or other user, and 36% reported buying 
the drugs from a friend or a dealer. Three percent reported they had recently stolen opioids 
(mainly MS Contin tablets), all of who injected them.
Almost all morphine users (97.5%) had acquired the drug illicitly. Thirty percent of 
participants had received the drugs via prescription in that time, with four percent reporting 
they had faked symptoms to obtain them, and many reporting visiting a number of doctors 
(up to 50) to acquire a prescription. More than half the sample (57%) had also acquired it as 
a 'gift' from a friend or other user, although around one-third each had bought them from a 
dealer or a friend.
Almost half (45%) reported they had been prescribed buprenorphine in the previous six 
months, while 11% said they had received it as a gift, but no-one had bought it from a dealer. 
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A quarter of the sample had been prescribed methadone syrup and nine percent reported 
receiving it as a gift. The majority of participants believed that suppliers of methadone were 
users sharing their own take-away doses.
More than one-quarter of participants (29%) reported stealing pharmaceutical drugs or 
prescriptions in the previous month, with nine percent reporting drug theft from a doctor’s 
surgery (mainly temazepam and MS Contin ), and three from a pharmacy, with opportunism 
the main reason cited for the behaviour. Seven participants reported they had forged a 
prescription in the previous month, mostly temazepam. More than one-third of the sample 
reported having their prescriptions or pharmaceuticals (temazepam and diazepam) stolen 
from them.
Links to crime
Two-thirds of the sample reported they had been arrested in the previous year, with charges 
relating mainly to property crimes (37%), fraud (14%), violence (11%), possession and 
intoxicated driving (6% each). A high proportion of the criminal behaviour was attributed to 
drug use, frequently benzodiazepines, and to a lesser extent to methadone.
Eleven percent of the sample reported recent contact with the police resulting from 
benzodiazepine use, while 24% reported having arguments. Benzodiazepines were blamed 
for aggressive behaviour (20%), getting into fights (13%) and getting into criminal trouble 
(12%), mainly property-related. These issues applied to a lesser extent to morphine.
Fourteen percent of those using benzodiazepines reported the effects of the drugs had caused 
them to commit a crime, while 12% reported that withdrawal from the drugs had resulted 
in criminal behaviour. Four morphine users blamed effects of the drug for causing them 
to commit crime, and the same number attributed withdrawal from the drug for criminal 
behaviour. Other opioids were blamed by very few participants for criminal behaviour.
Statistically, the main predictors of criminal involvement were age, frequency of heroin use, 
and frequency of illicit benzodiazepine use. Dependence on methadone (as measured by  
the Severity of Dependence Scale (SDS)) predicted a significantly lower likelihood of being 
involved in criminal behaviour. Higher dependence scores for benzodiazepines and morphine 
were related to committing crimes while intoxicated on the drugs, and higher dependence 
scores for benzodiazepines were related to committing crimes while withdrawing from them.
Thirty-nine percent of participants reported they had driven a vehicle while under the 
influence of prescription drugs in the previous month, and more than one-quarter reported 
they had done so five or more times (up to 120 times).
Implications for police and other frontline workers
Most participants had experienced some kind of injecting harms in the previous six months, 
mainly effects of a dirty hit, prominent scarring or bruising, and difficulty injecting, with many 
attributing their problems to having injected prescription drugs in that time. Nine percent 
reported they had experienced at least one overdose, with most attributed to heroin. 
Application of the SDS suggests that most participants may be dependent on benzodiazepines, 
morphine, methadone and/or buprenorphine. 
More than one-third of the sample reported experiencing memory loss or a blackout 
associated with benzodiazepines in the previous month, with several participants also 
attributing these symptoms to buprenorphine or methadone. 
A substantial number of participants had experienced social problems, such as relationship 
difficulties, anxiety, lack of motivation, or irritability in the previous month, which they 
attributed to pharmaceutical drugs.
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Interventions
There were conflicting reports about police activity targeting prescriptions drugs, with 38% 
reporting it had increased in the previous 12 months. Police activities included checking 
legitimacy of drugs on their person, and being arrested for having illicit prescription drugs. 
Five reported a higher police presence around chemists. Most (68%) did not consider that 
police activity had made it more difficult to access prescription drugs, but 16% thought it had. 
Other activity, such as GP or HIC crackdowns on prescribing practices and doctor-shopping 
were considered to have impacted on access to pharmaceuticals.
These findings suggest that reducing supply of prescription drugs may have the effect of 
increasing heroin, methamphetamine or alternative pharmaceutical use. They also suggest 
that supply reduction may result in a situation where increased efforts are made to access 
regular supply of other less common drugs such as cocaine, and may also increase doctor-
shopping, along with the involvement of large-scale dealing and criminal behaviour resulting 
from withdrawal syndrome and efforts to generate income to purchase drugs that are harder to 
obtain.
Man findngs (Stage three, Secondary Data)
Market characteristics 
Prescribing of both benzodiazepines and morphine decreased in recent years according to 
Pharmaceutical Benefits Scheme (PBS)/Repatriation Pharmaceutical Benefits Scheme (RPBS) 
data. Lifetime and recent use of both drug classes have also declined in the general population 
according to the National Drug Strategy Household Surveys (Australian Institute of Health and 
Welfare (AIHW) 1998, 2001). PBS/RPBS unpublished data provided for 2003 also show that 
prescribed doses of methadone have decreased, especially in Victoria, where buprenorphine 
treatment (and prescribing trends) for drug dependence has seen high acceptance. In 2002, 
Victorian prescriptions for buprenorphine represented 48% of all prescriptions issued in 
Australia under the PBS/RPBS.
The 2003 IDRS found that 80% of the sample had used benzodiazepines in the previous 
six months. The survey also found that 15% had injected them – a large decrease on the 
previous years, at 21% in 2002 and 40% in 2001. Overall, 69% reported they had injected 
benzodiazepines at some time. The most commonly used forms were diazepam, oxazepam, 
and temazepam. Almost half (45%) had obtained the drugs illicitly, and they were reportedly 
obtained through doctor-shopping or black-market street selling. Thirty-nine percent of the 
2003 IDRS sample had injected morphine, compared with 51% in 2002 and 32% in 2001, 
and 83% reported they had used the drug at some time. Over 39% of the sample reported 
they had injected buprenorphine in the previous six months (Jenkinson, Miller & Fry 2004). 
Diversion
The majority of forged prescriptions in the state were for temazepam gel capsules, or for 
alterations from temazepam tablets to capsules (Dobbin 2001).
Links to crime
Total pharmacy-related crime in Victoria showed a dramatic increase between 1998/99 and 
2001/02, from 805 incidents in 1998/99 to 2,410 in 2001/02, according to Guild Insurance 
Limited (2003) data – the increase corresponding to the time around the HIC regulation of 
10mg temazepam capsules. 
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The number of people arrested for heroin-related offences fell in 2000/01 compared with 
1999/00, whilst arrests for amphetamines and stimulant-related offences increased, probably 
reflecting the heroin drought.
For the majority of benzodiazepine and pharmaceutical drug seizures, specific information 
regarding the generic forms or brand names are not currently recorded in the Australian 
Customs Service drug statistics database. Detections of the remaining drug categories are 
recorded in the generic categories of 'Other benzodiazepines' and 'Prescribed drugs'. 
The detections of drugs within these categories, especially 'Other benzodiazepines' and 
'Prescribed drugs', has increased dramatically throughout that time.
Implications for police and other frontline workers
There was a general trend for decreases in non-fatal ambulance attendances at 
benzodiazepine-related cases in Melbourne in recent years, with 2,896 recorded in the 
2001/02 year, dropping to 1,711 in 2002/03, and with 678 recorded between July and 
September 2003. They remain at over 200 attendances per month however. 
The number of attendances at non-fatal morphine overdoses fluctuated in recent years. After 
peaking at 18 in October 2001, they showed a decrease at the end of the 2001/02 year (to n = 
7), then increased to peak again at 19 in March 2003, before declining dramatically towards 
the second half of the year (data obtained in 2004 from the Melbourne Ambulance Service 
and Turning Point Alcohol and Drug Centre databases).
Benzodiazepines were the most common drug identified in contributing, or incidental, to 
heroin-related deaths identified by the State Coroner’s Office, at 71% in 2000, and 55% of all 
deaths between 1997-2001. Morphine-related cases remained constant between 1997 and 
2001, peaking at 22% in 1999; however, morphine plus benzodiazepines comprised more 
than half of all deaths in recent years, reaching a high in 2001 (Wallington, Gerostamoulos & 
Drummer 2003). 
The number of temazepam-specific incidents contributing, or incidental, to heroin-related 
deaths increased from 6.4% in 1999 to 7.9% in 2000 to 20% in 2001 (Dobbin, 2001).
Man findngs (Stage four, Survey of 50 people who nject drugs)
The sample was equivalent to the PWID sample from stage two, with 68% male, a mean age of 32 
years and 88% unemployed. The sample identified that government benefits were the main source 
of income (mean = $361 per fortnight), followed by drug dealing (mean = $214) and begging/
charity (mean = $160). Half the sample was not in current drug treatment, while 10% were in 
current Methadone Maintenance Treatment (MMT) and 36% were in the buprenorphine program. 
A couple of notable differences from the first sample were a smaller proportion with a prison 
history (42%), and the second sample had spent on average a substantially longer period of time in 
drug treatment programs (mean = 14.7 months). 
Market characteristics 
Almost all (96%) of the sample had used heroin in the six months prior to the survey, while 
90% had used benzodiazepines orally and 58% had injected them (which was 13% higher 
than stage two). The most common forms used were temazepam, diazepam, oxazepam and 
nitrazepam. Temazepam was the most commonly injected drug, but diazepam, alprazolam 
and oxazepam were also reportedly injected. 
Gel capsules were reportedly easier to acquire on the street than from a doctor, with 16% 
reporting they were easy or very easy to obtain that way, although tablets were easier, with 
38% reporting that tablets were easy or very easy to obtain.
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PWID reported their benzodiazepine dealer was mainly a friend selling their own prescription 
(24%), a friend giving their prescription away (12%), or a user selling the drugs to fund their 
own use (12%). Just one reported buying the drugs from a small-time dealer or a dealer 
swapping drugs. Other drugs reportedly sold by benzodiazepine dealers included heroin 
(24%), cannabis (18%), methamphetamines (12%), and other benzodiazepines (20%).
Seventy percent of the stage four sample had used morphine in the previous six months, 
which was similar to stage two, with 16% taking it orally, and 64% of the sample having 
injected it. MS Contin tablets and Kapanol capsules were the most frequently used forms (in 
stage four, more PWID had used MS Contin than Kapanol – the opposite of the stage two 
finding). 
A quarter of the sample reported morphine was easy or very easy to obtain on the street, 
but about the same proportion considered it was difficult or very difficult. As in stage two, 
most suppliers of morphine were friends selling their prescription (30% of the sample), or a 
friend giving away their drugs (10%), or a friend selling to fund their own use (6%). Only two 
reported buying morphine from a small-time dealer. Other drugs reportedly sold by dealers 
of morphine were heroin and cannabis (14% each of the sample), other morphine types or 
amphetamines (10% each), and benzodiazepines (4%). Twenty-two percent of the sample 
believed the morphine market had changed substantially in the previous six months, with 8% 
each reporting it had become more difficult to obtain and more expensive. 
Over half the participants had used prescribed pharmacotherapies in the previous six months, 
with 38% reporting they had used them illicitly, and these findings were similar to stage 
two. Buprenorphine was the most commonly used (either licitly or illicitly) by 50% of the 
sample, and had been prescribed to 36% of the sample. Methadone syrup had been used 
by 22% of the sample, all but two of who had a prescription. Almost half (40%) reported 
injecting pharmacotherapies, the same proportion had injected buprenorphine, and 6% 
had injected methadone syrup. Illicit and prescribed buprenorphine were both injected by 
26% of the sample. Methadone was reportedly around one dollar per ml on the street, while 
buprenorphine tablets were between $5 and $20 each. 
Other opioids had been used by 46% of these PWID; namely, oxycodone, tramadol, codeine 
phosphate, and Panadeine forte . The use of oxycodone was much more frequent with this 
sample than the first sample. One reported forging a prescription. Eighteen percent of the 
sample reported opioids to be easy or very easy to obtain on the street, while 10% said it was 
difficult or very difficult. Two participants each reported their opioids dealers also sold heroin, 
amphetamines, and morphine, and one said they also sold benzodiazepines, and again 
most illicit users received the drugs from friends selling their prescription (29%) or a friend 
giving away their prescription (14%). One participant each received the drugs from a dealer 
swapping other drugs for them or from a small-time dealer selling them.
Diversion
Three-quarters (74%) reported they had used legally acquired benzodiazepines in the previous 
six months (20% less than stage two), and 78% reported using illicit benzodiazepines. 
Forty percent of the sample reported they had feigned symptoms to obtain a prescription for 
benzodiazepines, substantially more than stage two, and reports of doctor-shopping were 
frequent, with up to 15 doctors approached in the previous six months. Most respondents 
reported that gel capsules were too difficult to obtain medically, but tablets were reportedly 
mostly easy or very easy to obtain.
The pattern of illicit benzodiazepines was not dissimilar to stage two, with most obtained as a 
'gift' (92% of all illicits), followed by buying from a friend (44%, higher than stage two), and 
buying from a dealer (31%). Few PWID reported stealing them (n = 2), or forging prescriptions 
(n = 1). The drugs were swapped for other drugs by 12% of the sample (n = 6). 
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Similar to stage two, 62% of the sample had used illicitly acquired morphine, and 10% had 
obtained prescriptions. Most participants had not attempted to obtain morphine medically 
in the previous six months, considering it too difficult, but two had faked symptoms in 
an attempt to gain a prescription. There was some reported doctor-shopping, with eight 
respondents approaching up to 15 doctors for a prescription.
As with benzodiazepines, the most common method of obtaining morphine illicitly was as 
a gift (84% of illicit morphine users), and then buying them from a friend (64.5%), or buying 
from a dealer (45%), and 16% reported swapping other drugs for them. No participants 
reported stealing the drugs or forging prescriptions
For methadone syrup injectors, two were prescribed the drug and one obtained it illicitly. 
When pharmacotherapies were illicit, they were mostly a gift (67% of these users); otherwise 
they were bought from a friend (n = 3) or bought from a dealer (n = 3). Overwhelmingly, the 
drugs were obtained from other users giving away or selling their 'take-away' dose.
More than half (56.5%) had been prescribed them (tramadol and Panadeine forte ), and 61% 
had obtained them illicitly (oxycodone and codeine phosphate). Almost 30% of the sample 
had injected the drugs, mainly oxycodone (Oxycontin tablets), but also tramadol and codeine 
phosphate. Four participants (8%) had feigned symptoms to obtain opioids in the previous six 
months, and 28% altogether had attempted to obtain a prescription in that time. Some doctor-
shopping was apparent, with up to 15 doctors approached for the drugs. Where the drugs 
were acquired on the street, it was mostly as a gift (64% of illicit opioids users), then from 
buying from a friend (36%), and from a dealer (21%).
Links to crime
In terms of self-reported crime in the previous month in this sample, there were a few 
differences from stage two that suggest that the majority of property crimes committed by 
these PWID may be related to shoplifting. 
Twelve percent of participants reported having committed a crime involving violence in 
the previous month, with all reporting they had done so less often than once a week – the 
prevalence is less than stage two, but the frequency is higher. Most of these respondents 
(67%) indicated they had been intoxicated at the time of the offence, and the others reported 
they had been aggressive and started a fight. Offences included committing an assault during 
a bag-snatch, assaulting someone at the pub for no reason, assaulting a partner while on 
Valium, threatening someone to obtain temazepam from them, and attacking an ambulance 
officer and a police officer during a 'schizophrenic' attack.
More than half of the sample (52%) reported dealing drugs in the previous month, slightly 
more than in stage two – about a third of these (31%) reported they did so less than once a 
week and 70% reported dealing once a week or more. 
Twelve percent of participants reported they committed some form of fraud in the previous 
month, although 34% also reported having 'rorted' to obtain drugs (rorting was defined as 
obtaining money or goods dishonestly but not through theft, e.g. 'ripping people off', begging, 
asking charities for money, faking symptoms to obtain prescriptions, telling lies). Over one-
quarter also reported they had 'scammed' to obtain drugs (scamming was defined as similar to 
rorting).
More than one-third of the sample (36%) reported they had driven while under the influence 
of illicitly used drugs in the month prior to the survey. Most of these respondents (56%) did so 
less than once a week, but 44% reported they did so once a week or more frequently.
•
•
•
•
•
•
•
•
•
xx
Implications for police and other frontline workers
Eight percent believed that a decrease in benzodiazepine availability had caused an increase 
in crime by motivating stealing in order to pay for the drugs, by directly influencing behaviour 
(by increasing confidence and risk-taking), and by increasing violence.
The same proportion also believed that changes in the availability of the drugs had affected 
users’ relationships, because of aggression, fighting, and family breakdowns, as well as 
affecting people financially with the drugs being more expensive on the street.
Seventy percent of the sample reported they had behaved 'uncharacteristically' because 
of intoxication on drugs, and mostly blamed benzodiazepines (66%), heroin (38%), or a 
combination of the two (24% of the sample), and benzodiazepines combined with other drugs 
were blamed as well. Morphine (MS Contin and Kapanol ) and buprenorphine were each 
blamed by 8% percent of the sample, and methadone syrup by 8%. Three participants taking 
benzodiazepines had also been using morphine, as had half of those taking buprenorphine. 
The behaviours described as uncharacteristic and drug-induced were 'aggressive/abuse/
violent' (23% of those reporting such behaviour), 'criminal' (20%), 'high/silly/energetic' (20%). 
Two reported experiencing hallucinations while on benzodiazepines, and five participants 
reported blacking out or forgetting incidents they had been involved in whilst intoxicated on 
the drugs, such as car thefts, shoplifting, robbery or aggressive behaviour. 
Six respondents believed that benzodiazepines made it more likely they would commit 
criminal offences by lowering their inhibitions and increasing their confidence and feelings of 
'invincibility'.
Interventions
Twenty percent considered that benzodiazepines had become more difficult to obtain on 
the street in the previous 12 months, 18% reported doctors were becoming less willing to 
prescribe them, and 10% reported increasing police activity around the drugs, with police 
more likely to check PWID for them and check prescriptions.
The general consensus was that there had not been any increase in police activity around 
morphine or other opioids on the street.
Man findngs (Stage four, Health & Law Enforcement Key Informants Intervews)
Market characteristics 
Most of the 28 KI interviewed (n = 18 health workers, and n = 10 law enforcement personnel) 
reported heroin was the primary drug of choice for PWID using benzodiazepines and 
pharmaceutical opioids. 
It was considered benzodiazepines were primarily used by PWID to supplement heroin and 
increase its effects, rather than as a primary drug of choice. There were also reports that use of 
these drugs is fluid, with PWID alternating drugs according to availability, or their financial or 
health situation. 
In terms of opioids use, KI considered there was a combination of primary and supplemental 
use, with some PWID using pharmaceutical opioids, such as buprenorphine exclusively, and 
others topping up with heroin, although it was thought that people were less likely to top up 
the longer they were in the program.
Law enforcement KI considered that trafficking in pharmaceuticals was more likely to occur 
in Melbourne’s drug 'hot-spots', although they were doubtful about the existence of formal 
trafficking in buprenorphine, and believed that the drug was more likely to be a prescribed 
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dose shared by a patient. On the other hand, some KI reported a brisk street trade in 
buprenorphine. Similarly, some KI reported that the trade in benzodiazepines was reduced 
currently due to decreases in prescribing by doctors, but others disagreed with this. 
The general agreement seemed to be there was no organized crime element or organized 
black market in prescription drugs, with the possible exception of morphine, which is more 
difficult to obtain and therefore may be more valuable. It was agreed that dealing in these 
substances was more likely to comprise a disorganized system of trading, selling or sharing as 
part of a 'drug-sharing culture', rather than undertaken as a money-making activity.  This was 
because most KI did not consider the rewards of selling the drugs to be great. 
Diversion
KI considered that most of the prescription drugs available emanated from prescribing doctors, 
although this may differ according to different drugs, with temazepam more likely to be 
obtained at street level, and morphine originating from patients on pain relief or friends and 
family members with a legitimate prescription. 
Thefts from pharmacies or distributors’ or manufacturers’ premises were mentioned as 
possible sources for the drugs, although it was considered these had reduced considerably 
over the past two years. The Internet was not seen as a viable source for prescription drugs.
Doctor-shopping for both benzodiazepines and pharmaceutical opioids was considered to be 
rife, and relatively easy by some KI, and generally related to personal qualities of individual 
doctors (thinking they are doing the right thing, being known as 'easy' or 'soft', inexperienced 
or 'tired'). 
On the other hand it was considered that temazepam was now more difficult to obtain this 
way because of the regulation of 10mg gel capsules. 
All agreed that doctor-shopping did not apply to methadone and buprenorphine. 
Links to crime
The common attitude about the relationship between specific drugs and criminal behaviour 
was that the use of benzodiazepines may mean people are more likely to commit crimes they 
had already planned on committing, for instance shoplifting, but with less inhibition. 
A sense of 'invincibility' was also associated with the use of benzodiazepines, with KI 
considering it may be a factor in committing crimes such as shoplifting and burglary, and also 
increasing the likelihood they will be caught. 
Opioids were considered more likely to reduce crime than increase it. 
Where crimes were seen to be related to benzodiazepines and pharmaceutical opioids, they 
were most likely to be shoplifting, property crime, and burglaries, as well as pharmacy-related 
crime, crimes of violence, and trafficking in the drugs. 
There was a perception that the lack of availability of drugs, including benzodiazepines and 
opioids, may also precipitate crime aimed at attempting to obtain them.
Implications for police and other frontline workers
According to the KI, the most frequently used benzodiazepines were reportedly temazepam 
and diazepam. KI identified serious health issues resulting from benzodiazepine use, for 
instance vein damage, abscesses, amputations, dependence, poly drug use, and overdose. 
On the other hand benzodiazepines were considered useful for helping to manage withdrawal 
in drug dependent people. 
•
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•
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Law enforcement personnel mentioned the diversion of benzodiazepines to the black market 
because of their desirability.
According to the KI the most frequently used opioids were reportedly buprenorphine, MS 
Contin and Kapanol . Overwhelmingly, pharmacological drug treatments were considered to 
be of utmost importance, and significantly improved the health and well-being of drug users, 
with flow-on effects to employment and housing, thereby leading to continuing stability.
It was also considered that provision of drug treatments reduced crime as they reduced the 
need for substantial amounts of money for financing a habit. 
On the other hand, the cost of regular treatment could reportedly become prohibitive and may 
on occasion precipitate criminal activity. Law enforcement KI considered that the availability 
of pharmacotherapy treatments could disengage PWID from street supplies of heroin and may 
also help control heroin use, and diversion of the drugs was also seen as a problem.
Overall, the responses of the stage four law enforcement KI were similar to those in stage 
two: prescription drugs were not really an issue for police, or were seen as more or less the 
same as other drugs, having in themselves a small impact on their work, and that there was 
little point in focusing on them until they become 'huge'. The drugs were not seen to be the 
problem that illicit substances such as heroin and amphetamines were, and were not linked 
with criminal behaviour or organised trafficking networks in the same way, and thus did not 
generate the same level of attention. 
Police considered that it was more useful to focus on trafficking in pharmaceuticals than on 
users, and mentioned the production of the Victorian Police manual An investigation guide 
to pharmaceutical drug trafficking and use (Victoria Police, 2004) for all stations as a great 
benefit in identifying drugs and laying charges where appropriate. 
Interventions
Most KI did not consider that police activity had an effect on the use of prescription drugs by 
PWID, but impacted more on illicit drugs. However, a few mentioned that police cautioning 
and diversion programs were having an impact on all drug use, and that police activity in 
shopping malls was making access to drugs (including pharmaceuticals) more difficult and 
reducing crime in those areas, although it was noted that trafficking became more covert in 
response. 
It was also mentioned that people in possession of benzodiazepines without a prescription 
were charged, and that such activities resulted in prescription drug use becoming more 
discrete, or that people may be more wary of presenting forged prescriptions. 
It was considered that the displacement of illicit drug trafficking to other areas as a result of 
police crackdowns on illicit drugs leads to an increase in the use of benzodiazepines, as the 
illicit drugs become more difficult to obtain.
It was suggested that limiting prescribing of the drugs would reduce diversion, although it 
was also considered that most PWID obtained prescriptions for their own use rather than on-
selling.
It was also considered that tracking the prescriptions an individual has, more vigilance 
with prescription pads, crushing of buprenorphine in the pharmacy before administration, 
injectable buprenorphine delivered in the pharmacy, and more sharing of information 
between doctors about drugs preferred for diversion, would all be strategies that could 
effectively reduce diversion.
Police considered that strategies that would assist them in policing pharmaceutical drug 
misuse included: restricting the source of benzodiazepines and pharmaceutical opioids; 
dispensing pharmacotherapies from 24 hour clinics; establishing pharmacies in a wider 
•
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area to reduce the numbers of people flocking to 'hot-spots'; the development of a system 
that tracked batches of benzodiazepines as they are produced, cross-matched with data on 
dispensing; provision of information to police about emerging problems; and regular updating 
of the manual An investigation guide to pharmaceutical drug trafficking and use (Victoria 
Police, 2004).
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Market characteristics 
This current study specifically sampled PWID who used illicit benzodiazepine and/or 
pharmaceutical opioids. The findings in the main confirmed most 2003 IDRS findings, with similar 
prevalence of recent injecting of morphine and buprenorphine, and a higher prevalence of recent 
benzodiazepine injection found among the current sample. There were substantial overlaps in drug 
usage, with most PWID being poly drug users. It must be kept in mind that sampling of the PWID 
participants targeted those who misuse any/all of these types of drugs, and therefore the findings 
cannot be generalised to broader PWID populations. Nevertheless, clearly there exists a demand 
for diverted prescription drugs. 
Whilst temazepam has reportedly become more difficult to acquire, with most PWID considering 
it too difficult to obtain from a doctor, acquisition and use of the drug still continues, at least 
amongst some groups of PWID. These findings show that temazepam, morphine, and to a lesser 
extent buprenorphine, appear to have become established on the black market in Melbourne. 
These are reportedly not difficult to obtain, especially in the inner-city suburb of Footscray in 
the case of temazepam, and most areas for morphine and buprenorphine. Prescription drugs are 
seemingly chosen by PWID to increase the pharmacological effects of heroin, or as substitutes for 
heroin. They are considered to be of a consistent quality, reasonably priced and easy to acquire. 
However, several key informants also reported that the use of benzodiazepines is quite fluid, 
and that people will alternate between substances according to availability, health and financial 
situation, as well as a raft of other psycho-social factors. With regard to pharmaceutical opioids, 
key informants offered the suggestion that there is a blend of primary and supplemental use. 
Benzodiazepines were reportedly acquired by these PWID mainly via friends and medical 
prescriptions, and through small-time dealers, with tablets selling for as little as one dollar, and gel 
capsules for between $5 and $30 each. PWID also tended to inject buprenorphine that they were 
prescribed, or shared others’ doses. On the other hand, morphine tended to be acquired through 
friends or dealers, costing around $50 for 100mg. Respondents generally reported that dealers 
were other users with a prescription for sale, although there were frequent reports that many 
dealers sold other illicit drugs as well. There were some reports of prescription/prescription drugs 
thefts and doctor-shopping, which KI tended to believe were widespread. 
The findings suggest, therefore, that the prescription drugs market in Melbourne – with the possible 
exception of morphine which is more expensive and less easy to acquire than benzodiazepines 
and buprenorphine – does not at this stage appear to be large-scale, but seems to be dominated 
by small-time dealers, users selling to fund their own use, and a diffuse network of users sharing 
their own prescription drugs and swapping drugs amongst themselves. These reported patterns 
of dealing and use suggest an opportunistic way that poly drug using PWID might adapt to, 
and manipulate available drugs for maximum effect, according to the availability, price, and 
consistency of illicit drugs on the market at any given time, balanced against the widespread 
availability and relatively low price, as well as the predictable quality, of prescription drugs. 
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Diversion
Diversion of prescription drugs was reportedly widespread, with most participants having 
received prescribed benzodiazepines and illicit benzodiazepines, and most having received 
illicit morphine. The use of diverted buprenorphine was widespread as well. Law enforcement 
KI considered the drugs mostly originated from medical prescriptions, but also may come from 
pharmacy burglaries, and thefts from drug distributors, although reportedly these had declined in 
the past 12 months. PWID reported swapping their prescribed drugs for illicit drugs (or vice versa), 
mainly benzodiazepines, with other users, as well as selling/giving away their prescribed drugs. 
Doctor-shopping for benzodiazepines was common, although most participants considered it was 
too difficult to obtain temazepam gel caps that way. There was also widespread doctor-shopping 
for morphine, although reportedly not very successfully. Thefts of prescribed drugs were reasonably 
frequent amongst PWID, but mainly related to benzodiazepines, rather than opioids.
The findings suggest that policing of prescription drugs is complicated by the fact that the drugs 
themselves are legal, even if their possession or use is not; thus it is difficult to determine when an 
infringement has been committed.
Links to crime
This study suggests that prescribed drugs may be related to crime in several ways: firstly via 
diversion of the drugs to the black market, either through diverting of legitimate prescriptions 
by giving them away, swapping them for other drugs or selling them, or via thefts of the drugs or 
forgeries of prescriptions; secondly, PWID reported they were more likely to commit criminal 
offences when they were intoxicated by prescription drugs, especially benzodiazepines, and to a 
lesser extent morphine. 
Eleven percent of the first sample reported they had experienced contact with police because 
of their benzodiazepine use, and a high proportion of both samples of participants reported 
involvement in criminal activity, especially shoplifting, other property crimes, drug dealing, 
intoxicated driving, and to a lesser extent violence, and most blamed drugs for their offences. 
Past research has suggested that benzodiazepines, through their psychopharmacological effects, 
may cause personality changes, disinhibition, and bizarre behaviour, as well as precipitating 
feelings of over-confidence and invincibility. This accords with these current findings, where a 
high proportion of participants reported that they had behaved uncharacteristically while on drugs, 
and frequently attributed such behaviour to benzodiazepines, either alone or in combination 
with other drugs. There were also reports of participants committing offences whilst intoxicated, 
but having no memory of the events the following day. Participants frequently reported feeling 
'invisible', 'invincible' and more confident than usual, believing they could get away with 
behaviours they would not normally undertake.
The findings suggest that law enforcement KI assessment of the impacts of these drugs on 
behaviour may be underestimated when compared with PWID reports. It was found that the 
frequency of use of illicit benzodiazepines was related to the number of different kinds of criminal 
behaviours that respondents reported being involved in, and the degree of dependence on 
benzodiazepines was also related to whether a crime had been committed whilst intoxicated by, or 
withdrawing from, benzodiazepines. A relationship was also found for dependence on morphine 
and committing crime whilst intoxicated on the drug. The findings also suggest that dependence 
on methadone tends to reduce involvement in criminal behaviour, which is in accordance 
with previous findings that opioid use has not been directly associated with violence, and that 
methadone may mitigate against criminal behaviour. 
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A high proportion of these respondents reported dealing drugs, with a substantial proportion of 
their average income attributed to the activity. This suggests that they may be involved in a cycle of 
drug use and criminal activity that is related to an entrenched lifestyle, and possibly renders them 
more likely to offend, or to offend more frequently than if they were not using drugs. Alternatively, 
drug use and/or dependency may demand a higher income than can be attained legitimately.
When considered in their entirety, these findings do suggest a link between the use of prescription 
drugs and criminal behaviour: through changes in behaviour; self-reported offences attributed to 
the drugs by these PWID; the consideration that where dependency on a drug exists there is a need 
to maintain supply; and many of the drugs, in particular morphine and temazepam, are difficult 
to obtain and may be expensive and not affordable on a legitimate income (especially as the vast 
majority of the PWID gain most of their income from government benefits, begging and charity). 
Past research suggests that more serious and financially rewarding crimes tend to be committed by 
the heaviest drug users, and these participants tend to use a wide range of drugs frequently. 
Implications for police and other frontline workers 
The findings suggest PWID may be exhibiting many harms due to prescription drugs misuse. The 
main health harm attributed to prescription drugs by both previous research and PWID and KI 
in this study has been related to injecting, such as vein damage, thrombosis, 'dirty hits', scarring 
and infections, as well as dependence and overdose (especially when the drugs were combined 
with other drugs and/or alcohol). Almost two-thirds of these participants reported experiencing 
injection-related harms, and benzodiazepines and morphine were frequently blamed. KI also 
reported a relatively high incidence of sharing between partners, and there were reports that 
female drug users were sometimes coerced into undertaking sex work in order to make money to 
procure drugs for themselves and their partners.
In addition, law enforcement KI considered the availability of benzodiazepines on the black 
market to be driving diversion, and also suggested that inconsistencies in the dispensing of 
buprenorphine, such as not crushing the tablet on the spot – which then allows the drug to be 
diverted or injected – were a disadvantage of prescribing pharmaceutical opioids. KI also were 
concerned at the abuse of benzodiazepines, especially when used in conjunction with other 
drugs, and suggested that the 'easy' availability of benzodiazepines, and the prescribing of 
pharmaceutical opioids (e.g. buprenorphine) lead to harmful poly drug use.
The potential for a high prevalence of dependence on prescription drugs was also cause for 
concern. Two-thirds of these PWID recorded scores on the Severity of Dependence Scale (SDS) 
that suggest they may be dependent on benzodiazepines, morphine, buprenorphine, and/or 
methadone. High proportions reported negative consequences of using the drugs, such as: 
physical/health effects, overdose, volatile behaviour, and addiction (benzodiazepines); overdose/
death, physical/health effects, and addiction (morphine); addiction, physical/health effects 
(methadone); injecting/health effects; and addiction (buprenorphine). Health KI reported the habit-
forming nature of benzodiazepines was a potential negative consequence of their prescription, 
as well as injecting harms. They also contended prescription drugs overdose was a problem, 
especially with benzodiazepines when used with other drugs, and with methadone. Prescription 
drugs intoxication and withdrawal were also blamed by the PWID for social and relationship 
problems, anxiety, lack of motivation, and irritability. 
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Interventions
Police cautioning and diversion programs were considered to have an impact on all drug use, in 
that police activity in shopping malls was making access to drugs (including pharmaceuticals) 
more difficult, and was reducing crime. It was also considered this kind of police activity may 
reduce the incidence of forged prescriptions being presented. The production of the Victoria 
Police manual An Investigation Guide to Pharmaceutical Drug Trafficking and Use (Victoria Police 
2004) for all stations was seen to benefit policing efforts, allowing officers to correctly identify 
pharmaceuticals and to lay charges where applicable. It was considered that wider distribution of 
this or a similar publication may be useful.
It was contended, however, that police 'crackdowns' may in fact result in more 'underground' 
activity, cause drug trafficking to become more covert in response, and/or lead to increases in 
the use of benzodiazepines, as the illicit drugs become more difficult to obtain. Another side 
effect of police activity cited was people sharing injecting equipment, injecting 'on the run' and 
in unsanitary conditions, increasing injecting harms considerably and also increasing the risks of 
overdose. Development of harm reduction practices around injecting pharmaceutical drugs was 
prioritised.
Police considered that other strategies that would assist them in policing pharmaceutical drug 
misuse included: restricting the sources of benzodiazepines and pharmaceutical opioids; 
dispensing pharmacotherapies from 24 hour clinics; establishing pharmacies in a wider area than 
currently to reduce the numbers of people flocking to 'hot-spots'; the development of a system that 
tracked batches of benzodiazepines as they are produced, cross-matched with data on dispensing; 
provision of information to police about emerging problems; and regular updating of the manual 
An Investigation Guide to Pharmaceutical Drug Trafficking and Use (Victoria Police, 2004).
Temazepam injecting seems to have declined since the HIC regulated prescribing of the 10mg gel 
capsules under the PBS/RPBS in 2001, and the cessation of production of all gel capsules that has 
now occurred may be expected to have a further impact. Findings from the current study – that 
temazepam and morphine were very difficult to acquire medically, and there is no point in trying 
to get them this way – suggest that prescribing practices have reduced access to the drugs, and 
have most likely discouraged doctor-shopping for them. Expanded interventions in prescribing 
practices were suggested by these findings. For instance, limiting prescribing of some drugs, such 
as benzodiazepines, may reduce diversion. One way of doing this that was suggested, and was 
indeed reported by some PWID, involves daily pick-up of enough of the drug to maintain a person 
for the next 24 hours. A method of tracking the prescriptions an individual has may help reduce 
diversion of prescription drugs, and many doctors (e.g. Kamien 2004) are looking forward to 
availability of the HIC prescription shoppers data base, replacing the doctor-shopper hot-line as a 
way of enabling better control of over-prescribing and doctor-shopping. 
Other strategies suggested for reducing diversion included better vigilance with prescription 
pads, pharmacists calling police where forged prescriptions are presented, which often does 
not currently happen, crushing of buprenorphine in the pharmacy before administration (or 
administering a 'fizzy' form similar to Berocca ), injectable buprenorphine delivered in the 
pharmacy, and more sharing of information between doctors and police about drugs preferred for 
diversion. It was also suggested that data-sharing between relevant authorities, such as pharmacies, 
doctor-shopping, and law enforcement, would be useful. Privacy is obviously an issue with these 
suggestions.
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The findings suggest that a lack of supply could force both dependent and non-dependent 
benzodiazepine users to seek a more harmful replacement, thus causing a whole raft of new 
health and law enforcement problems. Health KI also considered that targeted and monitored 
benzodiazepines could be useful in a withdrawal treatment regime. In addition, health and law 
enforcement KI agreed that prescribing of pharmacological drug treatments were essential for the 
health and quality of life of drug users and for the reduction of crime. The reducing or waiving of 
costs of drug treatment programs was suggested in order to improve access to treatment as well 
as reduce the need for some people to commit crime. The findings suggest that diversion and 
maintenance of PWID into (affordable) treatment programs may have a positive effect on both 
health and law enforcement outcomes.
Summary
The current research has demonstrated clearly that misuse and injecting of benzodiazepines 
and pharmaceutical opioids, especially morphine and buprenorphine, has become entrenched 
among some groups of PWID in Melbourne. The findings suggest that the drugs are diverted to the 
black market and can be sold for considerable profit. The drugs may be diverted from legitimate 
prescriptions and prescribed doses, via doctor-shopping, or from forged prescriptions or stolen 
drugs. Prescription drugs appear to be relatively easy to obtain on the street, and seem to be 
available from a diffuse network of users, friends of users, dealers and suppliers, some of who 
also sell all kinds of illicit drugs. The findings also suggest criminal behaviour may be related to 
the dependence on, and the use of, prescription drugs; for instance shoplifting, property crime, 
drug dealing, violence and intoxicated driving. In addition, disinhibited, aggressive, and bizarre 
behaviour, and feelings of invincibility, were attributed to the drugs, in particular benzodiazepines. 
On the other hand, dependence on methadone may mitigate against the commission of crime. 
Besides criminal behaviour, other negative consequences of prescription drugs use were 
considered to be injecting harms, dependence and overdose, as well as social impacts such as 
relationship breakdown, effects on mood, anxiety and irritability. There were several potential 
interventions forwarded for consideration; for instance decreasing the costs of drug treatments, 
a more holistic approach to prescribing of drugs, close monitoring of PWID who are prescribed 
benzodiazepines, development of alternative forms of buprenorphine that cannot be diverted, 
keeping police and doctors up to date with prescribed drugs that are likely to be diverted, 
education of doctors and pharmacists about diversion of the drugs, and encouraging sharing of 
information between different bodies that produce data.
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Chapter one: Introduction
The purpose of this report is to examine the possible association between diversion and use of 
prescription drugs by injecting drug users and criminal behaviour in Melbourne. The available 
evidence indicates that the diversion of prescription drugs, in particular benzodiazepines and 
pharmaceutical opioids onto the black market, and their subsequent misuse by people who inject 
drugs (PWID), is increasing (Breen et al. 2003a; Dietze & Fitzgerald 2002; Dobbin 1998; Dobbin 
2001; Bruno & Fry 2001; Shand et al. 2003). 
The reduction of global opium production and the fall in the value of the Australian dollar, 
together with police and customs activity, contributed to a well-documented marked decrease 
in the availability of heroin in some areas of Australia, including Victoria, at the end of 2000. 
The magnitude of this decrease was demonstrated by the 90% decrease in the number of heroin-
related deaths identified by the Victorian State Coroner’s Office in 2001, with 29 deaths identified 
to the end of July 2001, a substantial drop from the figures for 1999 (258) and 2000 (248) (Dobbin 
et al. 2003). The heroin 'drought' was linked with a major increase in the use of amphetamines 
and 'pills' (pharmaceutical drugs), including temazepam use and injection of the capsule contents 
(Miller, Fry & Dietze 2001). Miller, Fry and Dietze (2001) found that injecting drug users reported 
they used pharmaceutical drugs more often than previously, and many reported commencing 
injection of pharmaceuticals during the drought. Pharmaceuticals were reportedly easy to obtain 
and trafficked via friends and street suppliers.
Makkai and Payne (2003) have reported that criminological research on the links between drugs 
and crime have consistently found that most offenders have used illegal drugs, minor offending 
precedes drug use, and that offenders who are drug users are more likely to report higher rates of 
offending. It is generally believed that the use of illicit drugs is responsible for much of the crime 
recorded by police; however, there is no accurate estimate of the proportion of crime caused by 
various kinds of illicit drugs (Makkai 2002; Weatherburn et al. 2002). Weatherburn et al. (2002) 
argue that it is, therefore, impossible to determine priorities among drug use control programs 
or assess the weight assigned to preventing crime as opposed to other adverse effects of illicit 
drug consumption. Makkai (2003) and Makkai, McGregor and Wei (2003) thus argue that the 
relationship between drugs and crime is complex, with the phenomena varying according to types 
of offenders and drug users, and a number of environmental, situational and psychological factors. 
They therefore contend that policy development needs to take into account the multi-faceted 
nature of the problem. 
There are several theories of the relationship between drug use and property crime, with the 
dominant being: 1. the 'enslavement model', in which it is held that drug-related offenders begin 
using drugs initially, and after becoming dependent are eventually drawn into crime to raise the 
financial wherewithal to finance their habit; 2.  the 'criminality model', where the drug-related 
offenders are proposed to be involved in crime and other disorderly behaviour before using drugs, 
and as time passes they are increasingly enmeshed in deviancy including drug use; and 3.  the 
'escalation model', wherein the offender begins a criminal career first and becomes involved in 
drugs as part of their overall criminal lifestyle, eventually becoming dependent and thus needing 
more money to finance their habit, in the process their criminality becoming higher than it 
normally would have been (Makkai 2002).
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In relation to violent crime, three models have also been forwarded in explanation. First, the 
'psychomarcological model' argues that certain drugs may produce violent reactions in an 
individual. The second model, the 'economic compulsive model', argues that some drug users 
commit violent crimes, such as armed robberies, to support an expensive drug habit (Makkai 
2002). The third model, the 'systemic violence model' describes the violence that occurs as a 
result of an individual playing their part within a system of drug use and distribution (Makkai 
2002). In terms of the first model, the drugs most reported to be associated with violent crime 
are stimulants (Makkai 2002). While opioid intoxication has not been directly associated with 
violence (Makkai 2002), intoxication with benzodiazepines on the other hand has been implicated 
in uninhibited and even bizarre behaviour, as well as blamed for enabling individuals to undertake 
criminal acts and feel 'invincible' (Bonn & Bonn 1998; Dobbin 2001; Rall, 1992). Mood swings 
and irritability associated with the withdrawal syndrome from opioids may on the other hand lead 
to violence, with studies finding that some offenders use the drugs purposely to reduce their fear of 
committing a crime (Makkai 2002). Similarly, withdrawal from benzodiazepines is associated with 
severe mood swings, irritability, and personality changes (Marshall & Longnecker 1992; Rall 1992). 
Many benzodiazepines and pharmaceutical opioids are also likely to produce dependency in a 
regular user (Marshall & Longnecker 1992; Rall 1992). 
The majority of research in Australia to date has found that heroin use is the most closely 
associated with criminal behaviour (Makkai, 2002), and no research has specifically addressed the 
links between prescription drugs and crime; however, the diversion of pharmaceutical drugs onto 
the black market may have a direct effect on the criminal behaviour of individuals who use them 
illicitly, in terms of a need to maintain supply where dependence on such a drug exists, as well as 
in psychopharmacological effects of intoxication and/or withdrawal from these drugs. 
Review of relevant Victorian literature
Use of benzodiazepines by Victorian people who inject drugs 
One hundred and fifty injecting drug users in each participating jurisdiction, including Melbourne, 
are surveyed annually via the national Illicit Drug Reporting System (IDRS) (Fry & Bruno 2002; 
Breen et al. 2003a; Shand et al. 2003). The purpose of the IDRS is to serve as a 'strategic 
early warning system, identifying emerging trends of local and national concern in illicit drug 
markets' (Breen et al. 2003a). Following the heroin drought, there was a recorded increase in 
benzodiazepine injection by PWID in the IDRS in Victoria, with the practice reportedly increasing 
from 19% of participants in 1999, to 36% in 2000 and 40% in 2001, as PWID opted for injecting 
mainly temazepam gel capsules (Fry & Miller 2002; Jenkinson, Fry & Miller 2003), although 
injection of other benzodiazepines such as Valium   tablets was also recorded (e.g. Jenkinson, 
Miller & Fry 2004). 
Key informants in the 2001 IDRS (Breen et al. 2002) reported that benzodiazepines were used 
either as a substitute when heroin was unavailable, or to enhance and supplement the effects of 
heroin or other drugs. Of particular concern is the injection of temazepam gel capsules, because 
of resulting vein damage from injecting, as well as the risk of overdose when used in combination 
with heroin (Dobbin 2002; Dobbin et al. 2003). Benzodiazepines were reportedly obtained 
through doctor-shopping, as well as black market street selling. Health harms associated with 
injection of drugs intended for oral use, and crimes associated with diverting the drugs to the black 
market, became widely reported (Dobbin 2002; Dobbin et al. 2003). Subsequent to these findings, 
two events occurred that could have been expected to result in reductions in the use and injection 
of benzodiazepines by PWID. First, the Victorian Department of Human Services (DHS) introduced 
the Temazepam Injection Prevention Initiative in November 2001 (Dobbin 2002) in order to 
reduce injecting of the gel capsules by educating prescribing doctors (Dobbin 2002).
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Second, changes to the prescribing authority for 10mg temazepam capsules on the PBS followed 
in May 2002 (Breen et al. 2003b). A medical practitioner must now receive a PBS authority to 
issue a prescription for these preparations. Prescriptions for the 20mg capsules may still be issued 
privately, however (without PBS authority).
Following these initiatives, the Australian Crime Commission (2003) suggested that as heroin 
re-emerged in quantity in the Australian market, those who supplement their heroin use with 
pharmaceutical drugs would be likely to return to using heroin alone, thus resulting in a reduction 
in the use of pharmaceutical drugs. The 2002 IDRS subsequently reported a return of heroin 
supply, as well as a decrease in price. An increased number of people reported using heroin daily, 
although not to pre-2001 levels, a situation that stabilised in 2003 (Breen et al. 2004; Jenkinson, 
Miller & Fry 2004). PWID continued to use benzodiazepines, and also continued to inject them 
(Breen et al. 2003b; Kinner & Fisher 2002), with 73% of Victorian PWID in 2002 reporting 
benzodiazepine use in the previous six months, and 21% reportedly injecting the drugs (Jenkinson, 
Fry & Miller 2003). Whilst injection decreased to 15% of the PWID in 2003, 80% reported they 
used benzodiazepines (Jenkinson, Miller & Fry 2004). The benzodiazepines most commonly 
reported as having been used in the six months prior to the survey changed after the regulatory 
changes in 2001/02, with temazepam used by 6% (compared with 45% in 2001), diazepam used 
by 62% (compared with 38% in 2001), and oxazepam used by 14% (compared with 9% in 2001). 
In March 2004 Sigma, the pharmaceutical company that manufactures temazepam gel capsules, 
discontinued their production and announced they were destroying all stocks (Dobbin 2004). 
This has completely removed the gel-cap formulation from Australia (Wilce 2004), a development 
which would be expected to impact use of these drugs eventually, depending on the extent of 
stock-piling that may have occurred by suppliers (Fry & Miller 2002).
Use of pharmaceutical opioids by Victorian people who inject drugs
Similar to trends for benzodiazepines, increased pharmaceutical opioids use and injection 
was reported following the heroin drought, with the majority of PWID participants in the 
Melbourne IDRS reporting that they obtained opioids illicitly (Jenkinson, Fry & Miller 2003). 
Further, notwithstanding an increase in heroin availability, levels of illicit use and injection of 
pharmaceutical opioids, such as morphine and buprenorphine, has not returned to pre-drought 
levels. For instance, in 2000, 49% of Victorian PWID in the IDRS reported using any opioid 
other than heroin (for instance, morphine, buprenorphine, methadone, other opioids) (this data 
was provided by Turning Point Alcohol and Drug Centre from an analysis they undertook in  
2004). Use remained stable at 49% in 2001, but increased substantially to 63% in 2002, and in 
2003 remained at 61% (Fry & Miller 2002; Breen et al. 2003a; Jenkinson, Miller & Fry 2004). 
The proportion of participants reportedly injecting any opioid in 2000 was 24%, increasing 
substantially to 36% in 2001 and increased again to 41.5% in 2003 (Fry & Miller 2002; Breen et 
al. 2003a; Jenkinson, Miller & Fry 2004). 
Morphine
The IDRS only commenced collecting specific information about morphine use in 2001, therefore, 
a direct comparison of findings for morphine prior to that year is not possible, but an increase in 
use of the drug was recorded between 2001 (32%) and 2002 (51%), with a reduction again in 
2003 (42%), although not to 2001 levels (Fry & Miller 2002; Breen et al. 2003a; Jenkinson, Miller 
& Fry 2004). Most participants reportedly using morphine also injected it, with the proportion of 
participants doing so in 2001 at 31%, increasing to 47% in 2002, and reducing slightly again in 
2003 to 39% (Fry & Miller, 2002; Breen et al. 2003a; Jenkinson & Fry 2004). Furthermore, police 
key informants in the 2003 IDRS reported that they thought there had been substantial increases in 
morphine use in 2002-2003 (Jenkinson, Miller & Fry 2004).
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The most commonly used brands of morphine in 2003 were reported to be MS Contin  tablets 
(64%) and Kapanol capsules (25%), with prices reportedly ranging from $20 - $50 for a 100mg 
tablet or capsule. The majority of respondents in the 2003 IDRS reported that morphine was easy 
to very easy to obtain (65%), with 73% indicating that availability had been stable over the past 
six months, and most obtained morphine either from friends (62%) or from street dealers (19%) 
(Jenkinson, Miller & Fry 2004).
Pharmacotherapies
Illicit use of opioids prescribed for drug treatment, such as methadone syrup and tablets 
(Physeptone  ), and buprenorphine (Subutex ), was also widespread, although use of the different 
drugs varied significantly between Australian jurisdictions (Kinner & Fischer 2002; Jenkinson, 
Miller & Fry 2004). For instance, whilst 24% of the respondents in the Victorian 2003 IDRS 
reported using licit methadone syrup in the previous six months, 12% of participants reported 
obtaining it illicitly, and two percent reportedly injected it. Rates of methadone syrup injecting 
was low in 2003 (3%), similar to 2002 (3%), and have consistently been much lower than in other 
states such as Tasmania and the Northern Territory (Breen et al. 2004; Jenkinson, Miller & Fry 
2004). Some diversion of methadone syrup has been consistently reported, with a street price of 
approximately $1 for one ml (Jenkinson, Miller & Fry 2004). The use of Physeptone  by Victorian 
IDRS PWID participants has not been widely reported to date, with only one participant each in 
2003 reporting their licit and illicit use (Jenkinson, Miller & Fry 2004).
Illicit use and injecting of buprenorphine in Victoria reflects the rapid acceptance of the drug as 
a treatment protocol since its introduction in 2000, and its subsequent approval for listing on the 
PBS/RPBS in 2001 (Jenkinson, Miller & Fry 2004). Licit buprenorphine was reportedly used in the 
previous six months by 38% of the 2003 IDRS sample, while 32% of the participants reported 
they used it illicitly (Jenkinson, Miller & Fry 2004). Injection of buprenorphine was much more 
prevalent in Victoria than injection of methadone, with 39% of the 2003 IDRS sample reporting 
having used this route of administration in the previous six months, an increase on the 2002 rates 
of 33%. Jenkinson, Miller and Fry (2004) reported the high prevalence of buprenorphine injection 
to be of concern. A number of health harms, similar to those associated with temazepam injection, 
such as vein damage and infection, are associated with the drug’s injection. In addition, diversion 
of the drug to the black market from treatment programs is reportedly widespread, with a dose 
reportedly selling for about $5 (Jenkinson, Miller & Fry 2004).
Other opioids
The use of other opioids has also been of concern, with over one-third (39%) of participants in the 
2003 IDRS reporting they had used them in the previous six months, and 3% reporting they had 
injected them (Jenkinson, Miller & Fry 2004). The main types reportedly used by the PWID were 
Panadeine forte  (75% of other opioids users), Mersyndol forte  (9%), Oxycontin  (5%), Pethidine 
(4%), Doloxon   (4%), and Codeine Phosphate (2%).
Crimes associated with the diversion of prescription drugs
'The extent and intensity around drug diversion and licit sources to illicit use, in particular the 
forgery of prescriptions and thefts from pharmacies, indicates a very strong demand for the drugs' 
(Dobbin 2002: p. 14). The Victorian Department of Human Services (DHS) in 2002 reported 
there was a strong demand for temazepam capsules, which were trafficked for up to $100 per 
pack (Dobbin 2001). The department indicated that pharmacies appeared to have been targeted 
by thieves for capsules, and that pharmacists should be alert to methods of diversion, including 
forged prescriptions, theft of drugs from the counter or behind the counter, substitution with other 
drugs such as over-the-counter liquid-filled gelatine capsules containing psychoactive drugs such 
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as diphenhydramine, 'doctor-shopping' where a patient is acquiring prescriptions from different 
doctors, aggressive behaviour and intimidation wherein people may become aggressive if their 
expectation that the pharmacist will dispense capsules is not met, and inappropriate prescribing 
if a patient appears to be receiving greater quantities, or presents prescriptions more frequently, 
than appears reasonable (Dobbin 2001). The doctor-shoppers hotline that formerly recorded these 
activities has been discontinued, and data from the replacement program 'prescriber-shoppers' is 
yet to become available (Kamien 2004).
KI in the Victorian IDRS study from 2000 to 2003 also suggested that prescribed drugs were 
accessed by PWID through 'doctor-shopping' and black-market street-level selling (Fry & Miller 
2002; Dobbin 2004; Jenkinson, Miller & Fry 2004). They further reported that temazepam 
was being exchanged for heroin by some dealers, and stockpiled, due to a reported fear that 
temazepam may soon be withdrawn from sale (Fry & Miller 2002; Jenkinson, Miller & Fry 2004). 
Thefts of pharmaceutical drugs
Opioid-based products have rarely been the targets of pharmacy burglaries or ram-raids in Victoria, 
due to enhanced security measures (such as floor safes) utilised for the storage of such drugs 
(Australian Bureau of Criminal Intelligence 2002). Individuals with legal opioid prescriptions, 
however, have been assaulted or threatened for their prescribed opioids, such as morphine, 
methadone, or buprenorphine; the drugs may then be used by the assailant, or else diverted to the 
black market and trafficked or swapped for heroin (Jenkinson, Miller & Fry 2004). 
Dobbin (2001) reported that many pharmacists have experienced pressure and intimidation for 
temazepam capsules, but the more serious consequences of the traffic of the capsules has been 
an escalation in the number of pharmacies experiencing robberies and break-ins, sometimes 
on multiple occasions. Aggressive and threatening behaviour has been widely reported by 
pharmacists and doctors and their staff, with temazepam capsules the main target of burglaries, 
ram-raids, stand-over attempts, and thefts of drugs and/or prescriptions and prescription pads. 
The Victorian DHS (2002) reported that 537 of Victoria’s 1,200 pharmacies (45%) were burgled 
between January 1 and August 30, 2001 (see also ABCI 2002). In a number of pharmacies plate 
glass windows or doors were reportedly smashed, and quantities of temazepam capsules stolen, 
whilst temazepam tablets were left on the same shelf. In many cases, temazepam capsules were 
the only drugs stolen. 
Guild Insurance Limited (2003) reported a large increase in the number of pharmacy break-ins 
where the thieves stole benzodiazepines, particularly temazepam capsules. Between 1998/99 and 
2001/02 the financial loss to Guild Insurance Limited because of malicious damage, burglaries, 
armed hold-ups, and thefts more than quadrupled in Victoria, from $500,769 to $2,410,770, and 
Victorian claims accounted for more than one-half of all claims received Australia-wide in 2001/02 
(from 26.7% of the total in 1999/00). (Guild Insurance Limited 2003). 
Forged prescriptions
Forgery or alteration of prescriptions have been used to obtain benzodiazepines, particularly 
temazepam capsules (Dobbin 1998; Dobbin et al. 2003). Dobbin et al. (2003) found that in the 
six months to end of May 2001 there were 185 forged prescriptions reported. Benzodiazepines 
accounted for 135 (74%) of these items, and temazepam accounted for 85% of all 
benzodiazepines. There were no alterations or forgeries for tablets, and all forgeries nominating 
a dose form were for capsules, indicating an overwhelming preference for capsules. Dobbin 
(2001) reported how, in one forgery case, a brother and sister presented more than 300 forged 
prescriptions in the 3 months to the end of February 2001 at 77 different pharmacies using 30 
different aliases. Pharmacies involved ranged across Melbourne. Forgeries were written on stolen 
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prescription stationery, some of which were stolen during burglaries. A possible additional 385 
prescriptions remain undetected. More recently, a number of computer-generated forgeries have 
been detected for Normison   20mg capsules x 50 (Dobbin 2001).
Crimes committed by people who inject drugs
Jenkinson, Miller & Fry (2004) reported that 59% (n = 89) of Victorian PWID respondents in the 
2003 IDRS reported engaging in some kind of criminal behaviour, such as property crime, dealing/
trafficking of drugs, fraud, and violent crime, in the preceding month. The overall findings were 
similar to the previous two years, which had seen a substantial increase from the figures in 2000, 
mainly due to reported increases in the frequency of committing property crimes. See Table 1.
Table . Reported criminal activity among injecting drug users in the month prior to the IDRS 
Survey, Victoria 2000, 2001, 2002 and 2003.
a Source: Fry & Miller (2002)
b Source: Jenkinson, Fry & Miller (2004)
These figures are typical of the findings available from studies conducted to date. While linking 
illicit drugs and crime in general the data do not establish relationships between specific drugs and 
particular types of crime. This is especially true regarding whether the use of specific prescription 
drugs is predictive of any types of crime. 
Prescription drugs and criminal behaviour
To date, besides diversion strategies for acquiring and trafficking, there have been no direct studies 
of the links between pharmaceutical misuse and crime carried out in Victoria, or in Australia 
as a whole. However, it is clear that misuse of pharmaceutical drugs by PWID in Victoria and 
other Australian jurisdictions is an emerging issue. These PWID have also reported significant 
involvement in criminal activity in the past. In addition, amongst incarcerated individuals, drug 
users tend to commit more property crimes than non-users (Makkai 2002; Makkai & Payne 
2003). Furthermore, there is evidence that there is widespread use of prescription drugs among 
the more serious youth offenders in Australia (SACACWG 2003). There is a complex relationship 
between drug use and crime, with more serious and rewarding crimes (financially speaking) 
tending to be committed by the heaviest users (SACACWG 2003). Furthermore, the effects of 
some benzodiazepines have been associated with bizarre uninhibited behaviour, personality 
changes, amnesia, criminal activity, and a sense of invulnerability and invincibility (e.g. Australian 
Crime Commission 2003; Bonn & Bonn 1998; Rall 1992). They could, therefore, be expected to 
precipitate criminal behaviours in some users.
Percentage of Respondents
Type of crime 000a 00b 00b 00b
Property crime 20 29 39 35
Dealing 34 37 41 40
Fraud 12 15 14 7
Violent crime 5 15 9 10
Any Crime 47 60 63 59
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Study rationale
The National Drug Law Enforcement Research Fund (NDLERF) sought tenders in 2002 for research 
to enhance law enforcement sector understanding of the structure and functioning of illicit drug 
markets in Australia. The request for tender for which the current study was developed (RFT 04/02) 
called for a focus on the impact of benzodiazepine and pharmaceutical opioid misuse on crime 
in Victoria, Tasmania and the Northern Territory. Available evidence at that time from sources such 
as the Illicit Drug Reporting System (IDRS) suggested that existing illicit prescription drug markets 
were consolidating in some major cities (e.g. Hobart and Darwin) and emerging in other cities (e.g. 
Melbourne) facilitated at least in part by the reduction in heroin supply which peaked between late 
2000 - early 2001 (Topp et al. 2002). In fulfilment of its aim of performing a monitoring and early 
warning function, the IDRS was able to identify key issues with respect to benzodiazepine and 
pharmaceutical opioid diversion and misuse that require further investigation.
One important area of investigation that is indicated relates to the possible law enforcement 
implications of benzodiazepine and pharmaceutical opioid diversion and illicit use. There 
have been few Australian studies that have sought to investigate the nexus between prescribed 
pharmaceutical drug misuse and crime. While the precise nature of this relationship remains to be 
clarified, some indications exist from previous research into the illicit drugs-crime nexus that has 
suggested the following: people who misuse illicit drugs are more likely to have an arrest record 
or to report property crime than those who do not (Blumstein et al. 1986); frequency of property 
offending is positively correlated with extent of illicit drug use (Blumstein et al. 1986; Salmelainen 
1995; Stevenson & Forsythe 1998); and violence and violent crime is typically employed by 
illicit drug manufacturers and distributors as a tool to support attempts to manipulate the market 
(Kleiman 1992). At this point the extent to which the broader illicit drugs and crime literature may 
assist in understanding prescription drugs and crime links is undetermined.
A second important area of investigation indicated relates to the health implications of 
benzodiazepine and pharmaceutical opioid diversion and use through injection. A large 
international literature exists on the public health implications of prescription pharmaceutical 
diversion and injecting, with reports from a number of countries concerning associations between 
misuse, significant health harms and dependence (Darke & Ross 2000). To date the literature 
has focused largely on health issues associated with benzodiazepine and pharmaceutical opioid 
diversion and use in illicit drug market settings. There is much less available data concerning the 
dimensions and characteristics of such illicit markets (for licit substances), or how law enforcement 
and public health concerns may intersect in these settings.
Evidence shows that illicit drug markets and patterns of illicit drug use may vary markedly 
between and within jurisdictions (Darke, Hall & Topp 2001; Fitzgerald, Hope & Dare 1999). It 
is reasonable, therefore, to predict that patterns of prescription pharmaceutical diversion and 
injection may also differ across settings. This needs to be better understood. A necessary step in 
devising appropriate responses around issues such as benzodiazepine and pharmaceutical opioid 
diversion and injection is to gather reliable local evidence regarding the nature and extent of the 
problem. Stakeholder perspectives are also of core importance when the responses may necessitate 
incorporation of regulatory interventions. In this regard the current lack of understanding of a 
number of key issues of relevance to benzodiazepine and pharmaceutical opioid diversion and 
crime links reduces the capacity for developing informed interventions. 
A comprehensive literature review was conducted in order to examine the following key issues of 
relevance to benzodiazepine and pharmaceutical opioid use and crime:
 Drugs and crime nexus – literature on illicit drug markets and interpretive utility for the case of 
illicit markets for prescribed pharmaceuticals.
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 Drug trends in Australia – evidence, dimensions, monitoring statistics (e.g. use trends, 
prescribing trends, crime/police activity, health, drug market characteristics and 
pharmaceutical use).
 Benzodiazepine and pharmaceutical opioids misuse and crime – types of crime, evidence, 
reasons, extent, etc. (e.g. robbery, prescription fraud, on-selling prescriptions, crimes 
committed under the influence).
 Supply reduction and law enforcement impact – evidence of impact for users and for law 
enforcement and other frontline workers.
 Appropriate interventions – responding to law enforcement and health impacts of the illicit 
benzodiazepine and pharmaceutical opioid markets and misuse.
One of the main aims of the Illicit Drug Reporting System has been to highlight issues that require 
further investigation through follow up specialist research in order to inform law enforcement and 
health sector policy and program responses to illicit drug use. Thus, the aim of this current research 
was to fulfil this second aim of the IDRS, by following up the identified emerging trend in illicit 
prescription drug use, and how that may impact on both criminal activity and health outcomes, by 
examining the nexus between illicit prescription drug use, illicit prescription drug markets, crime 
and health harms. Clearly, there has been a deficit in such Australian research to date. 
The increase in pharmaceutical-related crime has the potential to impact on the law enforcement 
sector through increased levels of theft from pharmacies and other suppliers, other methods of 
diversion of the drugs to the black market, crime committed whilst under the influence of the drugs 
or whilst withdrawing from them, and also the disinhibition ('Rambo effect') that is associated with 
benzodiazepine intoxication that may lead to violent behaviour and other types of crime. 
Study purpose and aims
The purpose of this study was to contribute to law enforcement sector understanding of the 
relationship between benzodiazepine and pharmaceutical opioid misuse and crime in three select 
Australian jurisdictions (Victoria, Tasmania, Northern Territory) where there is evidence of illicit 
prescription pharmaceutical markets. This report focuses on the Victorian aspect of the study, and 
the broader findings are presented in the National Overview Report (Fry et al. in press). While 
the primary focus of the study remains on law enforcement interests in relation to licit and illicit 
benzodiazepine and pharmaceutical opioid markets, these are discussed in relation to the broader 
public health implications of supply reduction efforts in a harm minimisation framework.
The primary aims of the study therefore were to:
1. Gain a greater understanding of illicit benzodiazepine and pharmaceutical opioid market-
place dimensions and characteristics.
2. Investigate the hypothesised relationship between benzodiazepine and pharmaceutical opioid 
misuse and crime.
3. Explore the implications for police and other frontline workers (e.g. accident and emergency 
staff, ambulance officers and health/youth workers) of emergent illicit markets for 
benzodiazepine and pharmaceutical opioids.
4. Consider appropriate interventions to address both the law enforcement and health impacts of 
benzodiazepine and pharmaceutical opioid misuse.
Chapter one: Introduction
A secondary, and broader, aim of the research was to examine the nexus between prescribed 
pharmaceutical misuse, illicit prescription pharmaceutical markets, crime and health harms. 
The primary aims of the research were forwarded in 25 research questions (Appendix A) and were 
further analysed by the research team, resulting in a final total of 33 questions pertaining to the 
key themes of links to crime, implications for frontline workers, diversion, market dimensions 
and characteristics and interventions. The prioritisation exercise with Victorian law enforcement 
personnel (n=13) revealed that this group expressed a wide interest in the questions and issues 
presented to them around benzodiazepines and pharmaceutical opioids, and how these relate to 
the key themes of links to crime, implications for frontline workers, diversion, market dimensions 
and characteristics and interventions. See Appendix B.
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Chapter two: Methodology
Stage one: Key informant interviews
The purpose of Stage one of the study was to serve a formative function for the main body of 
the research through the combined methods of literature review and KI interviews. A total of 13 
interviews were conducted with law enforcement personnel (n = 12 law enforcement personnel 
and n = 1 civilian Melbourne police employee) in July and August 2003. Stage one key informant 
interviews focused on participant experiences and perceptions of illicit benzodiazepine and 
prescribed opioid markets as well as the nature of operations, policing practices and nature of 
contacts. The KI were interviewed by phone or in person at their place of work, and asked a series 
of open-ended questions about local markets for benzodiazepines and pharmaceutical opioids, 
and methods of diversion of the drugs. They also discussed how the misuse of these drugs impacts 
on criminal activities and policing practices. Each interview was around an hour in length. KI were 
sent a copy of the interview schedule, project information, and a consent form to enable them 
to consider their suitability for participation. The interview schedule included questions about 
patterns of drug use, availability of drugs, links between various drugs and criminal behaviour 
and policing activity, as well as perspectives on controlling drugs, supply reduction, and harm 
minimisation strategies.
Nine informants stated their source of information was primarily from contact with either users 
or suppliers/manufacturers or both. Three informants sourced information from discussion with 
peers or the literature and one from the analysis of seized drugs. Eight informants were involved in 
investigation, two were involved in drug strategy, two were involved in the policy and operational 
management areas, and one in covert surveillance operations. The majority (11) of informants 
nominated heroin as the drug with which they had most contact. In addition to heroin, seven 
informants reported that they had frequent contact with cannabis, seven with methamphetamines 
and five commonly had contact with ecstasy. Other drugs mentioned were benzodiazepines (n = 
4) and ketamine (n = 2).
Stage two: Survey of people who inject drugs
In recognition of the importance of people who inject drugs (PWID) as a source of sentinel data on 
the operation of drug markets and associated drug-related behaviours, a face-to-face survey of 102 
PWID was conducted in Melbourne. The survey included core questions concerning: demographic 
details; drug use history and current benzodiazepine and pharmaceutical opioid patterns, as 
well as experiences while under the influence of drugs, sources of pharmaceuticals; market 
characteristics, recent involvement in criminal activity, health and other impacts of pharmaceutical 
opioid and benzodiazepine use; and perceptions of the potential impact of substantially changed 
availability of such products on the illicit market.
Participants were interviewed at needle and syringe program (NSP) premises in five Melbourne 
localities: Western Region AIDS & Hepatitis Prevention (WRAP), Footscray (n = 20); Youth Projects, 
Newmarket (n = 22); St. Kilda Crisis Centre, St. Kilda (n = 22); AIDS Prevention and Support Unit 
(APSU), Dandenong (n = 16); and Southern Hepatitis/HIV/AIDS Resource and Prevention Service 
(SHARPS), Frankston (n = 22). The participants were recruited via the NSP and word of mouth. To 
be eligible for the study, participants were required to have been resident for at least 12 months in 
the Melbourne metropolitan area and not have spent a substantial period of time out of the area 
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(such as in prison or moved away), as well as be a regular illicit user of either benzodiazepines 
and/or pharmaceutical opioids. A criterion of at least 30% of the sample injecting these drugs was 
imposed, but this was met naturally, with the majority of participants reporting the practice. 
Prior to conducting the interview, participants were fully informed of the contents of the 
questionnaire verbally and in writing, and their informed consent was obtained. In the interview, 
they were asked socio-demographic questions about themselves, about drug use, price, purity and 
availability of drugs, methods of obtaining drugs, and modes of diversion of prescription drugs into 
the illicit market. The participants were also asked about law enforcement activity, and the ways in 
which drugs may influence their behaviour, including involvement in criminal activity and contact 
with police and the criminal justice system. They were also asked about the impacts of drugs on 
their health.
The surveys averaged one hour in length, ranging from 40 minutes to two hours, and participants 
were reimbursed $30 each for their time and travel expenses. Ethics approval for this study was 
obtained from the Victorian Department of Human Services (DHS), Human Research Ethics 
Committee, and the Research Committee of the Victorian Police. Participants were treated in 
accordance with the National Health and Medical Research Council (NH&MRC) ethical guidelines 
for human research at all times. The interviewers assessed 48% of participants as not intoxicated 
during the interviews, with 41% assessed as intoxicated but coherent, and eight percent assessed 
as intoxicated and incoherent.
Stage three: Secondary indicator data – Victoria
A diverse range of secondary indicator data was sourced from Victorian law enforcement and 
health sectors, to provide an additional perspective on the issues under focus, and assist the study 
team in interpreting the relationships between crime and prescription pharmaceutical misuse. The 
sources included the following.
Use trends
Every three years the National Drug Strategy Household Survey (NDSHS) collects an array of 
information on drug use by Australians aged 14 years or more. Data on lifetime and recent 
use (past 12 months) of selected drugs from the last three National Drug Strategy Household 
Surveys (AIHW 1995, 1998, 2001) are displayed in this report. 
Prescribing trends
Data for prescriptions issued under the Pharmaceutical Benefits Scheme (PBS/RPBS) for all 
benzodiazepines in Victoria and Australia are collated annually by the Drug Utilisation Sub-
committee (DUSC) of the Pharmaceutical Benefits Branch. Relevant data for benzodiazepines 
prescribing in Victoria and Australia for the period 2000 - 2002 are presented here (Health 
Access and Financing Division, Australian Government Department of Health and Ageing, 
2004)
The Drug Use Monitoring System (DRUMS), part of the Treaties and Monitoring Team, 
Office of Chemical Safety, Therapeutic Goods Administration, records the total number 
of prescriptions for all pharmaceutical opioids, including morphine tablets and capsules, 
methadone, and buprenorphine issued under the PBS/RPBS. The data presented here refer 
to the period to 2002, extending back up to five years, depending on the drug and when it 
became available in Australia (DRUMS 2003).
Annual National Pharmacotherapy statistics to June 30, 2002 (Australian Government 
Department of Health and Ageing, 2003), provided information about prescribing of 
methadone and buprenorphine by public and private prescribers in that year.
•
•
•
•
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Data relating to forgery or alteration of prescriptions for benzodiazepines, particularly 
temazepam capsules, have been sourced from Dobbin (2001).
Crime/police activity
Each year Guild Insurance Limited collects data about pharmacy-related crimes, such as 
break-ins, burglaries, and thefts. The most recent data available relating to incidents and 
financial loss are displayed in this report, and report the four years to the end of June 2002 
(Guild Insurance Limited 2003). 
Law enforcement data were extracted from the Law Enforcement Assessment Program (LEAP) 
database by the Victorian Police Statistical Services Division and were examined for trends 
in offences reported against Victorian pharmacies/chemists between 1998/99 and 2002/03, 
and for trends in prescription drug-related offences including possession, trafficking, driving-
related offences and any other offences with prescription drug mentions.
Victorian Department of Health Services provide data for arrests of people for drug-related 
offences (possession and trafficking), which are analysed by Turning Point Alcohol and Drug 
Centre for publication in the Victorian Drug Statistics Handbook (DHS, 2002). The most recent 
data available at the time of publication of this report, 2000-01, are presented here.
Victorian Department of Justice (VDJ) collates Victorian Magistrate’s Court data annually on 
the number of drug charges (consumer and provider) finalised by offence category, and these 
findings are presented in the Victorian Drug Statistics Handbook (Victorian Department of 
Human Services, 2002). The most recent data at the time of publication of this report, 1998/99 
to 2000/01, are presented here. 
The Australian Customs Service collects data for seizures of illegal importation of drugs at 
Australian ports. For the majority of benzodiazepine and pharmaceutical drug seizures, 
specific information regarding the generic forms or brand names are not currently recorded 
in the Australian Customs Service drug statistics database. Detections of the remaining drug 
categories are recorded in the generic categories of 'Other benzodiazepines' and 'Prescribed 
drugs'. The data for 1999-2003 are presented here.
The Chemical Drug Intelligence (CDI) Team at the Victoria Police Forensic Services Centre 
collates data on drugs seized by Victorian police annually as a result of a drug possession or 
drug trafficking charge. They supplied data for benzodiazepines and pharmaceutical opioids 
seized by police between 1998 and March 2004 (i.e. data where actual amount seized is 
specified).
Health 
A census of specialist alcohol and drug treatment agencies was conducted in May 2001, to 
examine the main drug problems cited by clients seeking treatment. The findings for Victoria, 
2001, are presented here (Victorian Department of Human Services 2002). 
The Australian Needle and Syringe Program (ANSP) collates survey data on the prevalence of 
the last drug injected by Needle Syringe Program (NSP) clients across Australia. The findings 
for Victoria and Australia, for the two years 2000 and 2002, are presented here (Buddle, Zhou 
& MacDonald 2003).
Direct Line provides 24-hour counselling information and referral for Victorians for any 
drug-related issue. Findings for responses through 2000/01 where benzodiazepines were 
mentioned are presented here (Victorian Department of Human Services 2002).
The Victorian Emergency Minimum Dataset (VEMD) provided information on tissue and 
vascular harm cases presenting to emergency departments in Victoria, resulting from injection 
of temazepam from 1997 to the first quarter of 2001, and this is presented here (cited in 
Dobbin 2001.
•
•
•
•
•
•
•
•
•
•
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A database of Melbourne Metropolitan Ambulance Service (MAS) attendance at drug-related 
overdose incidents is maintained by Turning Point Alcohol and Drug Centre, and includes the 
monthly totals of non-fatal benzodiazepines overdoses, and non-fatal morphine overdoses, for 
May 2001 - April 2002, and May 2002 - June 2003 (excludes May - July 2001 and October 
2002 - February 2003). The findings are presented here.
The Victorian Department of Human Services maintains a database of admissions from private 
and public hospitals (the Victorian Admitted Episode Dataset, VAED). Turning Point Alcohol 
and Drug Centre conducts analyses on these data. A summary of the findings for opioid and 
benzodiazepines-related admissions for 2001/2002 is presented here.
Cases of heroin-related deaths are identified by the Victorian Institute of Forensic Medicine 
(VIFM) and the State Coroner’s Office in Victoria, and investigated using tissue samples and 
blood. Forensic toxicology screening for a range of drugs identified other drugs contributing 
or incidental to the deaths. Data for deaths including mentions of benzodiazepines, morphine 
and other opioids are presented here for the period 1997 - 2001 (Wallington, Gerostamoulos 
& Drummer 2002).
Australian Bureau of Statistics (ABS) collects data annually from Medical Certificate Cause 
of Death submitted to each State and Territory’s Registrar of Births, Deaths and Marriages, 
and from the National Coroner’s Information System. Accidental opioid overdose deaths in 
Victoria (accidental deaths by opioids, including heroin, morphine, pethidine, methadone and 
codeine) are presented in this report (Degenhardt & Barker 2003).
Drug market characteristics and pharmaceutical use
The Illicit Drug Reporting System (IDRS) is a national project designed to monitor emerging 
trends related to the use of opioids, methamphetamines, cocaine, cannabis, and other drugs 
(Jenkinson, Miller & Fry 2004). Each state undertakes surveys with a sentinel group of PWID, 
KI interviews with representatives of health and law enforcement organisations, and analysis 
of relevant secondary data. IDRS data for Victoria and Australia for 2001-2003 pertaining 
to opioid and benzodiazepine use are reviewed (Breen et al. 2004; Jenkinson, Miller & Fry 
2004). 
Stage four: Survey of people who inject drugs
The purpose of Stage four of the study was to facilitate interpretation of the data collected in 
the preceding study stages, and performs an added monitoring function through replication of 
core components of the Stage two user survey. A further series of face-to-face interviews were 
conducted with 50 regular pharmaceutical opioid or benzodiazepine injectors. The methodology 
for the Stage four IDU interviews was identical to Stage two. There were 50 IDU participants 
involved in the Stage four survey, and they were interviewed at the same locations, with the 
addition of Turning Point Alcohol and Drug Centre, Fitzroy. The number of participants at each 
site were: Western Region AIDS & Hepatitis Prevention (WRAP), Footscray (n = 9); Youth Projects, 
Newmarket (n = 14); St. Kilda Crisis Centre, St. Kilda (n = 9); AIDS Prevention and Support Unit 
(APSU), Dandenong (n = 6); Southern Hepatitis/HIV/AIDS Resource and Prevention Service 
(SHARPS), Frankston (n = 10); and Turning Point Alcohol and Drug Centre, Fitzroy (n = 2). Eight 
(16%) Stage four participants had participated in Stage two. The Stage four questionnaire took on 
average 46 minutes to administer, with a range of 25 to 75 minutes. The majority of participants 
were assessed by the interviewer to be intoxicated, but still coherent (n = 36, 72%); however, 
almost a quarter was considered intoxicated and incoherent (n = 12, 24%), and only two (four 
percent) were thought not to be intoxicated.
•
•
•
•
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Stage four: In-depth key informant interviews
In-depth qualitative KI interviews were also conducted with 28 experts and professionals across 
health and law enforcement sectors in order to examine the issues arising from the earlier research 
stages in greater depth. The methodology for the Stage four KI interviews was identical to Stage 
two. The KI pool consisted of 18 health workers, comprising NSP workers (n = 4), Community 
Education workers (n = 1), Drug Treatment workers (n = 2), User Group Representatives (n = 
1), Outreach Workers (n = 2), Youth Outreach Workers (n = 3), Researchers (n = 1), Medical 
Practitioners (n = 3), Pharmacists (n = 1), and there were 10 Law Enforcement personnel. 
Participants were sent a copy of the questionnaire prior to interview (unless otherwise requested) 
to confirm eligibility for the study. Interviews were recorded and transcribed with interviewee 
consent. Interviews took an average of one hour to complete. As with most KI, experience was 
with benzodiazepines, buprenorphine and methadone, and responses to questions regarding 
pharmaceutical opioids usually related to the latter two drugs, unless specified.
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Stage one: Key informant interviews
KI were asked to provide information on their perceptions of which drugs were most commonly 
associated with crime, and which crimes were most typically associated with different drug 
types. They were also asked to provide information on the impacts of pharmaceutical opioids 
and benzodiazepine use on policing, and the impact of the drugs on licit and illicit drug markets. 
They were asked whether there had been any measures to reduce supply and availability of 
pharmaceutical drugs, how prescription drugs impact on other drug use, how law enforcement 
could impact on prescription drug use, appropriate harm minimisation approaches to prescription 
drug misuse, and any implications of effective supply reduction on use of these drugs. The 
responses were separated into themes, and the number of responses to each theme in each 
category was calculated.
Drugs most commonly associated with crime
KI were asked to state which drugs they thought were most commonly associated with crime. Table 
2 shows that heroin, methamphetamines and cannabis were the most commonly nominated drugs.
Table 2. Drugs nominated by Melbourne law enforcement KI as most likely to be associated with 
crime (N = 13).
Note: Number of responses exceeds total number of KI as multiple responses allowed.
Thirteen KI identified heroin as a drug associated with crime and 10 believed that it was the 
primary drug associated with crime (i.e. first drug mentioned). Crimes typically associated with 
heroin were home burglaries, robberies and trafficking. The impacts on policing were identified as 
a drain on manpower, increased demand for police response, and increased demand on police to 
decrease the presence of PWID from public view.
Eleven KI identified methamphetamine as a drug associated with crime and one KI identified 
methamphetamine as the primary drug associated with crime (i.e. first drug mentioned). Most 
informants did not differentiate between methamphetamine type, choosing to refer to them as a 
collective; however, five KI specifically mentioned 'ice' and its involvement in violent behaviour. 
Drug/s
Identified by number 
of KI 
Heroin 13
Methamphetamine 11
Methamphetamine (Ice) 5
Cannabis 7
Benzodiazepines 6
Amphetamine-type analogues 2
Pharmaceutical Opioids 1
Alcohol 2
Inhalants 1
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All informants in this group identified the typical crime as robbery. The major impact on policing 
as identified by these KI was an increase in abusive behaviour. Two KI identified typical crimes 
associated with methamphetamine powder (speed) and crystalline methamphetamine as 'chaotic 
crime', violence and armed robbery (one KI) and trafficking and culpable driving (second KI). The 
impact on policing was identified as more violence and increased utilisation of specialist squads 
(one respondent). 
Seven KI provided information on cannabis and crime. Typical crimes were shoplifting and 
burglaries (identified by all seven respondents). Four KI observed that the impact on policing was 
as a drain on resources. Two felt that it had little impact on policing.
Two KI discussed amphetamine-type analogues and crime. The crimes generally associated with 
these drugs were use, possession and supply. One KI reported that the impact on policing was 
manpower and productivity and the other reported little impact at all.
Two KI identified alcohol as being linked with crime, citing it as the most prevalent. Crimes 
included family violence and drink driving. The impact on policing was identified as 'responses 
required for assaults, policing required around licensed venues, and breathalysing'.
Two KI identified benzodiazepines only as a replacement for heroin. Six KI identified 
benzodiazepines as being linked to crime, identifying culpable driving and drink spiking as the 
typical crimes, as well as burglaries, pharmacy break-ins, forged prescriptions and drug diversion. 
The impact for policing was identified as being similar to heroin for one KI, but minimal by most. 
Only one KI identified pharmaceutical opioids as being linked with crime, although no type or 
brand was stipulated. Typical crimes were stated as being the same for benzodiazepines and 
heroin, i.e. home burglaries and robberies. While the impact on policing was reported as being 
minimal by most KI, two KI reported an increased demand for police response. See Table 3.
Pharmaceutical opioids
Diversion of pharmaceutical opioids to the illicit market
Table 3.  KI information regarding diversion of pharmaceutical opioids onto the black market (N = 
13).
Note: Number of responses exceeds total number of KI as multiple responses allowed. 
One KI reported that in 2001/02, Victoria Police Crime Statistics showed that of the approximately 
1,200 pharmacies in Melbourne, roughly 720 had been burgled/robbed. While some robberies 
were reportedly pseudoephedrine-related, many were related to other drugs, particularly 
benzodiazepines and opioids.
Diversion method
Identified by number 
of KI
On-selling by user 6
Burglaries/stolen from pharmacies 4
Doctor-shopping 4
Prescription forgery 5
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Impact of illicit use of pharmaceutical opioids on policing
Nine KI did not identify any policing issues regarding the use of pharmaceutical opioids. It was 
reported that most use is not illegal, and, if it is, it’s very difficult to prove. One KI stated the issues 
were the same as for benzodiazepines use: unable to control the supply; drug driving; overdose; 
and black market increase in other drugs. 
Pharmaceutical opioid intoxication and policing
Regarding policing issues relating to intoxication by pharmaceutical opioids, one KI stated they are 
the same as with heroin use, i.e. concern for the welfare of the user. Another maintained that there 
was no difference from benzodiazepine use, i.e. drug driving and care of children, and another 
KI stated that there were management issues when an intoxicated person was in custody which 
required a nurse to be in attendance.
Impact of licit and illicit drug markets on pharmaceutical opioid misuse 
Nine KI stated that pharmaceutical opioid use was reliant on heroin trends. When there is less/
more heroin, the use of pharmaceutical opioids shifts. No specific types/brands of pharmaceutical 
opioids were mentioned.
Measures to reduce supply and availability of pharmaceutical opioids 
Eleven KI maintained there had been no measures to reduce supply, and one KI did not know. 
Two KI identified that the 'diversion desk' of the major drug investigation division is talking to 
pharmacists and the HIC regarding supply reduction.
Pharmaceutical opioid availability and other drug use 
Nine KI stated that pharmaceutical opioid use was reliant on heroin trends. When there is less/
more heroin the use of pharmaceutical opioids shifts. No specific types/brands of pharmaceutical 
opioids were mentioned.
How law enforcement could impact on pharmaceutical opioid misuse 
Four KI made suggestions. Two argued that if police 'cracked down' users would be less likely 
to use and possess. Another KI argued for supply reduction by increasing awareness among 
the police, performing safety audits on pharmacies to reduce likelihood of break-ins, and more 
effective policing. One KI proposed that if doctors who over-prescribed could be identified via the 
HIC or other avenues, some supply could be reduced.
Appropriate harm minimization approaches to pharmaceutical opioid misuse 
Only two KI suggested measures. One was to use discretion when revealing users in possession, 
i.e. overlook the possession. The second suggested education of users, supply reduction, diversion 
programs and referral into treatment services. 
Implications of effective supply reduction of pharmaceutical opioids  
Three KI made suggestions. Two stated that an alternative would be found, and one specifically 
stated that there would be an increase in heroin and amphetamine use. One KI suggested a 
reduction in crime would result. 
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Benzodiazepines
Diversion of benzodiazepines to the illicit drug market  
Table 4. KI information regarding diversion of benzodiazepines onto the black market (N = 13).
Note: Number of responses exceeds total number of KI as multiple responses allowed.
Impact of illicit use of benzodiazepines on policing  
Seven KI did not identify any policing issues around the use of benzodiazepines. One KI identified 
benzodiazepine use only as a substitute for heroin; the implication therefore was that 'dependence 
on heroin continues'. One further KI maintained that their use did impact on policing, as the 
supply cannot be controlled, and drug driving, overdose, and the black market increases when 
other drug types are scarce. Two KI believed benzodiazepine use had little effect on policing. One 
KI mentioned Rohypnol as a concern for 'drink spiking'.
Pharmaceutical benzodiazepine intoxication and policing  
Regarding policing issues relating to intoxication by benzodiazepines, one KI identified concern 
for drug driving and care of young children; another cited the welfare of the user as a concern. 
Impact of licit and illicit drug markets on benzodiazepine misuse
Ten KI stated that benzodiazepine use was reliant on heroin trends, such that when there is less 
heroin use benzodiazepine use increases. One KI maintained there was no association between 
drug availability and benzodiazepine use.
Measures to reduce supply and availability of benzodiazepines
Eight KI identified police initiatives that had been implemented, mainly awareness campaigns. 
One KI stated that there were no reduction measures, as police had not targeted this area. Another 
KI stated the change in Temazepam availability on PBS had reduced supply and availability. 
Two KI reported that there had been an expansion in the drug diversion department of the Major 
Drug Investigation Division (MDID), which will be placing greater emphasis on benzodiazepine 
diversion in partnership with the HIC. 
Diversion method
Identified by number 
of KI
On-selling by user 10
Doctor-shopping 10
Prescription forgery 8
Burglaries/stolen from pharmacies 7
Diverted from factories 2
From a family member 1
Out of date meds 2
Doctor selling directly 1
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How law enforcement could impact on benzodiazepines misuse 
Four KI cited supply reduction as a means to impact on misuse. Other KI identified legislative 
changes, raising awareness or police crackdowns as potentially effective measures. It was also 
suggested that greater vigilance by police surrounding benzodiazepines might eventuate in raised 
awareness of the problem at both the political and social levels.
Appropriate harm minimization approaches to benzodiazepine misuse
Five KI suggested supply reduction as an appropriate harm minimisation measure. One suggested 
creating a 'benzo drought'. One KI recommended education for drug users and using drug 
diversion programs as an alternative to arrests. One KI recommended referral to treatment. 
Implications of effective supply reduction of benzodiazepines 
Five KI thought there would be decreased use, two KI suggested an alternative would be found, 
one indicated that heroin and amphetamine use would increase and one suggested that crime 
would be reduced. One KI reported that reducing the supply of one drug results in another 
becoming more prevalent and that police just 'plug the holes as they occur'.
Summary
Heroin was identified as the major concern for Melbourne policing by this group of law 
enforcement officers. It was reported as the primary drug associated with crime in Victoria, and it is 
considered to be responsible for substantial demands on police resources, and manpower. Typical 
associated crimes included home burglaries, robberies, trafficking and shopstealing according to 
KI.
Methamphetamines were seen as the second most problematic substance for law enforcement 
in Melbourne. In addition to the problems associated with heroin, methamphetamines were also 
considered to increase violence experienced by police and the wider community, which according 
to KI sometimes requires the deployment of substantial police resources.
Benzodiazepines and pharmaceutical opioids (to a much lesser extent) were seen as being issues 
for police primarily in the context of acting as replacements for heroin when it was unavailable. 
Whilst it was considered that there was not a large amount of crime associated with either 
category of drug, KI identified a number of crimes, particularly related to the procurement of these 
drugs, including burglaries, pharmacy break-ins, forged prescriptions, and drug diversion. It was 
reported by KI that 2001/02 Victoria Police Crime Statistics showed that, of the approximately 
1,200 pharmacies in Melbourne, about 720 had been burgled/robbed.
Major methods of diversion included on-selling by users, doctor-shopping, and prescription forgery 
and pharmacy burglary/theft. It was reported that the drug diversion desk of the MDID within 
Victoria Police was implementing a notification scheme in partnership with the HIC. Few KI were 
aware of any recent legislative changes regarding benzodiazepines and pharmaceutical opioids.
No KI identified substantial policing issues regarding the use of benzodiazepines and 
pharmaceutical opioids. Most believed that awareness around the use of benzodiazepines and 
pharmaceutical opioids could be improved. The most important issues for policing identified by 
police KI were: knowledge about the localities/settings targeted by people committing crimes 
associated with benzodiazepines and pharmaceutical opioids; knowledge about the types of 
benzodiazepines/pharmaceutical opioids targeted by the illicit market; knowledge about the 
dealing and supply patterns of these drug types; and ways in which these can be impacted on. 
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Overall, most KI saw the use of benzodiazepines and pharmaceutical opioids as being of interest 
because of its illicit nature, but overall a proportionally small issue in comparison to the use of 
heroin, methamphetamines and cannabis, and their very strong relationships with crime.
The original 25 research questions of interest were further analysed by the research team, resulting 
in a final total of 33 questions pertaining to the key themes of links to crime, implications for 
frontline workers, diversion, market dimensions and characteristics, and interventions. The KI 
were asked to rank the research questions in order of importance, and the comparative results 
from the prioritisation exercises undertaken in each study site are presented in Appendix B. The 
prioritisation exercise with Victorian law enforcement personnel (N = 13) revealed that this group 
expressed a wide interest in the questions and issues presented to them around benzodiazepines 
and pharmaceutical opioids, and how these relate to the key themes of links to crime, implications 
for frontline workers, diversion, market dimensions and characteristics, and interventions. The 
average priority ranking of 32 of the 33 issues and questions presented was rated as 4 ('very 
important') for law enforcement, with no clear preference or higher priority indicated for different 
themes.
Stage two: Survey of people who inject drugs
One hundred and two PWID were surveyed on their demographic characteristics, and asked 
detailed questions about their drug use history and patterns of current drug use, including details 
of benzodiazepine and pharmaceutical opioid use. They were also asked to provide information 
about drug markets, including sources of supply, price and availability, and any changes that 
may have occurred in the markets in the previous twelve months. Participants were asked for any 
information about criminal behaviour, and involvement with police, and how this may relate to 
specific drug use. Experience of drug-related harms was also surveyed, and participants were 
asked their perceptions of the risks and benefits of using individual drugs, including prescription 
drugs. All responses were collated and descriptive analyses were performed. Where qualitative 
information was collected, responses were categorised, and the number of responses were 
calculated. In some instances, where appropriate, inferential statistical tests of significance were 
conducted, with the critical level set at  .05.
Overview of the sample of people who inject drugs 
Respondents were asked to provide information about themselves and their education, living 
situation, employment and income, and drug treatment and prison history. More than two-thirds 
of the sample was male, and a greater proportion of men in the study were aged over 32 (54%), 
whilst the opposite was the case for women participants, with 60% of the women aged less 
than 32 years. However, this difference was not statistically significant at .05. Table 5 displays 
comparisons between age and gender in the Stage two Melbourne sample. Age was categorised 
according to the median of 32.5 years.
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Table 5. The age and gender of the Melbourne Stage two PWID participants (N = 102).
Almost half the sample lived in a hostel or shelter, or had no fixed address, and most participants 
were unemployed at the time of the interview. The majority of participants derived most of their 
income from government allowances or benefits, although 15% reported they received most of 
their income from the proceeds of crime. Almost half the sample reported they were in some form 
of drug treatment at the time of the interview, with about half each undertaking the methadone 
maintenance treatment (MMT) program and the buprenorphine program. Almost two-thirds of the 
sample reported they had been imprisoned at some time in the past. See Table 6.
Table 6. Description of the Stage two PWID participants in Melbourne (N = 102).
Gender
Age Female (n) Male (n) Total (N)
Age 32 and Under 18 33 51
Age Over 32 12 39 51
Total 30 72 102
Demographic characteristics of the Stage 2 Melbourne PWID sample 
Gender % Male
Female
71
29
 Age (years) Mean
Range
32
18 - 50
ATSI % 4
Housing % House/flat
Parent’s home
Boarding house/hostel
Shelter
Homeless
39
15
19
13
8
Education Mean years
Range
9.6
4 - 12
Post school education % Trade
Uni
39 
5
Employment % Unemployed
Employed
Sex-worker
Student
Home duties
92
6
2
-
-
Main Income % Govt. benefits
Wage/salary
Crime
Sex work
77
4
15
2
Current Treatment % None
Methadone
Maintenance Buprenorphine
55
21
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Table 6 continued.
Drug use history of people who inject drugs
Respondents were asked about their patterns of drug use, including when they first used an illicit 
drug, when they first injected an illicit drug, and their frequency of injecting drugs. They were also 
asked if they had bought drugs yesterday, and, if so, which drug/s and how much they had paid. 
Detailed information about the PWID drug use history is contained in Table 7.
Age of drug use
Respondents in Melbourne reported first using an illicit drug on average at age 14 (sd = 3), with 
a range of 7 - 34 years, and reported that they first injected an illicit drug at a mean age of 18 (sd 
= 4.2), ranging from aged 11 - 39. Five percent of respondents reported injecting illicit drugs less 
often than once a week, whilst 11% reported the practice more than once a week and 9% reported 
that they did this daily, or more than once a day.
Heroin injecting 
Ninety-nine percent of participants had ever used heroin, and the same proportion had ever 
injected the drug. As well, 44% first injected heroin whilst 58% reported this was the drug they 
injected the most often in the month prior to the survey, and 67% reported heroin as their favoured 
drug. 
Methamphetamine injecting 
Methamphetamine was the drug that 49% reported injecting first, and had been injected at some 
time by all participants, with 15% reporting it as the drug they injected most often in the previous 
month, and 13% indicated it was their favoured drug.
Pharmacotherapy injecting 
No Melbourne respondents reported methadone syrup as the drug they first injected or injected 
most last month, or as their preferred drug. However, 72.5% had used prescribed methadone at 
some time (and been injected by 22%), and 41% had used illicit methadone (and been injected 
by 21%). Buprenorphine was nominated as the drug most injected last month by 10%, but was 
not selected as the drug of choice, or named as the drug first injected. However, prescribed 
buprenorphine had been used at some time by 53.5% of participants (injected by 35.5%), and 
illicit buprenorphine had been used by 41% (injected by 38%).
Demographic characteristics of the Stage 2 Melbourne PWID sample
Months in current treatment Mean (sd)
Median
Range
22 (30.5)
6
1 - 144
Treatment last 6 months % Yes
No
57
43
Prison history % Yes
No
64
36
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Morphine and other opioids injecting 
Forty percent of participants said they had used prescribed morphine at some time, and 33% 
reported they had injected it, while 88% indicated having used illicit morphine, and it had been 
injected by 86%. Two percent of respondents reported morphine as the drug they had first injected, 
while nine percent reported it as the drug they injected most last month, and five percent rated it 
as their preferred drug. The brands of morphine that were reportedly used most were MS Contin 
(mainly 100mg and 60mg) and Kapanol (mainly 50mg and 100mg). Prescribed other opioids had 
been used by 43.5% of participants, and injected by 20%, and illicit other opioids had been used 
by 28.5%, and injected by 15.5%. Five percent of respondents reported that they injected other 
opioids such as oxycodone or Panadeine forte most in the past month, although none of these 
drugs was selected as the drug of choice, or named as the drug first injected. 
Benzodiazepine injecting 
Nearly all participants had used prescribed benzodiazepines at some time (93%), with 39% 
having injected them. Most (97%) had also used illicit benzodiazepines at some stage, and 69.5% 
reported they had injected these drugs. No respondents reported that benzodiazepines were the 
drugs they had initially injected, with only one percent indicating they had injected them most 
in the previous month. Four percent ranked these drugs as their most favoured, with temazepam 
named as the favoured form.
Recent drug use of the PWID sample
Table 7 presents data on detailed information about participants’ drug use in the previous six 
months. In Melbourne 86% of respondents reported injecting heroin in the previous six months (an 
equivalent 90% of the Victorian 2003 IDRS sample reported this). A mean total frequency of use of 
75.5 days was reported, with the same frequency of injecting. The next most injected drug over the 
previous six months was illicit morphine at 72.5% (18 days injecting, 19 days total use), with 39% 
of the IDRS sample reporting this; and then illicitly acquired benzodiazepines at 42% (13 days 
injecting, 41 days total use), which contrasts with a much lower 15% of the 2003 IDRS sample 
(Breen et al. 2004). Prescribed buprenorphine had been used on average on 36 days (injected on 
16 days). The incidence of illicit buprenorphine injection was also notable in Melbourne, at 34% 
of the sample (9 days both for injecting and total use), which compares with 39% of the IDRS 
sample (Breen et al. 2004). Prescribed methadone had been used on average on 37.7 days and 
injected on average on 0.98 days, whereas methadone acquired illicitly was used on average on 
only 3.4 days and injected on 1.2 on average. Prescribed other opioids had been used on a total of 
six days, and injected on 0.40 days, whilst illicit other opioids had been used on average the same 
amount as when they were prescribed, but were more likely to be injected, at 3.6 days on average.
Differences in drug of choice and most used drug
Where respondents’ 'drug of choice' and drug most used last month differed (19% of the sample), 
in most cases (53%, n = 10) this was reportedly due to availability of the drug of choice, mainly 
heroin, with health effects (n = 2), purity (n = 2) and price (n =2) noted as less important reasons.
Respondents were asked which drug they had used (as opposed to injecting) most frequently in 
the previous month, and which drug they would choose to substitute for it if it were not available. 
They were also asked what they would use should their first substitute be unavailable as well. 
Presented here are the two reportedly most used drugs, and the first and second substitute drugs 
reported. 
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Heroin 
Heroin was reportedly the most commonly used drug in the month prior to interview in 
Melbourne, with 58% of respondents. Of these, 21% reported that if heroin were not available 
they would substitute benzodiazepines, 14% indicated methamphetamine, 11% cannabis, 8% 
reported they would substitute morphine or other opioids, and 4% selected methadone syrup. 
If their substitute drug was also not available, reported substitutes were benzodiazepines (21%), 
morphine or other opioids (11%), cannabis (9%), and methamphetamine (7%). A significant 
proportion of participants who had used heroin in the previous six months had also injected illicit 
benzodiazepines in that time (n = 42, 48% of heroin users), and a significant proportion had also 
injected illicit morphine (n = 66, 76% of heroin users). Almost one-third of people who had used 
heroin had also injected illicit buprenorphine in the same time frame (n = 27, 32% of the heroin 
users). All those who had injected illicit methadone (n = 9) had used heroin in the previous six 
months, which was 10% of those who had used heroin. 
Methamphetamines 
The second most used illicit drug was methamphetamine, with 15% of respondents. Three 
percent selected heroin as the drug they would substitute if methamphetamine were not 
available, whilst two percent reported they would use morphine and the same proportion selected 
benzodiazepines. Second choice substitutes were cannabis (4%), heroin and benzodiazepines 
(both 2%). A significant proportion of the 83 participants who had injected amphetamines in 
the previous six months had also injected illicit morphine (n = 64, 77% of all those who had 
used methamphetamines), and almost half had also injected benzodiazepines in that time (n 
= 37, 44.5% of methamphetamine users). Most of those who had injected other opioids in the 
last six months had used methamphetamines (n = 6, 7% of these amphetamines users), and all 
nine participants who had injected illicit methadone had also used methamphetamines in the 
previous six months (n = 9, 11% of methamphetamines users). Almost all those who had injected 
illicit buprenorphine in that time frame had also injected methamphetamines (n = 27, 33% of 
methamphetamine users).
Morphine 
Of the 74 participants who had injected illicit morphine in the previous six months, 33 (44.5%) 
had also injected benzodiazepines in that time, 8 had injected methadone (11%), 26 had also 
injected buprenorphine (35%), and 8 had injected illicitly acquired other opioids (15%).
These findings suggest that these participants tend to be poly drug users, and that benzodiazepines 
and pharmaceutical opioids were not generally the first drug of choice, but seemed to be largely 
considered supplementary drugs, and possibly substitutes, for the preferred drug of heroin. 
Nevertheless, use of multiple pharmaceutical drugs was prevalent within the sample and appears 
to constitute an important pattern of use distinct from other illicit drug use.
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Chapter three: Study findings
­Acquisition and price of drugs
Sixty-six percent of respondents (n = 67) indicated they had bought drugs the day before the 
interview. Table 8 shows the main drug bought and the average price paid by participants. Whilst 
the average amount spent on different drug types varied widely, it can be seen that on average 
more was spent on methamphetamines than any other drug ($220), although only a small 
proportion of participants purchased it (9%). Heroin was purchased by the largest proportion of 
participants (45%), at an average cost of $138. Substantially less was spent on benzodiazepines 
($33) or morphine ($5), which were also purchased by a smaller proportion of respondents (4% 
and 1% respectively). 
Table 8. Price paid for main drugs purchased the day before the interview (N = 67).
Recent benzodiazepine use
Routes of administration, sources of administration, and forms used
Respondents were asked about their use of benzodiazepines in the six months prior to the 
interview. All (N = 102) respondents reported that they had used benzodiazepines during that 
time, and 96% (n = 97) had used them in the previous month. Most of respondents (n = 100, 98%) 
had used benzodiazepines orally, with the average oral usage 92 days of the previous 180 (sd = 
68, ranging from one to 180 days). However, 45% (n = 46) reported they had injected the drugs, 
on average on 16 days (sd = 34, ranging from one to 180 days). Eighty-one percent of participants 
(n = 83) reported they had obtained their benzodiazepines via prescription, and used prescribed 
drugs on average for 80 days (sd = 80, range five to 180 days). Almost all participants, at 91% (n 
= 93), had acquired the drugs illicitly, and used them for an average of 41 days (sd = 51, range 
one to 180 days). Clearly, many participants used benzodiazepines both licitly and illicitly, as 
well as using them both orally and injecting them. Table 9 presents the percentage of participants 
using benzodiazepines orally and via injection, according to whether they had obtained them by 
prescription or illicitly.
Table 9. Percentage of all respondents taking benzodiazepines orally or via injection, according to 
their source of acquisition, in the six months prior to interview (N = 102 benzodiazepines users).
The most common types/brands of benzodiazepines used orally were reported to be: diazepam, 
with 70% of benzodiazepine users reporting swallowing it in the month prior to interview; 
oxazepam, reportedly taken by 58%; alprazolam, taken by 31%; clonazepam, taken by 29%; and 
Price Paid
Heroin
(n = 46)
(45%)
Cannabis
(n = 22)
(22%)
Methamphetamines
(n = 9)
(9%)
Benzodiazepines
(n = 4)
(4%)
Morphine
(n = 1)
(1%)
Average Cost $138 $34 $220 $33 $5
Range $20 - 600 $10 - 100 $40 - 400 $4 - 60 $0 - 10
Benzodiazepines Licit Illicit
Injected (%) 14.7 42
Oral (%) 78.4 76.5
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nitrazepam was taken by 27%. Some participants reported injecting these benzodiazepines, which 
are all in tablet form; for instance 7% of benzodiazepine users reported injecting diazepam, and 
two percent reported injecting alprazolam. 
Injection of temazepam was more commonly reported than its oral use. Many participants also 
reported using multiple brands and forms of temazepam. Temazepam was injected during the 
past six months in the following brands/forms: Normison - 20mg capsule, 24% of benzodiazepine 
users, 10mg capsule, 11%; Temaze - 20mg capsules and tablets, 13% each, 10mg capsule, 8%; 
Normison tablets and Euhypnos - 10mg capsules, 7% each; Euhypnos - 20mg capsules, 6%; and 
Temtabs, 1%. 
Sources of benzodiazepines
In terms of sourcing benzodiazepines, 80% of participants (n = 82) reported they obtained them 
via a doctor’s prescription on the basis of real symptoms, with 43% reporting this was the way they 
mostly obtained these drugs. Thirteen percent reported that a doctor prescribed them when they 
had presented with fake symptoms in order to get the drugs, with 8% reporting this was their usual 
mode of acquisition. 
Eighty-five percent of respondents reported requesting benzodiazepines from a number of doctors 
in the month prior to interview, although a substantial number reported that they didn’t bother 
attempting to get their preferred preparations, such as temazepam capsules, via prescription, as it 
was impossible due to doctors/HIC crackdowns on dispensing of these drugs. Some participants 
indicated also that they believed or knew they were marked as doctor-shoppers and so did not 
approach doctors.
In terms of benzodiazepine gel capsules (i.e. temazepam), the number of doctors approached 
for prescriptions within the previous six months ranged from one to 15. The number of doctors 
successfully asked for a script ranged from zero to nine (mean = 0.55, sd = 1.56), whereas the 
number of doctors unsuccessfully approached (i.e. number of visits resulting in failure to gain a 
script) ranged from none to 15 (mean = 1.14, sd = 3). 
The picture was similar for benzodiazepine tablets, with the number of doctors successfully 
approached for a prescription ranging from zero to 20 (mean = 1.83, sd = 2.3); 44% of participants 
approached just one doctor and were successful, while 14% approached 2 and received scripts 
from both, and 5% tried successfully to obtain a script from five doctors; while one participant 
reported that they had approached 20 doctors and were successful in each case. The number of 
doctors unsuccessfully approached for a script ranged from none to 18 (mean = 0.67, sd = 2.26), 
with one person trying unsuccessfully 18 times.
In terms of non-medical sources, 87% reported benzodiazepines were a 'gift', and 22% said this 
was their usual means of obtaining them, whilst 8% reported stealing them (one said this was 
'usual'), six percent said they had forged a script to obtain them (with no reports of this as usual), 
and 27% reported they bought them from a friend (with one only citing this as their usual source). 
When it came to buying them from a dealer, 32% reported they did this (5% reporting this as usual 
for them). Six percent reported they obtained them from another source, and named 'swapping' 
drugs for them (n = 3), getting them from a chemist, having an affair with a doctor and doctor-
shopping (all n = 1 only). See Figure 1.
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Figure 1: Percentage of benzodiazepines users accessing the drugs via different sources (N = 102 
benzodiazepine users)
For individual benzodiazepine users, temazepam preparations were obtained far more often 
via friends, dealers, or other sources (reported 104 times), than medically (30 times). However, 
temazepam most likely to be obtained via prescription was Normison 20mg gel capsules (seven 
reports, with four saying this was the usual source and that they had 'real symptoms'), and Temtabs 
(eight, with all participants using this drug citing this as their usual way of obtaining them). There 
were a further 15 reports of receiving Normison 20mg capsules as 'gifts', 10 of buying them 
from friends, and 14 of buying them from a dealer (with 10 participants saying this was their 
usual source). The source of these drugs is of particular interest because temazepam preparations 
generally, and Normison specifically, were reported by these participants as the most likely to be 
injected.
Price, availability and market changes
As previously discussed, buying benzodiazepines from friends or dealers was not as common 
for these respondents as acquiring them via prescription or else being given them, especially for 
the non-temazepam preparations. There were 29 reports of buying temazepam this way that also 
provided the price paid for them last time they were purchased. The prices on the street of the 
most commonly used benzodiazepine tablets reportedly ranged from $1 per tablet for Serepax 
(oxazepam) to $5 for Valium (diazepam) and Xanax (alprazolam). Hypnodorm (flunitrazepam) 1mg 
capsules were also bought for $2. 
For those who bought their temazepam either from friends or dealers, the price varied widely, 
ranging from $1 for a 20mg Normison capsule, to $30 for a 10mg Normison tablet, but there 
were reports that bottles of temazepam were sold for between $250 and $300 in some areas of 
Melbourne. See Table 10.
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Table 10. Average street price for temazepam preparations.
Types of suppliers, and other drugs sold by suppliers of prescription drugs
Whereas a high proportion of respondents reported they sourced illicit benzodiazepines via 
friends, 47% of illicit users did not know what kind of dealer their supplier of benzodiazepines 
was. However, nine percent of illicit users reporting their supplier was a friend selling their own 
prescription, a further nine percent reported buying them from user-dealers (selling to fund their 
own use), 16% bought them from small-time dealers, while only four percent said their supplier 
was a large-scale dealer. In fact, the highest proportion of participants buying any drugs from both 
user/dealers and large-scale dealers were illicit benzodiazepine users.
Many respondents reported that their benzodiazepines supplier also sold other pharmaceuticals 
and illicit drugs, which was inconsistent with the above information. For instance, 63% of those 
sourcing benzodiazepines reported their supplier also sold heroin, 34% reported morphine, 16% 
said they also sold methadone syrup, 37% reported they also sold cannabis, and 42% reported 
their dealer sold methamphetamines. 
PWID perceptions of the impact of greater availability of benzodiazepines 
Eighty-seven participants provided information on their perceptions of what would happen should 
benzodiazepines be more available than they currently are, while 89 participants provided 
information about how they believed their friends who use the drugs would respond to such a 
situation. Reported impacts for greater availability of benzodiazepines were: greater use of the 
drugs; higher incidence of criminal or problematic behaviour; less stress; and no effects. See Table 
11.
Table 11. Number of PWID holding different perceptions of the impact of greater availability of 
benzodiazepines.
Temazepam
Average Street Price 
Cost (Range)
Euhypnos 10mg capsules $7 ($5 - 10)
Euhypnos 20mg capsules $7.50 ($5 - 10)
Normison 10mg tablet $13 ($5 - 30)
Normison 10mg capsules $10 ($10)
Normison 20mg capsules $9 ($1 - 20)
Temaze 10mg capsules $7.50 ($5 - 10)
Temaze 20mg capsules $13 ($10 - 20)
Impact of more benzodiazepines
Respondent
(n = 87)
Friends of respondent
(n = 89)
Use more benzodiazepines 36 49
No effect 31 9
Commit crime/other problematic 
behaviour
3 12
Less stressed 8 7
Other effect 9 22
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PWID perceptions of the impact of reduced availability of benzodiazepines
Ninety-three respondents provided information about their perceptions of how a reduction in the 
availability of benzodiazepines would affect them, and 96 offered opinions of how such a situation 
would affect their friends who use the drugs. Reported impacts of a reduction in benzodiazepines 
supply were: no effect; anxiety or craving for the drugs; substitution for benzodiazepines with 
other drugs; higher incidence of crime or doctor-shopping as users search for alternative supply 
sources; and a sense of being better off without them. See Table 12.
Table 12. Number of PWID holding different perceptions of the impact of reduced availability of 
benzodiazepines.
Victorian law enforcement KI were asked to prioritise the initial 25 research questions (Appendix 
A). They indicated that most of the issues surrounding illicit use of benzodiazepines and 
pharmaceutical opioids were of importance to them (Appendix B). Therefore, depending on the 
relevance to the data, the questions have been distilled into several areas that provide an overview 
relating to illicit prescription drug use and markets, diversion of prescription drugs, implications for 
frontline workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
Market characteristics
The entire current PWID sample had used benzodiazepines in the previous six months, 
and almost half injected them in that time. There was a significant relationship between 
illicit benzodiazepine injecting and heroin use in the past six months, and between 
methamphetamine injecting and illicit benzodiazepine injecting in that time. 
Substantial proportions of those who had injected illicit buprenorphine, methadone and 
morphine in the previous six months had also injected illicitly acquired benzodiazepines. 
Almost one-quarter of heroin users reported they would substitute benzodiazepines for heroin 
if it were not available.
Access to benzodiazepines was predominantly through legitimate prescriptions, 'gifts' or 
purchases from friends, and a large proportion of respondents claimed not to know what other 
drugs their supplier sold. 
The suppliers were nominated mainly as friends selling their own prescription, and friends 
who were users selling to fund their own use. 
•
•
•
•
•
Impact of fewer 
benzodiazepines
Respondent
(n = 93)
Friends of respondent
(n = 96)
No change (just go without or 
find them anyway)
32 12
Very anxious/crave the drugs 23 19
Substitute other drugs 17 24
Commit crime/doctor-shop 11 17
Be better off 5 2
Don’t know - 10
Other effect 5 12
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Where dealers were the suppliers of benzodiazepines, they were reportedly mostly 'small-
time', who also sold heroin (reported by 24% of the sample), morphine, methadone syrup, 
cannabis and methamphetamines. 
Average purchase prices varied widely, ranging from $1 - $5 per 5mg Valium and 2mg Xanax 
tablets, to $1-20 for 20mg, and $5 - $30 for 10mg, temazepam gel capsules.
Benzodiazepines were used orally by most participants, and injected by almost half the 
sample. When benzodiazepines were obtained illicitly they were more likely to be injected, 
especially temazepam gel capsules (which were almost always injected regardless of the 
source).  
Six participants who stole benzodiazepines injected them, whereas two did not inject them, 
and the same proportion used them orally. 
Diversion
Most PWID participants (80%) received benzodiazepines through legitimate prescriptions 
from a medical practitioner, with 13% of participants 'faking' symptoms to obtain 
prescriptions.
It was more common for PWID participants to access benzodiazepines through gifts than via 
either prescription or illicit purchases, although buying from friends and dealers was reported 
by a large minority (27% and 32% respectively).
Almost 10% of participants had recently stolen benzodiazepines, while six percent had forged 
prescriptions (most for temazepam capsules, but also for alprazolam and diazepam).
More than one-third of participants reported they had had their benzodiazepines stolen from 
them (mainly diazepam, alprazolam, and temazepam).
While most participants had obtained prescriptions for benzodiazepines from one doctor, a 
large number of respondents had undertaken 'doctor-shopping' to obtain these drugs.
Participants reported that obtaining benzodiazepines tablets from doctors was easy or very 
easy; however, obtaining gel capsules was reported to be very difficult, if not impossible, and 
most respondents reported they would not bother trying to get a prescription for them. 
Participants had attempted to obtain gel capsules from up to 15 doctors, with one successfully 
gaining a prescription from nine doctors. 
Tablets were sought from up to 20 doctors, and one participant was successful with 20 
different doctors.
A substantial proportion of participants reported that if benzodiazepines were to become 
more difficult to obtain, they would doctor-shop.
Thefts or prescription forgeries were mainly aimed at obtaining temazepam gel capsules, 
although alprazolam and diazepam were popular also. 
Temazepam gel capsules were targeted because of the preference for injecting them, either 
alone or with heroin. This is probably related to perceived injectability of the gel substance, as 
well as relative potency and speed of effect of these formulations, which is well established in 
the literature (e.g. Dobbin 2001).
Recent pharmaceutical opioids use
Routes of administration, sources of administration, and forms used
Respondents were asked about their use of any pharmaceutical opioid in the six months prior to 
the interview. Use included licit and illicitly obtained opioids, and all modes of administration. 
There were large overlaps between means of obtaining opioids and routes of administration. 
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
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Ninety-eight participants (86%) reported using one or more opioid drugs either orally, by injection, 
or both. These proportions include participants on methadone syrup maintenance (MMT) and 
buprenorphine treatment (BT) programs. The average number of days that opioids were used orally 
in the previous six months was 67 (sd = 77.5, range one to 180 days), while they were injected on 
49.3 days on average (sd = 60.7, range one to 180 days). 
Table 13. Routes of administration of all pharmaceutical opioids in the six months prior to 
interview (N = 102).
Table 13 shows that around two-thirds of participants recorded swallowing opioids in the previous 
six months, while most reported they had injected them, and more than half said they had done 
both. By far the most commonly used opioid drug in the previous six months was morphine, with 
n = 80 (78% of the sample overall) reporting its use (82% of all opioid users), with 43% of all 
participants also reporting they had used morphine in the previous month. The most commonly 
reported brands/sizes of morphine used were MS Contin tablets and Kapanol capsules, with a total 
of 38 and 55 reported injectors respectively. See Table 14.
Table 14. Number of reported users of selected forms of morphine in the previous six months (N = 
102).
Morphine was about 60% more likely to be acquired illicitly (n = 78, 97.5% of morphine users) 
than via prescription (n = 23, 28.75%). Prescribed morphine was used on average on 16 days of 
the previous 280 (sd = 47, range one to 180 days), while illicitly acquired morphine was used on 
average on 19 days (sd = 32, range one to 180 days). 
Morphine was also more likely to be injected (n = 79, 98.75% of morphine users) than taken orally 
(n = 22, 27.5%) regardless of the method of acquisition, although this was amplified in the case of 
illicit morphine, where it was injected by almost five times as many participants as swallowed it. 
Prescribed morphine was injected on average on 13.5 days (sd = 44, range two to 180 days), and 
illicit morphine was injected on average on 18 days (sd = 32, range one to 180 days). See Table 14 
for the route of administration of the most common forms of morphine. 
The second most frequently used opioid was buprenorphine, with n = 46 users (47% of opioid 
users). Twenty-two percent of the sample was in 'current' buprenorphine treatment. A total of 
36% of the sample (n = 37) had been prescribed buprenorphine within the past six months (80% 
of users of the drug), while 32% (n = 33) of all participants used illicitly acquired buprenorphine 
Any Opioids: Oral Use last 6 Months
Any Opioids: Injected 
Last 6 Months
No (n) Yes (n) Totals (N)
No 4 11 15
Yes 32 55 87
Totals 36 66 102
Morphine
MS Contin 
60mg Tablets
MS Contin 
100mg Tablets
Kapanol 20mg 
Capsules
Kapanol 50mg 
Capsules
Kapanol 100mg 
Capsules
Oral 2 2 2 4 2
Injected 15 23 11 21 23
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(72% of buprenorphine users). Prescribed buprenorphine was used significantly more frequently 
than illicitly acquired drugs in the previous six months, with the former used on average on 36.3 
days (sd = 62, range six to 180 days), and the latter used on average on 8.7 days (sd = 27, range 
one to 180 days). 
More participants, however, had injected buprenorphine (n = 41, 89% of the drug’s users), than 
had taken it orally (n = 31, 67% of users), although the number of days the drug was taken orally 
did not differ substantially from the number of days it was injected. The drug was swallowed on 
average on 49.8 days (sd = 66.4, range one to 180 days), while it was injected on average on 44 
days (sd = 63, range one to 180 days). See Table 15 for a breakdown of use of buprenorphine 
according to the method of acquisition.
Methadone syrup had been used by a total of n = 37 participants within the previous six months 
(38% of opioid users), with 29% of all participants (n = 30) reporting they had undergone MMT 
within the past six months (81% of methadone users). Twenty-one percent of the sample was in 
'current' MMT. Twenty percent of all participants reported they had used the drug illicitly (54% 
of methadone users). Prescribed methadone was used significantly more frequently than illicitly 
acquired methadone, with the former used on average on 37.7 days of the previous six months (sd 
= 68, range two to 180 days), and the former used on average on 3.4 days (sd = 14, range one to 
100 days).
Methadone injection was significantly less likely than buprenorphine injection for this sample, 
with nine participants injecting methadone syrup (24% of methadone users). Methadone syrup 
was much more likely to be swallowed (n = 34, 92% of methadone syrup users). Methadone was 
taken orally significantly more frequently than it was injected as well, at 97.8 days on average of 
the last 180 (sd = 81, range one to 180 days), compared to being injected on average on six days 
(sd = 17.4, range one to 90 days). See Table 15 for the breakdown of use of methadone according 
to the method of acquisition).
Physeptone (methadone tablet) was used by eight participants (8% of opioid users). It was 
prescribed to half, and taken illicitly by seven (87.5% of Physeptone users). The drug was taken 
orally by half the Physeptone users, on an average of 10.5 days of the previous six months (sd = 
28, range one to 80 days), and injected on average on seven days (sd = 8.9, range two to 20 days) 
by five participants (62.5% of the Physeptone users). See Table 15.
'Other opioids' (mainly tramadol, oxycodone and Panadeine forte) were used by n = 26 
participants (26.5% of opioid users) within the previous six months. One-quarter of participants 
(n = 25, 96% of other opioid users) had been prescribed the drugs, using them on average on six 
days of the previous six months (sd = 24, range one to 180 days). Twenty respondents (77% of 
these users) had acquired them illicitly, and used them on average on 5.8 days (sd = 22.5, range 
one to 180 days). All the users of other opioids had taken them orally, whilst 15 (58%) had also 
injected them. See Table 15 for the breakdown in the use of the drugs according to their method of 
acquisition. 
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Table 15. Percentage of all respondents taking selected pharmaceutical opioid drugs orally, or 
injecting them, in the previous six months, according to whether the source of acquisition was licit 
or illicit (N = 102).
Sources of opioids
In terms of sourcing opioids, the majority either obtained them from a legitimate prescription or 
else as a 'gift'. Over half of the opioid users, at 62% (n = 61, 60% of the sample), reported that 
they obtained them via a doctor’s prescription on the basis of real symptoms (n = 44 reported 
that this was their usual mode of supply, reflecting the proportion of participants on a treatment 
program), whilst six percent said that a doctor had prescribed them when they had presented with 
fake symptoms in order to get the drugs (three reported this was their usual method). 
In terms of non-medical sources, 63% of opioid users (n = 62, 61% overall) reported the drug was 
a gift (for n = 51, this was their usual source). Nobody reported they had forged a script to obtain 
them, however three participants (3% of opioid users) reported stealing the drugs. A further 36% 
of opioid users each reported they had bought them from a friend or a dealer (with seven of those 
buying from friends reporting this as usual, and 11 of those buying from a dealer reporting this as 
usual), and three percent reported obtaining them from other sources (only one reported this as 
their usual mode of acquisition). Within this final category, two respondents reported swapping 
other drugs for opioids, and one reported obtaining them from his girlfriend. See Figure 2.
Figure 2: Percentage of opioid users accessing different sources of pharmaceutical opioids (N = 
98 opioid users)
Morphine Methadone Buprenorphine Physeptone Other Opioids
Mode of 
Acquisition
Inject Oral Inject Oral Inject Oral Inject Oral Inject Oral
Licit 17.6 12.7 3 29.4 26.5 29.4 3 1 6.8 19.6
Illicit 71.5 14.7 8.8 14.7 33.5 10.7 5 5 7.8 14.7
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For individual opioids, those utilised for treatment of drug dependence were the most commonly 
obtained legitimately via a doctor’s prescription. Buprenorphine was obtained legitimately by 30 
respondents (29% of the total sample, 31% of opioid users, and 65% of buprenorphine users); 
most (27) reported this as their usual way of obtaining the drug. Similarly, obtaining methadone 
syrup medically was reported by 25 respondents (this was 25% of the total sample, 25.5% of 
opioid users, and 68% of methadone syrup users), with all but one reporting this as their usual way 
of obtaining the drug. 
Many respondents reported requesting pharmaceutical opioids from a number of doctors in the 
month prior to interview, although a substantial number reported that they didn’t bother attempting 
to get their preferred preparations, such as morphine, via prescription as it was impossible due to 
doctors/HIC crackdowns on dispensing of these drugs. 
No respondents attempted to obtain a script for Physeptone in the previous month. Twenty-one 
percent of participants had attempted to obtain a prescription for morphine in the previous month. 
The number of doctors successfully approached for morphine ranged from zero to 5 (mean = 
0.86, sd = 1), with 13 succeeding in obtaining a script from one doctor, and just one gaining a 
script from five doctors, while seven were totally unsuccessful. The range of doctors approached 
unsuccessfully for morphine ranged from zero to 50 (mean = 4, sd = 11.6), with two respondents 
each trying unsuccessfully to obtain a script from two doctors and 10 doctors, and one respondent 
each attempted unsuccessfully with one doctor and 50 doctors. Thirteen participants reported they 
had not been refused a prescription for opioids at all.
Nine percent of the total sample, or 24% of those reporting methadone syrup use, said they 
received it as a gift, the second most common way of obtaining it after medical prescription. 
There were three reports of methadone syrup users buying it from dealers. There were reports of 
participants in the MMT Program obtaining the drug illicitly this way. See Table 16.
Table 16. Methadone syrup use by Melbourne PWID participants, according to self-reported 
treatment participation over the past six months, compared with receiving the drugs as 'gifts' (N = 
37 methadone syrup users).
Sixty-five percent (n = 30) of all buprenorphine users (n= 46, 45% of the sample) reported they had 
been prescribed the drug for legitimate symptoms in the past six months. Eleven percent overall 
and 24% of those reporting buprenorphine use said they received it as a gift, like methadone syrup 
the second most common way of obtaining it after medical prescription. There were no reports 
of buying buprenorphine from dealers, and only one report of buying it from a friend. There were 
reports of participants in buprenorphine treatment obtaining the drug illicitly this way. See Table 
17.
Methadone Syrup Treatment in past Six Months
Source Treatment (n) No Treatment (n) Totals (N)
Received as gift 4 5 9
Did not receive as gift 21 7 28
Totals 25 12 37
Bought from dealers 3 3 6
Did not buy from dealers 22 9 31
Totals 25 12 37
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Table 17. Buprenorphine use by Melbourne PWID, according to self-reported medical use over the 
past six months versus. receiving the drugs as gifts (N = 46 buprenorphine users).
Figure 3 shows how participants acquired buprenorphine illicitly depending on whether they were 
obtaining buprenorphine by prescription.
Figure 3: Number of buprenorphine users obtaining the drug via a gift, according to whether or 
not they were undertaking buprenorphine treatment (N = 46 buprenorphine users)
There were a total of 33 reports of morphine or other opioids being sourced via legitimately 
acquired prescriptions, with tramadol reportedly acquired this way by eight people, MS Contin 
60mg by six, Endone 5mg by four, Kapanol 100mg, Oxycontin, Pethidine, MS Contin 30mg, and 
100mg, each by three people, and Anamorph by one participant (using 'fake' symptoms).
Most (n = 20) of the 29% of morphine users (n = 23) who reported they had been prescribed 
morphine in the previous six months stated they had seen a doctor with 'real' symptoms, and four 
also reported they had reported 'fake' symptoms to receive a prescription for the drug. Fourteen 
participants who had received morphine via prescription had also received it as a gift, seven 
had bought it from a friend, and 11 had bought it from a dealer. Seventy-three percent of illicit 
morphine users (n = 57) received it as a 'gift', 42% buying it from a friend (n = 33), and 41% 
buying it from a dealer (n = 32). 
For individual morphine preparations, MS Contin 100mg tablets were reportedly received as a 
gift by 31 participants, bought from friends by 46, and from a dealer by 42. Ten of those reporting 
Kapanol 50mg capsule use indicated they received them as a gift, and eight said they bought 
them from a dealer. Six respondents reporting Kapanol 100mg capsule use indicated they were 
Buprenorphine Treatment in past Six Months
Source In Treatment (n) Not in Treatment (n) Totals (N)
Received as gift 11 13 24
Did not receive as gift 19 3 22
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a gift, while 10 said they bought them from a friend and seven bought them from a dealer. Six 
people were given MS Contin 30mg tablets; there were seven reports of buying them, three from 
a friend and four from a dealer. MS Contin 60mg tablets were also reported as gifts eight times, 
bought from a friend six times and from a dealer three times. Five participants reported receiving 
Anamorph tablets as gifts, two each bought them from a friend and a dealer, and one swapped 
other drugs for them. There were also 10 reports of Oxycontin as gifts. See Table 18, which shows 
the method of acquisition for morphine.
Table 18. Number of morphine users acquiring the drug by various means (N = 80 morphine 
users).
Price, availability and market changes
There were a total of 47 reports of buying pharmaceutical opioids from friends or dealers that were 
also accompanied by the reported price paid last time it was purchased. The drugs most commonly 
reported were Kapanol 100mg capsules (n = 15), Kapanol 20mg capsules (n = 8), and MS Contin 
60mg tablets (n = 6). For those who bought their opioids illicitly the price varied widely, ranging 
from a minimum of $5, paid for an MS Contin 15mg tablet, to a maximum of $100 paid for a 
Kapanol 100mg capsule and an MS Contin 200mg tablet. Table 19 shows the street price for the 
most common illicitly acquired opioids.
Table 19. Average street price for selected opioids (N = 47).
Morphine
Prescribed 23
'Gift' 67
Bought from friends 67
Bought from dealers 67
Opioids
Average Street Price 
(Range)
Anamorph $10 ($0 - 20)
MS Contin 5mg $40 ($40)
MS Contin 15mg $15 ($15)
MS Contin 30mg $15 ($10 - 30)
MS Contin 60mg $25 ($10 - 50)
MS Contin 100mg $30 ($0 - 50)
MS Contin 200mg $75 ($50 - 100)
Kapanol 20mg $24 ($10 - 75)
Kapanol 50mg $24 ($10 - 75)
Kapanol 100mg $40 ($10 - 100)
Ordine $22 ($15 - 30)
Physeptone $30 ($10 - 50)
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Whereas a high proportion of respondents reported they sourced illicit pharmaceutical drugs via 
friends, a smaller number reported buying them from user-dealers or small-time dealers, and very 
few said their supplier was a large-scale dealer. For instance, 44% of morphine users, 42% of 
buprenorphine users, 41% of methadone syrup users, and 33% of physeptone users reported they 
obtained the drugs from friends. This contrasted with buying methadone syrup (2%), morphine 
(7%) and buprenorphine (6.5%) this way. The highest proportion buying from user/dealers were 
those buying Physeptone (17%), and buprenorphine (10%).
Many respondents reported that their supplier of pharmaceutical drugs also sold other 
pharmaceuticals and illicit drugs. For instance, cannabis was reported with the highest frequency 
as also sold by suppliers, with 50% of those buying methadone syrup, 33% buying Physeptone, 
32% buying morphine and 33% of those buying buprenorphine reporting this. Methamphetamine 
was also reportedly sold, with 37.5% of methadone syrup users, 33% of Physeptone users, 40% of 
morphine users, and 22% of buprenorphine users reporting their supplier sold the drug. 
PWID perceptions of the impact of greater availability of pharmaceutical opioids
The participants were asked about how they believed they and their friends who use 
pharmaceutical opioids would respond if they were to become more available than they currently 
are. Eighty-two participants provided responses on behalf of themselves, while 67 provided 
opinions about their friends’ behaviour. The most commonly cited effects were: more use of the 
drugs; overdose; or no impact. See Table 20.
Table 20. Number of PWID holding different perceptions of the impact of greater availability of 
pharmaceutical opioids.
PWID perceptions of the impact of reduced availability of pharmaceutical opioids
When respondents were asked what they thought would happen for themselves if pharmaceutical 
opioids were less available, 88 responded, and 78 also gave their opinion about how they thought 
that situation would effect their friends who use the drugs. The most frequently nominated impacts 
that such a situation would have were: no effect; substitution of alternative drugs; sickness due to 
needing the drugs; and increased crime as users attempted to find alternative sources for the drugs. 
See Table 21.
Impact of more opioids
Respondent
(n = 82)
Friends of 
respondent
(n = 67)
No effect 40 9
Would use more opioids 42 33
Overdose 0 3
Other effect - 22
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Table 21. Number of PWID holding different perceptions of the impact of reduced availability of 
pharmaceutical opioids.
The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions. 
Summary with reference to NDLERF research questions
Market characteristics
Most of the current PWID sample had used opioids in the previous six months, and three-
quarters having injected them in that time. There was a significant relationship between 
illicit morphine injecting and heroin use in the past six months, with 90% of illicit morphine 
injectors having also used heroin in that time. 
There was also a significant relationship between methamphetamine injecting and illicit 
morphine injecting in that time, with 86.5% of illicit morphine injectors having also injected 
methamphetamines. 
Substantial proportions of those who had injected illicit buprenorphine, methadone and 
morphine in the previous six months had also injected illicitly acquired morphine. 
Six heroin users reported they would substitute morphine for heroin if heroin were not 
available, whilst one each indicated they would substitute methadone or other opioids.
Access to opioids was predominantly through legitimate prescriptions, 'gifts' or purchases 
from friends, and a large proportion of respondents claimed not to know what other drugs 
their supplier sold. 
The suppliers were nominated mainly as friends selling their own prescription, and friends 
who were users selling to fund their own use. 
Where dealers were the suppliers of opioids, they were reportedly mostly 'small-time'.
Three participants buying methadone reported their dealer also sold heroin, benzodiazepines 
and methamphetamines, one each reported they sold morphine and cocaine, and four 
reported they sold cannabis.
Thirteen percent of the sample also reported their morphine dealer sold heroin, 10% each 
reported methamphetamines and benzodiazepines, eight percent reported cannabis, and one 
percent each reported other opioids and methadone.
Average purchase prices varied widely, ranging from $1 per ml for methadone, to $5 for 
a dose of buprenorphine and from $10 to $50 for 20, 50, or 100mg morphine tablets and 
capsules. 
•
•
•
•
•
•
•
•
•
•
Impact of fewer opioids
Respondent
(n = 88)
Friends of 
respondent
(n = 78)
No effect (go without or find 
them anyway)
58 14
Would substitute other drugs 19 21
Be sick, 'hang out' 9 15
Increase in crime 2 10
Other 10 18
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Morphine was injected by most users, regardless of the source, whereas illicit users of 
buprenorphine and methadone were more likely to inject their drugs than licit users. 
All those who reported stealing their opioids also reported they had injected them rather than 
used them orally. 
Diversion
Most PWID participants had received opioids through legitimate prescriptions from a medical 
practitioner, with almost half of these participants currently undertaking either the MMT or 
buprenorphine program, or else as a 'gift' from another.
It was more common for PWID participants to access opioids through gifts (61% of the 
sample) than via either prescription (60% of the sample) or illicit purchases, although buying 
from friends and dealers was reported by more than one-third of participants (36% each).
Three percent of participants had recently stolen opioids (MS Contin), while none had forged 
prescriptions.
Twenty-one percent of participants had attempted to obtain morphine/other opioids (not 
including methadone and buprenorphine) prescriptions in the previous month, but reported 
great difficulty in doing so. 
Most who had succeeded (n = 13) had only received a prescription from one doctor, but one 
had reportedly succeeded with five. 
Those who were successful usually reported an ongoing medical history which meant they 
were treated as genuine patients in need of pain relief.
One respondent reported trying unsuccessfully to obtain morphine from 50 doctors. 
Therefore, while a number of participants had obtained prescriptions for morphine from one 
doctor, a large number of respondents had attempted 'doctor-shopping' to obtain these drugs. 
A small number of participants reported that if morphine was to become more difficult to 
obtain, they would doctor-shop, but most reported that it was to difficult to obtain this way 
and they wouldn’t bother to ask a doctor.
Thefts targeted morphine, namely MS Contin tablets. 
Morphine was preferred, as it most closely approximates the effects of heroin and/or increases 
heroin’s effects. The tablets or capsules are boiled down and liquefied and either combined 
with heroin or injected alone. 
Health benefits and risks
Injection-related health issues
Respondents reported experiencing between zero and six injection-related health problems, with 
on average 1.72 problems reported (sd = 1.4, median = 1.50). Injection-related problems were 
defined as a 'dirty hit', prominent scarring or bruising, difficulty injecting, thrombosis, abscesses 
or infections at injection sites, experiencing drug overdoses, and having Narcan (an antidote for 
opioid overdose) administered.
Twenty-two participants (22%) reported they had experienced a 'dirty hit' within the previous 
six months. Nine participants reported that the main drug they had been injecting at the time 
they experienced the dirty hit was heroin, whilst five reported injecting buprenorphine, four 
reported injecting methamphetamine, and three reported injecting morphine. Eight of those 
reporting a dirty hit also reported they had been injecting a second drug at the time, with five 
participants indicating the second drug to be benzodiazepines, and one each indicating it to be 
methamphetamine and morphine.
•
•
•
•
•
•
•
•
•
•
•
•
•
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Sixty-two percent of respondents (n = 62) reported they had experienced prominent scarring 
or bruising in the previous six months, and 53% reported they had experienced difficulty 
with injecting in the same time frame. Twelve percent and 14%, respectively, reported having 
experienced a thrombosis and/or abscesses or infections as a result of injecting drugs.
Drug overdose
Nine percent of all respondents (n = 9) reported they had experienced between one and seven 
drug overdoses in the six months prior to the interview (most participants reported one or two 
such incidents, with one reporting seven overdoses). Seven participants reported an overdose 
incident was due to heroin (ranging from between one and seven overdoses on this drug), and one 
each reported the overdose was due to methamphetamines and morphine. One participant also 
reported they had experienced three overdoses on benzodiazepines. Five respondents reported 
that, as well as heroin, they had also been taking benzodiazepines, whilst two reported also 
taking morphine with heroin, and one reported also drinking alcohol at the time of the heroin 
overdose. The total overdose episodes exceed the total of respondents reporting overdose, as some 
respondents reported multiple overdose experiences. 
Sixty-six percent of respondents reported they had received Narcan some time in the past. The 
median time since Narcan was last administered was six months (mean = 19 months, sd = 28.5 
months), ranging in time between one week and 12 years prior to the interview. 
Benzodiazepines benefits and risks
Participants were asked to name the benefits and the risks of taking benzodiazepines, with 77 
providing information about the former. The greatest proportion of responses regarding benefits 
related to relaxation, reducing anxiety and 'helping to sleep', escaping from reality, feeling good or 
feeling high, enabling respondents to 'feel normal' or 'get through the day', the drugs assisting with 
heroin withdrawal or 'hanging out' or 'coming down' from drugs, enhancing the effects of other 
drugs, and pain relief provided by benzodiazepines. See Table 22.
Table 22. PWID perceptions of benefits of benzodiazepines (N = 77).
Eighty-eight participants provided information about risks they believed were associated with 
taking benzodiazepines, which were: risks of physical effects such as seizures, blood clots, vein 
damage and amputations, and the risk of overdose; risk of developing an addiction to the drugs;  
and problematic behaviour, such as volatile mood, when taking benzodiazepines or withdrawing 
from them. See Table 23.
Benefits of benzodiazepines Number of respondents (%)
Relaxation 35 (47%)
Feeling good 15 (20%)
Feeling normal 8 (11%)
Help with withdrawal 6 (8%)
Enhance other drug effects 5 (7%)
Pain relief 4 (5%)
No benefits 4 (5%)
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Table 23. PWID perceptions of risks of benzodiazepines (N = 88).
Morphine benefits and risks
Respondents were asked what they believed were the benefits and risks of taking morphine. 
Thirty-eight participants provided responses about benefits of morphine. More of these respondents 
reported pain relief than any other factor as the main benefit, although almost as many reported 
morphine’s main benefit was as a substitute for heroin. A number of respondents reported the 
main benefit of the drug was for escaping reality, getting high or experiencing a sense of euphoria, 
others reported morphine reduced anxiety, helped them to relax, or helped them sleep. See Table 
24.
Table 24. PWID perceptions of benefits of morphine (N = 38).
Thirty-nine participants provided responses about the risks of using morphine. Almost half of the 
respondents who supplied information about the risks of morphine reported that the main risk 
associated with it was overdose or death. A lesser number reported the main risks were associated 
with physical effects, such as collapsed veins or blood clots, and fewer still reported that addiction 
was a problem. Others did not think there were any risks associated with morphine. See Table 25.
Risks of benzodiazepines Number of respondents (%)
Physical/health effects 21 (24%)
Overdose 21 (24%)
Volatile behaviour 10 (11%)
Addiction 8 (9%)
No risks 19 (22%)
Benefits of morphine Number of respondents (%)
Pain relief 15 (39%)
Substitute for heroin 13 (34%)
Escaping reality 6 (16%)
Relaxation 6 (8%)
Enhance other drug effects 3 (8%)
Pain relief 4 (5%)
No benefits 4 (5%)
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Table 25. PWID perceptions of risks of morphine (N = 39).
Methadone benefits and risks
Respondents were asked what they believed were the benefits and risks of taking methadone. 
Twenty-three participants provided responses about benefits of methadone. Respondents 
nominated the benefits as predominantly reduction in withdrawal symptoms and reduction in the 
need for heroin. See Table 26.
Table 26. PWID perceptions of benefits of methadone (N = 23).
Twenty-six participants provided responses about the risks, which were perceived to be mainly 
addiction to the drug, health risks or no risks. See Table 27.
Table 27. PWID perceptions of risks of methadone (N = 26).
Buprenorphine benefits and risks
Respondents were asked what they believed were the benefits and risks of taking buprenorphine. 
Thirty-one participants provided responses about benefits of buprenorphine. The responses 
generally centred on the drug reducing withdrawal or the need for heroin. See Table 28.
Risks of morphine Number of respondents (%)
Overdose/death 18 (46%)
Physical/health effects 8 (21%)
Addiction 2 (5%)
No risks 5 (13%)
Other 6 (15%)
Benefits of methadone Number of respondents (%)
Stop from 'hanging out' 8 (38%)
Stop me using heroin 6 (26%)
Help function normally 4 (17%)
Pain relief 2 (9%)
Reduced need for crime 1 (4%)
No benefits 2 (9%)
Risks of methadone Number of respondents (%)
Addiction 8 (31%)
Physical/health effects 5 (19%)
No risks 6 (24%)
Don’t know 2 (8%)
Other 5 (19%)
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Table 28. PWID perceptions of benefits of buprenorphine (N = 31).
Thirty-six participants provided responses about the risks of taking buprenorphine, with most 
responses focussing on health risks, addiction, or a perception there was no risk associated with 
the drugs. See Table 29.
Table 29. PWID perceptions of risks of buprenorphine (N = 36).
Benzodiazepine and pharmaceutical dependence
The Severity of Dependence Scale for substance use (Gossop et al. 1995) is a short validated scale 
for assessing substance dependence that takes around one minute to administer. The SDS has high 
diagnostic utility (Gossop et al. 1995; Kaye & Darke 2002) and correlates well with the Diagnostic 
and Statistical Manual of Mental Disorders - Fourth Edition (DSM IV) criteria for diagnosis 
(American Psychiatric Association 1994). 
The scale comprises five statements about a drug’s use, asking the respondent to select a level of 
agreement to each statement, from strong agreement to strong disagreement, with each statement 
assigned a weighted score from 0-3. The potential score thus ranges between a minimum of zero 
(5 x 0) and a maximum of 15 (5 x 3). The cut-off for a diagnosis of dependence for most drugs 
is three, with severe dependence diagnosed when the score is six or more. The SDS has been 
validated for many drug types, including heroin, cocaine, benzodiazepines and amphetamines, 
and may be reapplied as often as required and remains reliable (De Las Cuevas et al. 2000; 
Ferri et al. 2000; Gossop et al. 1995). Table 30 shows the mean SDS scores for the users of 
benzodiazepines, morphine, methadone and buprenorphine, and the proportion that may be 
dependent on the drugs.
Benefits of buprenorphine Number of respondents (%)
Stop me using heroin 19 (61%)
Help function normally 5 (16%)
Save money 3 (10%)
No benefits 2 (6%)
Other 2 (6%)
Risks of buprenorphine Number of respondents (%)
Injecting/health effects 12 (33%)
Addiction 3 (8%)
No risks 11 (31%)
Don’t know 4 (11%)
Other 6 (17%)
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Table 30. Mean SDS scores for the participants who used benzodiazepines, morphine, methadone 
and buprenorphine in the previous month (N = 102).
The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
What are the implications of benzodiazepine and pharmaceutical opioid use for police and other 
frontline workers such as accident and emergency staff, ambulance officers and health/youth 
workers?
Most of the current PWID cohort reported experiencing injection-related harms in the month 
prior to interview. The most commonly reported were scarring or bruising of the injection site, 
a 'dirty hit', swelling of the limbs, thrombosis or abscesses/infections as a result of injecting 
drugs. These harms may be related to the intravenous administration of non-sterile materials, 
and pharmaceutical products that were not designed for such use (Dobbin 2001), especially 
considering that while most nominated the primary drug they were injecting as heroin, a large 
proportion were also injecting benzodiazepines, buprenorphine or morphine, either alone or 
with heroin.
Eleven percent of the sample reported contact with the police as a result of their 
benzodiazepine use, while 24% reported having arguments, 20% reported being aggressive,  
13% reported getting into fights, and 14% reported getting into criminal trouble (mainly 
property-related) because of such use. These issues applied to a less extent to the opioids, 
morphine, methadone and buprenorphine.
More than one-third (38%) of the current sample reported experiencing memory loss or 
a 'blackout' associated with benzodiazepine use in the month prior to interview. Several 
participants using methadone and buprenorphine also reported this.
Almost 10% of the current sample had experienced at least one overdose in the past six 
months, with more than half of these attributing the episode/s to pharmaceutical drugs, or a 
combination of pharmaceuticals and heroin.
Across all of these target pharmaceuticals, a substantial proportion of participants had 
experienced social problems such as relationship difficulties, anxiety, lack of motivation, or 
irritability associated with use and/or withdrawal from these substances in the month prior to 
interview.
Combined with the ubiquitous diversion of these drugs onto the black market, these problems 
represent important considerations for law enforcement and health providers.
•
•
•
•
•
•
SDS Score
Benzodiazepines
(n = 98)
Morphine 
(n = 44)
Methadone 
(n = 30)
Buprenorphine 
(n = 37)
Mean 4.2 4.8 5.3 4.6
Median 4 5 3 3
Range 0 - 15 0 - 15 0 - 14 0 - 15
Percent scoring 3 or over 68 63.6 62 69
Percent scoring 6 or over 33 45.5 35 41.4
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Illegal activity among people who inject drugs
Prison history and arrest in the last 12 months
A total of 66% of respondents (n = 67) reported they had been arrested in the year prior to the 
interview on charges relating to property crimes, fraud, violence, possession, driving-related 
offences and failure to appear. The use of drugs, such as heroin, benzodiazepines, methadone 
syrup and morphine, were blamed for some of the offences. See Table 31. 
Self-reported property crime last month
Participants were asked whether they had committed any offences in the previous month, 
including offences they had not been charged for. More than half the respondents (n = 58, 57%) 
reported they had committed a property offence in the past month, with 42% (n = 24) of these 
reporting they had done so less than once a week, 14% weekly (n = 8), 28% more than once a 
week (n = 16), and 16% reported they had done this daily (n = 9, mainly shoplifting). 
For those who reported committing property offences, many reported it was drug-related, with 
the largest number of these (n = 25, 43%), saying they needed to obtain money for drugs (mainly 
heroin), and/or were under the influence of drugs at the time (mainly heroin) (n = 16, 27%), and/or 
were withdrawing from drugs at the time (mainly heroin) (n = 10, 18%). Many also reported they 
committed the offences for non-drug-related reasons, such as because they needed food or goods 
(n = 23, 39%), and/or needing money to support themselves or their family (n = 17, 29%). The 
total is more than 100%, as respondents could indicate more than one reason associated with the 
behaviour.
Self-reported drug dealing last month
Almost half the respondents (49%, n = 50) reported they had dealt drugs in the previous month 
(not necessarily charged for), with 25% of these reporting they had done so less than weekly (n = 
13), whilst 16% did so weekly (n = 8); 37% reported doing it more than weekly (n = 19), and 22% 
said they were dealing drugs every day (n = 11). The reasons given for dealing drugs were mainly 
in order to obtain money for drugs (64%, n = 32). They said this was either 'a little' the reason or 'a 
lot' the reason, although 29% (n = 15) reported they did so as they needed money for their family, 
and/or had debts, and 25% (n = 13) reported they needed food or goods. Again, respondents may 
have reported more than one reason for the behaviour.
Table 31. Participants reporting charges for criminal offences (N = 102).
Offence
Participants Charged 
with Offences % (n) 
Offences relating to 
Drug Use % (n)
Drugs Involved 
Property Crimes 37 (n = 37) 89 (n = 33) Heroin (n = 8),
benzodiazepines (n = 7),
methadone syrup (n = 3),
morphine (n = 1) 
multiple drugs (n = 8)
need money for drugs (n = 6)
Fraud 14 (n = 14) 14 (n = 2) benzodiazepines, n = 1,
heroin, n = 1
Violent Crime 11 (n = 11) 64 (n = 7) benzodiazepines, n = 2
methadone syrup, n = 1
morphine, n = 1
heroin, n = 1
ice, n = 1
cannabis, n = 1
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Table 31 continued.
Self-reported violent crime last month
For those who reported committing crimes of violence (a total of n = 13, 13%), 85%, n = 11, 
of these reported they did this less than once a week, and 15%, n = 2, more than once a week. 
Forty-two percent (n = 5) said they committed these crimes because they lost their temper, 19% (n 
= 3) reported needing food and/or 17% (n = 2) said they were under the influence of drugs at the 
time (mainly heroin). The same proportion (17%, n = 2) reported their group did this kind of thing, 
and/or they could not explain why they did it.
Self-reported other crimes last month
Other recent criminal behaviour reported were fraud, with n = 13, 13% of respondents reporting 
this behaviour less than once a week; and sex work (5% total), with two participants undertaking it 
less than weekly, and three weekly.
Associations between crime and pharmaceutical drugs last month
Fourteen percent of respondents (n = 14) who reported they had used benzodiazepines in the 
past month said that the effects of using these drugs had caused them to commit a crime (mostly 
property crime), and 12% (n = 12) reported that the effects of withdrawing from benzodiazepines 
resulted in them committing a crime (again, mostly property-related crime). 
Of those reporting they were current morphine users (n = 43), 9% (n = 4) blamed its effects for 
causing them to commit a crime, whilst the same proportion also blamed withdrawal from the 
drug for the behaviour. Very few participants attributed other opioid drugs with criminal behaviour, 
with only three respondents each blaming criminal behaviour on methadone syrup withdrawal 
(29% reported its use in the previous month), buprenorphine use, and buprenorphine withdrawal 
(36% reported buprenorphine use in the previous month).
Statistical relationships between drug use variables, individual characteristics, and 
criminal activity
Inferential statistical tests were conducted in order to examine more closely whether any factors 
or characteristics associated with the participants in the study were predictive of self-reported 
criminal behaviour. In all cases the critical level for a decision of statistical significance was a 
.05. First, a stepwise linear regression was conducted using various predictor variables against 
the variable 'total crime score' as the outcome variable, in order to explore associations between 
Offence
Participants Charged 
with Offences % (n) 
Offences relating to 
Drug Use % (n)
Drugs Involved
Possession 6 (n = 6) 100% heroin, n = 1
methamphetamine, n = 1
heroin & meth, n = 1
amphetamines & Rivotril, n 
= 1
Driving-Related 6 (n = 6) 67% (n = 4) alcohol, n = 1
amphetamines, n = 1
heroin, n = 1
Valium, n = 1
multiple drugs, n = 1
Failure to Appear 4 (n = 4)
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them. The total crime score was derived from a total of items related to responses to having taken 
part in criminal behaviours within the previous month, such that a score of one was allocated for a 
positive response to each of nine question items in the survey referring to undertaking any property 
crimes, violent crimes, frauds, and drug dealing within the month prior to the survey being 
conducted. A participant’s potential score was a minimum of zero and a maximum of nine. 
The predictor variables utilised were: age; years of school completed; finished any course post-
school; drug injected most last month; how often injected drugs last month; number of days 
used heroin last month; number of days used prescribed methadone last six months; number of 
days used illicit methadone last six months; number of days used prescribed Physeptone last six 
months; number of days used illicit Physeptone last six months; number of days used prescribed 
morphine last six months; number of days used prescribed morphine last six months; number 
of days used other prescribed opioids last six months; number of days used other illicit opioids 
last six months; number of days used methamphetamine last six months; number of days used 
prescribed benzodiazepines last six months; number of days used illicit benzodiazepines last six 
months; number of days used prescribed buprenorphine last six months; number of days used 
illicit buprenorphine last six months; any benzodiazepine – number days oral use last six months; 
any benzodiazepine – number days intravenous use last six months; any pharmaceutical opioid 
– number days oral use last six months; any pharmaceutical opioid – number days intravenous use 
last six months; SDS score for benzodiazepine dependence; SDS score for morphine dependence; 
SDS score for methadone dependence; and SDS score for buprenorphine dependence.
There were several significant (at .05) relationships, three positive and one negative. There was 
a strong positive relationship between age and the total crime score, meaning that the older the 
respondent the higher the total crime score (R2 = 0.98), as well as between the number of days 
that illicit benzodiazepines were used and the total crime score, meaning that as the number of 
days of use increased, so did the corresponding crime score (R2 = 0.84). The average number of 
days that benzodiazepines were used by these participants was 80 (sd = 87). There was also a 
positive association between the drug injected most often last month and the crime score, with 
heroin injecting more predictive of a higher score than injecting of other drugs (R2 = 0.495). A 
negative relationship was found between the total Severity of Dependence Score for methadone 
dependence and the total crime score; thus the higher the dependence score for methadone use, 
the lower the crime score for the user was likely to be (R2 = -0.602).
There were also some significant findings from a series of Student’s t-tests that were conducted in 
order to examine whether there was any relationship between self-reported criminal behaviour in 
the past month and the SDS scores for the various drug categories. Caution should be exercised 
when interpreting the following findings, as in some cases the numbers of respondents is small. 
The findings of significance cannot be inferred as generalisable to the generable population of 
users of the individual drugs.
Those who reported committing crimes whilst using benzodiazepines in the month prior (n = 
14) recorded a significantly higher SDS score for benzodiazepines than those who did not report 
criminal behaviour whilst using these drugs (n = 83), t (95) = -2.349 (the mean SDS score for 
participants reporting criminal behaviour was 6.21, for those reporting no such behaviour it was 
3.89). 
Those who indicated they had committed crimes whilst withdrawing from benzodiazepines (n 
= 13) also recorded a significantly higher SDS score than those participants reporting no such 
connection between benzodiazepine withdrawal and crime (n = 84), t (95) = -2.173 (the mean 
benzodiazepines SDS score for participants reporting criminal behaviour was 6.15, for those 
reporting no such behaviour it was 3.93).
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A similar picture existed for participants who reported committing crimes whilst using morphine in 
the month prior, with the number of participants who did so recording a significantly higher SDS 
score than the respondents who did not report criminal behaviour whilst using the drugs. However, 
this group was very small (n = 4 reporting committing crimes, compared with n = 39 who did not). 
The results should therefore be treated with caution; t (41) = -3.004 (the mean morphine SDS score 
for participants reporting criminal behaviour was 10.50, for those reporting no such behaviour it 
was 4.23). Only one respondent reported they had committed crimes whilst withdrawing from 
morphine.
There were no other statistically significant relationships between any criminal behaviours and 
any other variables, although it should be kept in mind that in many cases the sizes of the sub-
samples were too small to enable meaningful analyses to be conducted (for example, only a few 
respondents reported using individual drugs such as temazepam, MS Contin, Kapanol etc. and also 
reported committing any kinds of crime). That does not necessarily mean that no association exists, 
just that samples of participants representing these users would have to be deliberately targeted in 
order to investigate these relationships further.
Criminal activity directly related to prescription drugs last month
Twenty-nine percent of respondents (n = 28) reported stealing prescriptions and/or prescribed 
drugs within the month prior to the interview. For instance, five percent of respondents (n = 5) 
reported stealing prescriptions from other people (one person reported they had done this 10 times 
in the past month), and 12% (n = 12) reported having stolen prescription drugs from other people 
(one person had done this thirty times, or daily). Nine percent (n = 9) said they had taken drugs 
from a doctor’s surgery, whilst three percent (n = 3) reported having done so from a pharmacy. 
For around half of the reported thefts of prescriptions or drugs (n = 15), the reason given was 
opportunity, such as finding a prescription pad at a surgery, being presented with an opportunity 
to fill another person’s prescription, or finding the drugs somewhere they could easily be stolen, 
either in a pharmacy, hospital, doctor’s surgery or a private residence. Six of the nine respondents 
(69%) who reportedly stole drugs from a doctor’s surgery claimed they were easily obtainable in 
this way.
Examples of typical statements by respondents who had stolen prescriptions or drugs in this way 
were: 'She gave me the prescription to collect, and I ran away with it. It is their fault if they are 
stupid' (having stolen a prescription); 'I had none of my own and they were there', and '…I took 
Mum’s (two respondents on having stolen drugs from others); 'I wanted Normisons and they were 
there', and 'Temaz plus a script for MS Contin were in a basket at the pharmacy', and 'They left 
them in the tray and I needed them' (having taken drugs from a pharmacy); 'I stole three books 
that were stamped and ready to go' (on stealing a prescription pad from a doctor’s clinic), and 
'He walked out of the room, so I looked in the drawer and took some Valium', ' The opportunity 
was there…so I took them', and 'The opportunity was there. It was their own fault, they shouldn’t 
have left them' (after stealing drugs from a doctor). The other reason for the behaviour typically 
centred on the want/need for a particular drug: for example, 'I wanted Normisons'; 'I love the 
drug (Xanax)', 'Because they were benzodiazepines', 'To get pethidine and morphine', and 'I was 
hanging out'.
Seven respondents reported they had forged a prescription in the past month, with the most 
likely reason for this reportedly because particular drugs, mainly benzodiazepines (specifically 
temazepam) were desired. Comments included 'To get high and stop being sick'; 'To get 
Normisons'; 'To get temaz to sell'; and '…I wanted the caps not the tabs'.
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When it came to having their prescriptions and prescribed drugs stolen from them within the 
month prior to the interview, 16% of participants reported the former (n = 16), and 35% (n = 36) 
the latter (five people reported this had happened to them on 10 occasions, and one reported it 
had occurred 20 times). The drug most likely to be stolen from respondents was Valium (13 cases), 
and temazepam (six cases).
Thirty nine participants (38% of the sample) reported they had driven a vehicle while affected by 
prescription drugs, with 25% reporting having done so five or more times in the previous month 
(n = 26, 12 reported having done this daily, and one reported they had driven intoxicated on 120 
occasions). Many of these respondents reported that they drove intoxicated because they 'needed 
to get somewhere' (n = 14), and many also believed their driving ability was not affected by the 
drugs (n = 9). Several reported that as they take drugs daily (for instance methadone syrup), they 
have no choice.
One respondent reported they had spiked another person’s drink with prescription drugs during 
the past month, and that they had done so twice, with the reason given that they 'wanted to score'. 
In addition, one respondent claimed that her drink had been spiked.
The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
Links with crime 
More than half these respondents had been involved in property-related crime in the previous 
month (not necessarily charged with), while almost half reported they had dealt drugs in that 
time. Thirteen percent reported they had been involved in violent behaviour, 13% reported 
committing a fraud, and 5% had been involved in sex work.
Of those committing property offences, many reported they were drug-related, namely 
to obtain money for drugs, or were under the influence of drugs or in withdrawal (mainly 
heroin).
Of those committing crimes of violence, several attributed intoxication on drugs to their 
behaviour.
The reasons given for dealing drugs were predominantly to obtain money for their own drug 
supply.
Fourteen percent of respondents reported that the effects of benzodiazepines had caused them 
to commit a crime (mostly property-related), and 12% reported that the effects of withdrawing 
from these drugs resulted in them being involved in criminal activity.
Four current morphine users blamed intoxication on the drug for criminal behaviour, and the 
same number attributed their criminal activity to the effects of withdrawal from morphine.
Three participants each blamed buprenorphine intoxication and withdrawal, and methadone 
withdrawal on criminal behaviour.
In terms of individual crimes these participants had been charged for in the previous year, 
property crimes were related mainly to heroin and benzodiazepines use, with morphine and 
methadone also blamed, and the 'need for money for drugs' also blamed. 
Crimes of violence were attributed to a range of drugs, with benzodiazepines, heroin, 
methadone, Ice, and cannabis singled out for blame. Participants reported being charged with 
driving under the influence while using benzodiazepines, heroin, amphetamines and multiple 
drugs.
•
•
•
•
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Statistically, the strongest predictor of criminal behaviour was frequency of heroin use for 
these participants, in that the more frequent use predicted more likelihood of reporting such 
behaviour.
A minority of participants suggested that their recent pharmaceutical drug use had 
caused them to be involved in some form of criminal behaviour. These reports do differ 
significantly according to pharmaceutical drug class, namely those using and withdrawing 
from benzodiazepines were significantly more likely to report such behaviour (in particular 
property crime).
The degree of dependence on benzodiazepines and its frequency of use were significantly 
related to involvement in property crime. 
While some morphine users also reported this activity, the numbers were too small to conduct 
meaningful statistical tests. 
While financial imperatives and needing goods/essential items for self or family, were most 
commonly reported as reasons for involvement in property crime, opioid (especially heroin) 
addiction and withdrawal were also strong reasons provided for such behaviour.
Increased use of prescribed methadone syrup was predictive of less involvement in such 
activities.
Involvement in selling of drugs to others was unrelated to the extent of any particular 
pharmaceutical product, and was most commonly explained in terms of a means of financial 
support (for food, bills, debts) by PWID participants engaging in dealing.
Half of the n = 13 participants reporting involvement in violent crime (n = 6) were injectors of 
benzodiazepines. Most (n = 11) had injected heroin in the previous six months. 
Reasons for involvement in violent acts were mainly reported as being situational (e.g. 'lost 
my temper') rather than related to financial reasons (17% reported needing food or goods), 
although 17% were under the influence of drugs at the time (mainly heroin).
More than one-third of the sample (38%) reported driving under the influence of drugs, 
with one-quarter reporting they had done so five or more times in the previous month. The 
majority (n = 23) had used heroin the most frequently in that month, whilst five had been 
using or injecting morphine, eight buprenorphine, and one each benzodiazepines and heroin 
combined with benzodiazepines.
One PWID participant reported spiking another person’s drink with benzodiazepines in order 
to obtain sex. One other also reported this had happened to her.
Most of the 28 respondents who reported stealing prescriptions or prescription drugs 
nominated temazepam as the drug they had targeted, but alprazolam, diazepam, pethidine, 
morphine, and MS Contin were named as well. More than one-third of the PWID participants 
reported having some legitimately prescribed prescription drug stolen from them in the 
preceding six months, most commonly diazepam or temazepam.
Perceptions of police activity and impact
Changes to police activity in regard to prescription drugs last 6 months
The participants were not in general agreement about whether there had been noticeable changes 
in police activity targeted specifically at illicit prescription drug use within the year prior to the 
survey, although only one reported that there was less activity than previously. Thirty-six percent 
reported that police activity had been stable (n = 37), while 38% reported it had increased (n = 
39); a further 26% reported they did not know whether there had been a change in activity (n 
= 27). Forty-two percent of respondents reported specific police actions that had impacted on 
them around prescription drugs (n = 43), with 30% (n = 13) stating police were more vigilant in 
•
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checking the legitimacy of prescriptions and names on prescription bottles/packets, and 26% (n = 
11) reporting that police were targeting people on buprenorphine in particular for checking. Five 
respondents (13%) also reported that police presence was more obvious around chemists. 
Police activity making it more difficult to get drugs
The majority (67%, n = 68) of respondents reported that any changes that may have occurred in 
police activity in the past six months had not made it any more difficult to access prescription 
drugs, whilst 16% reported that police activity had made it more difficult to obtain them (n = 16), 
and 16% also reported that they didn’t know if such activity had had any effect (n = 16). Fifteen 
percent of respondents reported specific incidents that had made it more difficult for them to 
obtain drugs (n = 15), with almost half of them (47%, n = 7) saying that drugs had become harder 
to access as a result of police activity. Two respondents (13%) each reported that a greater police 
presence had made it harder to get drugs, they had had their scripts checked by police or they 
had been arrested for having prescription drugs without a script. A further two respondents (13%) 
reported that whilst there was more police activity around prescription drugs, this had not effected 
them personally.
Other activity making it more difficult to get drugs
On the other hand more than half of the respondents (55%, n = 56) reported that besides police 
activity, 'other' activity had made it more difficult to access prescription drugs. Explanations of the 
activities that had had this effect related to doctors or chemists 'cracking down' on prescribing and 
dispensing (75%, n = 44), authorities (HIC) 'cracking down' on doctor-shopping (10%, n = 6), and 
increased public awareness making it more difficult to access the drugs (5%, n = 3).
Market changes in the drug used most in the last 12 months
Eighty-five participants considered that the market in the drug they used most had changed in 
some way in the past 12 months, with 60 discussing heroin, and the rest discussing other drugs, 
such as buprenorphine (n = 2), methamphetamines (n = 6), benzodiazepines (n = 7), morphine (n 
= 6), and cannabis (n = 4). In terms of changes in the heroin market, many respondents were of the 
opinion the quality had increased (n = 23), although almost the same number felt it had declined 
(n = 21). Several (n = 3) thought the quality fluctuated, and the remainder believed it was fairly 
stable or had no opinion about the quality.
Of those offering information about the price of heroin, 17 indicated the price had increased, 
whilst only five reported it had become cheaper, the rest reported the price fluctuated. In terms 
of availability, the general consensus was that it was getting easier to obtain as time went by, 
following the drought, with almost all respondents reporting that it was easier now than a year ago, 
and only six believing it was harder to get; several respondents commented to the effect that 'it’s 
coming back', 'the drought’s gone', 'it’s the same as before the drought'. 
The two buprenorphine users were not in agreement about the market in the drug, with one each 
reporting it was harder to get and more expensive, and easier to get and cheaper. Information 
about methamphetamines was also inconsistent, with three users reporting the quality and potency 
of the drugs had increased, and two who reported the purity had declined, and the remainder 
reported it fluctuated. 
Benzodiazepines users were generally in agreement that the drugs were easy to obtain on the 
street, with one reporting that gel capsules were easy to get but expensive at $10 - $15 per 
capsule, and $180 - $220 a bottle. Only one respondent reported gel capsules were more difficult 
to obtain on the street, while one user reported that it was harder to get them from doctor-
shopping, saying that doctors were 'cracking down'. Information about morphine was inconsistent 
also. 
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Two morphine users reported that the drugs were harder to get on the street, with one saying the 
price had increased. Both of these respondents reported that crime had increased as a result of the 
reduced availability and increased prices. On the other hand, three reported that they were very 
prevalent with 'everyone taking them', and one respondent reported that 'doctors are prescribing 
them to everyone'. One respondent reported that tablets could be obtained on the street for as little 
as $10. All respondents reporting on cannabis indicated it had become more difficult to obtain and 
costs more.
Impact of market changes in drug used most
Depending on whether availability of the most used drug had increased/decreased or become 
cheaper/more expensive, the responses to the impacts of the market changes on respondents 
differed. For those reporting their drug had become more difficult to locate or costed more, 
the responses centred around committing more crimes to finance the increased price (n = 6), 
experiencing increased anxiety (n = 6), having to change sources (n = 3), using other drugs (n 
= 3), suffering financially (n = 17), having to search harder (n = 6), going without (n = 2), and 
experiencing negative effects on their relationship (n = 3). Respondents reported that the increased 
availability of drugs had a beneficial financial effect for them as they sold them (n = 4), while four 
reported it was good to be able to rely on the supply. Nineteen reported that any changes in the 
market of the drug they used most had no effect on them.
PWID perceptions of the impact of greater availability of drug used most
Many respondents indicated that a reduced availability of the drug they used the most would have 
multiple impacts on them and on their friends who also use the drug, therefore the responses do 
not add up to the total number of respondents. See Table 32.
Table 32. PWID perceptions of the impact of reduced availability of drugs they use most.
Many respondents indicated that greater availability of the drug they used the most would have 
multiple impacts on them and on their friends who also use the drug, therefore the responses do 
not add up to the total number of respondents. See Table 33.
Impact of fewer drugs
Respondent (number 
of responses)
Friends of respondent 
(number of responses)
Substitute other drugs/stop using 34 28 
Commit crime 19 29
Very anxious/crave the drugs 5 7
No effect 11 3
Use less 8 1
Sex work 4 2
Alcohol 2 -
Violence 1 6
Don’t know - 10
Other effect 8 15
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Table 33. PWID perceptions of the impact of greater availability of drugs used most.
Summary with reference to NDLERF research questions
Interventions 
The pattern of drug use for these participants is for poly drug use, rather than exclusive use 
of one drug. Most pharmaceutical opioid consuming PWID participants nominated heroin 
as their drug of choice, but were commonly using benzodiazepines and/or pharmaceutical 
opioids either as well as heroin, or in its place if it was difficult to obtain. There have also 
been reports of 'stockpiling' temazepam in preparation for increased regulation of the drug. 
This pattern, as well as increases in use of amphetamines, has increased since the heroin 
drought in Victoria. 
The logical consequences of supply reduction of benzodiazepines and morphine would be 
an even greater increase in the use of heroin and amphetamines, and greater diversion of 
prescribed opioids, in particular buprenorphine and methadone. 
Further, should supply reduction efforts reduce the availability of the pharmaceutical 
opioids, then this may have the potential to create a situation where increased efforts were 
made to establish lines of regular supply of other prescribed drugs such as morphine, 
and more uncommon illicits, such as cocaine, into the local market, and also to increase 
the involvement of large-scale dealing, which was reported with low frequency by these 
participants.
Evidence for an increase in other illicit markets is demonstrated by participant responses 
when they were asked to choose what drug they would substitute if the drug they used most 
were unavailable, with a large number reporting they would substitute illicit drugs. While 
one-quarter of heroin users nominated benzodiazepines as their second drug of choice, 
and 12% chose morphine, methadone or other opioids, 14% reported they would seek out 
amphetamines, and 11% nominated cannabis. Six of the 10 participants who nominated 
morphine as the drug they had used the most indicated they would use heroin if it were 
unavailable, whilst only one reported they would use some other form of morphine (e.g. 
substitute MS Contin for Kapanol). All four participants reporting that other opioids were their 
most frequently used drug reported they would substitute heroin for them if they could not get 
them. Three of the 10 participants who had used benzodiazepines most reported they would 
•
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Impact of more of the drug
Respondent (number 
of responses)
Friends of respondent 
(number of responses)
Use more drugs 45 44
No effect 19 6
Save money 6 3
Bad health 2 5
Overdose 4 -
Use less 2 7
Live normal life 5 -
Be happier - 7
Stop using 1 -
Don’t know - 7
Other effect 8 3
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choose amphetamines, and the same proportion reported they would substitute cannabis, 
whereas three reported they would substitute another benzodiazepine (e.g. use alprazolam 
instead of temazepam), and one said they would use morphine. 
Among PWID receiving benzodiazepines both licitly and illicitly, it was commonly reported 
that a substantial decrease in the availability of benzodiazepines would have a deleterious 
effect on drug-using, as well as psychological and social aspects of their life, increasing 
potential to use heroin, heightening anxiety and aggression, and decreasing the ability to cope 
with everyday life and withdrawal symptoms. 
Participants commonly reported they would use other means to obtain these drugs if they 
were to become more difficult to access, through doctor-shopping, reverting to violence 
or criminal behaviour, or finding some other way of diverting them. Some did report they 
would stop or reduce their use of the drugs in response to a decreased availability of diverted 
benzodiazepines.
There was also some suggestion that doctor-shopping, crime or violent behaviour may 
increase in response to such a market change, with participants reporting that availability of 
benzodiazepines kept down the need for crime.
Most respondents using diverted pharmaceutical opioids reported that they would not stop 
or decrease their use of these drugs if there was a substantial decrease in their availability, 
especially buprenorphine, and that they would locate their drug of choice 'somehow'.
Participants were more likely to report they would suffer financially, and reported that criminal 
activity may increase in order to obtain drugs, or to gain money to buy them illicitly. Very few 
participants reported that a decrease in the drugs would cause them to seek pharmaceutical 
maintenance therapy, although a large proportion reported they would use other drugs 
instead, such as heroin, methamphetamine or benzodiazepines. 
Summary
Market characteristics 
The findings from stage two suggest that this current sample of Melbourne PWID preferred heroin 
to any other drug; however, significant numbers of the participants also regularly used and injected 
pharmaceutical opioids and benzodiazepines. These drugs may be used to supplement the effects 
of heroin, or as a substitute for heroin if it is difficult or expensive to obtain, but they also seem to 
reflect a clear pattern of opportunistic and poly drug use amongst this sample. 
Almost all these participants reported they had used benzodiazepines recently, either medically, 
illicitly, or both, and that almost half of those who had used heroin in the previous six months had 
also injected benzodiazepines. The current findings suggest that while other studies, such as the 
IDRS, found last year that benzodiazepine injecting was decreasing amongst PWID since peaking 
in 2002, the practice still exists to a substantial degree, with almost half of these respondents 
reporting they had injected the drugs recently and with reasonably high frequency. 
The findings further suggest that PWID in Melbourne were able to obtain gel capsules illicitly 
relatively easily at the time these data were collected, with 10 or 20mg gel capsules of temazepam 
selling for between $1 and $30, with an average cost of $10 - $20 each (or up to $300 for a 
bottle in some locations), and tablets selling for between $1 and $5 each. In addition, some of 
these PWID reported injecting benzodiazepines other than temazepam, such as diazepam and 
alprazolam. 
The finding that most participants had used illicitly acquired morphine recently, and over 70% had 
injected it, suggests that the use and injection of morphine preparations, particularly MS Contin 
tablets and Kapanol capsules, may also be substantial and frequent among the PWID population 
•
•
•
•
•
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in Melbourne. In addition, the finding that three-quarters of the participants who had used heroin 
in the previous six months had also injected illicit morphine, further confirms the pattern of poly 
drug use and the availability of morphine in the market. Morphine for illicit use was reportedly not 
difficult to obtain in the city, with 100mg tablets and capsules selling for between $10 and $100, 
at an average price of $40 - $50 each.
The findings also suggest that the prevalence of buprenorphine injection is high amongst 
Melbourne PWID, with over one-third of these PWID (and almost one-third of recent heroin users) 
reportedly injecting the drug recently, a finding that reflects trends detected by recent IDRS studies 
(Breen et al. 2004). The findings further suggest that participants undertaking buprenorphine 
treatment are likely to inject the drug as well as take it orally. The consistent trends in the misuse of 
buprenorphine suggest that Melbourne PWID may use the opioid in a similar way to how Darwin 
PWID use the opioid morphine, and how Hobart PWID use the opioid methadone (e.g. Breen et 
al. 2004).
Diversion
Almost one-third of these respondents reported they had stolen prescriptions or prescription drugs 
in the previous month. In nearly all cases, the drugs involved were benzodiazepines, mainly 
temazepam, although other benzodiazepines and MS Contin were also targeted. Participants 
usually reported 'needing' particular drugs (benzodiazepines), and being opportunistic in stealing 
prescriptions and/or drugs from various locations, such as doctor’s surgeries, chemists, or other 
people, where they had been afforded easy access and took advantage of a situation when it arose. 
More than a third had also had their own prescription drugs, mainly diazepam and alprazolam, 
stolen from them. 
Illicit sources for the prescription drugs appear to be largely what could be termed 'low-grade' or 
'informal' diffuse and overlapping networks around the users, with the majority of opioids and 
benzodiazepines seemingly given to the respondents or sourced via friends, other users, and small-
time dealers where they are not prescribed. Where both morphine and benzodiazepines were 
purchased, they were most likely bought from someone who was selling their own prescription 
drugs, or from a known user/dealer, although substantial numbers of the suppliers reportedly 
also sold other pharmaceutical drugs, as well as illicits such as amphetamines and heroin. These 
current findings suggest that further research may be valuable in determining a clearer picture 
of the market intersection for these drugs by examining how the drugs move from the legitimate 
patient to the PWID for illicit use, and whether there are other sources further up the supply chain 
that could not be assessed in this study, such as internet pharmacies and illegal importation of the 
drugs.
Links to crime
These participants report a high prevalence of involvement in some kind of crime, with almost 
three-quarters having been imprisoned at some point in the past, and more than half reporting 
they had committed a crime, mainly property-related, in the previous 12 months. In addition, 
more than one-third had been charged with property offences in the previous 12 months, and 
over 10% had been charged with a crime relating to violence. Further, 40% of these participants 
reported they had driven a vehicle whilst under the influence of drugs in the past month, and 
around a quarter of the sample reported they did so frequently, in one case up to 120 times. The 
older the participant, the more different kinds of crimes they reported being involved in during 
the previous month. The strongest relationship found between drug use and crime was for heroin, 
with higher frequency of use associated with more offences. Participants frequently attributed their 
own criminal behaviour to the use of drugs, and the need for money for drugs, including heroin, 
benzodiazepines and methadone syrup.
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In terms of how the use of the prescription drugs relates specifically to criminal behaviour, findings 
are not clear-cut, mainly because of small numbers in the different categories. Self-reports indicate 
that participants frequently attribute criminal behaviour to drug intoxication and withdrawal. 
These current findings do suggest an association between frequency of use of benzodiazepines 
and committing crimes, in particular property crimes, with this relationship not seen for any other 
prescription drug. In addition, participants who reported having been involved in some kind of 
crime when either under the influence of benzodiazepines or else withdrawing from them in the 
past month, also recorded a higher score for dependence on the Severity of Dependence Scale 
(SDS) for the drugs than participants who did not report such criminal involvement. The same 
relationship was also seen for those committing crimes whilst intoxicated with morphine. These 
findings were not present for any other categories of drugs. However, caution should be applied 
when considering the generalisability of these findings, as the numbers of participants who 
actually reported committing crimes while under the direct influence of any drugs or withdrawing 
from them were low, in some cases too low to enable statistical tests to be conducted.
Implications for police and other frontline workers 
Reports of injecting harms implicating prescriptions drugs were frequent for this sample, with 
'dirty hits', venous damage, thrombosis, and overdoses the most commonly reported. Participants 
themselves named the biggest risks of using benzodiazepines and all pharmaceutical opioids 
as physical/health effects and the risk of addiction or overdosing. The level of dependence on 
pharmaceutical drugs within this sample appears to be high, with scores on the SDS suggesting 
that most participants are technically dependent on at least one prescription drug, with more than 
one-third possibly severely dependent on one or more drugs. This finding has implications for both 
law enforcement and health providers, as the need for a drug of dependence will naturally have 
profound effects on the users’ behaviours as they act to acquire the drug to alleviate craving and 
anxiety associated with withdrawal syndrome.
Interventions
There was a perception amongst the respondents that it had become more difficult to obtain 
prescription drugs in the previous year because of interventions either by police, or by doctors 
or other authorities such as the Health Insurance Commission (HIC). Whilst around one-third of 
participants believed that police activity around prescription drugs had increased, and the same 
number reported it had remained stable in that time, about 40% of respondents reported that 
police targeted pharmacies, searched for prescription drugs, requested prescriptions, and checked 
bottles for the name of the patient, and that such activities had made it more difficult to access 
the drugs illicitly. More participants, however, believed that other interventions had limited their 
access to the drugs, with over 50% reporting that increased public awareness about illicit use of 
the drugs, and initiatives by general practitioners or the HIC, had made it more difficult for them 
to access the drugs, because prescriptions were more difficult to obtain, and this impacted on 
street availability as well. Examples of such interventions included doctors refusing to prescribe the 
drugs, or limiting prescriptions to 'drip-feeds', where the patient receives only one or two doses at 
a time, and a belief by some participants that users were on a 'doctor-shoppers' database which 
meant they could not obtain prescriptions.
Stage three: Secondary indicator data
A range of secondary indicator data was sourced from National and Victorian law enforcement 
and health sectors to provide an additional perspective on the issues under focus, and assist 
in interpreting the relationships between crime and prescription drugs misuse in Victoria. The 
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most current data available are presented here, separated into broad categories of Use trends, 
Prescribing trends, Crime and police activity, Health, and Drug market characteristics and 
pharmaceutical use.
Jurisdictional indicators
Use trends
National Drug Strategy Household Survey 
Every three years the National Drug Strategy Household Survey (NDSHS) collects an array of 
information on drug use by Australians aged 14 years or more. Data on lifetime and recent use 
(past 12 months) of selected drugs from the last three surveys are displayed in Table 34 (AIHW 
2001). Specific information about morphine was not collected and data collection on methadone 
and other opioid use commenced in 2001. The table shows that the lifetime and recent use of 
heroin, painkillers, and benzodiazepines in Australia fluctuated over the surveys; however, the 
use of benzodiazepines and morphine in Victoria was generally higher than in Australia as whole. 
Seven percent of Victorians reported lifetime non-medical use of benzodiazepines in the NDSHS 
1998 (AIHW 1998), while four percent reported such use in the 12 months prior to the survey, and 
this usage more than halved in 2001. A similar pattern of use was seen for painkillers/analgesics, 
with 12% reporting lifetime use in 1998, six percent reporting recent use, which dropped to six 
precent and three percent respectively in 2001. Use of methadone declined in both Victoria and 
Australia. See Table 34.
Table 34. Lifetime and recent use of selected drugs in 1995, 1998 and 2001, Victoria and Australia 
(%).
Source: National Drug Strategy Household Surveys (AIHW 1995, 1998, & 2001).                                                         
* Standard error greater than 0.50   
na: Not available
Prescribing trends
Benzodiazepines
In 2001 there were over 1.92 million subsidised prescriptions for benzodiazepines issued 
under the PBS/RPBS (Victorian Department of Human Services, 2002). Approximately 80% of 
benzodiazepines issued through Australian pharmacies are subsidised. Hospitals also dispense a 
large number of prescriptions. Compared to the previous year there was a drop in benzodiazepine 
prescriptions issued in 2001, a trend which continued in the following two years. See Figure 4. 
LIFETIME USE RECENT USE
1995 1998 2001 1995 1998 2001
DRUG Vic Aus Vic Aus Vic Aus Vic Aus Vic Aus Vic Aus
Heroin 1.4 1.4 2.2 2.2 1.5 1.6 0.3 0.4 1 0.7 0.3 0.2
Other opioids na na na na 1.2 1.3 na na na na 0.4 0.3
Methadone na na 0.3 0.5 0.2 0.3 na na 0.2 0.2 0.1* 0.1
Tranq/sleepers 4 3.2 7.4 6.2 3.2 3.2 0.9 0.6 4 3.0 1.1 1.1
Painkillers/
analgesics
na na 12.2 11.1 6.0 3.2 na na 6.1 4.9 3.4 3.1
Injected illegal 
drugs
0.9 1.3 2.2 2.1 1.4 1.9 0.4 0.6 0.9 0.7 0.6 0.6
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Temazepam was the most commonly prescribed of the benzodiazepines, accounting for 40% 
of prescriptions, and together temazepam, diazepam and oxazepam account for 84% of all 
benzodiazepines issued under the scheme. 
Figure 4: Total number of prescriptions for benzodiazepines under the PBS/RPBS, 2001 - 2003
Source: DUSC Pharmaceutical Benefits Branch, Health Access and Financing Division, Australian Government Department 
of Health and Ageing (Drug Utilisation Sub-committee (DUSC) 2004).
The decrease in benzodiazepine prescriptions issued under the PBS/RPBS for the three years from 
2001 was reflected by a corresponding decrease in temazepam prescriptions (Breen et al. 2003b). 
The decrease in prescribing is less marked in Victoria than in Australia as a whole. See Figure 5. In 
1998, 7% of temazepam prescriptions were for tablets and 93% were for capsules – the proportion 
of capsules has declined since, with 22% of Victorian temazepam prescriptions in 2001 being for 
tablets (Dobbin 2001).
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Figure 5: Total number of prescriptions for temazepam (capsules and tablets) under the PBS/
RPBS, 2001 - 2003
Source: DUSC Pharmaceutical Benefits Branch, Health Access and Financing Division, Australian Government Department 
of Health and Ageing, 2004.
Pharmaceutical opioids
Morphine prescriptions
There was a slight decrease in prescriptions filled under the PBS/RPBS for morphine in tablet or 
capsule form (as brands Anamorph, MS Contin and Kapanol) in Victoria between 1998 (7,850 
prescriptions) and 2002 (1,557,734 prescriptions), reflecting the trend across Australia (from 
153,700 to 3,264,072 prescriptions) in that time. See Figure 6.
Figure 6: Total number of prescriptions for morphine tablets and capsules (branded as Anamorph, 
MS Contin and Kapanol) under the PBS/RPBS, 1998 - 2002
Source: DRUMS, The Treaties & Monitoring Team, Office of Chemical Safety, Therapeutic Goods Administration, 2003.
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Methadone prescriptions
Methadone syrup prescriptions in Victoria have decreased since 2000, reflecting an Australia-wide 
situation for the treatment drug, in particular since the introduction of buprenorphine treatment in 
2000, and that drug’s approval under the PBS/RPBS in 2001. See Figure 7.
Figure 7: Total number of methadone syrup prescriptions for Victoria compared with the whole of 
Australia under the PBS/RPBS, 1998 - 2002
Source: DRUMS, The Treaties & Monitoring Team, Office of Chemical Safety, Therapeutic Goods Administration.
Annual National Pharmacotherapy statistics to June 30, 2002 (Australian Government Department 
of Health and Ageing, 2003) provided information about prescribing of methadone by public and 
private prescribers in that year. There were large variations in the numbers of clients receiving 
treatment at public and private prescribers in different jurisdictions. See Table 35.
Table 35. Number of clients collecting doses of methadone at different types of prescribers in 
Victoria and Australia, 12 months to June, 2002.
Source: Australian Government Department of Health and Ageing, 2003.
Buprenorphine prescriptions
Concurrent with trends in the decreasing use of methadone syrup, buprenorphine prescriptions 
filled under the PBS/RPBS have increased rapidly, as it was taken up as accepted treatment 
protocol in 2000, particularly in Victoria, and approved for PBS prescribing in 2001. In 2002, 
Victorian prescriptions represented 48% of all prescriptions for buprenorphine issued under the 
PBS/RPBS. See Figure 8.
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Pharmacies 4,580 15,148
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Figure 8: Total number of prescriptions for buprenorphine in Victoria and Australia-wide under 
PBS/RPBS, 1998 - 2002
Source: DRUMS, The Treaties & Monitoring Team, Office of Chemical Safety, Therapeutic Goods Administration.
Annual National Pharmacotherapy statistics to June 30, 2002 (Australian Government Department 
of Health and Ageing, 2003) provided information about prescribing of buprenorphine by public 
and private prescribers in that year. There were large variations in the numbers of clients receiving 
treatment at public and public prescribers in different jurisdictions. These data, combined with 
those above confirm that Victoria represented the single largest prescriber of buprenorphine, at 
53% of all private and public registered clients in Australia. See Table 36.
Table 36. Number of clients collecting doses of buprenorphine at different types of prescribers in 
Victoria and Australia, 12 months to June, 2002.
Source: Australian Government Department of Health and Ageing, 2003.
Forged prescriptions
In 1995, 223 items were included on forged or altered prescriptions reported to the Drugs 
and Poisons Unit, Victoria (cited in Dobbin 2001). Benzodiazepines accounted for 49% of the 
forged items, with temazepam accounting for 29% of all benzodiazepine prescriptions forged 
(Dobbin 2001). In the six months to the end of May 2001, 185 forged items were reported, with 
benzodiazepines accounting for 74%, and temazepam accounting for 85% of all benzodiazepine 
prescription forgeries. All forgeries or alterations nominated capsules as the dose form. There were 
no alterations or forgeries for tablets (Dobbin 2001). See Figure 9.
No of clients collecting 
buprenorphine 
SA Vic QLD NSW Tas WA ACT NT TOTAL
Pharmacies N/A 2,711 450 134 47 709  18 4,069
Public clinics N/A 37 36 337  151 36  597
Private clinics    323     323
Correctional facilities N/A 54 26 81  17   178
Other  10 83 63     156
Total no of clients 0 2,812 595 938 47 877 36 18 5,323
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Figure 9: Reported forged benzodiazepine prescriptions in the six months to 31 May 2001
Source: Dobbin (2001)
Forgeries were written on stolen prescription stationery, some of which were taken during 
burglaries. A possible additional 385 prescriptions remain undetected. A number of computer-
generated forgeries were also detected for Normison 20 mg capsules x 50 (Dobbin 2001). 
Crime/police activity
Pharmacy Guild Insurance
Each year Guild Insurance Limited collects data about pharmacy crime-related claims. The most 
recent data are to the end of June 2002, and show a dramatic increase in total pharmacy-related 
crime claims in Victoria and Australia as a whole in 2001/02. Although this increase corresponds 
to the period around the Victorian Temazepam Initiative and the HIC regulation of 10mg 
temazepam capsules, it is not possible to ascertain the proportion of incidents that directly relate 
to prescription drug thefts from premises as such. See Table 37.
Table 37. The number of pharmacy crime-related claims for the four years ending June 30, 2002.
 Source: Guild Insurance Limited (2003)
Year
State Description of Incident 1998/99 1999/00 2000/01 2001/02
Victoria Malicious Damage 207 337 258 657
Burglary 171 339 669 1,524
Armed hold up/Threat 53 25 20 54
Theft 71 48 47 132
Larceny 44 56 44 52
Total 546 805 1,038 2,419
Australia Malicious Damage 868 832 560 1,411
Burglary 671 729 922 2,124
Armed hold up/Threat 335 238 232 220
Theft 106 87 62 350
Larceny 64 124 106 67
Total 2,044 2,010 1,882 4,172
Oxazepam
4%Diazepam
10%
Temazepam not 
specified
16%
Temazepam caps
69%
Flunitrazepam
1%
Total forged items 185, 
benzodiazepines 135 (74%)
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The financial loss to Guild Insurance Limited more than doubled from 2001/01 to 2001/02 for 
Australia-wide claims, and more than quadrupled in Victoria, from a total $2,178, 665 in 1998/99 
($500,769 in Victoria) to $5,258,757 in 2001/02 ($2,410,770 in Victoria). Victoria’s proportion of 
the total Australian figures increased substantially throughout the period, so that by 2001/02 they 
represent more than half of all claims received. The Victorian percentage of total claims was 26.7% 
in 1998/99, 40% in 1999/00, 55% in 2000/01, and 57.7% in 2001/02 (claims costs include costs 
of damage caused to premises as well as loss of stock/items etc.). See Figure 10.
Figure 10: Total number of claims for pharmacy-related crimes received by Guild Insurance 
Limited, 1998/99 - 2001/02
Source: Guild Insurance Limited (2003)
Law Enforcement Assistance Program
Data extracted from the LEAP database by the Victorian Police Statistical Services Division was 
examined for trends in offences reported against pharmacies/chemists between 1998/99 and 
2002/03. No information was available for the types of goods stolen in burglaries, or whether 
drugs were taken; however, the Victorian temazepam initiative occurred November 2001, and 
the PBS authority change for temazepam gel capsules occurred May 2002. Burglaries at Victorian 
Chemists almost doubled in number between 1998/99 and 2000/01 (from 253 to 531), and 
increased by almost a further 50% to the year 2001/02 (to 743). Then burglary offences more than 
halved between 2001/02 and 2002/03 (to 360) taking the total offences reported in that year to 
below the number reported in 1999/00. In terms of the total value of items stolen in the reported 
burglaries, the amount decreased substantially between 1998/99 and 2000/01, and increased 
again in the following year, remaining high in 2002/03. See Table 38.
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Table 38. Number of burglaries on chemists/pharmacies, 1998/99 - 2002/03.
­­Source: Data extracted from LEAP on 25/06/04 by Victorian Police Statistical Services Division.   
Data is subject to variation. 
Figure 11 demonstrates the trend in reported offences between 1998/99 and 2002/03.
Figure 11: Total number of burglaries from chemists/pharmacies reported, 1998/99 - 2002/03
Source: LEAP data, Victoria Police, 2004.
Offenders in age categories 17-39 were more common than offenders aged less than 16, or over 
40 years, in all years, and in particular in 2000/01 and 2001/02, the years when the offences were 
reported with the highest frequency. Table 39 shows that the majority of offences reported resulted 
in arrest of the offender, and that arrests increased from 56 in 1998/99 to 159 in 2000/01, and 
again to 187 in 2001/02, reducing somewhat in 2002/03 to 117.
Value
Financial 
Year
Offence 
Count
Median Mean Total
Financial 
Year
Total
1998/99 253 $258.00 $2,793.00 $452,407.00 1998/99 $452,407.00
1999/00 373 $200.00 $698.00 $174,549.00 1999/00 $174,549.00
2000/01 531 $266.00 $801.00 $272,211.00 2000/01 $272,211.00
2001/02 743 $233.00 $909.00 $397,951.00 2001/02 $397,951.00
2002/03 360 $500.00 $2,115.00 $363,745.00 2002/03 $363,745.00
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Table 39. Number of offenders processed for burglaries on chemists/pharmacies from 1998/99  - 
2002/03 by age and how dealt with.
­­­­­­­­­­­­­­Source: Data extracted from LEAP on 25/06/04 by Victorian Police Statistical Services Division.   
      Data is subject to variation.
Figure 12 displays the total number of people in different age categories charged for offences 
against chemists/pharmacies between 1998/99 and 2002/03. In all years the majority of offences 
were committed by individuals aged between 17 and 39 years, and offences within these age 
categories also increased in 2001/02, and 2000/01. Offences committed by individuals aged 
below 16 were minimal in this time, and offences decreased dramatically for the over 40 years age 
group in all years.
How Dealt With <16 17-25 26-39 40-54 Total
1998/99 Arrest 0 27 27 2 56
 Caution 1 0 0 0 1
 Not authorised 1 1 0 0 2
 Summons applied for/issued 1 4 0 2 7
Total 3 32 27 4 66
1999/00 Arrest 0 36 31 11 78
 Not authorised 0 0 1 0 1
 Summons applied for/issued 0 4 2 0 6
Total 0 40 34 11 85
2000/01 Arrest 5 82 63 9 159
 Not authorised 0 1 1 0 2
 Other 1 0 0 0 1
 Summons applied for/issued 1 7 1 1 10
Total 7 90 65 10 172
2001/02 Arrest 4 97 84 2 187
 Caution 0 0 1 0 1
 Not authorised 0 2 1 0 3
 Summons applied for/issued 2 10 22 2 36
Total 6 109 108 4 227
2002/03 Arrest 2 58 49 8 117
 Caution 1 0 0 0 1
 Not authorised 0 1 0 0 1
 Summons applied for/issued 2 9 10 2 23
Total 5 68 59 10 142
Grand Total 21 339 293 39 692
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Figure 12: Number of offenders processed for burglaries on chemists/pharmacies, 1998/99 - 
2002/03 by age
Source: LEAP data, Victoria Police, 2004.
Drug offences
The number of people arrested for drug-related offences fell during 2000-01 compared with  
1999-00, although this varied depending on drug type (see Table 40).
Table 40. Consumer and provider arrests, by drug type, Victoria, 2000-01.
Source: Victorian Department of Human Services, 2002.
Cannabis 
(n)
Heroin 
(n)
Amphetamine 
(n)
Cocaine 
(n)
Hallucinogens 
(n)
Steroids 
(n)
Other 
(n) 
Totals 
(N)
Consumer Arrests
Female 832 581 159 4 0 0 148 1724
Male 4,656 2,047 694 33 1 0 575 8,006
Unknown 28 1 2 0 0 0 2 33
Total 5,516 2,629 855 37 1 0 725 9,763
Provider Arrests
Female 147 301 66 1 0 0 32 547
Male 806 1,068 333 25 0 0 169 2,401
Unknown 4 5 1 0 0 0 0 10
Total 957 1,374 400 26 0 0 201 2,958
Total Arrests
Female 990 884 227 5 0 0 397 2,503
Male 5,501 3,118 1,033 58 1 0 1,974 11,685
Unknown 33 6 3 0 0 0 13 55
Total 6,524 4,008 1,263 63 1 0 2,384 14,243
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 Heroin and cannabis-related arrests decreased, while arrests for amphetamine-type stimulants, 
cocaine and other stimulants increased. More people were arrested for cannabis-related offences 
(consumer/provider) than any other drug type, and more men than women were arrested for 
trafficking and/or possession than women (Victorian Department of Human Services, 2002). See 
Table 40 (pharmaceutical drugs are categorised within 'other', and are not specified).
Number of drug charges finalised by offence category, 1998/99 to 2000/01
The Victorian Department of Justice (VDJ) collates Victorian Magistrate’s Court data related to 
drug offences, which are presented in the Victorian Drug Statistics handbook-2002 (Victorian 
Department of Human Services, 2002). In 1998/99, 22,456 drug-related charges were finalised. In 
2000-01 this fell to 17,397. The majority of finalised charges were for possession and use charges, 
rather than cultivate, manufacture and traffic. The majority of charges in 1998-99 related to heroin 
and cannabis. Numbers of finalised manufacturing and possession charges decreased across 
the three-year period for heroin and cannabis as a percentage of all finalised charges. Table 41 
demonstrates the sentencing outcome for the principal proven charges for each drug type during 
2000-01. Most charges for cultivation traffic and manufacture (46%) resulted in a fine or bond, 
with 32% resulting in suspended sentences. While 78% of possession and use charges resulted in 
a bond or fine, 11% resulted in custodial sentences, and 9% resulted in suspended sentences.
Table 41. Drug charge as principal proven charge by drug type and outcome, Victoria, 2000-01.
Source: Victorian Department of Human Services, 2002.
a Data relate to cases where all charges have been finalised and where the principal proven charge was a drug charge.
 The data do not relate to charges relating to cases that were finalised at a committal hearing or filing hearing.
b Custodial sentence = imprisonment, YTC (Youth Training Centre Detention), partially suspended, combined custody
and treatment order.
c Suspended sentence includes suspended sentences, ICO (Intensive Corrections Order), CBO (Community Based Order).
d Fine/bond includes fines or undertaking.
Cultivation, traffic and manufacture chargesa by drug type
Custodial 
sentenceb
Suspended 
sentencec  
Fine/bondd
Convicted & 
discharged
Total 
sentences 
by drug
Drug type N % N % N % N %
Cannabis 188 16.8 204 17.1 799 67.0 1 0.1 1,  192
Heroin 349 59.2 188 31.9 52 8.8 1 0.2 590
Amphetamines 51 58.6 27 31.0 9 10.3 0 0 87
Cocaine 0 0 0 0 0 0 0 0 0
Other 21 55.2 5 13.2 12 31.6 0 0 38
No drug specified 0 0 1 25.0 3 75.0 0 0 4
Sub-total 609 32.1 425 22.2 875 45.8 2 0.1 1,911
Possession and use charges by drug type
Cannabis 31 3.4 52 5.8 813 90.3 4 0.4 900
Heroin 183 18.7 121 12.2 673 67.9 14 1.4 991
Amphetamines 21 10 24 11.4 166 78.7 0 0 211
Cocaine 0 0 0 0 5 100 0 0 5
Other 12 12.2 11 11.2 74 75.5 1 1.0 98
No drug specified 6 18.8 2 6.3 23 71.9 1 3.1 32
Sub-total 253 11.3 210 9.39 1,754 78.4 20 1.0 2,237
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Australian Customs Service
For the majority of benzodiazepine and pharmaceutical drug seizures, specific information 
regarding the generic forms or brand names are not currently recorded in the Australian Customs 
Service drug statistics database. 
Table 42 provides drug detection figures for the relevant drug categories that are available from 
the Australian Customs Service database between 1999 and 2003. Detections of the remaining 
drug categories are recorded in the generic categories of 'Other benzodiazepines' and 'Prescribed 
drugs'. The detections of drugs within these categories, especially 'Other benzodiazepines' and 
'Prescribed drugs', has increased dramatically throughout that time. See Figure 13.
Table 42. Number of drug detections by Australian Customs Service of selected opioids, 
benzodiazepines and prescribed drugs for years 1999 - 2003.
Source: Data provided by Australian Customs Service drug statistics database, 2004.
Drug category 1999 2000 2001 2002 2003
Morphine 4 9 5 7 10
Methadone 1 4 4 3 4
Buprenorphine 0 1 3 0 2
Pethidine 1 1 1 2 1
Codeine 4 7 21 88 32
Diazepam 29 47 106 186 169
Lorazepam 13 21 36 93 76
Nitrazepam 0 4 11 21 7
Other Benzodiazepine N/A 1 63 552 362
Prescribed drugs 310 413 598 1,037 1,180
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Figure 13 shows the seizures of drugs within the different categories.
Figure 13: Number of seizures by Australian Customs of prescribed drugs, 1999 - 2003
Source: Data provided by Australian Customs Service drug statistics database, 2004.
Victoria Police Seizures
The Chemical Drug Intelligence (CDI) Team at the Victoria Police Forensic Services Centre 
collates data on drugs seized by Victorian police annually as a result of a drug possession or drug 
trafficking charge. They supplied data for benzodiazepines and pharmaceutical opioids seized 
by police between 1998 and March 2004 (where applicable). Temazepam was the drug most 
consistently seized between 1998 and 2003, followed by diazepam between 1999 and 2003. The 
trend for seizures of all these pharmaceutical drugs clearly has increased consistently in Victoria 
from 1998 to 2003 (from 3,070 seizures in 1998 to 16,381 in 2001, to 52,386 in 2003). See Table 
43.
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Table 43. Number of units seized of benzodiazepines and pharmaceutical opioids between 1998 
and March 2003.
 Source: The Chemical Drug Intelligence (CDI) Team at the Victoria Police Forensic Services Centre.
Figures 14 and 15 display the trend for seizures between 1998 and March 2003 in the most 
commonly seized benzodiazepines (clonazepam, diazepam, oxazepam and temazepam), and for 
the pharmaceutical opioids.
Figure 14: Number of units of the most frequently seized benzodiazepines, 1998 - 2003
Source: The Chemical Drug Intelligence (CDI) Team at the Victoria Police Forensic Services Centre.
1998 1999 2000 2001 2002 2003 2004
Aprazolam 33 81 4 590 75 159 10
Clonazepam 634 275 389 667 1,111 6,231
Diazepam 622 1,155 1,152 2,960 4,059 1,279
Flunitrazepam 391 166 16 8 340 15 76
Lorazepam 29 5 3
Nitrazepam 136 118 90 42 280 154
Oxazepam 399 327 245 999 1,455 276
Temazepam 826 3,088 1,504 11,110 4,898 44,272
Total 3,070 5,210 3,400 16,381 12,221 52,386 86
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Figure 15: Number of units of pharmaceutical opioids seized between 1998 and March 2003
Source:  The Chemical Drug Intelligence (CDI) Team at the Victoria Police Forensic Services Centre
Health
Alcohol and drug treatment services
A census of 75 specialist alcohol and drug treatment services reported that they had seen 
1,003 clients (users and non-users) on one day in May 2001. Fifty-four percent of the agencies 
reported the number of clients seen that day was typical. Table 44 shows the breakdown of 
the main problem drug of drug-using clients identified by the agencies. The majority of clients 
sought treatment for opioids (34%) and alcohol (33%), with a large proportion also having 
problems with cannabis (12%), and with poly drug use (11%). Three percent of clients mentioned 
benzodiazepines specifically as a problem.
Table 44. Main drug problems of clients attending specialist drug treatment agencies, Victoria, 
2001.
Source: Victorian Department of Human Services (2002)
Drug 2001 (n = 996)
Alcohol 33%
Opioids 34%
Cannabis 12%
Amphetamines 4%
Poly-drug use 11%
Benzodiazepines 3%
Tobacco 1%
Other drugs 1%
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Australian Needle and Syringe Program 
The Australian Needle and Syringe Program (ANSP) collates survey data on the prevalence of the 
last drug injected by Needle Syringe Program (NSP) clients across Australia. Between 2000 and 
2002, there was a clear decreasing trend in Australia in heroin reported as the last drug injected by 
clients, and a corresponding marked increase in the injection of amphetamines. The injection of 
other drugs, such as morphine and methadone, also increased between 2000 and 2002 (Buddle, 
Zhou & MacDonald 2003). See Table 45. 
Table 45. Prevalence of last drug injected in Victoria and Australia, 2000 - 2002 according to the 
Australian Needle and Syringe Program (ANSP) Survey.
Source Buddle, Zhou & MacDonald (2003).
Direct Line
Direct Line provides 24 hour counselling information and referral for Victorians for any drug-
related issue. Responses through 2000/01 where benzodiazepines were mentioned were cited 
as cause for concern. They accounted for five percent of all calls where a drug was identified, 
and two percent of all calls to Direct Line. Metropolitan Melbourne accounts for the bulk of calls 
(83%), and females made the majority (66%) of calls. Unlike other drug types, the majority of calls 
from benzodiazepine users (59%) were also made by women. The majority of users were aged 
between 22 and 40 years. See Table 46.
Table 46. Number of benzodiazepines and other minor tranquilliser-related calls to Direct Line, 
Victoria, 1997/98 - 2000/01.
Source: Direct Line Services database. Turning Point Alcohol and Drug Centre Inc, Victorian 
Department of Human Services, 2002.
2000 2001 2002
Drug
Victoria
(N = 293)
Australia
(N = 2,695)
Victoria
(N = 340)
Australia 
(N = 2,454)
Victoria
(N = 265)
Australia   
(N = 2,445)
Amphetamines 19 (6%) 582 (22%) 84 (24%) 914 (37%) 60 (23%) 809 (33%)
Benzodiazepines 0 11 (<1%) 2 (1%) 11 (<1) 0 8 (<1)
Buprenorphine - - -- - 12 (5%) 25 (1)
Cocaine 0 32 (1%) 05 (1%) 164 (7%) 0 29 (1)
Heroin 255 (87%) 1517 (56%) 197 (58%) 745 (30%) 150 (57%) 881 (36%)
Methadone 5 (2%) 94 (3%) 0 127 (5%) 1 (<1%) 165 (7%)
Morphine 5 (2%) 97 (4%) 9 (3%) 151 (6%) 6 (2%) 180 (7%)
More than one 9 (3%) 199 (7%) 24 (7%) 153 (6%) 24 (9%) 204 (8%)
Year
Benzodiazepines & 
other tranquillisers 
as drug of concern
% of drug identified 
calls
% of all calls
1997/98 1,392 6.7 3.6
1998/99 1,467 5.2 3.3
1999/00 1,167 4.9 3.0
2000/01 1,131 5.0 2.4
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Victorian Emergency Minimum Dataset 
The Victorian Emergency Minimum Dataset (VEMD) provides information on tissue and vascular 
harm cases presenting to emergency departments in Victoria resulting from injection of temazepam 
(cited in Dobbin 2001). The database was not designed for systematic searching of cases due 
to injury caused by a specific drug or mode of administration. Because of limitations of the 
VEMD search technique, only an unknown proportion of actual cases of harm resulting from 
injection of temazepam capsule contents will have been identified. These results may substantially 
underestimate the number of cases. Sixty-three cases were identified for the period 1996 to end 
of first quarter 2001. In a similar exercise seeking cases presenting as a result of injection of 
oxazepam and diazepam in the same period, only a handful of cases were identified, some of 
which appeared to be due to therapeutic injection of diazepam, or overdose. No cases of vascular 
harm were identified (cited in Dobbin 2001). See Table 47.
Table 47. All cases of temazepam capsule-related harms identified: year of presentation, 1996 
- 2001.
 Source: Dobbin (2001).
Non-fatal drug-related overdoses
A database of Melbourne Metropolitan Ambulance Service (MAS) attendance at drug-related 
overdose incidents is maintained by Turning Point. Figure 16 shows the monthly totals for non-
fatal benzodiazepine-related overdoses for the period August 2001 to September 2003 (excludes 
May - July 2001 and October 2002 - February 2003). There was a general trend for decreasing 
benzodiazepine-related cases attended by ambulance in Melbourne in the past several years, with 
2,896 attendances recorded in the 2001/02 financial year, dropping to 1,711 in 2002/03, with 
678 recorded between July and September 2003. Such attendances peaked at 337 in August 2001. 
However, they have remained at over 200 attendances per month.
1996 
(n)
1997 
(n)
1998 
(n)
1999 
(n)
2000 
(n)
2001
(1st quarter)
(n)
Total 
(N)
Vein or tissue harm 4 0 1 5 7 9 26
Other 3 4 3 7 12 8 37
Total 7 4 4 12 19 17 63
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Figure 16: Number of ambulance attendances at non-fatal benzodiazepines overdoses attended 
by Melbourne Ambulance between August 2001 and September 2003
Source: Data obtained from Metropolitan Ambulance Service and compiled by Turning Point Alcohol and Drug Centre Inc., 
2004.
The number of ambulance attendances at non-fatal morphine overdoses fluctuated; after peaking 
at 18 in October 2001, they showed a decrease towards the end of the 2001/02 financial year. 
Attendances then peaked again to 19 in March of 2003, before declining dramatically towards the 
second half of the year, until September when the most recent data are available. See Figure 17. 
Figure 17: Number of Ambulance attendances at non-fatal morphine overdoses attended by 
Melbourne Ambulance between August 2001 and September 2003
             
Source: Data obtained from Metropolitan Ambulance Service and compiled by Turning Point Alcohol and Drug Centre Inc., 
2004.
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Hospitalisations
The Victorian Department of Human Services maintains a database of admissions from private and 
public hospitals (the Victorian Admitted Episode Dataset). Turning Point Alcohol and Drug Centre 
conducts analyses on these data. A summary of the findings for 2000/2001 is presented here. See 
Table 48. The table shows that tobacco and alcohol are responsible for more hospitalisations than 
illicit drugs, causing 25% and 62% of all Victorian hospitalisations respectively. Benzodiazepines 
and other minor tranquilliser misuse accounted for 3.7% of admissions, compared with opioids 
at 2.7%, in 2000/01. Females accounted for the majority of benzodiazepines hospitalisations, 
whereas males accounted for the majority of other drug hospitalisations. There has been a steady 
increase in the number of hospitalisations for benzodiazepines since 1993. Most people were 
female (61%), and aged between 25 and 50 years (62%). The majority of hospital days (66%) 
also involved females (DHS 2002). There were 2,393 benzodiazepine-related hospital admissions 
in 2001/02, which has remained reasonably steady since 2000/01 (n = 2,436) and 1999/00 (n 
=2,176) (Victorian Department of Health and Community Services 2003). There were a total of 
934 opioid related hospital admissions in the 2001/02 financial year, with 46% (n = 427) due 
to poisoning, and 34% (n = 321) due to dependent use. This is a decrease on admissions in 
the 2000/01 year of 1815, and in 1999/00 of 2318. Fewer admissions in 2001/02 were due to 
dependence than in past years (44% in 2000/01; 52% in 1999/00, (Jenkinson, Fry & Miller (2003)).
Table 48. Number of drug-related hospitalisations in Victoria by drug type and sex, 2000/01.
           
             
   Source: Victorian Department of Human Services (2002).     
   * Includes multiple drugs or unknown drugs.
Drug deaths
Other drugs present in heroin-related deaths 
Cases of heroin-related deaths identified by the State Coroner’s Office in Victoria were investigated 
using tissue samples and blood (Wallington, Drummer & Gerostamoulos 2002). Since 1991, there 
have been a total of 1,772 deaths resulting from the use of heroin (Wallington, Gerostamoulos &  
Drummer 2003). There were 49 registered deaths from the use of heroin in Victoria in 2001, which 
was a dramatic decrease (-86%) from the number of deaths in 2000 (n = 331), preceding the 
heroin drought. Heroin-related deaths rose slightly again to 59 in 2002, and increased still more to 
100 in 2003 (Jenkinson, Miller & Fry 2004). At the time of submission of this report, heroin-related 
deaths in Victoria stood at 72 (Aug 31, 2004) (Coroner’s Court and Institute of Forensic Medicine, 
2004, cited in the Herald Sun, June 10, 2004: P. 20). 
Drug Males Females Total
Alcohol 11,473 5,788 17,261
Amphetamines 212 112 324
Benzodiazepines 955 1,476 2,436
Cannabis 314 151 465
Cocaine 13 10 23
Hallucinogens 37 27 64
Inhalants 7 1 8
Opioids 1,116 699 1,815
Polydrug* 375 184 559
Tobacco 27,181 14,241 41,423
Unspecified 798 1,254 2,052
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Forensic toxicology screening for a range of drugs identified other drugs contributing or incidental 
to the deaths. Benzodiazepines were the most common drug group identified in these deaths, 
and were detected in 71% of all cases in 2000, and 55% of all deaths involving heroin from 1997 
- 2001. Morphine-related cases remained fairly consistent between 1997 and 2001, peaking at 
22% of mentions in 1999; however, morphine, plus benzodiazepine mentions, comprised more 
than half the deaths in most years, reaching a high of 71% in 2001 (amphetamines mentions also 
peaked in 2001) (Wallington, Gerostamoulos & Drummer 2003). See Table 49. 
Table 49. Percentage of heroin-related deaths that included the presence of other drugs in the 
deceased’s bloodstream, Victoria, 1997 - 2001.
Source: Wallington, Gerostamoulos & Drummer (2003) 
na: Not available
Heroin-related deaths from 1991 to 2001 were also examined specifically for the presence of 
temazepam in the bloodstream (Dobbin 2001). See Figure 18.
Figure 18: Percentage of heroin-related deaths with temazepam present in the bloodstream, 
Victoria 1990 to August 2001 (data not available for 1995, 1996)
Source: Dobbin (2001)
Opioids-related deaths
The Australian Bureau of Statistics recorded data on opioid overdose deaths (accidental deaths by 
opioids, including heroin, morphine, pethidine, methadone and codeine). The Victorian rate for 
these deaths was 33.2 per million aged 15 - 24 years in 2002, compared with 26.4 per million 
in 2001 and 118.1 per million in 2000 (Degenhardt & Barker 2003). Victoria’s rate reflected 
the national rate in 2002, which was 32.3 per million. See Figure 19 for the number of opioid 
overdose deaths in Victoria from 1992 - 2002 (Degenhardt & Barker 2003).
Prevalence of drugs in 
heroin-related deaths
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(n = 168)
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(n = 268)
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(n = 359)
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(n = 331)
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(n = 49)
Overall 
Average
Morphine only 9% 16% 22% 17% 16% 16%
Benzodiazepines only na na na na 71% 55%
Morphine plus 
benzodiazepines
53% 40% 55% 55% 71% 55%
Morphine plus alcohol 29% 40% 32% 32% 31% 33%
Morphine plus other 
opioid drugs
8% 11% 7.3% 9% 4% 8%
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Figure 19: Number of accidental deaths due to opioids among people aged 15 - 24 in Victoria, 
1992 - 2002
Source: Degenhardt & Barker (2003).
Drug market characteristics and pharmaceutical use
2003 IDRS
Characteristics of the 2003 IDRS sample
Demographic characteristics of the current sample were compared with the 2003 Victorian sample 
of the IDRS (Jenkinson, Miller & Fry 2004), the findings of which are in Table 50. 
Table 50. Characteristics of the Victorian IDRS PWID sample for 2003 (N = 152).
Demographic characteristics of PWID sample of the 2003 IDRS
Gender % Male
Female
60
40
Age (years) Mean
Range
30
18 - 54
ATSI % 5
Housing % House/flat
Parent’s home
Boarding house/refuge/hostel
Homeless
51
13
21
7
Education Mean years 10
Post-school education % Trade
Uni
45
7
Employment % Unemployed
Full time
Part time/causal
Student
Sex worker
83
4
9
1
3
376
323
93
73
243
203
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Table 50 continued.
Source: Jenkinson, Miller & Fry (2004)
There were a few notable differences between the 2003 IDRS sample and the current participants, 
with the proportion of males higher in the current sample than in the IDRS, and the proportion 
of participants in methadone maintenance drug treatment lower than in the IDRS, whilst more 
participants in the current sample (64%) reported they had been to prison.
Drug use history
The mean age at first injecting within the 2003 IDRS Victorian sample was 17.7 (sd = 4.3), ranging 
from 10 - 40 years (Breen et al. 2004), which is similar to the current sample. 
Heroin injecting 
Eighteen percent of the IDRS sample reported injecting illicit drugs less often than once a week 
(compared with five percent currently), whilst 34% reported the practice more than once a week 
(compared with 11% of these participants), and 49% reported that they did this daily or more 
frequently (compared with only 9% of the current respondents).
In terms of the drug that respondents reported injecting most in the past month, 65% of the IDRS 
participants indicated heroin, and 69% reported it as their drug of choice (Breen et al. 2004), 
which was similar to the current findings. Ninety percent reported they had injected in the past six 
months, on average for 76 days, which was also similar to the current sample.
Methamphetamine injecting 
The IDRS sample reported that methamphetamine was the most injected drug for 25% (10% more 
than the current participants), and the favoured drug of 15% (Breen et al. 2004). Seventy percent 
had injected it in the previous six months, for an average of 10 days.
Benzodiazepine injecting 
No respondents reported that benzodiazepines were their drugs of choice, or the drug they 
injected most in the previous month, similar to the participants in the current study. However, 
the majority of respondents (80%, compared with all the current sample) reported having used 
benzodiazepines in the previous six months, with most obtaining them licitly (78%, compared 
with 93% currently), although 45% also received them illicitly (compared with 71% of this 
Demographic characteristics of PWID sample of the 2003 IDRS
Main income % Govt. benefits
Wage/salary
Crime
Sex work
77
4
15
2
Treatment last 6 months % Yes
No
63
37
Current treatment % Buprenorphine
Methadone maintenance
22
15
Months in current treatment Mean (sd)
Median
Range
19.6  (28.42)
6
1 - 144
Prison history % Yes 41
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sample). Fifteen percent of the respondents reported injecting benzodiazepines, for an average 
of five days, compared with 21% in the previous year, and 40% in 2001. Overall, 66% of 
respondents reported they had injected benzodiazepines at some time (compared with 69% 
of this sample). The benzodiazepines most commonly reported as having been used in the six 
months prior to the survey were diazepam (62%, compared with 38% in 2001), oxazepam (14%, 
compared with 9% in 2001), and temazepam (6%, compared with 45% in 2001). KI reported that 
benzodiazepines were used either as a substitute when heroin was unavailable, or to enhance 
and supplement the effects of heroin or other drugs. Benzodiazepines were reportedly obtained 
through doctor-shopping, as well as black market street selling.
Morphine and other opioids injecting 
Two percent of the IDRS sample indicated morphine as their drug of choice (Breen et al. 2004), 
about half as many as in the current sample. Nine percent of the current sample, however, 
reported injecting morphine most in the previous month, compared with two percent of the 
IDRS sample. The IDRS reported that both respondents and KI indicated widespread injection of 
morphine, with most of the drugs obtained illicitly (only 6% reported using prescribed morphine), 
and 39% of the sample had injected it in the previous six months, on an average of six days, which 
reflected a slight decrease on the proportion of the previous IDRS sample (51% in 2002), but is still 
higher than in 2001 (32%). Overall 83% reported lifetime use of the drug.
Pharmacotherapy injecting 
The responses of the participants in the IDRS were reflective of the current sample in terms of 
buprenorphine and methadone use, with no participants reporting them as their drug of choice 
(Breen et al. 2004). However, 10% of the current sample reported buprenorphine was the 
drug they used most in the previous month. Only one respondent each reported injecting licit 
methadone and illicit methadone. But the IDRS reported increasing injection of buprenorphine 
with over 39% of the respondents reporting the practice in the previous six months, on average on 
24 days where the drugs were licit and four days when they were illicit. 
Recent drug use 
In the IDRS 90% of respondents reported injecting heroin in the previous six months (compared 
with 86% of these participants). Fewer IDRS participants reported injecting illicitly acquired 
morphine or benzodiazepines than the current participants, at 39% and 15% respectively 
(compared with 72.5% and 42% here) (Breen et al. 2004). The incidence of recent injection of 
illicit buprenorphine by IDRS participants was similar, however, at 30% (33.5% for the current 
sample), and illicit methadone had been injected by just 1% of the IDRS sample compared with 
9% of the current sample (Breen et al. 2004).
The 2003 IDRS findings (Breen, et al. 2004) were broadly similar to the current findings, with 
the exception that the current participants were significantly more likely to have injected 
benzodiazepines and morphine. This suggests that these are intersecting populations of 
predominantly heroin users (or this is a sub-group of the usual IDRS population), with the 
current sample being polydrug users, who especially tend towards the use and injection of the 
benzodiazepines and pharmaceutical opioids, whether as substitutes for heroin, or in conjunction 
with it.
Law enforcement trends
Overall, the level of self-reported criminal activity was relatively stable and in most areas police 
activity had reportedly continued to decrease significantly from previous IDRS studies (Jenkinson, 
Miller & Fry 2004). The majority of respondents (79%) reported that police activity had had no 
effect on their ability to access drugs (Jenkinson, Miller & Fry 2004).
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Summary
Examination of Victorian-specific indicator data in relation to use and misuse of pharmaceutical 
opioids or benzodiazepines indicates the following.
Use trends
According to the National Drug Strategy Household Survey (Australian Institute of Health 
and Welfare 1995, 1998, 2001), lifetime and recent use of heroin, painkillers, and 
benzodiazepines in Australia fluctuated over the past three surveys; however, the use of 
benzodiazepines and morphine in Victoria was generally higher than in Australia as whole. 
Use of methadone declined in both Victoria and Australia. 
Prescribing trends
The Drug Utilisation Sub-committee (DUSC) of the Pharmaceutical Benefits Branch, 
Health Access and Financing Division, Australian Government Department of Health and 
Ageing (DUSC 2004) reported there was a steadily decreasing number of benzodiazepine 
prescriptions issued under the PBS/RPBS for the three years from 2001. The decrease in 
benzodiazepine prescriptions was reflected by a corresponding decrease in temazepam 
prescriptions (Breen et al. 2003b). The decrease was less marked in Victoria than in Australia 
as a whole. In 1998, 7% of temazepam prescriptions were for tablets and 93% were for 
capsules – the proportion of capsules has declined since, with 22% of Victorian temazepam 
prescriptions in 2001 being for tablets.
The Drug Use Monitoring Scheme (DRUMS) of the Treaties & Monitoring Team, Office of 
Chemical Safety, Therapeutic Goods Administration (DRUMS 2003) reported an increase in 
prescriptions filled under the PBS/RPBS for morphine in tablet or capsule form (as brands 
Anamorph, and Kapanol) between 1999 and 2001, but a slight decrease was seen in 2002, 
although the decrease was not as marked in Victoria as it was in Australia. Methadone syrup 
prescriptions in Victoria have decreased since 2000, reflecting an Australia-wide situation 
for the treatment drug, in particular since the introduction of buprenorphine treatment in 
2000, and that drug’s approval under the PBS/RPBS in 2001. Concurrent with trends in the 
decreasing use of methadone syrup, buprenorphine prescriptions filled under the PBS/RPBS 
have increased rapidly, as it was taken up as accepted treatment protocol in 2000, particularly 
in Victoria, and approved for PBS prescribing in 2001. In 2002, Victorian prescriptions 
represented 48% of all prescriptions for buprenorphine issued under the PBS/RPBS.
According to the Annual National Pharmacotherapy statistics to June 30, 2002 (Australian 
Government Department of Health and Ageing, 2003), there were large variations in 
the numbers of clients receiving treatment at public and private prescribers in different 
jurisdictions. These data, combined with those above, confirm that Victoria represented the 
single largest prescriber of buprenorphine, at 53% of all private and public registered clients 
in Australia.
In 1995, 223 items were included on forged or altered prescriptions reported to the Drugs 
and Poisons Unit, Victoria. Benzodiazepines accounted for 49% of the forged items, with 
temazepam accounting for 29% of all benzodiazepines prescriptions forged. In the six months 
to the end of May 2001, 185 forged items were reported, with benzodiazepines accounting 
for 74%, and temazepam accounting for 85% of all benzodiazepine prescription forgeries. 
All forgeries or alterations nominated capsules as the dose form. There were no alterations or 
forgeries for tablets (Dobbin 2001).
Crime/police activity
Each year Guild Insurance Limited collects data about pharmacy crime-related claims. The 
most recent data were to the end of June 2002, and showed a dramatic increase in total 
•
•
•
•
•
•
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pharmacy-related crime claims in Victoria and Australia as a whole, in 2001 - 2002. This 
increase corresponded to the period around the Victorian Temazepam Initiative and the 
HIC regulation of 10mg temazepam capsules, although the actual relationship cannot be 
ascertained as these data are not available. The financial loss to Guild Insurance Limited 
more than doubled in that time for Australia-wide claims, and more than quadrupled in 
Victoria, from a total $2,178, 665 in 1998/99 ($500,769 in Victoria) to $5,258,757 in 
2001/02 ($2,410,770 in Victoria). Victoria’s proportion of the total Australian figures increased 
substantially throughout the period so that by 2001/02 they represented more than half all 
claims received. The Victorian percentage of total claims was 26.7% in1998/99, 40% in 
1999/00, 55% in 2000/01, and 57.7% in 2001/02.
The Victorian Department of Justice (VDJ) collates Victorian Magistrate’s Court data related to 
drug offences. The number of people arrested for drug-related offences fell during 2000/01 
compared with 1999/00, although this varied depending on drug type. Heroin and cannabis-
related arrests decreased, while arrests for amphetamine-type stimulants, cocaine and 
stimulants increased. More people were arrested for cannabis-related offences (consumer/
provider) than any other drug type, and more men than women were arrested for trafficking 
and/or possession than women (cited in Victorian Department of Human Services 2002).
In 1998/99, 22,456 drug-related charges were finalised. In 2000/01 this fell to 17,397. The 
majority of finalised charges were for possession and use charges, rather than cultivate, 
manufacture and traffic. The majority of charges in 1998/99 related to heroin and cannabis. 
Numbers of finalised manufacturing and possession charges decreased across the three-
year period for heroin and cannabis as a percentage of all finalised charges. Most charges 
for cultivation traffic and manufacture (46%) resulted in a fine or bond, with 32% resulting 
in suspended sentences. While 78% of possession and use charges resulted in a bond or 
fine, 11% resulted in custodial sentences, and 9% resulted in suspended sentences (cited in 
Victorian Department of Human Services 2002).
Data extracted from the Law Enforcement Assistance Program (LEAP) data base by the 
Victorian Police Statistical Services Division was examined for trends in offences reported 
against pharmacies/chemists between 1998/99 and 2002/03. No information was available for 
the types of goods stolen in burglaries, or whether drugs were taken; however, the Victorian 
temazepam initiative occurred November 2001, and the PBS authority change for temazepam 
gel capsules occurred May 2002. Burglaries at Victorian Chemists almost doubled in number 
between 1998/99 and 2000/01 (from 253 to 531), and increased by almost a further 50% in 
the year 2001/02 (to 743). Burglary offences then more than halved between 2001/02 and 
2002/03 (to 360) taking the total offences reported in that year to below the number reported 
in 1999/00. In terms of the total value of items stolen in the reported burglaries, the amount 
decreased substantially between 1998/99 and 2000/01, and increased again in the following 
year, remaining high in 2002/03. Offenders in age categories 17-39 were far more common 
than offenders aged less than 16 or over 40 years in all years, and in particular in 2000/01 
and 2001/02, the years when the offences were reported with the highest frequency. The 
majority of offences reported resulted in arrest of the offender, and arrests increased from 56 
in 1998/99 to 159 in 2000/01, and again to 187 in 2001/02, reducing somewhat in 2002/03 
to 117.
For the majority of benzodiazepine and pharmaceutical drug seizures, specific information 
regarding the generic forms or brand names are not currently recorded in the Australian 
Customs Service drug statistics database. Data are provided for drug detection figures for the 
relevant drug categories that were available from the Australian Customs Service database 
between 1999 and 2003. Detections of the remaining drug categories are recorded in the 
generic categories of 'Other benzodiazepines' and 'Prescribed drugs'. The detections of 
drugs within these categories, especially 'Other benzodiazepines' and 'Prescribed drugs', has 
increased dramatically throughout that time.
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The Chemical Drug Intelligence (CDI) Team at the Victoria Police Forensic Services Centre 
collates data on drugs seized by Victoria police annually as a result of a drug possession or 
drug trafficking charge. They supplied data for benzodiazepines and pharmaceutical opioids 
seized between 1998 and March 2004 (where applicable). Temazepam was the drug most 
consistently seized between 1998 and 2003, followed by diazepam between 1999 and 
2003. The trend for police seizures of all these pharmaceutical drugs clearly has increased 
consistently in Victoria from 1998 to 2003.
Health
A census of 75 specialist alcohol and drug treatment services reported seeing 1,003 clients 
(users and non-users) on one day in May 2001. The majority of clients sought treatment for 
opioids (34%) and alcohol (33%), with a large proportion also having problems with cannabis 
(12%), and with poly drug use (11%). Three percent of clients mentioned benzodiazepines 
specifically as a problem.
The Australian Needle and Syringe Program (ANSP) collates survey data on the prevalence of 
the last drug injected by Needle Syringe Program (NSP) clients across Australia. Between 2000 
and 2002, there was a clear decreasing trend in Australia in heroin reported as the last drug 
injected by clients, and a corresponding marked increase in the injection of amphetamines. 
The injection of other drugs, such as morphine and methadone, also increased between 2000 
and 2002 (Buddle, Zhou, & MacDonald 2003).
Direct Line provides 24 hour counselling information and referral for Victorians for any drug-
related issue. Responses through 2000/01 where benzodiazepines were mentioned were cited 
as cause for concern. They accounted for five percent of all calls where a drug was identified, 
and two percent of all calls to Direct Line. Metropolitan Melbourne accounts for the bulk 
of calls (83%), and females made the majority (66%) of calls. Unlike other drug types, the 
majority (59%) of calls from benzodiazepine users were also made by women. The majority of 
users were aged between 22 and 40 years (cited in Victorian Department of Human Services, 
2002).
The Victorian Emergency Minimum Dataset (VEMD) provides information on tissue and 
vascular harm cases presenting to emergency departments in Victoria resulting from injection 
of temazepam. Sixty-three cases were identified for the period 1996 to end of first quarter 
2001. In a similar exercise seeking cases presenting as a result of injection of oxazepam 
and diazepam in the same period, only a handful of cases were identified, some of which 
appeared to be due to therapeutic injection of diazepam, or overdose. No cases of vascular 
harm were identified (cited in Victorian Department of Human Services 2002).
Non-fatal benzodiazepine overdoses for May 2001 - April 2002, and May 2002 - June 2003 
(excludes May - July 2001 and October 2002 - February 2003) showed there was a general 
trend for decreasing benzodiazepine-related cases attended by ambulance in Melbourne 
in the past several years, with 2,896 attendances recorded in the 2001/02 financial year, 
dropping to 1,711 in 2002/03, with 678 recorded between July and September 2003. Such 
attendances peaked at 337 in August 2001. They have remained at over 200 attendances 
per month however (Data obtained from Melbourne Metropolitan Ambulance Service and 
compiled by Turning Point Alcohol & Drug Centre, Inc, 2003).
The number of ambulance attendances at non-fatal morphine overdoses fluctuated; after 
peaking at 18 in October 2001, they showed a decrease towards the end of the 2001/02 
financial year. Attendances then peaked again to 19 in March of 2003, before declining 
dramatically towards the second half of the year, until September when the most recent data 
are available (Data obtained from Melbourne Metropolitan Ambulance Service and compiled 
by Turning Point Alcohol & Drug Centre, Inc, 2003).
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The Victorian Admitted Episode Dataset is a database of admissions from private and 
public hospitals. There has been a steady increase in the numbers of hospitalisations for 
benzodiazepines since 1993. In contrast to 1999/00, where opioids were the most common 
cause of illicit drug-related hospitalisations, benzodiazepine and other minor tranquilliser 
misuse accounted for 31% (compared with opioids at 23%) in 2000/01. There were 2,393 
benzodiazepine-related hospital admissions in 2001/02, which has remained reasonably 
steady since 2000/01 (n = 2,436) and 1999/00 (n = 2,176). Females accounted for the 
majority of benzodiazepines hospitalisations, whereas males accounted for the majority of 
other drug hospitalizations (cited in Victorian Department of Human Services, 2002). 
There were a total of 934 opioid-related hospital admissions in the 2001/02 financial year, 
with 46% (n = 427) due to poisoning, and 34% (n = 321) due to dependent use. This is 
a decrease on admissions in the 2000/01 year of 1,815, and in 1999/00 of 2,318. Fewer 
admissions in 2001/02 were due to dependence than in past years (44% in 2000/01, 52% in 
1999/00 (cited in Victorian Department of Human Services, 2002).
Forensic toxicology screening for a range of drugs identified other drugs contributing, or 
incidental to, heroin-related deaths identified by the State Coroner’s Office in Victoria 
between 1997 and 2001. Benzodiazepines were the most common drug group identified in 
these deaths, and were detected in 71% of all cases in 2000, and 55% of all deaths involving 
heroin from 1997 - 2001. Morphine-related cases remained fairly consistent between 1997 
and 2001, peaking at 22% of mentions in 1999; however, morphine plus benzodiazepine 
mentions comprised more than half the deaths in most years, reaching a high of 71% in 2001 
(amphetamines mentions also peaked in 2001) (Wallington, Gerostamoulos & Drummer 
2003).
The Australian Bureau of Statistics recorded data on opioid overdose deaths (accidental deaths 
by opioids, including heroin, morphine, pethidine, methadone and codeine). The Victorian 
rate for these deaths was 33.2 per million aged 15 - 24 years in 2002, compared with 26.4 
per million in 2001 and 118.1 per million in 2000. Victoria’s rate reflected the national rate in 
2002, which was 32.3 per million. See Figure 19 for the number of opioid overdose deaths in 
Victoria from 1992 - 2002 (Degenhardt & Barker 2003).
Drug market characteristics and pharmaceutical use
There were a few notable differences between the 2003 IDRS (Jenkinson, Miller & Fry 
2004) sample and the current participants, with the proportion of recent benzodiazepine 
and morphine injectors substantially higher in the current sampling, reflecting the targeted 
recruitment undertaken for this survey. However, buprenorphine use and injection was similar, 
as were the demographic characteristics of both samples (Jenkinson, Fry & Miller 2003). The 
characteristics of the current sample compared with the most recent IDRS findings suggest the 
current sample may be a particular sub-set of the population that is normally captured by the 
IDRS recruitment process.
Stage four: Survey of people who inject drugs
Fifty Melbourne PWID were surveyed on their demographic characteristics, and asked detailed 
questions about their drug use history and patterns of current drug use, with particular focus 
on details of benzodiazepine and pharmaceutical opioid use. They were also asked to provide 
information about drug markets, including sources of supply, price and availability of prescription 
drugs, and any changes that may have occurred in the markets in the previous twelve months. 
Participants were asked for any information about drug-related and criminal behaviour, and how 
this may relate to specific prescription drug use. All responses were collated, and descriptive 
analyses were performed. Where qualitative information was collected, responses were 
categorised, and the number of responses were calculated. 
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Overview of the sample of people who inject drugs 
Sixteen percent of PWID participants in Stage four (n = 8) had also participated in the Stage two 
interviews. Stage four respondents were asked to provide information about themselves and their 
education, living situation, employment and income, and drug treatment and prison history. The 
proportion of male and female participants in each age group for this stage was similar, with 47% 
of men aged over 31 and 44% of women aged below 31.
Table 51. Cross tabulation of gender and age for Melbourne Stage four PWID participants (N = 50).
 
 This distribution differed from Stage two, where a higher proportion of men were older than the 
median age of 32 years, and a higher proportion of women were younger than the median. It is 
possible that the reported differences between the two samples may be a product of sampling, 
with the Stage four sample half the size of Stage two. See Table 51, which displays comparisons 
between age and gender in the Melbourne sample. Age was categorised according to the median 
of 31.5 years.
Table 52. Description of the PWID Stage four participants in Melbourne (N = 58).
Gender
Age Female (n) Male (n) Total (N)
Age 31 and Under 7 18 25
Age Over 31 9 16 25
Total 16 34 50
Demographic characteristics of the Stage 4 Melbourne PWID sample 
Gender % Male
Female
68 
32
Age (years) Mean
Range
31.64
21 - 55
ATSI % 8
Housing % House/flat
Parent’s home
Friend’s house
Boarding house/hostel
Shelter
Homeless
44
14
6
22
8
6
Education Mean years (Range) 9.9 (5 - 12)
Post-school education % Trade
Uni
40
8
Employment % Unemployed
Employed
Sex-worker
Student
Home duties
88
12
-
-
-
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Table 52 continued.
A question that asked respondents how much they had earned in the previous fortnight from 
various sources that did not appear on the Stage two survey questionnaire was included on the 
Stage four survey. This question was in place of the Stage two question asking about the 'main' 
source of income. The responses to the new question indicate that participants on average 
obtained most of their income from government benefits ($361), drug dealing ($214), 'other' 
sources, such as charities and begging ($160), and crime ($80). 
There were two notable differences between the Stage two and Stage four samples. First, 
participants in Stage two spent a substantially longer time on average in drug treatment programs 
than those in Stage four, although their median time was higher, thus there was greater variance. 
Second, 34% fewer participants in Stage four reported having a prison history than in Stage two. 
See Table 52.
Drug use history of people who inject drugs
Respondents were asked about their history and patterns of drug use, including their drug of 
choice, what happened if they could not get their drug of choice, which drug they had injected 
most in the previous month, and their injecting patterns. They were also asked if they had bought 
drugs in the previous fortnight, and, if so, which drug/s and how much they had paid. More detail 
about drug use history is contained in Table 53.
Almost half the respondents (48%, n = 24) reported they inject drugs at least once a day, whilst 
24% (n = 12) reported they do so almost every day (4 - 6 days a week), 22% reported they inject 
two to three days a week, and 4% (n = 2) indicated they do so less often than once a week. Most 
of the respondents (57%, n = 28) reported they usually inject while in a private home, while 
24% (n = 12) reported they inject in a public place such as a street, park or bench, and 12% (n 
= 6) reported they inject in a public toilet. The remaining participants said they inject in a car or 
'anywhere'.
Heroin injecting 
Most (96%) of the participants had injected heroin during the previous six months, which was 
higher than Stage two. The average frequency was higher also, at 90.5 days (75.5 in Stage two). The 
drug of choice for 72% of these respondents (n = 36) was heroin, which was a little higher than in 
Demographic characteristics of the Stage 4 Melbourne PWID sample
$ Income from different 
sources - Mean (sd)
Govt. benefits
Wage/salary
Crime
Sex work
Drug dealing
Loans/gifts
Other (begging, charity etc)
$361 (125)
$69 (205)
$80 (149)
$41 (200)
$214 (1,062)
$28 (49)
$160 (394)
Current treatment % None
Methadone Maintenance
Buprenorphine
Detoxification
50
10
36
4
Months in current treatment (Mean (sd))
Range
14.7 (14.8)
0.50 - 48
Treatment last 6 months % 64
Prison history % 42
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Stage two. In the past month, 75.5% of participants had injected heroin more often than any other 
drug – this was around 50% higher than in Stage two. A greater proportion of these participants 
(96%, n = 48) than in Stage two (86%, n = 43) injected heroin in the previous six months. These 
participants also injected heroin on a greater number of days on average as well, at 90 days of the 
past 180, compared with 75 days.
Methamphetamine injecting 
A little more than half (54%) of participants had injected methamphetamines in the previous six 
months, which was substantially less than in Stage two (83%). The frequency of use had declined 
also, at 14 days on average (compared with 28 days in Stage two). Ten percent of this sample 
reported methamphetamines (n = 5) as their preferred drug, while 8.2% of the respondents 
injected methamphetamine most often in the past month, somewhat fewer than in Stage two. Fifty-
four percent (n = 27) had injected methamphetamine in the previous six months, on average 14 
days of the previous 180 days.
Pharmacotherapy injecting 
No Melbourne respondents reported methadone syrup or buprenorphine as the drug they 
preferred. However, buprenorphine was nominated as the drug most injected last month by 10% 
(n = 5), which was the same as for Stage two, and methadone was injected by 2% (n = 1) (no one 
injected methadone most in the past month in Stage two). Twenty participants (40%) injected 
buprenorphine in the previous six months (13 injected prescribed drugs and the same number 
injected illicit drugs), while three (6%) injected methadone (two injected prescribed methadone, 
and three injected illicit methadone), and one injected Physeptone (illicitly acquired). Licit 
pharmacotherapies were injected on average on 35.5 days (sd = 62.5), and were swallowed on 
average on 57 days (sd = 65). Illicit pharmacotherapies were injected on an average of 9.8 days (sd 
= 31), and swallowed on 0.70 days (sd = 2.4).
Table 53.  Drug use history for Victorian Stage four PWID respondents (N = 50).
Injected 
last 6 
mths
Used 
ORA last 
6 mths
Drug Class N %
Number days injected 
last 6 mths
N %  Days used last 6 mths
1. Heroin 48 96 Mean 90.5 (sd  180) 
Range 0 - 180 
1 2 Mean 90.5 (sd 180)
Range 0 - 180
2. Homebake 2 4 Mean 3.9 (sd 0.22)
Range 0 - 150
2 4 Mean 3.9 (sd 0.22)
Range 0 - 150
3. Methamphetamine 27 54 Mean 14 (sd 37.7)
Range 0 - 180
0 Mean 14 (sd 37.7)
Range 0 - 180
4. Pharmaceutical
stimulants
0 0 - 2 4 Mean 1.6 (sd 9)
Range 0 - 60
5. Cocaine 6 12 Mean 0.20 (sd .7)
Range 0 - 4
9 18 Mean 0.31 (sd ,77)
Range 0 - 4
6. Hallucinogens 1 2 Mean 0.14 (sd 1)
Range 0 - 7
3 6 Mean 0.18 (sd 1)
Range 0 - 7
7. Ecstasy 8 16 Mean 0.41 (sd 1.3 )
Range 0 - 8
13 26 Mean 1.2 (sd 3.2)
Range 0 - 15
8. Alcohol 0 0 - 31 62 Mean 301 (sd 52)
Range 0 - 180
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Table 53 continued.
Morphine and other opioid injecting 
Four percent of respondents chose morphine (n = 2, one each for Kapanol and MS Contin) as 
their drug of choice, similar to Stage two, but only half that proportion injected it most in the past 
month, compared with nine percent of the Stage two sample. Participants injected licit morphine 
on an average of four days of the previous 180 (sd = 15), and used them orally on average on five 
days (sd = 30.5). Illicit morphine was injected on an average of 26.5 days (sd = 40), and swallowed 
on 0.69 days (sd = 2.6). Other opioids prescribed were injected for an average of seven days (sd 
= 20), and swallowed on 22.6 days (sd = 53.4), and where they were acquired illicitly they were 
injected for an average of four days (sd = 8), and swallowed on 1.4 days (sd = 4).
Injected 
last 6 
mths
Used 
ORA last 
6 mths
Drug Class N %
Number days injected 
last 6 mths
N % Days used last 6 mths
9. Cannabis 0 0 - 47 94 Mean 115 (sd 73)
Range 0 - 180
10. Anti-Depressants 0 0 - 14 28 Mean 24.3 (sd 58)
Range 0 - 180
11. Inhalants 0 0 - 1 2 Mean 0.04 (sd 0.3)
Range 0 - 2
All licit 
pharmacotherapies
16 32 Mean 35.5 (sd 62.6) 
Range 1-180
25 50 Mean 57 (sd 65)
Range 1-180
All illicit 
pharmacotherapies
14 28 Mean 9.75 (sd 40) 
Range 1-180
5 10 Mean .72 (sd 2.4)
Range 0-10
All methadone syrup 3 6 Mean 6.75 (sd 34.6) 
Range 1 - 180
11 22 Mean 23 (sd 57.7)
Range 1-180
Licit methadone syrup 2 4 - 10 20 -
Illicit methadone syrup 3 6 - 1 2 -
All buprenorphine 20  40 Mean 20 (sd 54)
Range 1-180
17 34 Mean 19 (sd 55)
Range 1 -180
Licit buprenorphine 13 26 - 17 34 -
Illicit buprenorphine 13 26 - 4 8 -
Illicit Physeptone 1 2 Mean 0.1 (sd 0)
Range 1
1 2 Mean 1(sd 0)
Range 1
Licit morphine 4 8 Mean 4 (sd 15)
Range 1-80
2 4 Mean 5 (sd 30.5)
Range 3-80 
Illicit morphine 31 62 Mean 26.5 (sd 40) 
Range 1-160
7 14 Mean 0.69 (sd 2.6)
Range 0 - 15
Licit other opioids 7 14 Mean 7 (sd 20)
Range 1-90
8 16 Mean 22.6 (sd 53.4) 
Range 1-180
Illicit other opioids 16 32 Mean 4 (sd 8)
Range 1-90
6 12 Mean 1.4 (sd 4)
Range 1-15
Licit benzodiazepines 12 24 Mean 15 (sd 41)
Range 6-180
37 74 Mean 80.5 (sd 78)
Range 2 - 180
Illicit benzodiazepines 23 46 Mean 13.5 (sd 31) 
Range 1-120
31 62 Mean 22 (sd 31)
Range 1-120
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Most (94%, n = 29) illicit morphine injectors had also injected heroin in the previous six months, 
while two-thirds (n = 31) had also injected amphetamines, 45% (n = 14) had injected illicit 
benzodiazepines, and 35% (n = 11) had injected illicit pharmacotherapies.
Benzodiazepine injecting 
One respondent (2%) selected benzodiazepines (Serepax) as their drug of choice, and, as in Stage 
two, one respondent injected them most in the past month. One respondent also reported that 
Normison and heroin combined was their preferred drug; however, no one reported injecting it 
most in the previous month. In Stage two, four percent nominated benzodiazepines as their drug 
of choice. Prescribed benzodiazepines were injected for an average of 15 days of the previous 
six months (sd = 41 days), and were swallowed for an average of 80.5 days (sd = 78). Where they 
were illicit, they were injected for an average of 13.5 days (sd = 31), and swallowed on average on 
22 days (sd = 31).
All participants who had injected illicit benzodiazepines in the previous six months (n = 23) had 
also injected heroin in that time, two-thirds (n = 15) had also injected methamphetamines, 61% (n 
= 14) had also injected morphine, and 30% (n = 7) had injected illicit pharmacotherapies.
Differences between preferred drug and drug most injected last month
In most cases, the participant’s drug of choice was the drug they had injected with the most 
frequency in the previous month. However, for the 19% (n = 7) of participants who preferred 
heroin but did not inject it most, three injected buprenorphine the most, while two injected 
methamphetamines and one each injected benzodiazepines (temazepam) and methadone. Two 
(40%) respondents who preferred methamphetamine injected heroin instead, and one (20%) 
injected buprenorphine. 
Half of those who reported morphine as their preferred drug (n = 1) injected it the most in the past 
month, with the other respondent injecting heroin most. One participant injected MS Contin. The 
respondent who selected benzodiazepines as their drug of choice reported they injected heroin 
the most, and similarly the one respondent who reported that heroin and Normison combined was 
their drug of choice reported injecting heroin more frequently. 
Eight percent of respondents (n = 4) reported that their drug of choice was the non-injectable 
cannabis, but two reported they had injected heroin more often than they had injected any other 
drug in the previous month, while one had injected buprenorphine the most. One participant 
reported that they had injected heroin with the most frequency, but they preferred alcohol.
Where there was a difference between the preferred drug and the drug injected most often, in 12% 
of cases (n = 6) this was because of availability, while in six percent of cases (n = 3) it was because 
of price. Other reasons for the difference related to health effects (n = 2, 4%), and the heroin 
blocking effects of buprenorphine (n = 1, 2%). Ten percent of participants (n = 5) reported the 
difference was due to their preferred drug being non-injectable. The main reasons for being unable 
to get heroin – the most frequently used and injected drug – were cited to be availability by 36% 
(n = 18) and price by 32% (n = 16).
When respondents were asked whether they would substitute another drug if the drug they used 
most was unavailable, 28% (n = 14) said they would not, 22% (n = 11) indicated they would 
substitute benzodiazepines (mainly diazepam and temazepam) – which was the same proportion 
of Stage two participants – 10% (n = 5) each said they would use morphine (MS Contin), 
similar to Stage two, or cannabis instead, and 8% each (n = 4) reported they would substitute 
methamphetamines or buprenorphine. Most participants reported no problems obtaining heroin 
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most of the time; however, if there was difficulty, 32% (n = 16) reported the main reason they 
could not get it was because of price, and 36% (n = 18) reported that availability had stopped 
them from accessing it.
As with the Stage two sample, these participants clearly preferred to use heroin, and mainly 
injected it more often than any other drug, but would use pharmaceuticals as an alternative if it 
was difficult or expensive to access. Most of these respondents reported they had purchased heroin 
(82%), cannabis (66%) and benzodiazepines (56%) within the previous two weeks. The mean 
total cost paid for heroin was $732, for cannabis was $116, and for benzodiazepines was $92.50. 
Sixteen percent of respondents also reported buying morphine in the previous fortnight, spending 
on average $69, and 22% reported they had bought amphetamines, spending a total of $183 on 
average. See Table 54.
Table 54. Price paid for main drugs purchased the previous two weeks (N = 67).
Other drugs that had been purchased in the previous fortnight were base (n = 1), cocaine (n = 3), 
other opioids (n = 3), antidepressants (n = 3), and illicit methadone (n = 1). Participants spent a 
substantial amount on alcohol and tobacco, with an average of $82 spent on the former, and $76 
on the latter. 
In terms of treatment drugs, four participants had bought methadone in the previous two weeks, 
and spent between $50 and $60, while 30% (n = 15) had bought buprenorphine, spending on 
average $50, ranging from $10 to $70. Seventy-three percent of participants who had purchased 
buprenorphine legally (n = 11) had spent $50 or more on the drug.
These purchase findings appear quite different from those of Stage two, with a higher proportion of 
the current sample buying most drugs and spending more on them; however, it should be kept in 
mind that the equivalent Stage two question related to the previous day only rather than the past 
fortnight, therefore the data are not directly comparable.
Recent benzodiazepines use
Three-quarters of the participants (74%, n = 37) reported using benzodiazepines they had obtained 
legally within the previous six months, about 20% less than in Stage two. A slightly higher 
proportion (78%, n = 39) reported they had used illicitly acquired benzodiazepines within the 
same period, also about 20% less than in Stage two.
Routes of administration and forms used
Ninety percent of participants (n = 45) reported using benzodiazepines orally in the previous 
six months, which was a little less than in Stage two (98%). Sixty-two percent (n = 31) of all 
participants reported oral use of illicitly acquired drugs (this was 79.5% of illicit benzodiazepines 
users). However, all participants who had received them via prescription (n = 37) reported they 
administered them orally. The number of days that prescribed drugs were taken orally ranged 
between two and 180 days in the previous six months, averaging 80.50 (sd = 78.4). When the 
drugs were illicit, they were taken orally on average for fewer days, at 22 days (sd = 31), ranging 
from one to 120 days. 
Price Paid
Heroin
(n = 41) 
(82%)
Cannabis
(n = 33) 
(66%)
Methamphetamine
(n = 11)
(22%)
Benzodiazepines
(n = 28)
(56%)
Morphine
(n = 8)
(16%)
Average cost $732 $116 $183 $92.50 $69
Range $50 - 3,500 $10 - 600 $150 - 250 $3.60 - 1,000 $3.80 - 300
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The most common forms of benzodiazepines reported were temazepam, diazepam, oxazepam, 
alprazolam, and nitrazepam (numbers may add to more than the total participants as some 
respondents used more than one brand of a drug). There were a total 67 reports of temazepam use, 
55 reports of diazepam use, 32 reports of oxazepam use, 21 reports of alprazolam use (Xanax), 
and 16 reports of nitrazepam (Mogadon) use. See Table 55.
Table 55. Number of PWID using and/or injecting the different forms of benzodiazepines in the six 
months before the survey.
Fifty-eight percent of all participants (n = 29) reported they had injected benzodiazepines in the 
previous six months, an increase on the Stage two sample (45%). Injecting of benzodiazepines 
was almost twice as likely to occur when they were acquired illicitly, with 24% (n = 12) of all 
participants (32.5% of licit benzodiazepines users, compared with 16% of these users in Stage 
two) reportedly injecting benzodiazepines when they had been acquired medically. This compared 
with 46% (n = 23) of participants (59% of illicit benzodiazepines users) reporting they had injected 
illicitly acquired drugs (43% of these users in stage two). Six participants injected both prescribed 
and illicit benzodiazepines. Six injected their prescribed benzodiazepines, but did not inject illicit 
drugs. There were also 17 participants (n = 34% of the total, and 59% of all benzodiazepines 
injectors) who reported they had injected benzodiazepines when they were illicit but not when 
they were prescribed. See Table 56. 
Brand of benzodiazepines
Used last six 
months (n)
Injected last 
six months (n)
Temtabs 5 -
Temaze tablets 7 -
Temaze 20mg capsules 5 5
Temaze 10mg capsules  10 8
Euhypnos 20mg capsules 10 10
Euhypnos 10mg capsules 6 5
Normison 10mg tablets  7 2
Normison 20mg capsule 10 9
Normison 10mg capsule  7  6
Diazepam generic 2 -
Valpam 3 1
Antenax 13 -
Valium 37 5
Serepax 21 2 
Alepam 6 -
Murelax 5 -
Xanax 21 2
Mogadon 16 2
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Table 56. Percentage of all participants using benzodiazepines orally and via injection, according 
to method of acquisition.
Although the prevalence of injecting benzodiazepines for this sample was greater when the drugs 
were illicit than when they were prescribed, the frequency of injecting did not differ substantially. 
Where benzodiazepines were prescribed they were injected on average on 15 days (sd = 41) of 
the previous 180, ranging from 6 - 180 days, and when the drugs were illicit they were injected on 
average on 13.5 days (sd = 30.6), ranging from one to 120 days.
The most common form of injected benzodiazepines reported was temazepam, but there were 
reports of diazepam, oxazepam and alprazolam injection as well. There were 45 reports of 
temazepam injection, six reports of injecting diazepam, two reports of injecting oxazepam 
(Serepax), and two reports of alprazolam (Xanax) injecting. See Table 55. There were a further two 
reports of the oral use and three reports of the injecting of Unisom, an over the counter sedative.
Supply, availability and market changes
More than half of those respondents reporting they had been prescribed benzodiazepines (54%, 
n = 20) indicated they had faked symptoms to receive them, with 32% (n = 12) reporting this was 
their usual method of obtaining them – this was substantially more than in Stage two (13%). As in 
Stage two, most (92%, n = 34) of the respondents obtaining benzodiazepines medically reported 
that their symptoms were genuine, with two-thirds (65%, n = 24) reporting this was their usual 
method of obtaining the drugs.
Most respondents (78%, n = 39) who used prescribed benzodiazepines had attempted to obtain 
benzodiazepines in the previous six months, with on average 2.3 doctors (sd = 2.2) being 
successfully approached for a prescription. The number of doctors successfully approached ranged 
from none to 12, with the majority of respondents acquiring a prescription from one doctor (n 
= 16) or two doctors (n = 12). The number of doctors who had been asked for a prescription but 
had refused was on average 1.3 (sd = 2.95), ranging from none to 15. Most respondents who had 
approached doctors for a prescription reported they had not been refused at all (59%, n = 22), and, 
of the remainder, six reported refusal by one doctor, and two doctors refused four. One respondent 
each reported being refused a prescription by 3, 4, 5, 10 or 15 doctors they had approached. No 
respondents had attempted to buy benzodiazepines over the Internet in the previous six months.
Participants were asked about the difficulty or ease of obtaining prescriptions for benzodiazepine 
gel capsules. The most frequent response was that no attempt had been made to obtain them in 
this way (n = 19, 38%), with 20% of the respondents stating that there was no point in asking for 
gel capsules, as they would be refused. Fourteen respondents (28%) indicated it was difficult or 
very difficult to obtain a prescription for gel caps, with 11 (22%) reporting it had become more 
difficult over the past year. Only four (8%) participants reported it was easy, with none reporting it 
was very easy, and nobody reported it had become easier since a year before. 
Obtaining a prescription for benzodiazepine tablets on the other hand was reportedly substantially 
easier, with 62% (n = 31) indicating they were easy or very easy to obtain, and only 12% (n = 
6) stating it was difficult, although 28% (n = 14) reported it had become more difficult over the 
previous 12 months. No one reported it was very difficult. In terms of approaching a doctor 
Benzodiazepines Injected Oral
Licit (%) 24 74
Illicit (%) 46 62
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with the aim of obtaining benzodiazepine tablets, 26% (n = 13) reported they had an ongoing 
relationship with their regular doctor and so were able to get a script without difficulty, while 18% 
(n = 9) reported that getting a script depended on the doctor and the 'story' told to them, with 10% 
(n = 5) stating they only had to ask for a script to receive it.
Participants were asked for a description of the last time they had attempted to obtain a 
prescription for benzodiazepines, and 78% (n = 39) of the participants provided some information.
Almost half of these (46%, n = 18) detailed attending a normal appointment with the usual 
general practitioner, who wrote a prescription without equivocation. Almost a quarter (23%, n = 
9) reported that in order to obtain a prescription they had doctor-shopped, with the result they 
were successful. Twenty-one percent (n = 8) reported they really wanted to obtain the drugs either 
for detoxification, because they could not sleep, or because they were 'hanging out', and were 
successful in their attempt. Only five percent (n = 2) reported their last attempt at obtaining a script 
was unsuccessful.
Acquisition of illicit benzodiazepines for these participants was generally similar to those in stage 
two. The most frequently reported mode of obtaining illicit benzodiazepines was as a 'gift', with 
92% (n = 36) of respondents who had acquired the drugs illicitly reporting this (for 59%, n = 23, 
this was their usual method). The next most frequent method of obtaining the drugs illicitly was via 
a friend, with 44% (n = 17) of these kinds of users reporting this (for 26%, n = 10, this was their 
usual method), which was higher than in Stage two (27%). Thirty-one percent of these respondents 
(n = 12) also reported buying benzodiazepines from a dealer (with 5% (n = 2) reporting this as 
their usual source). Few respondents reported stealing the drugs or prescriptions (5%, n = 2) or 
forging prescriptions (2.5%, n = 1). Swapping other drugs for benzodiazepines was named as a 
source for the drugs by 15% (n = 6) of the respondents. See Figure 20.
Figure 20: Percentage of both licit (n = 37) and illicit (n = 39) benzodiazepine users obtaining the 
drugs via the different sources
A large number of participants (42%, n = 21) had not attempted to obtain gel capsules on the 
street or from friends, or did not know how easy or difficult they were to obtain. However, they 
were reportedly easier to acquire that way than from a doctor, with 16% (n = 8) of the participants 
reporting they were very easy or easy to acquire, while 12% (n = 12) reported they were difficult 
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or very difficult to obtain. Also, 28% (n = 14) of participants reported they had become more 
difficult to access over the previous 12 months, but nobody considered they had become easier to 
get, and 32% (n = 16) were of the opinion that they had increased in price in that time as well.
Whilst 38% (n = 19) of the participants had not attempted to access benzodiazepine tablets on 
the street or from friends or else did not know how easy they were to acquire, according to 38% 
of respondents they were easy or very easy to obtain, and only one reported they were difficult to 
get. Thirty percent (n = 15) reported that the ease of obtaining the tablets had remained stable for 
the past year, and 22% (n = 11) also reported their price had not changed. Fourteen percent (n = 
7) reported it had actually become easier to access them on the street or from friends in that time, 
although only one respondent reported their price had decreased. 
Respondents were asked about other drugs that their dealer sold other than the benzodiazepine 
that the respondent bought from them. The findings were quite different from those in Stage two. 
While 21% of illicit benzodiazepines users (n = 8) reported their dealer sold no other drugs, 31% 
(n = 12) reported they also sold heroin, 25.5% (n = 10) reported they sold other benzodiazepines, 
23% (n = 9) reported they sold cannabis, 15% (n = 6) reported they sold methamphetamines, and 
2.5% (n = 1) each reported they also sold cocaine and ecstasy.
There was reportedly little or no organised or high level dealing of the benzodiazepines acquired 
by these respondents, as they were accessed most frequently either: from a friend selling their 
prescription (by 24%, n = 12, 31% of illicit benzodiazepines users); from a friend giving away 
their prescription (by 12%, n = 6, 15% of illicit benzodiazepines users); or else from a user 
selling to fund their own use (the same proportion). Only one respondent each received their 
benzodiazepines from a small-time dealer or from a dealer swapping other drugs for prescription 
drugs.
Sixty percent (n = 30) of the participants described what happened the last time they had 
attempted to obtain benzodiazepines on the street or from a friend. The most frequently reported 
scenario involved contacting a regular dealer or a friend with a benzodiazepines prescription, 
and obtaining the drugs quickly (by 40%, n = 12). A further 23% (n = 7) described being given the 
drugs by a friend without searching for them, and the same proportion explained they obtained the 
drugs opportunistically, happening upon a dealer or vice versa.
Few respondents felt able to comment on the benzodiazepine market, or believed it had changed 
substantially in the previous 12 months. However, 22% (n = 11) reported there had been changes, 
with 20% (n = 10) considering the drugs were less available on the street, and 10% (n = 5) 
reporting it took longer to score them. Eighteen percent (n = 9) also reported that doctors were 
less willing or refused to prescribe the drugs. Ten percent (n = 5) reported that there had been an 
increase in police activity around prescription drugs. These respondents described how police 
were more likely to check people for the drugs, and check identification against prescriptions, 
as well as fining people for being in possession of temazepam capsules and for selling 
benzodiazepines. 
Eight percent (n = 4) considered that changes in the availability of the drugs had caused an 
increase in crime by motivating stealing in order to pay for the drugs, directly influencing 
behaviour ('lots of pills increase confidence, this leads to increased crime – people think they are 
superman'), and by increasing violent crime ('users will try and rob those who have them'). Eight 
percent (n = 4) also believed that changes in the availability of benzodiazepines had affected 
relationships of users, causing family breakdowns, fighting and aggressive behaviour. The same 
proportion reported that market changes had affected them financially, as the drugs were more 
expensive and therefore increased difficulties.
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The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
Market characteristics
Three-quarters of these participants (n = 37) obtained benzodiazepines via legitimate 
prescriptions, whilst slightly more than that acquired them illicitly (n = 39).
More than half of those who had received prescriptions for the drugs (n = 20) reported they 
had feigned symptoms, which was substantially more than in Stage two, but most had had 
genuine symptoms (n = 34), with some participants reporting both.  
As in Stage two, illicit acquisition of benzodiazepines was generally via a 'gift', with 72% of 
participants reporting this. 
Thirty-four percent of participants had bought them from a friend, which was similar to Stage 
two, and 24% bought them from a dealer (less than Stage two).
Again, few respondents reported stealing the drugs (n = 2), or forging prescriptions for them (n 
= 1).
Some participants swapped other drugs for benzodiazepines (12%).
Similar to Stage two, participants reported their dealers were friends selling their prescription 
(24%), or friends giving away their prescription (12%), or a dealer selling to fund their own 
use (12%).
Again, reports of other drugs sold by suppliers seemed inconsistent with the above 
information, with 16% of respondents reporting their benzodiazepines dealer sold no 
other drugs, and 24% reporting they also sold heroin, 20% reporting they sold other 
benzodiazepines, 12% noting amphetamines, and 18% cannabis, whilst there were a few 
reports of other drugs such as cocaine and ecstasy. 
Diversion
Again supporting the findings of the earlier survey, PWID participants reported little difficulty 
in receiving benzodiazepines tablets medically. However, they reported it was very difficult if 
not impossible to obtain gel capsules this way, and generally did not bother to try.
Doctor-shopping appeared to be slightly more prevalent with these respondents than in 
the previous survey. Most participants in this survey (78%, n = 39) had attempted to access 
these drugs from 2.3 doctors on average in the previous six months, with one participant 
successfully approaching 12 doctors. Most (58%) had not been unsuccessful at all, though 
most were successful with only one doctor (n = 16), or two doctors (n = 12). 
Quite a few participants had been refused by at least one doctor, and one participant had 
attempted to obtain the drugs unsuccessfully from 15 doctors. 
Most participants who reported difficulty suggested that the reason for the refusal was due to 
the doctor realising they were a drug user.
Participants reported seeking benzodiazepine prescriptions from medical practitioners 
predominantly for issues relating to sleeping difficulties or anxiety, or for the alleviation of 
withdrawal syndrome. Most participants reported that if they were unsuccessful with one 
doctor they would keep trying until they obtained a prescription, with a common response 
being 'it depends on the doctor'.
•
•
•
•
•
•
•
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Recent pharmaceutical opioids use
Morphine
Seventy percent of these participants (n = 35) had used morphine in the previous six months, with 
89% reporting they had used illicitly acquired morphine and 14% (n = 5) reporting they had used 
morphine obtained legally. Four of the participants who used morphine medically had also used 
it illicitly. This finding was similar to the Stage two participants, 78% of whom reported using 
morphine in total.
Routes of administration and forms used
Eight participants (16%) reported oral use of some form of morphine. All except one of these 
participants reported the drug was acquired illicitly; they comprised 95.5% of oral morphine users. 
Thus 22.5% of illicit morphine users had taken the drug orally. Two participants who had received 
morphine via prescription reported they had taken it orally (40% of licit morphine users), with one 
also taking illicit morphine orally. See Table 57. The number of days that prescribed drugs were 
taken orally ranged between three and 180 days in the previous six months. When the drugs were 
illicit, they were taken orally between one and 15 days.
Morphine was generally acquired illicitly by this sample, but regardless of the source, it was likely 
to be injected rather than swallowed, with almost two-thirds of all participants (64%, n = 32), and 
91.4% of morphine users, reporting they had injected morphine in the previous six months. Four 
participants (8% of all participants, 80% of the licit morphine users) reported injecting morphine 
when it had been acquired medically, compared with all illicit morphine users (n = 31) who 
reported they had injected it. Three participants injected both prescribed and illicit morphine. 
One respondent injected their prescribed morphine, but did not inject illicit drugs. There were 
28 participants (56% of the total, and 87.5% of all morphine injectors) who reported they had 
injected morphine when it was illicit but not when it was prescribed. These findings reflect those of 
Stage two. See Table 57.
Table 57. Percentage of all participants using morphine orally and via injection, according to 
method of acquisition.
While the prevalence of using and injecting morphine for this sample was greater when the drugs 
were illicit than when they were prescribed, the frequency of injecting also differed substantially.  
Where morphine was prescribed it was injected on average on four days (sd = 15) of the previous 
180, ranging from one and 80 days, and when the drugs were illicit they were injected on average 
on 26.5 days (sd = 40.3), ranging from one to 160 days.
The most common forms of injected morphine reported were MS Contin tablets and Kapanol 
capsules, but in Stage two, more participants injected Kapanol than MS Contin, the opposite of 
these findings. There were 41 reports of MS Contin tablets injection, comprising mainly 100mg 
tablets, 25 reports of injecting Kapanol capsules, six reports of injecting other morphine. Oral use 
was much less frequent, with six participants reporting this. See Table 58.
Morphine Injected Oral
Licit (%) 8 14
Illicit (%) 62 4
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Table 58. Number of PWID using orally and/or injecting different forms of morphine in the six 
months before the survey.
Supply, availability and market changes
Most respondents had not attempted to obtain morphine from a doctor in the previous six months, 
with 16% (n = 8) reporting having done so. Only two respondents reported they had faked 
symptoms to receive morphine from a doctor, with one reporting this was their usual method of 
obtaining them. Most (n = 4, 80%) of the respondents obtaining morphine prescriptions reported 
their symptoms were genuine, and that this was their usual method of obtaining the drugs.
An average of 2.5 doctors (sd = 5), ranging from none to 15, were successfully approached for 
a prescription. Three respondents acquired a prescription from one doctor, while one each was 
successful with two doctors and 15 doctors, and three participants had tried to obtain a script 
but failed. The number of doctors who had been asked for a prescription but had refused was on 
average three (sd = 3.9), ranging from one to 10, with one participant each turned down by two, 
five, seven and 10 doctors. Four participants reported they had not been refused a script by any 
doctors. No respondents had attempted to buy morphine over the Internet in the previous six 
months.
Participants were asked about the difficulty or ease of obtaining prescriptions for morphine. Most 
(n = 42, 84%) had not tried to do so, but two respondents (4%) indicated it was easy or very 
easy to obtain a prescription for morphine, saying they had a 'permit' because of legitimate pain. 
Three respondents (6%) reported it was difficult or very difficult to obtain a prescription, and the 
same number also reported morphine had become more difficult over the past year, while two 
considered the level of difficulty had remained stable.
Brand of morphine
Oral use last six 
months (n)
Injected last six 
months (n)
MS Contin 100mg - 22
MS Contin 60mg - 8
MS Contin 50mg - 6
MS Contin 10mg 1 3
MS Contin 15mg 1 1
MS Contin 200mg - 1
Kapanol 50mg - 11
Kapanol 100mg - 9
Kapanol 20mg - 4
Kapanol unknown -  1
Morphalgin 1 1
Anamorph 1 3
Morphine linctus - 1
'Morphine' - 1
Ordine liquid 2 1
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Participants were asked for a description of the last time they had attempted to obtain a 
prescription for morphine, and 14% (n = 7) of the participants provided some information. Three 
reported that they only needed to ask for a prescription as they were in genuine pain, therefore 
their last visit to the doctor was straightforward and resulted in obtaining a prescription easily. 
One participant reported the doctor was reluctant to prescribe morphine at the last visit, but after 
'extensive tests', had written a prescription. A further three respondents stated they had asked a 
doctor for morphine for 'pain', but had been turned down. 
The most frequently reported mode of obtaining illicit morphine was as a 'gift', with 84% (n = 26) 
of respondents who had acquired the drugs illicitly reporting this (for 29%, n = 9, this was their 
usual method). The next most frequent method of obtaining the drugs illicitly was via a friend, with 
64.5% (n = 20) of these kinds of users reporting this (for 52%, n = 16, this was their usual method). 
Forty-five percent of these respondents (n = 14) also reported buying morphine from a dealer, with 
22.5% (n = 7) reporting this as their usual source. No respondents reported stealing the drugs or 
forging prescriptions. Swapping other drugs for morphine was named as a source for the drugs by 
16% (n = 5) of the respondents. One participant reported they had received morphine via another 
source, which they named as 'a chemist giving them away'.
Six participants (12%) had not attempted to obtain morphine on the street or from friends, or 
did not know how easy or difficult they were to obtain. However, they were reportedly easier to 
acquire that way than from a doctor, with 24% (n = 12) of the participants reporting they were 
very easy or easy to acquire, while 26% (n = 13) reported they were difficult or very difficult to 
obtain. Also, 16% (n = 8) of participants reported they had become more difficult to access over 
the previous 12 months, while 10% (n = 5) considered they had become easier to get, and 26% 
(n = 13) did not think the level of difficulty had changed. In terms of the street price of morphine, 
20% (n = 10) reported it had not changed in the past year, whereas 12% (n = 6) considered it had 
increased, and eight percent (n = 4) thought it had decreased. 
Respondents were asked about other drugs that their dealer sold other than the morphine type that 
the respondent bought from them. While nearly one-third of morphine users (n = 10) reported their 
dealer sold no other drugs, 22% (n = 7) each reported they also sold heroin and cannabis, 15.5 
percent (n = 5) each reported they sold other morphine types and methamphetamine, 6% (n = 2) 
reported they sold benzodiazepines, and 3% (n = 1) reported they sold ecstasy and inhalants.
As in Stage two, there was reportedly little or no organised or high level dealing of the morphine 
acquired by these respondents, as they were accessed mainly via informal networks. Almost half 
of the morphine users (n = 15) received morphine from a friend selling their prescription. A further 
16% of morphine users (n = 5) obtained the drug from a friend giving away their prescription and 
about 10% (n = 3) bought it from a user selling to fund their own use. Only two respondents (6%) 
each received their morphine from either a small-time dealer or from a friend swapping other 
drugs for prescription drugs.
Fifty-eight percent (n = 29) of the participants described what happened the last time they had 
attempted to obtain morphine on the street or from a friend. The most frequently reported scenario, 
reported by 38% of these respondents (n = 11) involved an opportunistic 'score', where the 
respondent 'happened to come across a dealer', or vice versa. The next most common situation 
involved a friend giving the respondent morphine, described by almost a third (n = 9). Seven 
participants (24% of these respondents) described meeting up with a regular dealer or someone 
they know with morphine and buying it from them in a straightforward financial transaction. One 
other participant stated that he went walking in the street looking for a dealer from whom to buy 
morphine.
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Eleven respondents (22%) believed the morphine market had changed substantially in the previous 
12 months, with eight percent (n = 4) reporting it had become more difficult to obtain the drug 
from a doctor, and five (10%) considering it had also become more difficult to access on the 
street. Four participants also stated morphine had become more expensive, and six considered it 
now took longer to score than before, with three having to travel further to find it. On the other 
hand, two participants believed that morphine was actually easier to get than a year ago, and 
three considered it had become cheaper. One participant thought there was less demand now 
than previously, and another said Kapanol was easier to get than 'grey nurses' (MS Contin 100mg 
tablets). Three participants stated there had been a change in the type of people selling morphine, 
with all saying they were now cancer patients rather than dealers. Only one respondent reported 
that there had been an increase in police activity around morphine, saying that police used 
scanners to detect drugs wrapped in alfoil, and targeted the same areas as where known heroin 
dealers were. One participant stated that there was no police activity associated with morphine, as 
the police 'don’t know what they are dealing with'.
The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
Market characteristics
Replicating findings identified in the earlier PWID survey, most morphine was accessed 
illicitly rather than via prescription, with most participants (84%) not attempting to obtain it 
from a doctor in the previous six months. 
As in Stage two, most participants received morphine from friends as a 'gift' (52% of 
participants). Otherwise participants bought morphine from a friend (40%), or from a dealer 
(32%), or they swapped other drugs for morphine (10%). 
No respondents reported stealing morphine or forging prescriptions. 
One-quarter (25%) of participants reported morphine was easy or very easy to obtain on the 
street, however a similar proportion (26%) reported they were difficult or very difficult to 
acquire.
Participants reported typically purchasing morphine from friends selling their prescription 
(30% of respondents), friends giving away their prescription (10%), and friends selling to fund 
their own use (6%). Only four percent of respondents each reported buying morphine from 
small-time dealers, or swapping other drugs for morphine.
Almost one-third of morphine users (20% of the sample) reported their morphine dealer 
sold no other drugs; however, 14% each reported they sold heroin and cannabis, 10% 
each said they sold methamphetamines and other morphine types, 4% reported they sold 
benzodiazepines and one participant each reported they sold ecstasy and inhalants.
Diversion
Four participants reported they had genuine symptoms and were thus able to obtain a 
prescription, and just two participants had feigned symptoms in an attempt to obtain 
morphine. 
There was some attempt to doctor-shop by some participants, with an average of 2.5 doctors 
approached successfully for morphine, and on average 3.9 approached unsuccessfully. The 
number of doctors who supplied a prescription ranged from 1 to 15, with three participants 
•
•
•
•
•
•
•
•
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successful with just 1 doctor, and one participant each successfully approaching 2 and 15 
doctors. The number of doctors who refused to supply a prescription ranged from 1 to 10, 
with one participant each trying with 2, 7, 5, and 10 doctors. 
Two participants reported it was easy to obtain a morphine prescription, but said this was 
because they had a genuine medical condition and a long-standing relationship with their 
doctors. The remainder reported morphine was very difficult to obtain this way.
Pharmacotherapeutic treatment opioids 
Over half of the participants (54%, n = 27) reported they had used prescribed 
pharmacotherapeutic opioids within the previous six months, while 38% (n = 19) reported they 
had used these drugs illicitly. Use of treatment drugs by this sample was similar to Stage two 
participants. Buprenorphine was the most used of these drugs, licit or illicit, oral or injected, 
by these participants in the past six months. Half of the respondents (n = 25) reported they had 
used buprenorphine, 18 (72%) reported they had been prescribed the drug, which was 36% of 
the sample. Methadone syrup was used by 22% of participants (n = 11), 10 (91%) of who had a 
prescription; this was 20% of the sample. Just one participant reported using Physeptone, and it 
was illicitly acquired.
Routes of administration and forms used
Half of all participants reported taking prescribed pharmacotherapies orally in the previous 
six months (92.5% of pharmacotherapy users). Five participants reported using illicit 
pharmacotherapies orally (18.5% of pharmacotherapy users). All participants who reported they 
had used methadone indicated they had swallowed it, with all prescribed methadone syrup users 
taking the drug orally, and one illicit user doing so. Not all buprenorphine users swallowed the 
drug, however, with n = 17 (34% of the sample) doing so. Illicit buprenorphine was swallowed by 
16% of the drug’s users (n = 4), and prescribed buprenorphine was swallowed by 56% (n = 14). 
One participant swallowed illicit Physeptone. See Table 59. The number of days that methadone 
syrup was taken orally ranged between one and 180 days in the previous six months, with 
an average of 23 (sd = 57.7). Buprenorphine was swallowed less frequently, on an average of 
19.17days (sd = 55), ranging between one and 180 days.
Forty percent of participants (n = 20) reported injecting prescribed pharmacotherapies in the 
previous six months (71% of pharmacotherapy users), with illicit pharmacotherapies injected by 
46% of pharmacotherapy users (n = 13). Buprenorphine users were more likely to inject the drug 
than use it orally, with 40% of the sample (n = 20) doing so. Three participants (27% of methadone 
syrup users) injected methadone syrup, prescribed users were n = 2, and there was one illicit 
methadone syrup injector. Illicit buprenorphine was injected by 26% of the sample (n = 13), the 
same proportion as injected prescribed buprenorphine. Illicit Physeptone tablets were injected by 
one participant. See Table 59.
Table 59. Routes of administration for main pharmacotherapy treatment drugs according to method 
of acquisition.
 Note: The categories are not mutually exclusive, thus do not add up to the total pharmacotherapy users
•
Methadone Syrup Buprenorphine Physeptone
Injected (n) Oral (n) Injected (n) Oral (n) Injected (n) Oral (n)
Licit 2 10 13 17 - -
Illicit 1 1 13 4 1 1
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The number of days that methadone syrup was injected ranged between one and 180 days in the 
previous six months, with an average of 6.74 (sd = 34.6). Buprenorphine was injected much more 
frequently, on average on 23 days (sd = 54), ranging between one and 180 days.
Supply, availability and market changes
All (n = 27) of the respondents obtaining prescriptions for these drugs reported their symptoms 
were genuine, and that this was their usual method of obtaining the drugs. Only one respondent 
reported they had faked symptoms to receive a treatment drug from a doctor. Almost half the 
sample (46%, n = 23) reported currently being in a pharmacotherapeutic drug treatment program, 
with five (10%) in current methadone syrup maintenance treatment, and 18 (36%) currently in the 
buprenorphine program. Five (10%) other participants had taken prescribed methadone at some 
time in the past six months, and a further two (4%) had attempted to access the MMT program in 
that time. Seven other respondents (14%) had used buprenorphine in the previous six months, and 
six (12%) had attempted to gain entry to the program in the same time period.
The most frequently reported mode of obtaining illicit pharmacotherapies was as a 'gift', at 67% (n 
= 18) of respondents who had used these drugs (56%, n = 15 reported this as their usual method 
of acquiring the drug). The other methods for obtaining the drugs illicitly was buying from a friend 
(n = 3), or buying from a dealer (n = 3) (for one participant each, this was their usual method). The 
price of methadone on the street was reportedly about one dollar per ml, while buprenorphine 
tablets reportedly sold for between $5 and $20 each.
Participants were asked about the street market in pharmacotherapeutic opioids. Because 
the proportion of participants using methadone syrup illicitly was small, there was very little 
information provided about the market in that drug. Three (6%) participants reported it was easy or 
very easy to access on the street, while one reported it was difficult. Comments regarding buying 
methadone syrup included knowing people on the program who would sell their take-away doses, 
and sharing with friends. Eight (16%) participants reported it was easy or very easy to access 
buprenorphine on the street, and 10 (20%) reported availability of the drug had remained stable 
during the past year, while one reported it had become easier to get. Six respondents also believed 
that the street price had remained steady in that time. Three (6%) respondents reported the drug 
had become less available during the past 12 months, and two considered it had become more 
difficult to access in that time, with one reporting the price had also increased. 
Respondents were also asked about drugs that their dealer sold other than pharmacotherapies. 
Four methadone users reported the dealer sold only methadone, and one participant each reported 
their methadone dealer also sold heroin, methamphetamines, and cannabis. Four respondents 
also reported their buprenorphine dealer sold no other drug, while three reported they also sold 
cannabis, two reported they sold heroin, and one each reported they also sold methamphetamines 
and morphine.
According to these participants, there was little or no organised or high level dealing of the 
pharmacotherapies acquired by these respondents, as they were accessed mainly via informal 
networks, generally via others’ bought or gifted take-away doses. All participants (n = 6) providing 
information about dealers of methadone believed their dealer fitted this picture, with n = 2 saying 
they were a friend selling their prescription, n = 3 reporting they were a friend giving away their 
prescription drugs, and n = 1 indicating they were a friend swapping their script drug for other 
drugs. Participants providing information about buprenorphine dealers mostly reflected these 
reports, with n = 4 reporting their dealer was a friend selling their buprenorphine take away dose, 
and n = 7 reporting they were a friend giving away their take away dose. One participant reported 
their dealer gave the drug away in return for goods and services.
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Three participants described what happened the last time they had attempted to obtain methadone 
syrup on the street or from a friend. The respondents all described themselves as sick and 
needing the drug, and finding a friend who shared their own prescribed drug dose with them. 
Ten buprenorphine users described similar motivations and methods of obtaining the drug, 
describing how a friend shared or sold their dose. However, two participants reported that there 
are many dealers of buprenorphine on the street and it was very easy to buy. Three also described 
having to search for someone with buprenorphine who would be willing to share it or sell it 
before they were able to access a dose. Three respondents were of the opinion that the market in 
buprenorphine had changed substantially in the previous year, mainly in terms of demand for it on 
the streets, stating it was popular, and people with prescribed doses would often be approached 
to sell them, and one respondent believed that people were substituting the drug for heroin. Only 
one participant considered that police activity around these drugs had increased in the previous 
year, stating that police were 'busting people' with buprenorphine.
The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
Market characteristics
Over half these participants (54%) reported using prescribed pharmacotherapies in the 
previous six months, while 38% had used them illicitly. 
Half these respondents (50%) had used buprenorphine and 22% reported using methadone. 
Just one reported using Physeptone.
Methadone syrup was most commonly accessed through legitimate prescription via the MMT, 
and buprenorphine was acquired via treatment programs by 36% of participants.
The most frequent route of access illicitly for these drugs was as a 'gift' (36% of respondents). 
Several participants reported buying it from a friend (n = 3), or from a dealer (n = 3).
Three participants reported that methadone was easy to acquire on the street, selling for one 
dollar per ml. But most information suggested that supplies came from friends sharing their 
take-way dose.
Eight participants (16%) reported it was easy or very easy to obtain buprenorphine on the 
street also, and that it cost between $5 and $20 a dose. Again, most illicit buprenorphine was 
acquired from friends sharing their dose (which they hold under their tongue until they leave 
the pharmacy, and then crush it).
Participants reported predominantly accessing diverted methadone syrup and buprenorphine 
from friends receiving these medications legitimately. These people infrequently sold other 
drugs. However, one methadone user reported their dealer sold methamphetamines and 
cannabis, and four buprenorphine users reported their dealer sold methamphetamines, heroin 
and morphine. 
Most users of these drugs reported they accessed them when they were in need of heroin or 
more of the treatment drug.
Other pharmaceutical opioids 
Almost one half of the sample (46%, n = 23) reported they had used some other type of opioid 
drug, besides morphine and pharmacotherapies, within the previous six months, with 56.5% of 
these (n = 13) reporting they had obtained these drugs legally, and 61% (n = 14) reporting they had 
obtained them illicitly (two participants reported both).
•
•
•
•
•
•
•
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Routes of administration and forms used
Almost half of the other opioid users (n = 12) reported oral use of the drugs, which was almost a 
quarter of the sample. Eight of the oral users reported swallowing their medically acquired drugs 
(61.5% of licit users). Six reported they swallowed illicitly obtained drugs (43% of illicit users), 
with two doing both. Almost two-thirds of the users of other opioids (65%, n = 15) reported 
injecting the drug; this was 30% of the entire sample, and twice as many as in Stage two. Seven of 
the injectors reported using this route of administration for their medically acquired drugs (this was 
54% of those who had obtained them medically). Eight participants reported their injected drugs 
were illicit (57% of illicit users). Again, two did both. See Table 60.
Table 60. Percentage of all participants using other opioids orally and via injection, according to 
how they were acquired.
The drugs that were reportedly taken orally were: oxycodone Proladone suppository, Oxycontin 
tablets, tramadol Tramal and Zydol, and Panadeine forte. The Tramadol and Panadeine forte 
preparations were acquired by prescription, whereas the Oxycontin tablets and suppositories were 
acquired illicitly. This pattern was largely reflective of the Stage two findings. Oxycodone was the 
most frequently reported 'other opioid' injected by these participants, with 22 reports, far more 
than reported in Stage two. The reported breakdown of injection of various brands of opioid was: 
oxycodone Oxycontin 10mg tablet, Oxycontin 20mg tablet, Oxycontin 40mg tablet, Oxycontin 
80mg tablet, MS Mono 90mg capsules, MS Mono 120mg capsules, Endone 5mg tablet; tramadol 
Tramal 50mg capsule, tramadol Tramal ampoule, Panadeine forte tablets; and codeine phosphate. 
See Table 61. The oxycodone preparations and the codeine phosphate were acquired illicitly, 
whereas the Tramal and the Panadeine forte were prescribed.
Table 61. Number of PWID using orally and/or injecting different forms of other opioids in the six 
months before the survey.
Other Opioids Injected Oral
Licit (%) 14 16
Illicit (%) 16 12
Brand of other opioid
Used orally last 
six months (n)
Injected last six 
months (n)
Proladone  suppository 1 -
Endone 5mg 2 3
MS Mono 120mg - 2
MS Mono 90mg - 1
Oxycontin 80mg - 7
Oxycontin 40mg - 1
Oxycontin 40mg - 3
Oxycontin 20mg 1 3
Oxycontin 10mg - 3
Tramal 50mg capsule 6 1
Tramal ampoule - 1
Zydol 50mg capsule 1 -
Panadeine forte 1 1
Codeine phosphate - 3
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The number of days that prescribed opioids was taken orally ranged between one and 180 days in 
the previous six months, with an average of 22.6 (sd = 53.4). Illicit opioids were swallowed much 
less frequently, with an average of 1.35 days (sd = 3.7), ranging between one and 15 days. There 
were 12 reports of swallowing other opioids. Prescribed opioids were injected more frequently 
than illicit drugs, with the former injected between one and 90 days, with an average of 6.96 (sd = 
19.9), and the latter injected an average of four days (sd = 7.9), ranging between one and 30 days. 
There were 28 reports of injecting other opioids. 
Supply, availability and market changes
Four respondents (31% of licit opioid users) reported they had faked symptoms to receive opioids 
(tramadol or Panadeine forte) from a doctor (with three indicating this was their usual mode of 
obtaining them). Eleven participants (84.6% of licit opioid users) reported their symptoms were 
genuine, with 10 reporting this was how they usually obtained the drugs.
Twenty-eight percent of the respondents (n = 14) had attempted to obtain other opioids from a 
doctor in the previous six months. An average of 2.57 doctors (sd = 3.8), ranging from none to 15, 
were successfully approached for a prescription, with most respondents receiving a prescription 
from one doctor only (n = 7). One respondent had no success, while three respondents were 
successful with two doctors, two were successful with four doctors, and one participant 
successfully requested prescriptions from 15 doctors. The number of doctors who had been asked 
for a prescription but had refused was on average 0.79 (sd = 1.7), ranging from none to five, with 
11 participants reporting they had not been refused at all, and one each reportedly turned down by 
two, four, and five doctors. No respondents had attempted to buy other opioids over the Internet in 
the previous six months.
Participants were asked about the difficulty or ease of obtaining prescriptions for opioids. Eighteen 
percent (n = 9) indicated it was easy or very easy to obtain a prescription for these drugs, while 
eight percent (n = 4) reported it was difficult to obtain a prescription. Nine participants (18%) 
reported there had been no change in the level of difficulty of acquiring a prescription, but three 
(6%) considered it had become more difficult. Six participants reported they were prescribed the 
drugs for pain relief, and five said that they had a long history with the doctor and just have to ask 
for them. One participant reported that they doctor-shop and present well, therefore there is no 
problem acquiring multiple prescriptions.  
Participants were asked for a description of the last time they had attempted to obtain a 
prescription for opioids, and 24% (n = 12) of the participants provided some information. Five 
reported that they had presented to the doctor with legitimate pain, such as backache, toothache, 
or pain from an injury, successfully obtaining a prescription for pain killers, either Panadeine 
forte or Tramal. Four participants explained they had doctor-shopped, and had simply asked for 
a prescription, which they received. Several participants suggested the doctors were aware they 
were prescribing for drug using people, with a couple expressing concern, but others apparently 
unconcerned.
As in stage two, the most frequently reported mode of obtaining illicit opioids (mainly oxycodone) 
was as a 'gift', with 64% (n = 9) of respondents who had acquired the drugs illicitly reporting this 
(for most, n = 8, this was their usual method). The next most frequent method of obtaining the 
drugs illicitly was via a friend, with 36% (n = 5) of these kinds of users reporting this as their usual 
method. Three of these respondents (21% of illicit opioid users) reported buying opioids from a 
dealer. One respondent each reported forging prescriptions for the drugs or swapping other drugs 
for opioids.
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Eighteen percent (n = 9) of participants reported opioids were very easy or easy to acquire on 
the streets, while 10% (n = 5) reported they were difficult or very difficult to obtain. Only one 
participant reported they had become more difficult to access over the previous 12 months, 
while 18% (n = 9) considered there had been no change in the ease of acquiring them. Three 
respondents stated that they found it easy to acquire the drugs 'if you know the right people', 
whereas four reported they had to 'put in a bit of effort'. In terms of the street price of opioids, 10% 
of participants (n = 5) reported it had not changed in the past year, whereas one participant each 
considered the price had decreased or increased.
Respondents were asked about drugs that their dealer sold other than the opioids type that the 
respondent bought from them. Twelve respondents reported they did not know whether they sold 
any others, while three opioid users reported their dealer sold no other drugs. Two participants 
each reported the dealer also sold heroin, methamphetamines, and morphine. One each reported 
the dealer also sold benzodiazepines, cannabis, and other opioids. 
As with the other pharmaceutical drugs, there was reportedly little or no organised or high level 
dealing of the opioid acquired by these respondents, as they were accessed mainly via informal 
networks. Four participants (29% of illicit users) received their drug from a friend selling their 
prescription. A further two participants (14% of illicit users) obtained the drug from a friend giving 
away their prescription and one swapped another drug with a friend for the prescription drugs. 
One participant each received the drugs from a dealer swapping drugs for prescribed drugs, and 
bought drugs from a small-time dealer.  
Seven participants described what happened the last time they had attempted to obtain opioid 
drugs on the street or from a friend. The most frequently reported scenario, reported by three of 
these respondents (21.5% of illicit users) involved an opportunistic 'score', where the respondent 
'happened to come across' someone with the drugs. The next most common situation involved 
organising to meet with a friend or dealer who was known to have the drugs (n = 2, 14%). Other 
scenarios described included dealers offering Oxycontin as a replacement for morphine, and being 
offered the drugs by a friend who was sympathetic to the respondents’ need for drugs (n = 1 each). 
Only one respondent believed the opioids market had changed substantially in the previous 
12 months, stating they were harder to get on the street now because doctors were reluctant to 
prescribe them. This respondent reported difficulty in obtaining opioids and this had caused a 
reduction in their drug use because they now only used them on 'pay day', or when their partner 
was able to obtain them.
The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
Market characteristics
Almost half the sample had used other opioids, with over half of these (26% of the sample) 
reporting they received them legally, and 28% of the sample reporting illicit use.
Most users of the other opioids Panadeine forte and tramadol had received them legitimately.
Almost one-quarter of the sample (22%) reported their symptoms were genuine, whilst eight 
percent reported they feigned symptoms to acquire the drugs.
There was some doctor-shopping for these drugs, with between one and 15 doctors 
successfully approached for a prescription, and between one and five unsuccessfully 
approached.
•
•
•
•
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Eighteen percent of participants reported it was easy or very easy to obtain the drugs 
medically, whilst eight percent reported it was difficult. The discrepancy could be related 
to the variety of drugs within this category, varying in strength from Panadeine forte to 
oxycodone.
Oxycodone use was significantly more prevalent in this sample than in the first. Most users 
of illicit other opioids had used oxycodone and generally acquired them as 'gifts' (18% of the 
sample), or bought them from friends (10%). Six percent reported buying them from a dealer. 
One respondent each had forged prescriptions for these drugs and swapped other drugs for 
them.
Eighteen percent of participants reported other opioids were easy or very easy to obtain on the 
streets, whilst 10% reported they were difficult to obtain.
Eight percent of the sample reported their supplier was a friend selling their prescription, 
while four percent reported they were a friend giving away their prescription, and one 
participant had received the drugs from a dealer who swapped other drugs for them, and one 
had bought them from a small-time dealer. 
Most participants using these drugs (24% of the sample) did not know whether their dealer 
sold other drugs, and three users said they sold no others. However, two participants each 
reported their dealer sold heroin, methamphetamines, and morphine. One each also reported 
they sold benzodiazepines, cannabis and other opioids.
Drug-related behaviour
Intoxication
Almost all the participants (n = 47, 94%) reported they had been intoxicated with drugs in the 
previous month, and 75% of these respondents (n = 35) reported that as a consequence of being 
intoxicated they had behaved uncharacteristically. Such behaviour reportedly occurred up to 30 
times (daily) in the past month, with an average of six times (sd = 8.90). Benzodiazepines, heroin, 
or a combination of the two were blamed by most of these respondents for the behaviour, and 
benzodiazepines were blamed in combination with other drugs as well. Benzodiazepines were 
named by two-thirds of these respondents (66%, n = 23) as responsible. Heroin was the drug 
attributed with causing uncharacteristic behaviour by more than half of these respondents (54%, n 
= 19), with benzodiazepines and heroin combined blamed by 34% (n = 12).
Cannabis was named by 26% (n = 9); alcohol by 17% (n = 6, with four of these reporting they 
had combined it with benzodiazepines); morphine and buprenorphine by 11% each (n = 4, for 
the morphine, MS Contin, n = 2, Kapanol, n = 1, both combined, n = 1); methadone by 9% (n 
= 3); and methamphetamines by 6% (n = 2). Three of those taking morphine combined it with 
benzodiazepines, and half those taking buprenorphine had also been using benzodiazepines. 
The brands of benzodiazepines held responsible were: Normison (temazepam), n = 5; temazepam 
generic, n = 1; Serepax (oxazepam), n = 6; Valium (diazepam), n = 3; Xanax (alprazolam), n = 
3; 'all' benzodiazepines, n = 2; Valium and Serepax combined, n = 1; and Valium and Xanax 
combined, n = 1. Drugs attributed with the behaviour totals more than the participants reporting 
uncharacteristic behaviour, as respondents may have indicated more than one drug as being 
responsible for their behaviour. See Figure 21.
•
•
•
•
•
•
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Figure 21: Percentage of all respondents nominating different drugs that they believed caused 
their uncharacteristic behaviour in the previous month (N = 35)
Eight participants (23% of those reporting uncharacteristic behaviour) reported the kind of 
behaviour they had displayed as 'abusive', 'aggressive' or 'violent', and seven (20%) reported 
their behaviour as criminal. A further seven (20%) reported their behaviour as 'high', 'silly' or 
'energetic', and two (6%) reported they had hallucinated while intoxicated. Five respondents 
(14%) reported that when they were intoxicated on benzodiazepines they were forgetful or 
'blacked-out', and were aggressive or committed offences such as shop-stealing, robbery, or car-
theft, and that they did not recall their activities afterwards. Six respondents (17%) also reported 
that benzodiazepines caused them to be more likely to commit criminal offences, as they lowered 
their inhibitions and increased their confidence and 'cockiness', with several describing the effect 
as 'being invincible', or 'thinking you are superman'.
Shoplifting
Over one-third of participants (36%, n = 18) reported they had shoplifted in the previous month, 
61% (n = 11) of who reported doing so once a week or more. Reasons given for shoplifting were 
taking necessary items, such as food or personal items, for themselves or their family, n = 7 (14% 
of participants); having no inhibitions while on drugs, n = 5 (10%); taking items in order to sell 
them for money for drugs, n = 2 (4%); and 'liking the challenge', n = 1 (2%).
Property crime
Ten percent of participants (n = 5) reported committing a property theft in the previous month, 
compared with more than half of the participants in Stage two. Most (n = 3) reported they had 
committed such an offence less than once a week, and two did so once a week or more. Reasons 
given for such activity by two respondents were that taking drugs made it more likely thefts would 
be committed, and two said they needed money, while one respondent cited opportunism, stating 
'if it is there to be taken, I will'.
Dealing
More than half the participants (n = 26, 52%) reported having dealt drugs in the previous month, 
slightly more than in Stage two. About a third of these (31%, n = 8) reported they had done so less 
than once a week, while 12% reported dealing once a week. Over one half of these respondents 
reported dealing once a week or more, with 34.6% (n = 9) reporting the activity more than once a 
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week and 23% (n = 6) indicating dealing daily. Eleven participants (22%, 42% of those reporting 
dealing) reported their dealing was motivated by money, while three respondents said they dealt 
to help friends, and two respondents each said they sold drugs to enjoy selling it, or they were 
'moral' dealers, selling only cannabis to adults.
Swapping drugs
Almost half of the participants (46%, n = 23) reported they had swapped drugs for other drugs in 
the previous month. Most (56.5%, n = 13) reported swapping drugs less than once a week, while 
26% (n = 6) said they did so once a week, and 17% reported doing it more than once a week 
or daily. Motivations for swapping drugs were mainly in order to experience something different 
(n = 15, 65% of these respondents), and having no cash to buy illicit drugs such as heroin, 
methamphetamines or morphine and being able to acquire them with prescribed drugs (n = 4).
Services in exchange for drugs
A fifth of participants (n = 10) reported they had provided services in exchange for drugs in the 
past month, with most (n = 7, 70%) reporting they had done this less than once a week, one 
reporting the activity once a week, and two reporting they had done so more than once a week. 
Services provided included company or driving people places (n = 3), fixing things (n = 2), sex 
work (n = 1), and providing a place to stay (n = 1).
Three participants (6%) also reported providing illegal services in exchange for drugs, with two 
reporting they had done so less than once a week, and one reporting it more than once a week. 
Two participants reported they stole goods such as mobile phones in exchange for drugs, and one 
reported stealing pipes from abandoned factories in order to obtain drugs.
Eleven (22%) participants reported they had provided goods in exchange for drugs within the 
previous month, with most (n = 7, 64%) reporting they had done so less than once a week, one 
stating this had happened once a week, and three (27%) reporting they had done so more than 
once a week. Goods reportedly provided for drugs were clothes, electrical goods, jewellery, 
computer games, laptop computers, bicycles, and cameras. Five participants (45% of these 
respondents) reported the goods were stolen, and two (18%) reported the goods were theirs, while 
in three cases (27%) it was unclear whom the goods belonged to.
Fraud
More than one-third of participants (34%, n = 17) reported having 'rorted' to obtain drugs in the 
past month, with an equal proportion (29%, n = 5) having done so less than once a week or once 
a week. Three (17.6%) reported rorting more than once a week, and four (23.5%) rorted daily. 
The definition of rorting was unclear, with the most common explanation provided relating to 
obtaining money or goods dishonestly but not via theft (n = 14, 82%), but also included begging 
(n = 4, 23.5%). Activities that were described as rorting included begging (n = 4), asking charities 
for money that would be used for drugs (n = 1), taking copper pipes from abandoned buildings to 
sell for cash (n = 2), faking symptoms to obtain prescriptions (n = 1), scoring drugs for someone 
and not returning (n = 1), exchanging drugs and money (n = 1), misrepresenting a situation (n = 1), 
pawning goods (n = 1), telling lies for credit (n = 1), using EFTPOS to obtain money from an empty 
bank account on the weekends when this is possible (n = 2).
Over one-quarter of participants (26%, n = 13) also reported they 'scammed' for drugs or money 
for drugs, with 38.5% of these (n = 5) reporting they did so less than once a week, 15% reporting 
it once a week, and 23% (n = 3) each reporting scamming more than once a week or every day. 
Scamming was defined as the same as rorting by 38% of all respondents, and descriptions of 
scamming activities were the same as for rorting, centring around begging, approaching charities 
for money, 'ripping people off', deception, or 'conning' in order to get money or drugs.
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Twelve percent of participants (n = 6) reported committing a crime involving fraud in the previous 
month, with half each reporting they had done so once a week or less than once a week, which 
was similar to Stage two. Activities cited as fraud by two respondents each were credit card fraud, 
forging, and deliberately overdrawing on a bank account when the ATM goes down. 
Violent crime
Twelve percent of participants (n = 6) reported having committed a crime involving violence in 
the previous month, with all reporting they had done so less than once a week. The prevalence is 
similar to Stage two, but the frequency is higher. Most of these respondents (n = 4, 67%) reported 
they were intoxicated at the time of the offence, and the remainder (n = 2, 33%) reported they 
had been aggressive and started a fight. Offences included committing assault during a bag-snatch 
robbery (n = 1), assaulting someone at a pub for no reason (n = 1), assaulting a partner while 
on Valium (n = 1), threatening someone to acquire temazepam from them (n = 1), attacking an 
ambulance officer and a police officer while having a 'schizophrenic attack' (n =1). 
Driving under the influence of drugs
Almost one-third of participants (n = 18, 36%) reported having driven under the influence of 
illicitly used drugs in the previous month, with most (n = 10, 56% of these respondents) reporting 
they did so less than once a week. Six participants (33%) reported driving under the influence 
more than once a week, and two (11%) reported doing it daily. The reason given for this behaviour 
with the greatest frequency was necessity to get somewhere, to 'score', or go home after obtaining 
drugs (n = 7, 39% of these respondents). Four participants (22%) reported they knew the dangers 
of driving intoxicated, but do it anyway, and three (17%) claim to be capable of driving when 
intoxicated, or even more able to drive then than when sober. Two (11%) stated that when they are 
high on drugs they don’t care what they do, so are likely to drive then.
The original research questions were distilled into areas that provided an overview relating to 
illicit prescription drug use and markets, diversion of prescription drugs, implications for frontline 
workers of the use of prescription drugs, and implications for interventions.
Summary with reference to NDLERF research questions
Links with crime
Three-quarters of participants reported behaving uncharacteristically as a result of drug 
intoxication. Benzodiazepines were named by two-thirds of these respondents (46% of 
the sample) as responsible for the behaviour, heroin was blamed by more than half (38% 
of the sample), and a combination of the two was blamed by 34% (24% of the sample). 
Other drugs named were cannabis (18% of all), alcohol (12% of the sample), morphine and 
buprenorphine (8% each), as well as various combinations of benzodiazepines and other 
drugs (n = 5). Three who had taken morphine (MS Contin or Kapanol or both) had combined 
it with benzodiazepines. The benzodiazepines that were held responsible for the behaviour 
were temazepam (n = 6), oxazepam (n = 6), diazepam (n = 3), and alprazolam (n = 3), and 
combined forms of the drug (n = 4). 
Respondents reported that benzodiazepines caused them to behave aggressively, bizarrely, or 
become violent, or to black-out and not remember their behaviour later.
Six respondents (12%) reported that taking benzodiazepines caused them to be more likely 
than normal to commit crimes, by lowering their inhibitions and increasing their confidence 
('invincible' and 'thinking you are Superman' were used as descriptive terms by several 
participants).
•
•
•
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Dealing drugs was cited as the second highest source of income for these participants 
(providing on average $214 per fortnight in income), and 'crime' was cited as the fourth 
highest (accounting for $80 per fortnight on average).
Over one-third of participants (36%) reported shoplifting in the previous month, and 10% 
reported committing a property theft (this appears much lower than in Stage two, but the 
category of property crime was not separated into sub-categories in the first survey, so it 
cannot be directly compared). 
More than half these participants reported dealing drugs, which is slightly higher than in Stage 
two.
Almost half also reported they had swapped prescription drugs for other drugs, and 20% 
reported they had provided services in exchange for drugs (such as scoring drugs for others), 
and 22% reported providing goods in exchange for drugs (named as their own or stolen 
electrical goods, jewellery, computer games, computers, bicycles and cameras).
More than one-third of participants reported committing some kind of fraud in the previous 
month, mainly begging, approaching charities for money, overdrawing their bank accounts, 
removing copper pipes from buildings to sell, and 'ripping people off'.
The most commonly reported reasons for committing most offences were needing food or 
money for themselves or their family, and needing money for drugs, or opportunism, or else 
for the experience.
A little over 10% of the current sample had recently been involved in violent crime, all less 
than once a week. The prevalence was similar to Stage two, but the frequency was higher. 
Most reported being intoxicated at the time of the behaviour. Offences included bag-snatch 
and assault, assault of a partner while on Valium, threatening a person to acquire temazepam 
from them, and attacking a police officer and an ambulance officer.
Summary
Market characteristics 
The findings from Stage four were similar to those of Stage two, with some differences that may be 
due to sampling, or may be due to changes in drug markets and use patterns since the first survey 
was conducted (approximately five months prior to the second). It may be notable that the use of 
heroin was more prevalent and more frequent in this sample than in the first, whilst the injection 
of amphetamines had decreased in prevalence (and apparently in the amount spent on it) and had 
become less frequent.
The use of benzodiazepines was slightly less than in Stage two, but they were still used by most 
participants. More than half of the participants had bought them in the previous two weeks, 
spending an average of $92.50 (and up to $1,000) on them. As in Stage two, illicit acquisition 
of benzodiazepines was generally via a 'gift', with 72% of participants reporting this. Thirty-four 
percent of participants had bought them from a friend, which was similar to Stage two, and 24% 
bought them from a dealer (less than Stage two). Some participants swapped other drugs for 
benzodiazepines (12%). Reports of other drugs sold by suppliers seemed inconsistent with 16% 
of respondents reporting their benzodiazepine dealer sold no other drugs, and 24% reporting they 
also sold heroin, 20% reporting they sold other benzodiazepines, 12% noting amphetamines, and 
18% cannabis, whilst there were a few reports of other drugs such as cocaine and ecstasy. 
The prevalence of morphine use was similar to Stage two. Also similar to the earlier PWID survey, 
most morphine was accessed illicitly rather than via prescription, with most participants (84%) 
not attempting to obtain it from a doctor in the previous six months. Sixteen percent of the sample 
had bought them in the previous two weeks, spending on average $69 on them (and up to $300). 
•
•
•
•
•
•
•
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A difference that emerged in Stage four was a change in the brand of morphine, with more 
participants reporting they used MS Contin tablets this time, whereas more had used Kapanol 
capsules in Stage two. Whether this reflects the availability of MS Contin versus Kapanol in the 
market, or is simply a fluctuation, is uncertain. 
As in Stage two, most participants received morphine from friends as a 'gift' (52% of participants).  
Otherwise participants bought morphine from a friend (40%), or from a dealer (32%), or they 
swapped other drugs for morphine (10%). Four participants also stated morphine had become 
more expensive, and six considered it now took longer to score than before. Almost one-third 
of morphine users (20% of the sample) reported their morphine dealer sold no other drugs; 
however, 14% each reported they sold heroin and cannabis, and 10% each said they sold 
methamphetamines and other morphine types, four percent reported they sold benzodiazepines 
and one participant each reported they sold ecstasy and inhalants. One-quarter (25%) of 
participants reported morphine was easy or very easy to obtain on the street; however, a similar 
proportion (26%) reported they were difficult or very difficult to acquire. Twenty-two percent of 
participants, however, believed the morphine market had changed substantially in the previous 12 
months, and 10% considered it had also become more difficult to access on the street in that time. 
One participant said Kapanol was easier to get than 'grey nurses' (MS Contin 100mg tablets).  
Over half these participants (54%) reported using prescribed pharmacotherapies in the previous six 
months, while 38% had used them illicitly. This was similar to Stage two. Half these respondents 
had used buprenorphine and 22% reported using methadone. Just one reported using Physeptone. 
Four participants had bought methadone in the previous two weeks, spending between $50 and 
$60, while 30% of the sample (n = 15) had bought buprenorphine, spending on average $50 (up 
to $70). Seventy-three percent of participants who had purchased buprenorphine legally (n = 11) 
had spent $50 or more on it in that time. The most frequent route of access illicitly for these drugs 
was as a 'gift' (36% of respondents). Several participants reported buying from a friend, or from a 
dealer. Sixteen percent of participants reported it was easy or very easy to access buprenorphine 
on the street, and that it cost between $5 and $20 a dose, and 20% reported availability of the 
drug had remained stable during the past year, while one reported it had become easier to get. 
Twelve percent of respondents also believed that the street price had remained steady in that time. 
Six percent of respondents reported the drug had become less available during the past 12 months, 
and two considered it had become more difficult to access in that time, with one reporting the 
price had also increased. Three participants reported that methadone was easy to acquire on the 
street, selling for one dollar per ml. Three respondents were of the opinion that the market in 
buprenorphine had changed substantially in the previous year, mainly in terms of demand for it on 
the streets, stating it was popular, and people with prescribed doses would often be approached 
to sell them, and one respondent believed that people were substituting the drug for heroin. 
Participants reported predominantly accessing diverted methadone syrup and buprenorphine 
from friends receiving these medications legitimately. These people infrequently sold other drugs. 
However, one methadone user reported their dealer sold methamphetamines and cannabis, and 
four buprenorphine users reported their dealer sold methamphetamines, heroin and morphine. 
Most users of these drugs reported they accessed them when they were in need of heroin or more 
of the treatment drug.
Almost half the sample had used other opioids, with over half of these (26% of the sample) 
reporting they received them legally, and 28% of the sample reported illicit use. Oxycodone use 
was significantly more prevalent in this sample than in the first. Most users of illicit other opioids 
had used oxycodone and generally acquired them as 'gifts' (18% of the sample), or bought them 
from friends (10% of the sample). Six percent reported buying them from a dealer, one participant 
had received the drugs from a dealer who swapped other drugs for them, and one had bought 
them from a small-time dealer. Eighteen percent of participants reported other opioids were easy 
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or very easy to obtain on the streets, whilst 10% reported they were difficult to obtain. Only one 
respondent believed the opioids market had changed substantially in the previous 12 months, 
stating they were harder to get on the street now because doctors were reluctant to prescribe them. 
Most participants using these drugs (24% of the sample) did not know whether their dealer sold 
other drugs, and three users said they sold no others. However, two participants each reported 
their dealer sold heroin, methamphetamines, and morphine. One each also reported they sold 
benzodiazepines, cannabis and other opioids.
Diversion 
Three-quarters of these participants (n = 37) obtained benzodiazepines via legitimate prescriptions, 
whilst slightly more than that acquired them illicitly (n = 39). More than half of those who had 
received prescriptions for the drugs (n = 20) reported they had feigned symptoms, which was 
substantially more than in Stage two, but most had had genuine symptoms (n = 34), with some 
participants reporting both. Similar to Stage two, participants reported their benzodiazepine 
dealers were friends selling their prescription (24%), or friends giving away their prescription 
(12%), or a dealer selling to fund their own use (12%). Again, few respondents reported stealing 
the drugs (n = 2), or forging prescriptions (n = 1). 
Four participants reported they had genuine symptoms and were thus able to obtain a prescription 
for morphine, and just two participants had feigned symptoms in an attempt to obtain the drug. 
Participants reported typically purchasing morphine from friends selling their prescription (30% 
of respondents), friends giving away their prescription (10%), and friends selling to fund their own 
use (6%). Three participants stated there had been a change in the type of people selling morphine, 
with all saying they were now cancer patients rather than dealers. No respondents reported 
stealing morphine or forging prescriptions.
Methadone syrup was mostly accessed through legitimate prescription via the MMT, and 
buprenorphine was acquired via treatment programs by 36% of participants. Most information 
suggested that methadone supplies came from friends sharing their take-way dose, and most illicit 
buprenorphine was also acquired from friends sharing their dose (which they hold under their 
tongue until they leave the pharmacy, and then crush it). 
Most users of the other opioids Panadeine forte and tramadol had received them legitimately. 
Almost one-quarter of the sample (22%) reported their symptoms were genuine, whilst eight 
percent reported they feigned symptoms to acquire the drugs. One respondent had forged 
prescriptions for these drugs. Eight percent of the sample reported their supplier was a friend 
selling their prescription, while four percent reported they were a friend giving away their 
prescription.
Links to crime 
These participants reported that drug dealing and crime contributed a significant amount to their 
income in the previous fortnight. Over one-third of participants (36%) reported shoplifting in the 
previous month, and 10% reported committing a property theft (this appears much lower than 
in Stage two, but the category of property crime was not separated into sub-categories in the first 
survey, so it cannot be directly compared). More than half these participants reported dealing 
drugs, which is slightly higher than in Stage two. Almost half also reported they had swapped 
prescription drugs for other drugs, 20% reported they had provided services in exchange for 
drugs (such as scoring drugs for others), and 22% reported providing goods in exchange for 
drugs (named as their own or stolen electrical goods, jewellery, computer games, computers, 
bicycles and cameras). More than one-third of participants reported committing some kind of 
fraud in the previous month, mainly begging, approaching charities for money, overdrawing their 
bank accounts, and removing copper pipes from buildings to sell, and 'ripping people off'. The 
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most commonly reported reasons for committing most offences were needing food or money 
for themselves or their family and needing money for drugs, or opportunism, or else for the 
experience.
A little over 10% of the current sample had recently been involved in violent crime, all less 
than once a week. The prevalence was similar to Stage two, but the frequency was higher. Most 
reported being intoxicated at the time of the behaviour. Offences included bag-snatch and assault, 
assault of a partner while on Valium, threatening a person to acquire temazepam from them, and 
attacking a police officer and an ambulance officer.
Implications for police and other frontline workers 
Doctor-shopping for benzodiazepine tablets appeared to be slightly more prevalent with 
these respondents than in the previous survey. Participants reported seeking benzodiazepine 
prescriptions from medical practitioners predominantly for issues relating to sleeping difficulties or 
anxiety, or for the alleviation of withdrawal syndrome. Most participants reported that if they were 
unsuccessful with one doctor they would keep trying until they obtained a prescription, with a 
common response being 'it depends on the doctor'.
Eight percent of the sample considered that reduced availability of benzodiazepines had caused an 
increase in crime by motivating stealing in order to pay for the drugs, and by directly influencing 
behaviour ('lots of pills increase confidence, this leads to increased crime – people think they are 
superman'), and by increasing violent crime ('users will try and rob those who have them'). Eight 
percent also believed that reduced availability of benzodiazepines had affected relationships of 
users, causing family breakdowns, fighting and aggressive behaviour. The same proportion reported 
that market changes had affected them financially, as the drugs were more expensive and therefore 
increased difficulties, as they had to spend a higher proportion of their income on them.
There was some attempt at doctor-shopping for morphine by some participants, with an average 
of 2.5 doctors approached successfully for morphine, and an average of 3.9 approached 
unsuccessfully. The number of doctors who refused to supply a prescription ranged from one to 
10. There was also some doctor-shopping for other opioids, with up to 15 doctors successfully 
approached for a prescription.
Three-quarters of participants reported behaving uncharacteristically in the previous month as a 
result of drug intoxication. Benzodiazepines were named by 46% of the sample as responsible 
for the behaviour, heroin was blamed by 38% of the sample, and a combination of the two 
was blamed by 24% of the sample. Other drugs named were cannabis, alcohol, morphine, and 
buprenorphine, as well as various combinations of benzodiazepines and other drugs (10% overall). 
Three participants who had taken morphine (MS Contin or Kapanol or both) had combined it 
with benzodiazepines. The benzodiazepines that were held responsible for the behaviour were 
temazepam, oxazepam, diazepam, and alprazolam, and combined forms of the drug. 
Respondents reported that benzodiazepines caused them to behave aggressively, bizarrely, or 
become violent, or to black-out and not remember their behaviour later. Six respondents (12%) 
reported that taking benzodiazepines caused them to be more likely than normal to commit 
crimes, by lowering their inhibitions and increasing their confidence ('invincible' and 'thinking 
you are Superman' were used as descriptive terms by several participants).
Interventions
Supporting the findings of the earlier survey, PWID participants reported it was very difficult if 
not impossible to obtain gel capsules medically, and generally did not bother to try, and 18% of 
the sample also reported that doctors had become less willing, or refused, to prescribe tablets. 
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Most participants who reported difficulty in obtaining prescriptions suggested that the reason for 
refusal was due to the doctor realising they were a drug user. Ten percent of participants reported 
that there had been an increase in police activity around benzodiazepines. These respondents 
described how police were more likely to check people for the drugs, and check identification 
against prescriptions, as well as fining people for being in possession of temazepam capsules and 
for selling benzodiazepines.
Eight percent of participants reported that morphine had become more difficult to obtain from 
a doctor in the previous 12 months. Two participants reported it was easy to obtain a morphine 
prescription, but said this was because they had a genuine medical condition and a long-standing 
relationship with their doctors. The remainder reported morphine was very difficult to obtain this 
way. Only one respondent reported that there had been an increase in police activity around 
morphine, saying that police used scanners to detect drugs wrapped in alfoil, and targeted the 
same areas as where known heroin dealers were. One participant stated that there was no police 
activity associated with morphine, as the police 'don’t know what they are dealing with'.
Only one participant considered that police activity around pharmacotherapeutic drugs had 
increased in the previous year, stating that police were 'busting people' with buprenorphine. 
In terms of other opioids, 18% of participants reported it was easy or very easy to obtain other 
opioids medically, whilst eight percent reported it was difficult. The discrepancy could be related 
to the variety of drugs within this category, varying in strength from Panadeine forte to oxycodone. 
One respondent believed they were harder to get on the street now than previously because 
doctors were reluctant to prescribe them.
Stage four: In-depth key informant interviews
In-depth qualitative KI interviews were conducted with 28 experts and professionals across health 
and law enforcement sectors in order to examine the issues arising from the earlier research 
stages in greater depth. As most KI experience was with benzodiazepines, buprenorphine and 
methadone, responses to questions regarding pharmaceutical opioids usually related to the 
latter two drugs, unless specified. The responses were separated into themes, and the number of 
responses to each theme in each category was calculated.
General questions concerning use and market characteristics
KI were asked to identify the primary drug of choice for benzodiazepine and pharmaceutical 
opioid users. Table 62 shows that heroin, cannabis and methamphetamines were the most 
commonly nominated drugs.
Table 62. Drugs nominated by total KI pool (N = 28).
Note: Multiple responses, therefore n exceeds total number of KI
Drug/s
Identified by number of 
informants
Heroin 27
Methamphetamine 2
Cannabis 4
Alcohol 1
Benzodiazepine 1
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Twenty-six KI identified heroin as the primary drug of choice of pharmaceutical opioid and/or 
benzodiazepine users. One KI commented that this depended on the setting and geographical 
area, whilst another said that the combination of heroin and benzodiazepines was a pattern for 
some drug users. Two KI identified amphetamines as the primary drug of choice of pharmaceutical 
and/or benzodiazepine users. One commented that this may only be when heroin is not available, 
whilst the other identified amphetamine use as being amongst younger clients. Four KI identified 
cannabis as being the primary drug of choice of pharmaceutical and/or benzodiazepine users. 
Again, one informant advised that this depended on setting, in this case geographical setting, 
whilst another related primary cannabis use to a younger age group of drug users. The two 
remaining informants made no further comment on cannabis use. One KI identified alcohol as the 
primary drug of choice of pharmaceutical and/or benzodiazepine users. This was partly related 
to the division of clients at this service, with heroin users commonly being treated by a separate 
unit. One KI identified benzodiazepines as the current drug of choice of pharmaceutical and/or 
benzodiazepine users. This was the case for only two clients that the informant could identify.
KI were also asked to identify the most commonly used benzodiazepines and pharmaceutical 
opioids. KI restricted their answers to substances that were being 'misused'. See Table 63. As a 
result methadone does not appear on this table as it is not regarded as commonly misused.
Table 63. Most common pharmaceuticals used as identified by Melbourne health and law 
enforcement KI (N = 28).
Note: Multiple responses, therefore n exceeds total number of KI
Several KI commented that Rohypnol had been more commonly used in the past; however, use has 
decreased as Rohypnol has become more difficult to obtain.
Who is most likely to use pharmaceutical benzodiazepines/morphine/methadone/
buprenorphine?
Health
Many KI identified long term injecting drug users as the most likely to use pharmaceutical 
benzodiazepines/morphine/methadone or buprenorphine. As one KI commented, 'the most 
likely is going to be the heroin user who leads a fairly chaotic sort of lifestyle – street-based 
Pharmaceutical
Identified by number of 
informants
Temazepam/Normison/Unisom 24
Valium/diazepam 21
Ms Contin (morphine) 9
Serapax/oxazepam/Urilax 9
Buprenorphine 9
Kapanol (morphine) 2
RivotrilTclonazepam 3
Xanax/alprazolam 3
Mogadon/nitrazepam 1
Flunitrazepam/Rohypnol 4
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injecting drug users'. Several KI also reported that there is a relatively high proportion of 
benzodiazepine use relating to anxiety and mental health issues both within this group and 
amongst short term drug users. Two KI identified clients on a methadone program as being likely 
to use pharmaceutical benzodiazepines, because 'they have a more constant relationship with 
their doctor'. A percentage of methadone clients tend to be prescribed benzodiazepines as well: 
'often that’s the daily pick-up, methadone and Valium at the same time'. Further to that, one KI 
commented that illicit morphine may be used as a replacement for methadone where the routine 
of methadone pick-ups is prohibitive or inconvenient. 
Four KI felt unable to identify any specific group of people who may use benzodiazepines/
morphine/methadone or buprenorphine. As one KI stated, 'I can’t say that there’s a certain type 
of person. I’ve just seen it misused by varying people from different backgrounds and different 
genders and everything'. One KI identified women as more likely to be using benzodiazepines, 
although this may have been related to the demographics at that service: 'I think we’ve got more 
females generally at the moment, so that’s probably why'. Finally, one KI indicated that the misuse 
of morphine is occasionally related to a habit that develops as a result of being treated for illness 
or injury in hospital.
Law enforcement
Of the Law Enforcement personnel who were able to comment on who is most likely to use 
benzodiazepines/morphine/methadone or buprenorphine, all KI answered that 'people in the 
local street culture' or 'heavier drug users' were most likely to use, especially when there was a 
shortage of heroin. 'I think if [a] supplier becomes disconnected…anything that takes the stress 
and withdrawal feelings away [would be used]'.
For you, what are the pros and cons of prescribing benzodiazepines/opioids to drug 
users?
Health
Advantages: Benzodiazepines
The majority of KI reported that the use of benzodiazepines is a 'pro' when used in the treatment 
of withdrawal from both illicit drugs and alcohol, especially when appropriate supervision and 
care is provided: 'Well obviously within treatment there are benefits to prescribing or giving 
injecting drug users – heroin users – benzodiazepines during their withdrawal'. The provision of 
benzodiazepines helps to 'alleviate pain and aches and assist with sleeping and relaxing and that 
type of thing'. Several KI also reported that the use of benzodiazepines in home-based withdrawal 
was of benefit. Some KI also suggested that the use of benzodiazepines may help to keep people in 
treatment by helping to reduce heroin use. 
Offering a variety of treatment options to drug users was seen as another 'pro' of prescribing 
benzodiazepines, as was the suggestion by one KI that the supervised use of benzodiazepines may 
mean that drug users do not have to go on 'arduous [pharmacotherapy] treatment programs'. Many 
KI also discussed the usefulness of benzodiazepines in treating anxiety in drug users, with several 
stating that drug users had as much right to access benzodiazepines as the 'general population'. 
'People genuinely have problems that they might need [benzodiazepines for]…and just because 
they are drug dependent doesn’t mean that they haven’t got depression or anxiety'. One KI 
commented that the need to provide a controlled detoxification or maintenance program to drug 
users who are benzodiazepine dependent is a positive aspect of benzodiazepine prescription. 
Detoxification or maintenance programs may prevent 'seizures and serious consequences, like 
potentially dying from a seizure', that can occur with a sudden cessation of benzodiazepine use. 
118
Benzodiazepine and pharmaceutical opioid misuse and their relationship to crime
The overwhelming impression given by KI was that benzodiazepines are a useful tool in regards 
to withdrawal, being most effective when both 'appropriate prescribing and supervision are taking 
place'. 
Disadvanges: Benzodiazepines
KI identified a variety of negative aspects of benzodiazepine prescription. As identified above, 
many KI considered 'irresponsible' prescribing of benzodiazepines as a major 'con'. There were 
two main discussions occurring around this, one associated with a perceived shortcoming in the 
treatment of the underlying mental health conditions of drug users: 'I think with benzodiazepines it 
just needs to be a supported program, and I don’t mean that as a medically supported program, but 
I think clients need more counselling and support and better access to counselling and support…If 
you are prescribing something like a benzo, you should be looking at 'why' and supporting [drug 
users] through the process'. 
The second problematic aspect of the prescription of benzodiazepines was seen as the lack 
of a supervised withdrawal regime and related aftercare, including a lack of information for 
users about the possible side effects of benzodiazepines. The experience of many KI is that 
benzodiazepines are 'sent out the door with a stamp of approval' without 'monitoring by GPs’, so 
that benzodiazepine use can 'quite easily get out of control'. As one KI said, 'Doctors just writing 
scripts without providing any other form of support is a major negative…[they aren’t] looking at 
the bigger picture and it often ends up having negative effects for the clients. Especially if they 
haven’t been given enough information about the possible side effects of drugs'.
Other 'cons' of prescribing benzodiazepines to drug users were seen to be the negative health 
impacts arising from injecting, including serious vein damage, abscesses, and in two separate and 
severe cases, testicular amputation. KI added to this the risk of overdose – when benzodiazepines 
are used in combination with both licit and illicit drugs – with two KI specifically mentioning 
overdoses where benzodiazepines are used in combination with methadone. One of those KI 
posited that 'something like 80% of methadone-related deaths involve prescription drugs, and 
the most conspicuous category of drugs is benzodiazepines'; however, it was also acknowledged 
that 'attributing death to any one drug [in combination with methadone] is problematic'. Several 
KI identified the abuse (injection and exceeding doses) of benzodiazepines by drug users as 
a negative aspect of prescribing. Many KI also identified benzodiazepines as extremely habit 
forming, a consequence of which may be poly drug dependency. Injection of benzodiazepines 
was specifically stated by one KI as a 'con' of prescribing benzodiazepines to drug users, while 
two others named changes in behaviour and loss of memory as a particularly potent combination. 
Often the occurrences seen to be the 'cons' of prescribing benzodiazepines to drug users 
were related back to the way in which prescription occurs. 'I don’t think it helps anyone being 
prescribed [benzodiazepines] their entire life'.
Advantages: Pharmaceutical opioids
The vast majority of KI see the prescription of pharmaceutical opioids to drug users – and in 
particular methadone and buprenorphine – as a 'vital and important treatment option'.  Many KI 
reported that methadone and buprenorphine maintenance programs improve the health of drug 
users, with potential follow-on effects in the areas of housing and employment. 'All the studies 
[around buprenorphine and methadone programs] point to the benefits psycho-socially and 
economically' for those on the programs. KI also testified that maintenance programs help drug 
users 'stop their merry-go-round lifestyle' by creating a sense of stability and allowing people to 
'concentrate on getting better'. Several KI commented that this can also involve removing the 
'criminal element' from people’s lives, or the need to commit crime to support an illicit drug habit. 
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The flexibility of programs and the availability of treatment options are seen by many KI to be vital 
to achieving the best possible outcomes for drug users. As will be explored later, the option of 
take-away doses is seen to be a very important aspect of pharmaceutical maintenance programs. 
Three KI also commented more specifically on the benefits of pharmaceutical opioids as an 
alternative to injecting heroin. Firstly, it was reported that it may be easier for drug users to 'step 
down' their drug use by beginning a program of buprenorphine maintenance and then later 
withdrawing from buprenorphine. Secondly, two KI stated that whilst injection of buprenorphine 
may not be ideal, it 'may be preferable to heroin in terms of overdose risk if it is not accompanied 
by benzodiazepine use'. 
One KI talked about the benefits of prescribing morphine to a particular drug user who had been 
prescribed morphine after an accident. After his doctor ceased writing prescriptions, the client was 
forced back into a more 'chaotic and taxing' lifestyle associated with illicit heroin use, which had 
serious effects on his health and emotional well-being. In the view of this KI, the positive aspects of 
prescribing morphine were that it had the potential to prevent deterioration in the clients’ quality 
of life. However, this KI also specified that illicit morphine use was not particularly common 
amongst the clients at the service. 'It’s very difficult to get prescribed something like morphine, and 
doctors are usually really wary of that stuff'.
Two KI also reported that pharmaceutical opioid maintenance programs may be of particular 
benefit to younger drug users whose drug dependencies may not be as deeply entrenched as 
older users. 'I had a young boy, quite young, maybe 19 or 20, he’s been coming in for a while and 
injecting heroin, looking really haggard and unhappy, and he came in a couple of weeks later 
and he was on bupe and he’s just – his whole outlook had changed – he was positive, he was 
bouncing, he was happy…the change in a very short period of time was extraordinary'.
Disadvantages: Pharmaceutical opioids
There was general agreement amongst many KI about the various 'cons' of prescribing 
pharmaceutical opioids to drug users, with the most commonly mentioned issue being the rigour 
of pharmacy pick-ups: 'I’ve had a couple of…people who have just jumped off methadone, 
whether it’s due to [issues] with the chemist dispensing it, not being very pleasant to them and 
giving them a hard time, the fact that they are sick of having to go and pick it up every day, [they] 
can’t work, can’t get employment [because of the regime] and there are often problems with 
transport as well, especially if they don’t have cars'. Another KI commented, 'I think you get a 
sub-class of people who are dependent on methadone [and so therefore] they’ve got to deal with 
doctors and pharmacies and the rest of it, and it’s quite bureaucratic, it’s self limiting that they’ve 
got to pick up everyday…'. Several KI also mentioned the difficulties created by the unavailability 
of buprenorphine take-aways. 'I think the no bupe take-away thing is a really tricky factor. Even if 
you’re in every second day to pick up bupe, you know, if something was to happen you can’t just 
kind of duck interstate'. 
Accessibility issues were also raised in relation to the number of prescribing doctors: 'Only a small 
proportion of GPs actually become pharmacotherapy prescribers…but ideally it would be great 
if most people could do it', and in relation to the number of prescribing doctors in rural areas. 
'Well, per capita we’ve probably got as many rural prescribers, but given they’re dispersed, it’s a 
bit harder for clients [to get access]'. KI also suggested that the cost of pharmacotherapies to drug 
users was a problem. 
Several KI reported that one of the 'cons' of prescribing pharmaceutical opioids to drug users was a 
lack of information about the side effects and potential impacts on users’ health. 'People are put on 
methadone and they’re not told carefully enough that they need to make sure that they’re drinking 
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and producing saliva in their mouth so their teeth remain good and there’s not enough care around 
the administration of these drugs'. One KI pointed out that '[pharmaceutical opioid maintenance] 
has got some secondary complications and its certainly…some people are at risk because of their 
Hep C status and their alcohol abuse…'
KI also commented on a perceived lack of rigour in dispensing pharmaceutical opioids 
– buprenorphine in particular – and the resultant impact on clients’ drug use and health. 'I 
often think the opioids, particularly bupe…are not being managed by the chemist. It’s creating 
more problems in terms of it’s not being crushed, it’s not being administered directly onto the 
clients tongue etc… so they are spitting it out, selling it or using it themselves to inject and 
we are certainly seeing more health problems associated with that'. In relation to this, several 
KI commented that as the reality is that clients 'are' injecting pharmaceutical opioids, it is a 
continuing frustration that pharmaceutical companies do not produce buprenorphine, for example, 
in an injectable form, with accompanying health advice: 'In an ideal world, I think that would 
happen'.
Law enforcement
Advantages: Benzodiazepines
According to KI from Law Enforcement, the main 'pro' of prescribing benzodiazepines to drug 
users is that it may assist with drug dependency, or more specifically 'with the withdrawal 
process'. Several KI also commented that contact through a doctor in relation to benzodiazepine 
prescription may mean that drug users can be monitored more closely. 'I’m not up to date with 
the policy as far as prescription drugs [go]; however, I would say in a personal opinion, you could 
monitor someone’s dosage of the drugs'.
Several KI commented that the prescribing of benzodiazepines may help improve drug users’ 
health, and, further, that this is of benefit because the health of drug users impacts on the 
frequency of drug-related crime. 'If it assists them to divert away from committing crimes, that 
would be the most important one, and obviously to keep them in a state that they feel healthy 
enough to live a normal lifestyle'.
One KI commented that the prescription of benzodiazepines to drug users may assist with anxiety 
and sleeping problems.
Disadvantages: Benzodiazepines
KI identified a handful of 'cons' of the prescribing of benzodiazepines to drug users. Several KI 
reported that benzodiazepines are desirable on the black market and that either the theft of scripts 
from drug users, or drug users selling personal scripts, can be a problem for police. The abuse of 
prescribed benzodiazepines was also reported as a negative aspect of benzodiazepine prescribing, 
especially when used supplementally to 'jack up on other drugs'. This was reported in conjunction 
with concerns that benzodiazepines don’t 'help users to get off drugs', because 'they’re not really 
getting off heroin; they’re just boosting it with benzodiazepines'.
One KI expressed concern that the prescription of benzodiazepines to drug users was risky when 
doctors 'don’t know what somebody is already consuming', and therefore inadvertently 'prescribe 
something to maintain somebody when you’re not sure…perhaps they’re not honest about…other 
substances they are taking', the consequences of this being (a) that drug users’ health is put at risk, 
and (b) that doctors might unintentionally provide scripts to drug users which will then be sold on 
the black market.
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Advantages: Pharmaceutical opioids
Law enforcement KI reported that the positive effects on drugs users’ health due to 
pharmacotherapy programs was a 'pro' of prescribing pharmaceutical opioids to drug users. 
With regard to methadone, for example, one KI said that 'obviously from what you see in studies 
here and overseas, methadone can alleviate peoples’ problems and keep them leading a normal 
lifestyle'. Further to that, KI commented that the legal supply of pharmaceutical opioids creates 
a situation where drug users may become disengaged from street supplies of heroin. As one KI 
commented, 'At least there’s a process and somewhere for them to go in order to attempt to 
address their drug issues and there’s some form of health intervention, so we’re actually forcing 
them into some form of marketplace, so that if…their behaviour is such that they need significant 
health [advice], someone can actually advise them…so we’re actually forcing [drug users] away 
from each other or swapping around the streets, so there is some form of control'.
Several KI mentioned the control of heroin use by regulated dispensing of pharmaceutical opioids 
was a positive. 'It enables whoever needs to, to monitor the treatment…they’ve got access to 
doses and regularity of patients using it'. Although the potential for abstinence from heroin use 
was mentioned as a positive of the prescribing of pharmaceutical opioids, it was also noted that 
buprenorphine may help drug users to decrease their drug use. 'A lot of the users are on bupe 
as they call it. I’ve found that it’s helped quite a few, not completely get off heroin, but certainly 
withdraw from daily use to maybe once or twice a week'. 
One KI also commented that buprenorphine and methadone programs can be 'a very clean and 
efficient maintenance system while [drug users] try to get their lives in a bit of order to work out 
what direction they want to go in rather than chasing drugs all the time'.
Disadvantages: Pharmaceutical opioids
Of the negatives mentioned by KI in relation to prescription of pharmaceutical opioids, the most 
common was that drug users are not solely using their buprenorphine or methadone, but are using 
other drugs, either licit or illicit, at the same time. 'I think the difficulty is that same dilemma [as 
with benzodiazepines] that people often aren’t using it alone'. Another KI commented that, in his 
experience, drug users on pharmaceutical maintenance programs were supplementing their daily 
pick-ups with either heroin or benzodiazepines.
Two KI said that the issue of drug users not having enough 'will power' may result in the 
prescription of pharmaceutical opioids being a negative. 'It gets down to anything, any medication 
or any program they’re put on, they’ve got to have the will, naturally they’ve got to have the 
will to get off the stuff and that’s the big key'. Similarly, one KI stated that the prescription of 
pharmaceutical opioids to drug users 'keeps people on the straight and narrow to a limited 
amount'.
One KI raised the issue of the diversion of buprenorphine having increased in the past two years, 
with an established street trade of buprenorphine being established.
Are there benefits of easy availability of pharmaceutical benzodiazepines/morphine/
methadone/buprenorphine?
Health
Several KI questioned whether or not it is accurate to say that benzodiazepines and 
pharmaceutical opioids 'are' easily available to drug users. With regard to pharmaceutical 
opioids, some KI related this to the availability of prescribing doctors and dispensing pharmacists, 
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especially in terms of dealing with a variety of cultural groups: 'There are a lot of issues with 
getting people onto programs, there’s a real lack of prescribers in the west, [and] there’s certainly 
a lack of ethnic Vietnamese prescribers'; while others considered the regime of pharmaceutical 
maintenance programs negated any sense of 'easy' availability. For example, one KI commented, 
'I don’t think it can ever be too easy to get bupe and I don’t think it’s easy at all. I think the fact 
that clients have to check in like they’re on parole is really inappropriate…they’re getting on these 
programs so they can fix their lives, so they can have a regulated normal life like other people 
– why do they have to check in? You know, why can they not have a holiday when they want to, 
why can they not go and visit their grandmother without it being a real hassle?' Several KI also 
mentioned the cost of pharmaceutical maintenance programs as being prohibitive for drug users.
With regard to the easy availability of benzodiazepines, KI mentioned that they believe it has 
become much harder to obtain prescriptions, with one commenting, 'I can’t think of anything 
more arduous than trying to convince a GP [that you need benzodiazepines]'. Despite these 
concerns, many KI provided feedback in response to the question.
Benzodiazepines
The vast majority of KI responded that the easy availability of benzodiazepines is a positive 
thing for drug users, 'provided it’s done safely, and managed'. One KI added that prescription of 
benzodiazepines should be done on a 'case-by-case' basis: that is, 'benzodiazepines are really 
beneficial for some people and easy availability would be really beneficial for some people'. To 
add to that, another informant commented that 'people need to get onto treatment readily…you 
might have a problem sleeping, or you know, there’s mental health issues, you might be stressed 
in your work, and again, not all users are dependent users and they might have pain management 
issues.' 
Another issue raised by two KI was that the easy availability of benzodiazepines either provides 
drug users with alternatives if they are unable to score heroin or amphetamines – thus assisting in 
emotional wellbeing and health issues – or prevents drug users from having to use potentially more 
harmful substances.
Pharmaceutical opioids
The overwhelming response by KI in regard to the easy availability of pharmaceutical opioids 
(concerns about availability aside) was that the benefits of pharmaceutical opioid-based 
maintenance programs are simply 'amplified the easier they are [to access]'. KI responded that 'the 
more available they are, the more people can use them, the better' or 'I have no doubt in my mind 
that increasing the availability of those products increases the number of people who use them', 
and therefore access to the benefits of being on a maintenance program. 
One KI also commented that 'increasing the availability of morphine would have a similar effect' 
in terms of benefits for drug users; however, that would be complicated not only by the existence 
of only one 'morphine product which would be suitable for once daily supervised administration', 
but also because it would be 'unchartered waters in Australia' and may lead to 'diversion' and the 
'creation of a black market' in morphine where one does not already exist.
Law enforcement
Benzodiazepines
The overwhelming response from law enforcement KI in response to the easy availability of 
benzodiazepines to drug users was that easy availability leads to harmful poly drug use. One 
KI remarked, 'I can’t see a benefit because…unfortunately there is a segment in the drug using 
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community that will just use anything and if they can get easy access, they just load up on them, 
[and] unfortunately that’s pretty much your basis for a lot of the overdoses'. Another KI commented 
that he has never seen the use of benzodiazepines work in a positive way for drug users, whilst 
remarking that this is also in part due to the fact that drug users who do not have problematic 
use do not come to the notice of the police. 'From a street policing point of view, I don’t see the 
benefits because we only see the abuse'. 
One KI thought that the benefits of easy availability of benzodiazepines to drug users was 
debatable: 'I don’t know if that’s a problem in respect of helping them or causing more problems 
for us on the street with misuse'. The same KI went on to comment that the restriction of access to 
benzodiazepines may also have a negative impact in that 'the availability assists the misuse, but to 
restrict availability might restrict the ability of users to get off heroin'.
Pharmaceutical opioids
Most of the KI who responded to this question reported that the easy availability of pharmaceutical 
opioids to drug users was generally a positive thing. 'Well the simple fact is that it’s there for 
them and it’s another opportunity if they want to withdraw to get on that program'. One KI also 
remarked that 'if it can be used as a substitute to help people get back on track and look at where 
they want their lives to go…' then that is a positive thing.
However, one KI commented that he was not seeing any positives of the easy availability of 
pharmaceutical opioids at all. 'I’m not seeing a benefit. What I’m seeing is that every person 
that we arrest and process for heroin use is on the program. From my perspective there might be 
thousands of people out there who are on these programs and not using heroin, but the ones we 
deal with are using heroin and they are [also] on the program'.
Are there problems associated with the easy availability of pharmaceutical 
benzodiazepines/morphine/methadone/buprenorphine?
Health
KI reported that one of the problems associated with the easy availability of benzodiazepines in 
particular is that if doctors are not always able to be vigilant – and several KI remarked that they 
are aware that this is difficult – easy availability may lead to serious health problems in drug users 
who are benzodiazepine dependent or who are injecting benzodiazepines. Included in this is 
the risk of overdose, with KI reporting that overdose may relate to the use of benzodiazepines in 
conjunction with other substances, but also that overdoses are 'more to do with the illicit nature of 
drug use and a lack of education about drug use, rather than the drugs themselves'. The provision 
of information is seen to be a way of reducing the harms associated with the easy availability of 
benzodiazepines.
Two KI commented that as benzodiazepines are highly addictive, their easy availability may 
result in drug users developing another drug dependence. Two KI identified the diversion of 
benzodiazepines as a problem related to easy availability, saying that 'there is the possibility that 
there is going to be misuse or diversion into the black market'.
There were no KI who reported any difficulties with the easy availability of pharmaceutical 
opioids.
Law enforcement
Of the law enforcement KI who responded to this question, one identified the diversion of 
benzodiazepines and pharmaceutical opioids onto the street as a problem of easy availability, 
and the other reported that as long as the 'ethical pharmacist…complies with all the rules and 
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regulations' in a 'highly regulated industry' there should not be any problems. However, this KI 
also added that there is a 'fine line' between these regulations and the reality that pharmacies are 
also operating as a business, with the need to make a profit.
Are there problems associated with the poor availability of pharmaceutical 
benzodiazepines/morphine/methadone/buprenorphine?
Health
The majority of KI considered the 'poor availability' of benzodiazepines or pharmaceutical opioids 
to include the practicalities around access, but also the broader social issues that may arise for 
drug users with regard to access to benzodiazepines or pharmaceutical opioids.
Benzodiazepines
The main concern expressed by KI in regard to the poor availability of benzodiazepines was that 
if they become more difficult to come by, both dependent and non-dependent benzodiazepine 
users would be forced into a situation where they will have to source a potentially more harmful 
replacement. In addition to this, several KI expressed the view that the poor availability of 
benzodiazepines to drug users reinforces discriminatory notions of who 'deserves' access to 
particular drugs. As one KI put it, 'people are deserving of a bit of calmness in their life…and I 
think that’s quite appropriate. And if you can’t get it naturally, then we do go looking for something 
to augment'. Another KI remarked that 'they are really widely prescribed to the general population, 
so there’s no reason why [drug users] should be excluded from that…I don’t think you could say 
users shouldn’t get them when, you know, 40% of the population is getting them anyway…'.
Again, as mentioned earlier, KI express strong concerns that the availability of benzodiazepines 
should be accompanied by advice, education, and, in some instances, supervision. However, 
many KI also expressed concern at the possibility of daily pick-ups of benzodiazepines 
'contributing' to their poor availability. Rather than being viewed as a support mechanism, one KI 
remarked that '[daily pickups] would be restricting for clients because it means that their lifestyle 
is impacted upon because they have to go to the chemist every day on top of everything else…and 
they often might not get there, so then they miss out on their dose'.  
One KI remarked that the poor availability of benzodiazepines, particularly liquid gel caps, may 
impact negatively on older people in the community, in that they may have difficulty ingesting 
benzodiazepine tablets, or may have issues with the size of tablets in the event that they 'drop 
them on the carpet'.
Pharmaceutical opioids
Several KI made suggestions about the impact of the poor availability of pharmaceutical opioids 
to drug users. Primarily, there was concern that the cost of buprenorphine and methadone 
maintenance programs is prohibitive to many drug users. 'Generally these clients are trying to 
sort themselves out, kind of straighten up so to speak, but I think it’s a really significant amount of 
money, particularly if you are on Centrelink benefits'. In addition to this, one KI commented that 
the cost of pharmaceutical opioid maintenance means that drug users are put in a position where 
they may need to engage in criminal activity to procure the funds for their daily dose: 'I think that 
clients are still kept in the [drug using] lifestyle by the fact that they need to do crime in order to 
pay for bupe or methadone. I’ve seen clients kicked off bupe and methadone programs because 
they can’t pay the chemist and, again, that’s really negative and it keeps people in that world of 
having to do other things…people are having to pay out $50 a week – it’s a hell of a lot on top of 
rent and food and bills and all that kind of stuff'.
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A second aspect of the poor availability of pharmaceutical opioids that was identified by several 
KI was the rule regarding pharmaceutical maintenance programs. KI commented on the fact that 
clients often don’t have to do anything serious to be excluded from a maintenance program, 
which forces clients back into an illicit drug using lifestyle and makes it more difficult to access 
a program on subsequent occasions. 'They only have to stuff up a little bit and they are off these 
programs, then it puts them back into the whole cycle you know, mixing with people who are 
taking heroin or chasing heroin. People aren’t always going to be as reliable or as sort of forward 
thinking as perhaps those of us who have more to lose, so you are going to get people who can’t 
keep up with the actual procedure…and then they get taken off [the program] and they’re angry at 
themselves but it’s really hard for them to then establish again another prescription'.
Again, as with benzodiazepines, potential discrimination by pharmacists is seen as being an 
element of the poor availability of pharmaceutical opioids in that it effects people’s willingness 
to engage with pharmacies and therefore their ability to remain on buprenorphine or methadone 
programs. 'Yeah, I’d say there’s an underlying distaste about having to have somebody 'like that' 
in your shop, and you’re seeing chemists suddenly putting on gloves to serve somebody and 
you’ll see it in their body language in terms of how they treat that person and how they treat 
[another] customer; it’s outrageous'. One KI suggested that a 'one stop shop' offering a clinic 
with a pharmacy attached would be useful in addressing these aspects of the poor availability of 
pharmaceutical opioids. Drug users could be offered counselling and support as well as access 
to pharmaceutical opioids like buprenorphine and methadone, which would help to facilitate 
availability of maintenance programs.
Law enforcement
One KI responded to this question, suggesting that the poor availability of pharmaceutical opioids 
may lead to criminal behaviour: 'you will see a variety of behaviours around getting it and 
procuring it, whether it’s burglaries or whatever'. 
What proportion of pharmaceutical benzodiazepines/morphine/methadone/
buprenorphine use is primary versus supplemental? [i.e. being drug of choice rather being 
a substitute when drug of choice is not available]?
Health
Benzodiazepines
The majority of KI reported that benzodiazepines are being used as a supplement rather than a 
drug of choice. 'With benzodiazepines, it’s definitely supplemental, it’s there to increase the effects 
of heroin that they might be using'. However, many KI also added that benzodiazepines are being 
used in a more fluid way than this question allows, according to availability, health, financial 
situation and a range of other factors. 'I think that it swaps back and forward depending on where 
they are physically and emotionally'. Another KI added: 'we’re seeing mixed patterns where people 
will use cannabis for a period of time, slow down the cannabis, start using benzodiazepines for 
a while, start using heroin, come back to amphetamines and sometimes parallel processes where 
they’re actually using benzodiazepines, using cannabis…it seems to be a mixed changing picture'.
Two KI reported that they believed that benzodiazepines were being used as a primary drug of 
choice. One of these two commented that temazepam in particular has become very common as a 
drug of choice in preference to heroin. The other remarked that where drug users may have had an 
existing opioid dependence: '[users] have just substituted over time and [benzodiazepines] have 
sort of taken over. It’s easier to get, it’s cheaper, it’s unique and it will maintain you for a bit longer'.
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Pharmaceutical opioids
Where pharmaceutical opioids are concerned, KI reported that there is a blend of both primary 
and supplemental use. Some people 'are on the program and that’s how they are using their 
bupe' whilst others 'are using it and then topping up with [heroin]'. One KI reported some people 
on buprenorphine may have initially been topping up with heroin, and then later reverted to 
buprenorphine as their primary drug of choice. 'It’s a really interesting question with the bupe, 
because when it first came out people obviously just supplemented and there were…these doctors 
that were prescribing bupe at an enormous rate, but they were injecting it too, that’s what they 
really like, they actually had a pharmacotherapy that cost them $5 a day that they could inject…a 
lot of them reported that they actually really liked it, better than heroin…'.
Law enforcement
All law enforcement KI reported that benzodiazepines and pharmaceutical opioids are used as a 
supplement to heroin, except when heroin is not available. 'I do think it’s primarily supplemental 
because I do think if people can get what they want illicitly and that’s their drug of choice they 
will stay with that. But I think if there is a disruption to supply or…income dries up or whatever, 
then there’s a bit of a sort of shift around to try to find a substitute or a support until something else 
happens'.
Drug trading
What are the patterns of drug sharing with friends? (which drugs, how often, reasons, 
social context etc.); i.e. how do users get benzodiazepines/morphine/buprenorphine and 
where from?
Health
Many KI commented that drug sharing amongst partners is a common occurrence, with both 
benzodiazepines and pharmaceutical opioids. 'I get the impression that there is quite a bit of drug 
sharing out there particularly between boyfriend and girlfriend or partners'. One KI reported that 
a client who had been prescribed morphine in very large amounts for an injury was sharing that 
morphine regularly with her partner. This KI also commented on the existence of relationships in 
which female partners are coerced into engaging in sex work to obtain drugs to share with male 
partners.
As well, KI identified various patterns of drug sharing amongst friends. One KI remarked that 'the 
nature of drug use' is that people will share their substances with other people because 'you don’t 
want to be seen to be mean'. Informants noted that this could involve a wide range of quite fluid 
patterns of sharing, trading, buying and selling, although several KI also commented that they 
haven’t been seeing a 'network' as such, rather a system of 'mates rates' – 'I’ll give you some choof 
if you give me that, sort of stuff' – and 'helping out a friend', i.e. 'Look, I always help you out with 
Normies, just give us a shot now, next week I’ll throw in a Normi for free'. 
One KI also reported that he had heard of a casual sharing of buprenorphine occurring when the 
person who had been prescribed buprenorphine did not have the money to pick up their dose. A 
friend would pay for the dose, and the person would leave the pharmacy with the buprenorphine 
on them and then give their friend 'a chop' in return. However, the KI added that, 'there’s not a 
big black market in diversion [of buprenorphine], it just doesn’t attain that [status]'. One other KI 
commented that the sharing of buprenorphine seems to have lessened due to pharmacists being 
more vigilant about the crushing of tablets and ensuring they are ingested on the premises.
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Several KI reported that there is little or no trade in benzodiazepines at the moment due 
to the increased difficulty of obtaining them. 'I think everybody is pretty greedy with their 
benzodiazepines, I don’t think many people want to hand them out'. One KI also commented, 'I 
get the sense that people are more likely to share a hit that they’ve bought on the street of heroin 
or speed rather than share their prescribed medication'.
One KI also reported that they were not aware of any trade in buprenorphine. 'Well I haven’t heard 
that because mostly they’re taking it out of their mouths and injecting themselves'.
Law enforcement
Law enforcement KI reported that drug sharing and trading happens in the 'hotspots' around 
Melbourne. One KI suggested that 'a lot of users will hook up together, go off and say pool their 
money, buy [illicit drugs] and split it, or some will traffic. Same with bupe and other drugs, so 
yeah, it’s quite common'. Another KI commented that the sharing of pharmaceutical opioids 
in particular is connected to dispensing pharmacies. 'A lot of individual users are on-selling it, 
crushing it up, selling it as something else, or injecting it, exchanging it for other things, telling 
them it’s one thing and it’s another, that sort of stuff, so there’s that street trading. Where we find 
pharmacies that are bupe outlets we find usually a bit of a healthy street trade around those 
pharmacies'.
When people have legal access to pharmaceutical benzodiazepines/morphine/
methadone/buprenorphine, what proportion would give away, trade, on-sell their drugs, 
or keep their drugs entirely for themselves? Why?
Health
Many KI commented that it was hard to know the answer to this question, given that the 
relationship between themselves and their clients is often not one where this question would be 
asked, or else that relationship exists in a context where information about on-selling would be 
deliberately concealed.
However, several KI from differing geographical areas did make comments on on-selling. One KI 
reported a high level of on-selling: 'it would be really high, yeah', but only with buprenorphine 
and not benzodiazepines, because benzodiazepines have become more expensive due to the 
difficulty in acquiring scripts. A number of KI commented that any trade in benzodiazepines that 
existed previously has significantly lessened in recent time. 'Because they are so difficult to get, 
people like to keep that quiet to themselves and not let too many people know and just like to 
have it to themselves'. Another KI, from a different geographical area, reported that drug users may 
'sell or give away their benzodiazepines', but 'clients don’t seem to talk as much about actually 
selling or buying their bupe'. However, this KI also commented that '[I’ve] certainly seen a lot of 
clients who will say that they are taking bupe, but they’re not being prescribed it'.
Several KI reinforced earlier comments about the lack of a 'black market' and the more common 
occurrence of people passing on or selling benzodiazepines or pharmaceutical opioids to friends, 
although one KI speculated that on-selling may be more common with morphine, which is harder 
to get, and more 'unusual' in terms of availability.
One KI linked the amount of benzodiazepines prescribed to an individual with the likelihood 
of on-selling. The bigger the script, the more likely the person will be to on-sell a percentage. 
'It’s a proportional thing. Like if you walk out and you’ve actually got two scripts for a couple 
of hundred diazepam, well, wonderful, so you keep 50 and sell 150. But if all you’ve got is 25, 
you’re probably not going to move it on'. Another KI added that people who are not dependent on 
benzodiazepines but can get scripts might be more likely to on-sell or trade.
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Finally, one KI commented that the on-selling or trading of benzodiazepines was not generally 
associated with alcohol clients, but with illicit drug users, due to 'more of a community base and 
an acceptance of that stuff within that particular culture'.
Law enforcement
Law enforcement KI responded that there is a proportion of on-selling and trading in 
benzodiazepines, but not so much with pharmaceutical opioids. 'There is a trade, there’s no doubt 
in any drug culture in any area, there is a trade on'. In one area in particular, 'there’s a big trade in 
Normison tablets'. However, KI commented that they would be speculating as to the proportion 
of benzodiazepines or pharmaceutical opioids that would be given away, traded or sold. One KI 
commented that there has not been a large number of benzodiazepine seizures in comparison 
with heroin seizures, and that 'as far as benzodiazepines are concerned, it’s not really a major 
issue', especially in the past couple of years when there has been a 'slow and steady increase' in 
the purity and availability of heroin.
Why do you believe people deal pharmaceutical benzodiazepines/morphine/methadone/
buprenorphine?
The majority of KI from health, and all law enforcement KI, responded that people deal in 
benzodiazepines and pharmaceutical opioids, 'for the same reasons that people sell anything' – to 
get money, and regularly to get money to support a heroin habit. It’s 'a way of making money so 
they can either buy drugs or just buy food and all that kind of stuff, or to pay for the next lot of 
prescriptions'. 
One KI remarked that people are able to deal in benzodiazepines in particular because they have 
become highly sought after as a result of stricter prescribing. 'It’s only when people are having 
treatment withheld that they actually need because of their mental health or physical health that 
they become valuable'.
Another KI reported that the idea of people selling buprenorphine for money was 'mad' and 
'ridiculous' given that buprenorphine tablets are sold for as little as $2.50. Instead, this KI 
suggested people are selling buprenorphine either to help out friends, or to 'add to the blend and 
that psycho-social sort of stimulus' related to a drug using culture.
Source
Where do pharmaceutical benzodiazepines/morphine/methadone/buprenorphine 
available to your clients/people you have contact with come from? (Internet sources?)
Health
Many KI reported that the benzodiazepines and pharmaceutical opioids available to their clients 
where coming from prescribing GPs. There was also some suggestion that this may differ according 
to each particular substance. In terms of an illicit supply of benzodiazepines, KI reported that 
whilst Valium is still commonly prescribed by GPs, Normison has become more difficult to get and 
as a result people may need to purchase it on the street. Several KI reported that there is a strong 
street market in Normison. With regard to buprenorphine, many KI reported that, in the main, 
people are being prescribed by GPs, with a small amount traded amongst friends or sold at a street 
level. Regarding morphine, the difficulty of getting a script means that 'a lot of it is [coming from] 
people on pain relief for backs, necks whatever' or people who have been diagnosed with cancer, 
who then sell their medication. Some KI reported that people might obtain benzodiazepines from 
family, friends or a partner.
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Two KI commented that people may source benzodiazepines from chemist burglaries – although 
this was seen to have decreased significantly – or shoplifting from pharmacies, which was 
also seen to be more difficult than previously. One KI mentioned that people may obtain 
benzodiazepines or morphine by forging prescriptions on a stolen prescription pad.
All KI reported that they had not heard of anyone sourcing benzodiazepines or pharmaceutical 
opioids over the Internet, although they were aware that this option existed. One KI commented 
that the process of internet shopping may be discouraging: 'you’ve got to pay for it in US dollars, 
so you’ve got to convert it, then there’s postage, and a lot of it would be stopped at customs I 
imagine'. Another commented that 'this is a very marginalised group of people, they don’t always 
have a computer, don’t always have the net, don’t always have education that is sophisticated 
enough to actually order off the net'.
Law enforcement
The majority of law enforcement KI reported that people were accessing benzodiazepines via 
chemist burglaries or burglaries carried out at manufacturers or distributors, the latter occurring 
when out of date benzodiazepines are discarded without proper security. One KI suggested 
that benzodiazepines had been stockpiled after burglaries that occurred over 12 months ago. 
However, there was also a strong suggestion that chemist and warehouse burglaries had dropped 
significantly with the increase of heroin supply. 'If you asked this question two years ago, we had 
stats to show how many burgs there were in this area…when the drought was on, that was what 
they [drug users] were doing. But the burgs have dropped dramatically'.
Several KI also stated that people acquire benzodiazepines via a street market and trafficking. 
There was no such suggestion regarding pharmaceutical opioids.
Two KI suggested that people obtain benzodiazepines and pharmaceutical opioids from GPs, and 
one KI reported that people routinely kept their prescription on them so as to be excluded from 
suspicion of trafficking.
What proportion of pharmaceutical benzodiazepines/morphine/methadone/
buprenorphine trading involves organised crime?
Health
The vast majority of KI suggested that there is not any real element of organised crime in 
benzodiazepine and pharmaceutical opioid trading. 'It’s not organised – this is very disorganised'. 
In terms of the practicalities of organised crime, one KI commented, 'I don’t think there would 
be the overseas connections and networks through major transport routes and all that type of 
thing that the heroin market has or the amphetamine market, it’s more lower level stuff that’s 
happening…people who are connected at the street level rather than people who organise things 
from higher up'. Another KI commented that the relatively low financial value of benzodiazepines 
and pharmaceutical opioids meant that organised crime was unlikely to develop. 'I would say that 
it’s "organised" at a street level, but I can’t imagine there being enough money in benzodiazepines 
to have an organised crime racket going on'. 
One KI commented that although the trading of benzodiazepines may even be 'very organised at 
a certain level', below the entry point into the black market it 'immediately becomes disorganised'.
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Law enforcement
The perception of law enforcement KI is that there is not any organised crime involved in 
benzodiazepine or pharmaceutical opioid trading. As with KI from the health sector, law 
enforcement personnel reported that trading of benzodiazepines and pharmaceutical opioids exists 
at a street level: 'there are networks based around groups where people can get these things and 
distribute them amongst themselves without any repercussions', but not at a higher level as with 
amphetamines and heroin. One KI reported that although occasionally police will do a search 
where they may find benzodiazepines, 'generally they are at the bottom end of the market…a lot 
more disorganised crime'.
Why might it be harder to obtain pharmaceutical benzodiazepines/morphine/methadone/
buprenorphine in some geographical areas than others?
Health
Many KI reported that it might be harder to obtain benzodiazepines and pharmaceutical opioids 
in some geographical areas because of a lack of prescribing doctors, a lack of bulk billing doctors, 
or a lack of dispensing pharmacies. This is applicable to both suburban access – several KI 
commented that there is a lack of services in perceived 'middle class' suburbs – or to rural access, 
where people seeking treatment have to travel long distances or do not have access to bulk billing 
doctors. In addition to this, KI also commented on the 'sympathies' of doctors, stating that doctors 
who are more inexperienced with drug users may be either less likely to prescribe to people: 
'Some doctors have just put blanket policies up, nah, not doing that kind of thing', or conversely, 
some doctors may be more likely to prescribe due to a lack of experience and education with drug 
users. 'I think, you know, you hear of people going out to Croydon or Malvern, the suburbs…if you 
go and see a doctor that doesn’t see people that [are drug dependent]…they may be more inclined 
to [prescribe]'. 
KI also commented that it may be easier to access both benzodiazepines and pharmaceutical 
opioids in areas where there may be a concentration of doctors or pharmacists who are not as 
rigorous with prescribing and dispensing. For example, with buprenorphine, 'In ***** there was 
a situation where the pharmacist was for some reason very slack with it, so it got out onto the 
street a lot more'. Several KI also reported that it is easier for drug users to access benzodiazepines 
and pharmaceutical opioids where a street trade is more prevalent. Finally, one KI suggested that 
policing may be a factor in making it more difficult to obtain benzodiazepines and pharmaceutical 
opioids in some areas, although it wasn’t a key factor.
Law enforcement
Several KI reported that it would be easier to access benzodiazepines and pharmaceutical opioids 
in Melbourne’s drug 'hot spots' where the drug street trade is more prominent. However, one KI 
suggested, 'However…I do think it’s far more widespread than just the six hotspots, I think it’s in 
every community, it’s just a question I suppose as to whether it reaches a visible level amongst 
the gatekeepers, whether it’s the pharmacist or the doctor or the police…I think it’s there in every 
community just like alcohol is, but I think it’s just whether it becomes a public problem'.
One KI suggested that difficulty in obtaining benzodiazepines and pharmaceutical opioids in some 
geographical areas was due to policing.
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What is the extent and ease of 'doctor-shopping' to obtain benzodiazepines and 
pharmaceutical opioids? 
Health
KI were fairly evenly split in regards to the extent and ease of 'doctor-shopping'.
Firstly, KI reported that 'doctor-shopping' was occurring to a significant extent. 'In terms of 
benzodiazepines, I think it’s really rife actually and I think it’s quite easy'. Another KI commented 
that 'doctor-shopping' is not as common with Normison, but that there seems to be a fairly 
constant supply of Valium: 'I’ve never seen a decline in people being able to access Valium tablets, 
they seem to always be around, people never seem to have trouble getting them'. These KI also 
suggested that 'doctor-shopping' is 'easy – some people do it lots and some doctors get it more 
than others'. In addition to that, one KI added that the range of treatment from GPs contributed to 
the ease of obtaining medication: 
'I’m really surprised at how easy it is, like I’m shocked, I think it’s because you’ll always 
have doctors at different levels of giving service, some of them are really tired and old and 
they don’t care and they just want to retire, some of them are probably thinking they’re 
doing a good job and being very nice and understanding and probably don’t really know 
what is going on or they’re not opening their eyes to perhaps what is going on, some of 
them are really strict of course, so you get this whole range of responses from doctors for 
a whole lot of different reasons and yeah I think that while you’ve got that, which is pretty 
much a given, people are going to try to get a doctor that they can get what they want 
from.'
Alternately, KI suggested that doctor-shopping has in fact become much 'harder' in recent times. 
'I think it’s really difficult actually, and I don’t know if there’s a lot that goes on anymore'. In terms 
of both extent and ease, one KI remarked, 'It’s certainly gotten harder, it’s not just the case of going 
in and saying 'I really need to have something to help me sleep'. Another commented, 'I believe it 
would be very very difficult. Being that it’s all on notification to the pharmacy board and doctors 
have to get permits to prescribe these sorts of things. I don’t think it’s as easy as people make it out 
to be'. Several KI also commented on the complexity of the term 'ease', suggesting that it is in fact, 
very 'arduous': 'I don’t think it’s easy for people to present every couple of days for the doctor to 
try and get drugs….I think 'ease' is actually a loaded term that implies a moral perspective that I’m 
not comfortable with'. Two KI also reported knowledge of young women being asked to engage in 
sexual acts with doctors in exchange for benzodiazepines.
All KI agreed that it would be difficult if not impossible to 'doctor-shop' for buprenorphine or 
methadone, and all remarked that obtaining morphine in this way would not be 'hugely common': 
'I haven’t heard of anyone being able to get that through a doctor in terms of doctor-shopping'.
Law enforcement
Of the three KI who responded to this question, two suggested that doctor-shopping was 'rife' or 
'not at all difficult', while one suggested that although he believed it was happening to a quite 
large extent, doctors have become more aware of the problem and reacted accordingly. 'They’re 
no fools. Doctor-shopping is predominant, but I don’t believe that they are successful'.
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How much prescription/doctor-shopping occurs for personal use vs. obtaining scripts for 
on-selling?
During doctor/patient consultations, how do clients report getting scripts? [what strategies 
do they use?] 
Of the small number of KI who responded to the first question, all suggested that 'doctor-shopping' 
occurs primarily for personal use. One KI added that people would then occasionally share with 
friends, rather than 'on-selling' their benzodiazepines or pharmaceutical opioids. Another KI 
suggested that any on-selling was opportunistic rather than 'organised'. 'I mean you don’t have 
people running around with drug dependencies to get prescriptions which aren’t their primary 
drug of choice to then go out and sell on the street, it’s just ridiculous'.
Again, a small number of KI responded to the question of how clients report getting scripts. One KI 
said that clients simply 'ask for it and the doctor thinks that they are the only doctor prescribing it', 
while several KI reported that clients may complain of trouble sleeping or of being in pain. 
Another KI responded by saying that the term 'doctor-shopping' is a 'very loaded term when you 
are talking about people who have drug dependencies and need to use drugs every day…I’m 
disappointed to see it described that way and if our system were working correctly then perhaps 
people wouldn’t be seeking these alternatives'.
What would make prescriber’s role easier regarding limiting diversion of pharmaceutical 
products?
Health
Many KI suggested that changes to health care would make a prescriber’s role easier regarding 
limiting diversion of pharmaceutical products. Firstly, one KI suggested that reducing 
benzodiazepine prescribing in general, including weaning all clients – not just those suspected 
of 'doctor-shopping' – off benzodiazepines would result in a reduction of diversion. However, 
this KI also suggested that just saying 'no' to benzodiazepines prescribing is not the answer either, 
recommending instead that doctors develop 'alternative prescribing practices', ask questions about 
drug use, and utilise the services of drug and alcohol agencies. 
Several KI advocated a more 'holistic' approach to health care, suggesting that doctors forming 
a 'better relationship with their patient' and approaching treatment from a more wide-ranging 
perspective may result in less benzodiazepines prescription and therefore less diversion. Several KI 
also acknowledged the difficulty this presented for doctors in terms of lacking the time or resources 
to ask questions of people seeking benzodiazepines or pharmaceutical opioids. In response, it was 
suggested that a system could be developed whereby 'a primary drug and alcohol service is made 
available to GPs…in other words, you might have seven people [in an area] who are available to 
GPs for secondary consultation and advice' including being able to sit in on consultations with 
people whose drug use GPs may be concerned about. These measures were seen as having the 
potential to reduce inappropriate prescription of benzodiazepines in particular, and again, reduce 
diversion as result.
Another KI suggested that although it is a very complex problem 'the short answer is to have a 
lot more services for people who are using drugs and to administer those sorts of drugs in those 
services like the primary health care facilities'. This KI suggested that this approach may deal with 
the 'conflict of interest' that many pharmacists feel between 'not actually wanting the drug user 
in the shop' and 'getting money for administering the drug'. It was suggested that this conflict is 
potentially responsible for the poor administration of buprenorphine, allowing diversion to take 
place more easily.
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In terms of accountability for the diversion of benzodiazepines and pharmaceutical opioids, for 
both drug users and doctors, some KI suggested that 'tracking people in terms of what they have 
been prescribed could be one way' of limiting diversion. This 'tracking' could be monitored 
through GPs or pharmacies. It was also suggested that further measures should be taken to secure 
prescription pads and in addition that there be increased accountability for doctors when pads 
are stolen. One KI also suggested that there be more questions asked of doctors about the level of 
benzodiazepines prescribing.
Two KI suggested that daily pick ups of benzodiazepines may be a way of limiting diversion, but 
emphasised that it be done on a 'case-by-case' basis to limit the element of 'social control' which 
was perceived to be part of a daily pick up routine.
In relation to pharmaceutical opioids – and buprenorphine in particular – one KI suggested 
that 'the fast dissolving preparation that’s been talked about for a couple of years', whilst still 
undergoing testing, may be 'looking promising'. This preparation 'fizzes up in your mouth and 
you can’t inject it', thereby preventing diversion. This KI also commented on the benefits this form 
of pharmaceutical opioid could have in terms of limiting diversion from pharmacies, considering 
that pharmacists may not have the resources or the motivation to prevent diversion, or that doing 
so is even their responsibility. 'I mean, logistically, the business of expecting pharmacists to stop 
diversion is just impractical…they’re not paid to do it, they’re not going to do it, we shouldn’t even 
be thinking that they [can]. To get them to crush [buprenorphine] is about as much as you can 
expect and that’s messy and time consuming'.
One KI also mentioned that the availability of Suboxone may also help prevent diversion. The 
combination of buprenorphine and naloxone can in some cases cause withdrawal when injected, 
thereby discouraging people from diverting from pharmacies for that purpose.
Finally, several KI suggested that acknowledging 'the culture of drug use' and allowing people to 
safely inject pharmaceutical opioids would render the problem of diversion for personal use a non-
issue. 
'There’s learnt behaviours and practices that people follow and sometimes it’s part of 
their own personal ritual about injecting and it’s odd that it’s seen as illegal to inject that 
drug but you can inject another drug. Like diabetics can inject and it’s not an issue – it’s 
seen as a treatment, it’s a treatment plan. I don’t understand why if [drug users] feel 
injecting would help them, they can’t use that option. I mean it could be done through 
pharmacies, if they could provide it in an injectable format, and if they 'have' to, if the 
government feels that, they could have them inject on site. Then you’d have to provide 
safe injecting facilities. If you want to reduce the concept that [drug users] are using 
[pharmaceutical opioids] illegally, then allow them to inject it safely'. 
In addition, another KI added that the health benefits of allowing injection would also be 
considerable, especially in terms of injecting health.
Law enforcement
KI from law enforcement suggested that pharmacists ensuring that tablets are crushed and ingested 
on the premises is one way of limiting diversion of pharmaceutical opioids, or possibly dispensing 
substances in a liquid form. 
Another KI suggested that the sharing of information between doctors about strategies to deal with 
feeling intimidated by clients seeking benzodiazepines and pharmaceutical opioids may help 
in a reduction of supply and a resulting reduction in diversion. 'They [doctors] can share tactics 
and strategies about how they can go about deflecting [aggressive patients]'. In addition, it was 
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suggested that programs of awareness for all doctors about which drugs in particular have the 
potential for diversion may have helped in limiting diversion, again, by limiting supply to people 
seen as potentially problematic drug users. 'Doctors say, 'oh, we didn’t realise that [MS Contin] 
was a common drug of abuse'.
If there was a total ban on take-away doses of methadone, how would this impact on 
your service? Your clients/people you have contact with? Others?
The overwhelming majority of KI responded that a total ban on take-away doses of methadone 
would have a 'massive' impact on the wellbeing of clients and retention rates in the methadone 
program.
Some examples of the positive impact of methadone take-aways were provided to highlight the 
'devastation' that banning take-away doses would have. One KI discussed the situation of a client 
who was nursing a seriously ill friend in a rural town:
'I have a client that I work with and he is supporting a friend who is dying of cancer. He 
lives in Melbourne and his friend lives up in *****. And, you know, he travels back and 
forward when she has chemo, he goes and stays with her for three or four days to look 
after her through her chemo. Now who are you punishing if you take that dose away? I 
mean that’s…it would be inconceivable'.
Many KI reported that a total ban on take-away doses would have a serious impact on the self-
esteem and sense of self-worth of people on methadone, that it would adversely affect people 
who have to travel considerable distances to their dispensing pharmacies and that it would have 
the potential to prevent people with mental illness, who may find it difficult to leave their homes, 
from accessing the treatment. In addition, it would lock people into geographical areas of pick up 
– one KI gave the example of a person who worked close to their dispenser but lived very far away, 
meaning that the person would have to devote a significant amount of every weekend to travelling 
to pick up their dose – and have a major impact on the ability of people to remain employed. 'I 
mean, if you’re a doctor or a police officer or a nurse and you have to go to the pharmacist every 
day, try living with that and try holding down a job and having a social life; you know, I think 
people need a bit of time off'. All of these factors are seen as affecting retention rates in treatment, 
therefore forcing people to return to illicit drug use. 'I think that [a total ban on methadone take-
aways] would push clients to go and use more illegal drugs, I think it would take away the one 
thing that makes them legitimate parts of society and able to treat themselves and look after their 
own illness. I mean it would be easier to go and use an illegal drug rather than deal with the 
regime [of no take-aways]'.
Several KI also pointed out that the diversion or injection of methadone is unusual and 
uncommon. 'The nature of methadone is that most people, if they don’t take their methadone 
take-away, they feel sick and I think that’s a significant enough incentive for people generally to 
use their take-aways. I don’t see many problems from methadone take-aways'. Another KI added, 'I 
mean, who is going to go and swallow all their methadone to have a really good time?! It’s one of 
the most dramatic kinds of drugs that you can take, it has horrible withdrawals and, you know, it’s 
not by any means a party drug…people go on it because they have to'.
Crime
Do you believe there are some circumstances where pharmaceutical benzodiazepines/
morphine/methadone/buprenorphine are directly related to specific crimes? How? What 
sorts of crime?
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Health
The suggestions of many KI fitted in to two main themes in relation to benzodiazepines and 
pharmaceutical opioids and crime. 
The first was that rather than being directly related to specific crimes, the use of benzodiazepines 
simply means that people may commit crimes they were already intending to commit, but with 
less inhibition: 
'Now I don’t know if there is any specific crimes that are being committed because of 
benzo use. I think for some people it’s just part of what they do because they are also 
using heroin and cannabis and other drugs; if they haven’t got the money to support their 
habits they are going to do something to get the money. So I don’t think it’s any specific 
crime that they’re doing'.
Overwhelmingly, the most common example of a crime that may have already been going to 
be committed – but now with a large amount of disinhibition – was shoplifting. KI commented 
that people almost guaranteed that they were going to get caught, relating instances of people 
shoplifting directly in front of a store assistant or walking out of a shop with a stereo in their arms. 
'I think most of the time they would have occurred anyway, but I think that people might feel a bit 
more…I don’t know how to explain it…I think people are not so aware of what’s going on around 
them because they are on pills, they are in their own little world not realising what’s going on and 
therefore are probably going to get caught'. Another KI added, 'I think that people who are out of it 
on benzodiazepines get caught doing things definitely [but] I don’t think there are specific crimes 
that people who are out of it on benzodiazepines do'.
Alternatively, KI reported that the use of benzodiazepines may cause people to commit crimes 
that they would not have committed before or that were 'out of character'. Again, shoplifting 
was commonly mentioned, as were burglaries. Two KI commented that people who have taken 
a significant amount of benzodiazepines, particularly in combination with alcohol, may also 
become violent or aggressive. The reason for this uncharacteristic behaviour was seen to be the 
profound sense of 'invincibility or invisibility' that benzodiazepines afford some people. One KI 
suggested that benzodiazepines have the potential to push people over the 'threshold' of what they 
would normally consider acceptable.
In addition, a single KI mentioned ram raids on chemists and theft from chemists as crimes that 
may be related to benzodiazepines rather than pharmaceutical opioids, although according 
to other KI this has decreased in the past 12-24 months. One KI suggested that the theft of 
prescription pads may be specifically related to benzodiazepines use.
In terms of buprenorphine, one KI commented that as it has 'brought more people into treatment 
that weren’t in treatment before…I think that has got to [reduce] crime', whilst another mentioned 
the diversion of buprenorphine as a crime in itself.
Law enforcement
All law enforcement personnel reported that there is a 'definite correlation' between 
benzodiazepines and pharmaceutical opioid use and crime, with burglary and theft being the 
crimes that are seen to be specifically related. Included in this were: bag snatching; thefts from 
motor cars; drug users stealing from families; theft of prescription pads; robberies; and thefts from 
pharmacies or doctors surgeries.
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In relation to thefts from pharmacies and doctors’ surgeries, however, one KI commented that, 
'in the last 12 months it’s now dropped to half what it was two years ago, through pharmacies 
taking better crime prevention measures'. Another commented that the crime statistics may be 
related to 'people wanting to obtain more illicit drugs, like heroin' rather than benzodiazepines or 
pharmaceutical opioids.
In addition to thefts, one KI reported that although he couldn’t name specific crimes related to the 
use of benzodiazepines and pharmaceutical opioids, he did think that there was a connection to 
shoplifting in order to then on-sell goods. 'That’s a big one we’re getting now, shoplifting, because 
we’ve got a lot of receivers [of stolen goods] in the community'.
A single KI commented that armed hold ups committed using a knife or syringe were related to 
benzodiazepine and pharmaceutical opioid use. Another suggested that some crimes of violence, 
such as male partners assaulting women, are related to benzodiazepines and pharmaceutical 
opioid use.
A further KI reported that trafficking in benzodiazepines and pharmaceutical opioids was a 
specifically related crime.
Overall, do you believe the availability of pharmaceutical benzodiazepines/morphine/
methadone/buprenorphine reduces or increases crime? How?
Health
As with earlier questions, KI differentiated between benzodiazepines and pharmaceutical opioids 
when answering this question.
The majority of KI responded by saying that the availability of benzodiazepines to drug users 
would not significantly increase crime because any criminal behaviour that is occurring is 'pre-
existent'. That is, 'If people are into stealing cars or shoplifting, they are going to do it anyway, and 
whether they are on benzodiazepines or not I think is pretty irrelevant'. One KI also suggested 
that when benzodiazepines are freely available to drug users there is a corresponding lack of 
crime, both because people do not need to commit crime to obtain substances and because with 
the development of a high tolerance to benzodiazepines, people 'really don’t get into that sort of 
stupor' that has been associated with shoplifting and burglaries.
Three KI thought that the availability of benzodiazepines might increase crime; however, two of 
those KI also believed that crime was connected to the level of disassociation caused by large 
doses of benzodiazepines. 'I think the availability of benzodiazepines does increase crime…but 
the strongest thing is that they are more likely to get caught'. Another KI suggested that the free 
availability of benzodiazepines would lead to more 'marketplace bartering', but not necessarily 
trafficking.
In relation to pharmaceutical opioids, all KI bar one suggested that the availability of 
pharmaceutical opioids reduces crime. In addition, others also said that the 'poor' availability of 
pharmaceutical opioids would 'increase' crime. 'I’d say it reduces crime majorly! If that access 
to the pharmacotherapy program is removed, clients would be more likely to have to sustain 
their drug use or their self-treatment plan elsewhere. That costs a lot of money because they’d be 
buying from the black market and they’d have to come up with the money somehow'. One KI also 
commented that if pharmaceutical opioid-based maintenance programs were both more available, 
and less expensive, 'I think there could be a further reduction [in crime]'.
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One KI suggested that 'the diversion of methadone and bupe probably does contribute to some 
criminality' but that, 'on the other side of that is that people on methadone and bupe are generally 
more stable and less likely to carry on a criminal lifestyle than they were because of the stability of 
their drug source'.
Law enforcement
Most law enforcement KI restricted their comments to whether the availability of pharmaceutical 
opioids reduces or increases crime. Several KI believed that the availability could reduce crime, 'it 
obviously would be working to assist some people with their drug addictions, so therefore there’s 
probably a good chance that it would be certainly stopping some people from offending or re-
offending', although one KI commented that this would only be the case if people were not 'still 
using heroin for which they’ve got to commit crime' which in his experience was not generally 
the case. This KI summarised by saying that the availability of pharmaceutical opioids 'has the 
propensity or possibility of reducing crime, but the flipside is that it can increase it as well'.
One KI suggested that the availability of pharmaceutical opioids may increase crime, and that the 
type of crime that may be increased would not necessarily be either reported or reflected in police 
statistics; for example, the forgery of prescription pads or Medicare cards. Another KI reported 
that there was an increase in crime in suburbs where there are a lot of pharmaceutical opioid 
prescribers and a subsequent influx of people from other areas.
Two KI commented that the availability of benzodiazepines and pharmaceutical opioids simply 
maintained a 'status quo' and that they are not 'having a direct impact on crime' at all.
How does police activity influence the use of pharmaceutical benzodiazepines/morphine/
methadone/buprenorphine?
Health
Many KI agreed that police activity has little or no effect on the use of benzodiazepines and 
pharmaceutical opioids. 'If you’ve got more street police around, or visual police presence, people 
will go and deal [illicit] drugs in different areas, but I can’t see how that would relate to people 
using benzodiazepines or injecting bupe. Mostly people would do it in their own homes'. Several 
KI commented that because police activity is generally aimed at illicit drugs, the effect is not only 
to 'displace' illicit drug use to another area, but to actually increase the use of benzodiazepines 
if the supply of heroin becomes harder to find. One KI said that in the past this had lead to an 
increase in overdoses from benzodiazepines use. In addition, it was suggested that police activity 
also has no effect on the 'illegitimate' prescribing of benzodiazepines and pharmaceutical opioids, 
including morphine, 'except on the rare occasion that they bust the corrupt prescriber and that 
appears to be a very hard thing to do'. Another KI commented, 'I don’t think police activity ever 
really stops any drug use'.
One KI reported that a police presence may make injecting benzodiazepines and pharmaceutical 
opioids in laneways a 'more haphazard thing because people are worried about getting caught'. 
This KI also added that police awareness of forged scripts and pharmacists contacting police in 
these instances 'may make people a lot more wary about fronting up to pharmacies with altered 
scripts and things like that'. One other KI also reported that people using benzodiazepines without 
a script were being charged by police. It was also suggested by one KI that when people are 
actually arrested by the police it may lead to a 'pathway into treatment' for their drug use.
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Law enforcement
There was a strong sense from law enforcement KI that police activity is focusing on drug 
traffickers and not drug users, although users do sometimes 'fall into the trap'. There was also a 
perception that benzodiazepine and pharmaceutical opioid use is 'not a big problem' and that 
most police operations focus on illicit drugs, particularly heroin.
Having said that, several KI mentioned that the option of drug diversion, including cautioning, 
was an important aspect of policing and was having a significant impact on various forms of 
drug use. In some areas, officers actively 'push diversion to try to give the kids a chance', whilst 
others suggest that 'possibly for the first time offender or somebody who hasn’t had any contact 
with police or other support networks like [drug and alcohol centres] then that certainly would 
have a little bit of an impact you would like to think'. In addition to this, one KI suggested that the 
changing nature of the police force – in that police now recognise drug use as a health problem 
– has had an impact on drug users, including people using benzodiazepines and pharmaceutical 
opioids, in that policing is no longer 'zero tolerance' and users may have more access to services 
once they have come to the attention of the police. However, this KI also emphasised that officers 
still have to 'police the area and get rid of drug traffickers'. 
Several KI reported that police activity around areas like shopping malls where drug trading is 
more prevalent is having an impact on drug use, presumably not just illicit drug use, but the use 
of benzodiazepines and pharmaceutical opioids as well. 'I think the police activity is very much 
a positive and we’ve reduced the amount of activity in our shopping centre and made it so much 
more difficult to hook up for people coming in to the suburb'. In the opinion of one KI, the flow 
on effect of this is that 'coincidentally we’ve seen a severe drop in our crime rates', including 
burglaries, robberies and armed robberies. One KI also suggested that because this activity has 
a 'really positive influence' on the reduction of drug availability and drug use, people 'may just 
go and address the issues in their life'. However, KI also reported that police activity directed at 
drug trafficking also caused those targeted to 'become more covert', using mobile phones and 
vehicles to distribute substances. It is not clear whether or not this includes people trafficking 
benzodiazepines, but when police activity is focused on traffickers of heroin, people may be more 
likely to use benzodiazepines and pharmaceutical opioids. 'I guess you could say that if there is 
activity around the illicit market, people may shift to other accessible products through doctors 
and scripts and all that stuff'.
One KI also suggested that police activity and a visible police presence had an impact not just on 
crime, but on the 'perception' of crime, with a significant drop in reported levels of fear in one 12-
18 month survey.
Finally, another KI also suggested that 'the initial work that’s been done in a proactive way 
between police, doctors and pharmacists' has had an impact on the use of benzodiazepines and 
pharmaceutical opioids. These groups have gotten together and talked about common issues, 'how 
things can be solved' and are starting to 'learn from each other'. One example of the practical 
application of this co-operation is when police feed back to a pharmacist that buprenorphine is 
being diverted, the pharmacist reacts accordingly by keeping an eye on a particular client and also 
contacts their doctor, who in turn 'is in a better position to then talk about the quantities they want 
to prescribe or not prescribe, or using an alternative'.
How can existing data systems be better used to enhance the understanding of the nature 
of the illicit benzodiazepine and pharmaceutical opioid market and its impact on crime? 
e.g. IDRS, hospital data, police data, arrests.
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Health
Given that the perception of many KI is that there is not a large or organised benzodiazepine 
and pharmaceutical opioid market, especially compared to heroin or amphetamines, the 
responses to this question were limited. One KI responded that it is very difficult to get data on 
the illicit benzodiazepine and pharmaceutical opioid market from clients, because reporting is 
'so incredibly variable', and because it is a process which takes a very long time and requires a 
significant build up of trust. Another KI suggested that enhancing the understanding of the nature 
of the illicit benzodiazepines and pharmaceutical opioid market is not necessary. 'We’re just about 
helping people, supporting them through their treatment and providing accessibility to health 
services so, if we’ve got good health information then that’s all that we need'. 
Information dispersal was the final issue that was raised. One KI commented that it would be 
useful if data gathered by pharmacies on doctor-shopping could be fed back to doctors and 
emergency centres at hospitals to prevent misuse, and also that a regular forum of drug and 
alcohol workers, pharmacists and police would be useful in terms of enlightening everyone of 
what was happening in the community; for example, people travelling to a particular area for 
buprenorphine diversion. Finally, it was suggested that being able to access different sources of 
data sets – for example, police data – may help in understanding the nature of the benzodiazepine 
and pharmaceutical opioid market and its impact on crime. For example, law enforcement 
statistics on the toxicity reports of culpable drivers, or statistics on drug-related sexual assaults or 
armed robberies – if they exist – would undoubtedly enhance understanding of the ramifications of 
benzodiazepine and pharmaceutical opioid misuse.
Law enforcement
Several KI from law enforcement reported that it is difficult to obtain statistics about the misuse 
of licit drugs or any potential market that exists because benzodiazepine and pharmaceutical 
opioids are often legally prescribed. One KI reported that although there is a need for statistics 
around the benzodiazepine and pharmaceutical opioid market, 'a lot of this stuff (like chemist 
burglaries) doesn’t really get to crime data'. This KI argued that there is a need for a 'Victoria-wide 
picture of things' but that it was very difficult to get that picture 'because of the legal availability of 
these things; you can go to the doctor and get them and deal amongst a group of friends and have 
relative safety from prosecution or intervention'.
In addition, one KI suggested that, of the statistics that are available, 'we hardly see or hardly 
charge anybody with possession or use of benzodiazepines or trafficking in methadone or that 
sort of thing. I’d have to say, to be honest about it, we don’t focus on it because we’re focused 
on heroin or the other illegal drugs'. This KI commented that unless police liaison with outreach 
services or drug and alcohol workers showed that benzodiazepine and pharmaceutical opioids 
were becoming a huge issue, police would probably continue to focus on illicit drug use.
Are there any questions that need to be asked of existing data or existing trends that you 
believe are not currently being asked? i.e. Is there any info about these drugs and their use 
that could be collected that you think would be useful to you in your work?
Firstly, one very strong response from KI to this question was that there needs to be significant 
inroads made into the sharing of data, and that linkages between different data sets are essential 
to the strengthening and deepening of knowledge around benzodiazepine and pharmaceutical 
opioid use.
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Some of the agencies or areas that KI reported could share data sets are: alcohol and drug 
agencies; Transport Accident Commission; Workcover; Coroners Court; pharmacists; hospital data; 
ADIS (Alcohol and Drug Information System); and mental health data. KI did acknowledge that 
there would be issues of confidentiality to address, and also that the collection and entry of data 
can be seen as burdensome for some organisations.
Further to that, KI suggested that progress could be made in the following areas by utilising pre-
existing data.
More analysis of benzodiazepine prescribing – 'what harm results from it and what benefits'. 
The gathering together of national data on why people are injecting temazepam and why they 
inject in the groin.
Further use of information coming from pharmacology research around health and injecting 
practices.
Questions asked around the trend of punishing 'doctor-shopping' and why we have particular 
views of drug users seeking medication.
Questions asked of mental health data concerning the psycho-social issues around patterns of 
use.
More analysis of the causative factors of substance use and more analysis of 'what works and 
what doesn’t work' in terms of treatment.
Use of existing data sets to instigate some 'sociological' drug and alcohol research.
Asking questions about why heroin can’t be legalised to allow people to 'lead a normal life' 
because we are 'set on a particular type of drug medicine' (pharmaceutical opioids) and how 
that relates to people’s benzodiazepine use.
Utilising existing data to undertake some gender-orientated analysis of benzodiazepine and 
pharmaceutical opioid use.
Impact
How does misuse of benzodiazepines/morphine/methadone/buprenorphine impact on 
your work?
Health
The majority of KI reported that the health problems associated with injecting benzodiazepines 
and pharmaceutical opioids have an impact on their work. Three KI stated that it did not especially 
impact on their work any more than other drug use.
KI listed blood clots, deep vein thrombosis, infections, abscesses, collapsed veins, gangrene, 
complications with groin injection and, in severe cases (as mentioned earlier), amputations as 
the main health problems caused by injecting benzodiazepines – and temazepam in particular 
– and pharmaceutical opioids. Many KI also reported problems arising from poly drug use, such 
as dealing with more overdoses or having to present more clients to accident and emergency, 
and one KI commented that clients can sometimes be agitated. Several KI also commented that 
clients can be more 'high risk' in general because of poly drug use involving benzodiazepines 
and pharmaceutical opioids. One KI noted that the use of benzodiazepines and the misuse of 
pharmaceutical opioids can complicate the management of opioid dependence.
Many KI also mentioned the difficulty of withdrawing from benzodiazepines and the impact that 
had on their work. One person commented that benzodiazepine withdrawal is 'particularly nasty' 
and that they may have to deal with crises resulting from sudden withdrawal. Another KI also 
mentioned that it was difficult to get people into a detox unit to withdraw from benzodiazepines 
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or pharmaceutical opioids because of the extra time and sometimes complicated variables 
involved. 'I think that withdrawal still remains a problematic area, because usually to reduce 
somebody it’s very difficult to get them admitted to a unit'. In addition to this, getting people off  
benzodiazepines 'requires sophisticated counselling and that’s not always available'.
As a result of the health problems associated with benzodiazepines and pharmaceutical opioid 
misuse, KI also reported that the impact on their work resulted in the provision of more vein care 
and injecting health information to their clients, and in particular several KI mentioned information 
on filtering processes where buprenorphine was being taken from the mouth and injected into 
the bloodstream. A couple of KI mentioned that because of the effect that benzodiazepines can 
have on memory this information often had to be provided more than once, although one of these 
added that having to repeat information is not necessarily a negative. 'You might spend time with 
them on an issue and they’ll come back the next day and will have completely forgotten what you 
said. So, you will have to go over it again, but that’s not so much a negative impact because, you 
know, we’re always prepared to go over things with people'. In addition to this, one KI remarked 
that the health issues arising from benzodiazepines and pharmaceutical opioid misuse sometimes 
created a situation where a more robust connection could be made with a client. 'It ends up being 
quite intensive and often that’s really good, like it’s a really positive kind of interaction, so we’ve 
got to know people really well'.
Finally, two KI mentioned that it can be more difficult to engage with clients who have taken 
benzodiazepines, and one of these mentioned that a service may have to monitor young drug users 
on the premises if a large amount of benzodiazepines had been taken.
Only two KI reported that the use of benzodiazepines and pharmaceutical opioids had a different 
impact on their work to other drugs, and that was because of issues of vein damage.
Law enforcement
Four law enforcement KI responded to this question. One KI commented that benzodiazepine and 
pharmaceutical opioid misuse represented no special problems, but were the same as heroin in 
terms of impact on police work. 'The issues for heroin are the same as the issues for the misuse of 
bupe and methadone and other prescription drugs…they’ve somehow got to pay for it, so therefore 
they commit crimes generally. The dole only goes so far'. 
The second KI addressed the injection of benzodiazepines and pharmaceutical opioids, observing 
that there may be health considerations for officers: 'as far as injecting goes, the only thing that 
springs to mind is they’re obviously using needles and therefore it’s a safety issue for us. That’s the 
biggest thing with any type of intravenous drug use, is first and foremost needle stick injuries'.
The third KI discussed the delay in processing which may occur if a person has taken a significant 
dose of benzodiazepines – particularly Normison – and the added responsibility of officers to 
ensure that the person does not overdose whilst in custody waiting to be charged.
Finally, the fourth KI reported that the use of benzodiazepines and pharmaceutical opioids had no 
impact on police work, which was significantly different to other illicit substances.
For police
Historically, what have been the benefits and problems of policing efforts that you are 
aware of in response to pharmaceutical misuse?
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Benefits
KI reported on a variety of benefits of policing efforts in response to pharmaceutical misuse. 
Firstly, one KI reported that the more that police can 'reduce the illicit use' of pharmaceuticals 
(particularly by focusing on traffickers), 'then you see a reduction in crime. If it’s left unchecked it 
gets out of control and increases the crime'. 
In direct relation to this, one other KI reported that police statistics in a particular area show that 
in the case of pharmaceutical-related burglaries, or 'chemist burgs', offences are well down as a 
result of policing efforts. This was done by working with the statistics that had been gathered: 'We 
solved the problem with our database because we knew what times they were committing the 
offences, so we ran operations and sat off the premises and apprehended the offenders'. This KI 
suggested that, in most areas, stations would have addressed this issue and reduced the number of 
'chemist burgs'.
Another benefit of policing efforts was seen to be that police members are treating the use of 
pharmaceutical drugs as a health issue and, therefore, are relaying offenders into diversion 
programs so as to focus on those people who are trafficking in pharmaceuticals.
Finally, the production of the guide 'An Investigation Guide to Pharmaceutical Drug Trafficking and 
Use' (Victoria Police 2004) was mentioned by several KI as a significant development in policing 
efforts, in that it enables officers to more readily identify pharmaceutical substances. 'That’s been 
a sensational resource and we’ve used it here in the office, because when we go out, we do a lot 
of search warrants on addresses and it’s increased the information and awareness of my members. 
When they go to an address or check someone in the street…and discover tablets or whatever, if 
they can’t identify it there and then they can use the guide back at the station. So that’s been a real 
positive, that guide'.
One KI identified a problem with policing efforts which was that the procedure of having to check 
people for scripts and then cross reference with pharmacies was time consuming and created a 
lot of paperwork. 'Probably the only problem is increased workload. You know, without the users 
carrying their scripts around that creates a problem because you’re stuck between a rock and a 
hard place; you don’t know, are they supposed to have it, or not. Also time constraints because 
you’ve got to go and check with the pharmacies'.
What would make your policing/role easier regarding pharmaceutical products? 
Several KI identified restricting the source and tracking the dispensing of pharmaceutical products 
as a significant way of making their policing role easier. That is, the ability to 'police and control' 
how people 'get hold' of benzodiazepines and pharmaceutical opioids in the first place, including 
putting more measures in place to prevent the theft of prescription pads, and steps to monitor 
where pharmaceuticals go once prescribed. One KI suggested that benzodiazepines as well as 
pharmaceutical opioids used for maintenance programs be dispensed from 24 hour clinics on a 
daily basis because 'as soon as you have access to it and it’s up to [drug users] where and how 
they take it, they’re going to abuse it'. A separate KI also suggested that clinics and pharmacies 
be available in a wider variety of areas to prevent an influx of 'criminal activity' into particular 
suburbs where prescribers are common.
On a broader note, another KI suggested that 'there should be some system, some accountable 
system to track every batch when it comes out of the factory – where it goes. It’s probably not 
simple, but it’s like some system where say ***** produces X amount, you know, two million 
tablets, and [there must be] one million sold and one million retrieved and destroyed or something 
like that'. In addition, there could be a 'national database [where] pharmacists have all their 
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dispensing linked, so that if someone came out with a prescription, they’d search and go, ahh, 
here’s a name'. This KI suggested that although some people would get around this system by 
using false identification, at least it would have some effect on reducing supply, and therefore, 
potentially make policing easier.
One KI pointed to the fundamental importance of information in improving policing with regard to 
benzodiazepines and pharmaceutical opioids. 'All policing relies on information, from whatever 
source, and without it we don’t survive, that’s a significant issue, so the more information we have 
[the more it] actually creates a picture, creates intelligence, and then it actually allows you to 
make decisions as to where we need to focus our investigations. There may be a really significant 
issue for the community that we know nothing about because we don’t have the information, and 
at some point in time we have to reassess the way we do our business to say, 'we need to start 
concentrating on this'.
Finally, several KI again mentioned the continued use of the resource 'An Investigation Guide 
to Pharmaceutical Drug Trafficking and Use' (Victoria Police 2004) in making their policing role 
easier. In addition, one KI suggested that the handbook would be even more useful if it was to be 
expanded and made more practical. It could include 'more information on why the user is using 
[particular pharmaceuticals]' and include the street names of drugs so that 'it’s much easier to talk 
to the users and you get a bit more credibility if you know what they are calling them'. Officers 
would then also be aware of street names if approached for drugs themselves.
Summary
Market characteristics
The majority of KI reported that heroin was the primary drug of choice for people using 
benzodiazepines and pharmaceutical opioids. KI noted that people were using a variety of 
benzodiazepines, but that the most common benzodiazepines were temazepam/Normison, closely 
followed by Valium. Long-term injecting drug users were identified by the majority of informants 
as the most likely to use benzodiazepines and pharmaceutical opioids. Some KI also noted that 
people with anxiety and mental health disorders are also using these drugs, as well as a percentage 
of methadone clients.
Most KI from the health sector, and all KI from law enforcement, reported that benzodiazepines 
are being used as a supplement to a primary drug of choice rather than being a drug of choice 
themselves. Health KI commented that benzodiazepines might be used to increase the effects of 
heroin use, to ease symptoms of withdrawal, or to deal with sleeplessness or anxiety. However, 
several KI also reported that the use of benzodiazepines is quite fluid, and that people will 
alternate between substances according to availability, health and financial situation, as well as 
a raft of other psycho-social factors. Two KI reported benzodiazepines being used as a primary 
drug of choice, with one suggesting that temazepam in particular was being used by one client 
in preference to other drugs. The second KI that identified benzodiazepines being used as a 
drug of choice commented that this had come about as a result of the supplementary use of 
benzodiazepines gradually shifting to primary use over time as a consequence of the relative 
affordability of benzodiazepines and the perception that at times they offer a longer lasting effect 
than heroin.
With regard to pharmaceutical opioids, KI offered the suggestion that there is a blend of primary 
and supplemental use. Whilst some people use only their buprenorphine, for example, others 
may top up with heroin when required. There was also some suggestion that when buprenorphine 
initially became available people were more likely to supplement with heroin, but that as more 
people remained on the program their heroin use ceased. 
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Despite these suggestions, there were still fairly consistent reports from KI that the trade of 
benzodiazepines, which may have previously existed, has significantly decreased. In addition, 
several KI reinforced earlier comments about the lack of an organised black market in 
benzodiazepines and pharmaceutical opioids, although one KI speculated that on-selling may 
be more common in the case of morphine, which is notoriously hard to get and therefore more 
valuable. One KI from law enforcement reported that because the trading and on-selling of 
benzodiazepines and pharmaceutical opioids exists, but is not a major problem, it would be pure 
speculation to comment on the proportion of drugs that are traded.
The response from almost all KI from both the health and law enforcement pools suggested that 
the primary reason that people might deal in benzodiazepines or pharmaceutical opioids was the 
need to make money. This money would be used to meet the basic daily needs of survival in terms 
of food, housing or drug use. One KI suggested that the monetary value of benzodiazepines and 
pharmaceutical opioids was so low that it was 'ridiculous' to suggest people were dealing to make 
money. Instead, dealing or trading was simply an entrenched facet of a drug using culture.
Diversion
A small number of KI reported that when 'doctor-shopping' does occur, it is most likely to be for 
personal use rather than for on-selling. One KI suggested that people would perhaps share with 
friends and another that any on-selling would be opportunistic rather than pre-arranged. When 
asked about the patterns of drug sharing amongst friends, KI reported a relatively high incidence 
of sharing between partners. KI suggested that people may also share drugs with other users to 
avoid appearing to be 'mean', but, more broadly, that a disorganised social network of sharing, 
trading, buying and selling exists, where a person may exchange cannabis for benzodiazepines or 
heroin, or where a promise of something in return 'next week' will result in the sharing of heroin 
or benzodiazepines. 
One KI commented on an instance where someone who is not able to afford to pick up their dose 
of buprenorphine will make an arrangement with a friend to pick it up, and the buprenorphine 
will then be shared. Another commented that they were not aware of a trade in buprenorphine. 
In addition, KI were doubtful about the existence of more formal trafficking in buprenorphine, 
particularly where pharmacists have become more wary of clients leaving without the tablet 
having been crushed and ingested. Law enforcement KI added that drug trading is more likely to 
occur in Melbourne’s 'drug hotspots' and may also centre around pharmacies that are dispensing 
buprenorphine.
Several KI suggested that there is little or no trade in benzodiazepines at the moment due to the 
increased difficulty in obtaining scripts from doctors. The result of this is that people are much 
more reluctant to share a scant personal supply of benzodiazepines and instead are more likely 
to share heroin or amphetamines if they are sharing at all. When people have legal access to 
benzodiazepines and pharmaceutical opioids, the proportion that is traded, given away or sold 
can depend on the geographical area. In one area KI reported a high level of buprenorphine 
on-selling, but not of benzodiazepines, again because benzodiazepines have become harder to 
acquire. Alternatively, in another area, one KI reported that people may be selling or giving away 
their benzodiazepines, but that the trading or sharing of buprenorphine was less common. One KI 
suggested that the level of trading or selling of benzodiazepines depends on the size of the script 
that a person is given. If prescribed a large amount of benzodiazepines, then the person might sell 
or trade some and keep some for themselves, whereas a smaller script is more likely to be kept for 
personal use. 
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Many KI reported that the majority of benzodiazepines and pharmaceutical opioids available 
to their clients are coming from prescribing general practitioners. However, there was also the 
suggestion that this arrangement differs with regard to substances. For example, whilst KI reported 
that Valium is still commonly prescribed by GPs, Normison has become significantly harder to get. 
Therefore the supply of Normison might be more likely to be provided at a street level. Several KI 
reported that there is a stronger market for Normison than other benzodiazepines. With regard to 
morphine, some KI reported that the difficulty of obtaining a script means that a lot of the available 
morphine would be coming from people on pain relief for physical injury or illness, or from family, 
friends or a partner.
Two KI suggested that people may source benzodiazepines from chemist burglaries or raids – 
although this was seen to have decreased significantly – or by shoplifting from pharmacies, which 
was also seen as being more difficult than in previous times. The majority of law enforcement KI 
also suggested that people were accessing benzodiazepines via chemist burglaries or burglaries 
carried out at manufacturers or distributor premises, although they also reported a considerable 
decrease in these offences over the past twelve months to two years. Several law enforcement KI 
suggested that people obtain benzodiazepines and pharmaceutical opioids from the street market, 
and two law enforcement KI suggested people obtain them from GPs. No KI had heard of people 
sourcing benzodiazepines or pharmaceutical opioids over the Internet. Doing so was considered 
by one KI as inconvenient and unreliable, as well as being inaccessible to many drug users either 
as a result of a lack of access to resources or a lack of knowledge about the Internet.
Links to crime
The majority of KI from both health and law enforcement did not believe there was any aspect of 
organised crime related to benzodiazepines or pharmaceutical opioid use. Instead, KI reported 
that any trading, sharing or selling was more likely to be disorganised. Whilst connections and 
networks might exist at a street level – and in that sense may exhibit some organisation – KI did 
not believe that it went 'any higher up' or that there was any sort of 'crime racket' going on. In 
part this was seen to be a result of the relatively low financial rewards to be gained from trafficking 
benzodiazepines and pharmaceutical opioids. 
When asked if there are some circumstances where benzodiazepines and pharmaceutical 
opioids are related to specific crimes, KI gave two main responses. The first was that the use of 
benzodiazepines may mean that people commit crimes they 'already intended to commit', but 
with far less inhibition. In terms of the type of crimes that may already have been committed, KI 
mentioned shoplifting in particular. This was the primary response from KI. The second was that 
the use of benzodiazepines may be a factor in crimes committed, again like shoplifting, but also 
on occasion burglary, because of the sense of 'invisibility' that benzodiazepines create. In both 
circumstances KI reported that people are much more likely to get caught committing crime 
because of this sense of invincibility.
With regard to pharmaceutical opioids, the response from most KI was that maintenance 
programs reduce crime in general. One KI noted that the diversion of buprenorphine was a crime 
specifically related to its availability.
All law enforcement KI reported that there was a correlation between benzodiazepines, 
pharmaceutical opioids and crime, suggesting that property crimes such as thefts (including 
shoplifting) and burglaries had been most prevalent. However, one KI suggested that 
pharmaceutical-related crime (especially burglaries on chemists) had dropped in the past 
twelve months, while another suggested that police crime statistics might also relate to people 
wanting to obtain illicit drugs. One KI suggested that crimes of violence may be connected to 
benzodiazepines and pharmaceutical opioid misuse, whilst another reported that trafficking in 
benzodiazepines or pharmaceutical opioids was occurring.
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Overall, the majority of KI reported that the availability of benzodiazepines would not significantly 
increase crime because the criminal behaviour of people pre-exists the use of benzodiazepines. In 
addition, one KI suggested that when benzodiazepines are freely available there is a corresponding 
lack of crime due to the fact that their availability removes the need to commit crime to obtain 
illicit drugs, and also because when benzodiazepines are freely available people quickly develop 
a tolerance, and do not get into the 'stupor' that is associated with shoplifting in particular. 
Three KI thought that the availability of benzodiazepines increased crime. Of these three, one 
added that it meant people were much more likely to get caught and one that the availability of 
benzodiazepines may lead to marketplace bartering rather than trafficking. 
In regard to pharmaceutical opioids, all KI but one suggested that their availability reduces crime. 
Others added that the 'poor' availability of pharmaceuticals would increase crime because it 
would mean that people would turn to illicit drug use, and the maintenance of that drug use might 
involve crime. One KI also commented that wider and less expensive access to pharmaceutical 
opioids could reduce crime. One KI suggested that the diversion of buprenorphine and methadone 
probably does contribute to some criminality but that people on these programs are also able to 
carry on a more stable lifestyle.
Law enforcement KI restricted their comments to pharmaceutical opioids, with several KI agreeing 
their availability could reduce crime. However, one law enforcement KI commented that the 
availability of pharmaceutical opioids could increase crimes that may not necessarily be reported 
such as the forging of Medicare cards. Another KI suggested that there was an increase in crime in 
suburbs that host a high number of prescribing pharmacies.
Implications for police and other frontline workers
The health implications of injecting benzodiazepines and pharmaceutical opioids had the most 
impact on the work of KI working in the drug and alcohol field; although three KI reported that the 
misuse of benzodiazepines and pharmaceutical opioids did not have any special impact on their 
work but was the same as other drugs. KI reported having to deal with clients developing blood 
clots, deep vein thrombosis, infections, abscesses, collapsed veins, gangrene or having to undergo 
amputation, as well as the complications arising from withdrawal from benzodiazepines. 
Many KI also reported problems arising from poly drug use such as dealing with overdoses or 
having to take clients to hospital, whilst others added that clients who were poly drug users 
were generally much more high risk than others. As a result of the impact of benzodiazepine 
and pharmaceutical opioid misuse, KI needed to be familiar with information about vein care 
and general injecting health. One KI commented that clients could sometimes become agitated. 
Finally, two KI mentioned that it could be more difficult to engage with clients who have taken 
a large amount of benzodiazepines, with one of these KI adding that young clients who are 
intoxicated with benzodiazepines may have to be monitored at the service, which sometimes 
disrupted other clients.
With regard to policing, one KI reported that benzodiazepines and pharmaceutical opioid use had 
no impact on police work, whilst another commented that benzodiazepines and pharmaceutical 
opioids had the same impact as other drugs. One KI suggested that the risk of needle stick injury, 
when people were injecting benzodiazepines and pharmaceutical opioids, was of concern. 
Finally, one KI observed that the delay in processing which occurs with significant doses of 
benzodiazepines, and the resultant responsibility for that person’s health, impacted on officers’ 
work.
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As for the extent and ease of 'doctor-shopping', KI were divided in their responses. Some KI 
reported that it was 'rife' or occurring to a large extent with some benzodiazepines, and that it was 
relatively easy to do. One KI thought that although that is the case, it is subject to the availability 
of doctors who are inexperienced, 'tired' or of the view that they are doing the 'right thing'. In 
contrast, other KI thought that 'doctor-shopping' had become much harder in recent times and 
that it had lessened to a significant degree, mostly because doctors had become more aware 
of its occurrence, and because the prescription of 10mg temazepam gel capsules must now be 
authorised by the PBS. These KI saw 'doctor-shopping' as being arduous and difficult for drug 
users. Three KI from law enforcement echoed the response from KI from the health sector.
All KI from the health sector agreed that it would be extremely difficult if not impossible to 'doctor-
shop' for buprenorphine or methadone and all considered that obtaining morphine would be very 
difficult. Law Enforcement KI did not comment on 'doctor-shopping' for pharmaceutical opioids. 
With regard to how people report getting scripts, again a small number of KI responded by saying 
that people may just ask for prescriptions and are provided with them because the doctor is not 
aware that they have already been prescribed elsewhere, whilst several others reported that people 
may complain of difficulty sleeping or of experiencing physical pain. 
Two KI reported that female drug users were sometimes coerced into undertaking sex work in 
order to make money to procure drugs for themselves and their partners. The majority of KI 
reported that the prescribing of benzodiazepines to drug users should be viewed as a positive 
when forming part of a withdrawal program, or by helping to keep people in treatment by 
lessening the need to use heroin. The prescription of benzodiazepines was generally seen as a 
positive because it provides a treatment option for drug users as an alternative to taking part in 
pharmacotherapy programs, which are sometimes viewed by drug and alcohol workers and drug 
users alike as being overly regimented. However, there was also firm agreement from many KI that 
benzodiazepines should be prescribed with some vigilance and that drug users who are prescribed 
benzodiazepines be offered support and counselling or be encouraged to access support and 
counselling. KI from law enforcement added that positive impacts on health might convert into a 
reduction in crime, and that another benefit of the prescribing of benzodiazepines might be that 
drug users can be more closely 'monitored'.
One of the 'cons' of prescribing benzodiazepines to drug users was seen to be a perceived lack 
of support, as mentioned above. In addition, KI thought that the lack of information concerning 
the potential side effects of benzodiazepines was a negative aspect of prescribing. Another strong 
theme that emerged from KI in regards to the 'cons' of prescribing benzodiazepines to drug users 
was the serious health issues connected to the injection of these substances such as vein damage, 
abscesses, and in serious cases, amputations. The risk of overdose was also mentioned many times, 
most often in with regard to the use of benzodiazepines in conjunction with other drugs. Finally, 
the habit-forming nature of benzodiazepines was cited as a potential negative consequence of 
their prescription. Law enforcement KI also mentioned the desirability of benzodiazepines on the 
black market and the abuse of benzodiazepines, especially when used in conjunction with other 
drugs, as negative aspects of benzodiazepines prescription.
With regard to the provision of pharmaceutical opioids to drug users, the overwhelming 
response – again, keeping in mind that unless otherwise specified KI answered in response to 
buprenorphine and methadone – was that opioid-based pharmacotherapy programs were of the 
utmost importance in drug treatment. KI reported that the provision of pharmaceutical opioids 
significantly improved the health and wellbeing of drug users, with flow on effects to employment 
and housing, thereby offering people the chance to create some stability in their lives. As a result 
of the legal provision of pharmaceutical opioids, KI also suggested that people no longer need to 
commit crime to pay for illicit substances. Another positive aspect of prescribing pharmaceutical 
opioids to drug users was seen to be the potential to 'step down' from heroin use to buprenorphine 
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use, for example, and then from buprenorphine to abstinence if that was desired. Law enforcement 
KI echoed these thoughts, adding that the availability of pharmaceutical opioids may reduce crime 
by disengaging people from street supplies of heroin and may also help to control peoples’ heroin 
use.
KI mentioned very few 'cons' of prescribing pharmaceutical opioids in terms of the drugs 
themselves, but were more concerned with the regime of dispensing (daily pick ups) and the lack 
of take-away doses for buprenorphine clients, seeing these as having an impact on retention rates, 
and therefore an impact on the possibility of positive outcomes from treatment. Other issues of 
accessibility were also raised by KI, primarily the lack of both prescribers and dispensers in rural 
and suburban areas. And, as before, a lack of information about the side effects of pharmaceutical 
opioids was also seen to be one of the negatives of prescribing them to drug users. Finally, KI 
suggested that inconsistencies in the dispensing of buprenorphine, such as not crushing the tablet 
on the spot – which then allowed the drug to be diverted or injected – were a 'con' of prescribing 
pharmaceutical opioids. Law enforcement KI saw the use of pharmaceutical opioids and other 
drugs (such as heroin) in combination as one of the main drawbacks of prescribing. Two KI saw the 
provision of pharmaceutical opioids as a 'bandaid' solution which does not address drug use, and 
one KI raised the issue of the diversion of buprenorphine as a negative aspect of prescribing.
A number of KI questioned the assumption that benzodiazepines and pharmaceutical opioids were 
easily available to drug users, positing that a lack of available prescribers (with pharmaceutical 
opioids) and the difficulty of obtaining prescriptions from doctors (with benzodiazepines) meant 
that people often had problems with access. However, several KI did respond by repeating that 
the easy availability of benzodiazepines to drug users was a positive thing when done with 
consideration and support, noting that benzodiazepines were very beneficial to people suffering 
from sleeplessness and mental health issues as well as those who require benzodiazepines for pain 
management. The easy availability of benzodiazepines was also seen as a positive because they 
can provide an alternative to potentially more harmful substances. Law enforcement KI added that 
the easy availability of benzodiazepines was problematic because it leads to harmful poly drug 
use.
With regard to pharmaceutical opioids, easy availability was seen to be a positive thing first and 
foremost because the more available pharmaceutical opioid-based maintenance programs are, 
the higher the reward in terms of both uptake of programs and success of programs. One KI also 
suggested that were there to be ease of availability of morphine, this could also produce some 
positive outcomes very similar to those achieved by the use of opioid replacements. Many of the 
law enforcement KI also reported that one of the benefits of the easy availability of pharmaceutical 
opioids was a positive impact on the health of drug users; however, one KI commented that he was 
not personally aware of these benefits.
Many KI reported that there are problems with the easy availability of benzodiazepines when they 
are dispensed without vigilance. These include a variety of serious health problems as well as 
the risk of overdose and death. Whilst daily pick-ups of benzodiazepines were also seen to be a 
problem because they placed restrictions on people’s lives – especially when not considered on 
a case-by-case basis – KI did report that a more interested prescribing of benzodiazepines could 
contribute to solving these problems. Of the law enforcement KI who responded to this question, 
both identified the diversion of benzodiazepines and pharmaceutical opioids as a problem 
associated with easy availability.
No KI from the health sector reported any problems with the easy availability of pharmaceutical 
opioids. In terms of problems with the poor availability of benzodiazepines, several KI suggested 
that lack of supply could force both dependent and non-dependent benzodiazepines users to 
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seek a more harmful replacement, thus causing a whole raft of new health and law enforcement 
problems. KI also suggested that one of the problems associated with a deliberately poor supply of 
benzodiazepines to drug users was that it endorsed a discrimination which is not experienced by 
the broader population, to whom benzodiazepines are widely available. Several KI also suggested 
that daily pick-ups of benzodiazepines could be considered to be a poor supply because it would 
reduce access by imposing restrictions on use that cannot always be met by people with often 
chaotic lives.
Several KI reported that the cost of pharmaceutical opioids was a significant factor when thinking 
about the problems of poor availability. If the cost of programs is prohibitive – and for the majority 
of drug users the sometimes $5 a day cost of buprenorphine can be prohibitive – the obvious 
outcome is less access to treatment and, as mentioned earlier, less improvement in the health 
and wellbeing of drug users. In addition, the poor availability of pharmaceutical opioids may also 
lead to an increase in crime for some people as they are compelled to commit crime to pay for 
their dose. The one KI from law enforcement who responded to this question also suggested that 
poor availability of pharmaceutical opioids may also lead to criminal behaviour. Finally, one KI 
commented that the poor availability of benzodiazepines in liquid form such as temazepam may 
impact on the elderly population for whom the gel caps were originally designed. 
KI thought that it might be harder to obtain benzodiazepines and pharmaceutical opioids in 
some geographical areas than others primarily because of a lack of prescribing doctors, a lack 
of bulk-billing doctors (which means that people cannot afford the consultation) and, especially 
where pharmaceutical opioids are concerned, a lack of dispensing pharmacies. This was an 
issue across the board, in both rural and suburban areas. In addition, several KI commented that 
doctors who may be inexperienced with drug users, or who are not comfortable with treating drug 
users, might be less likely to prescribe benzodiazepines or pharmaceutical opioids (conversely, 
some KI also suggested that inexperience with drug users may also mean that doctors are 'more' 
likely to prescribe). It was also suggested that it might be easier to access benzodiazepines and 
pharmaceutical opioids in areas where there was a concentration of doctors or pharmacists who 
were not as rigorous with prescribing and dispensing. 
Interventions 
One KI suggested that policing might have a minor effect on access to benzodiazepines and 
pharmaceutical opioids in some geographical areas. One KI from law enforcement agreed with 
this assertion, whilst several others suggested that it might be easier to obtain benzodiazepines and 
pharmaceutical opioids in Melbourne’s drug 'hotspots'.
Many KI suggested that changes to health care would make a prescriber’s role easier regarding 
the limiting of pharmaceutical products. One KI suggested that the reduction of benzodiazepine 
prescribing in general would have an effect on diversion, however, did not think that this was the 
only alternative option. Several KI recommended a that more holistic approach to prescribing 
would reduce the opportunity for the diversion of pharmaceutical products because this approach 
would mean doctors would be less likely to prescribe them in large doses. With regard to 
buprenorphine, one KI suggested that the provision of more prescribing pharmacies where drug 
users were 'welcome' would result in increased vigilance with dispensing and as a result less 
opportunity for diversion. In addition, another KI commented that the development of a fizzy 
'Berocca™ like' form of buprenorphine may prevent diversion. Some KI suggested that tracking 
the amount of prescriptions an individual has, taking extra care to secure prescription pads 
and arranging daily pick-ups on a case-by-case basis for benzodiazepines may limit diversion. 
Several KI suggested that if an injectable form of pharmaceutical opioid were to be introduced 
via pharmacies, the motivation for diversion would be removed. Law enforcement KI agreed 
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that ensuring that buprenorphine tablets are crushed and ingested on the spot would help with 
diversion. One law enforcement KI suggested that the sharing of information and strategies 
amongst doctors would ensure that all doctors were aware of which drugs are targeted for 
diversion, and as a result could reduce the amount they prescribe.
The vast majority of KI reported that a total ban on take-away doses of methadone would have a 
disastrous impact on their clients. Health and self-esteem would be affected, it would discriminate 
against people who have to travel significant distances to pick up their daily dose, and it would 
potentially limit the access of people suffering from mental illness to the program. The removal of 
take-away doses would affect peoples’ ability to become or remain employed and also had serious 
implications in terms of forcing people back into using illicit drugs if they were unable to adhere to 
the daily pick up regime. Many KI commented that the diversion of methadone was not common 
at all.
Most KI did not think that police activity had any effect on the use of benzodiazepines and 
pharmaceutical opioids. Police presence was seen as more influential in terms of illicit drug use. 
Several KI commented that the displacement of illicit drug trafficking to another area as a result 
of policing could lead to an increase in benzodiazepine use, if illicit drugs were more difficult 
to obtain. This was seen by one KI as contributing to the number of overdoses occurring. One KI 
thought that police activity might result in benzodiazepine use becoming more discreet, and also 
that, as a result of pharmacists calling police when scripts seemed suspicious, people might also be 
more wary of presenting forged scripts to pharmacies. One KI mentioned that people in possession 
of benzodiazepines without a script were being charged. Police activity was seen as having little or 
no effect on corrupt prescribing of benzodiazepines or pharmaceutical opioids.
Law enforcement KI suggested that policing was having an effect on drug traffickers rather than 
drug users, and many KI reported that the primary focus of police was on 'illicit' substances 
rather than on benzodiazepines and pharmaceutical opioids. However, KI commented that police 
cautioning and diversion programs were having an impact on various forms of drug use. As well, 
several KI reported that police activity in areas like shopping malls was having an influence on 
drug use by making access more difficult and in turn reducing crime in those areas. However, two 
KI also suggested that police activity around trafficking has caused trafficking to become more 
covert. Finally, one KI suggested that increased co-operation between police and pharmacies had 
the potential to influence the use of benzodiazepines and pharmaceutical opioids.
With regard to using existing data systems to better understand the nexus 'between the illicit 
benzodiazepines and pharmaceutical opioid market and crime'; the perception of many KI is that 
there is not a large or organised market at all. 
One KI responded that it is very difficult to obtain data about this in the first place, while 
another commented that a better understanding of the relationship between any existing illicit 
benzodiazepines and pharmaceutical market was unnecessary for health workers given that 
their job is to provide support and treatment. One KI suggested that it would be helpful for 
data collected by pharmacists on 'doctor-shopping' to be fed back to doctors and Accident and 
Emergency (A&E) departments at hospitals. A final KI observed that access to different sorts of data 
sets – for example, law enforcement data – may be of use. 
Law enforcement KI added that it was also difficult for police to compile statistics about the misuse 
of licit drugs. In addition, because the benzodiazepines and pharmaceutical opioid market was 
seen as relatively insignificant in comparison to the licit market, law enforcement may not have 
enormous use for this data until it becomes a 'huge' issue.
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KI came up with a range of questions that could be asked of existing data or trends that they 
believe are not currently being addressed. Primarily, this centred on obtaining access to data, and 
ensuring that there was 'talking' amongst data sets and sharing of data. KI suggested links could be 
made in a variety of ways between alcohol and drug agencies, the Transport Accident Commission, 
Workcover, the Coroners Court, pharmacists, hospital data, mental health data and ADIS for 
example. KI suggested a variety of other questions could be asked, for example, about the harm 
and benefits that are associated with benzodiazepines prescribing or about the development of 
harm reduction practices around injecting pharmaceutical drugs.
In terms of the historical benefits and problems of policing in regard to pharmaceutical opioid 
misuse, law enforcement KI reported a variety of benefits. Policing efforts had reduced the use 
of pharmaceuticals and, hence, the incidence of crime, as reflected in crime statistics. Another 
benefit of policing in regards to pharmaceutical misuse was seen to be the changing approach of 
police towards drug users. With the diversion of drug users into cautioning programs, police are 
more able to focus their efforts on the trafficking of pharmaceuticals. The production of the guide 
An Investigation Guide to Pharmaceutical Drug Trafficking and Use (Victoria Police 2004) for all 
stations was also seen to benefit policing efforts, in that it allowed officers to correctly identify 
pharmaceuticals and to lay charges where applicable. One KI identified the time consuming 
nature of the paperwork associated with police efforts to check and cross-check personal scripts as 
being a problem of some policing efforts.
In response to the question of what would make their policing role easier, law enforcement KI 
made a range of suggestions. Restricting the source of benzodiazepines and pharmaceutical 
opioids as well as dispensing them from a 24 hour clinic would be of assistance, as would 
establishing pharmacies in a wider range of areas to prevent people from flocking to 'hot-spots'. 
One KI also suggested that there be a system to track batches of benzodiazepines as they come out 
of the factory in conjunction with a national database of dispensing. Another KI remarked that the 
provision of information to police around emerging problems would make policing easier. Finally, 
KI reinforced the positive impact of An Investigation Guide to Pharmaceutical Drug Trafficking and 
Use (Victoria Police 2004) and suggested that the updating of the guide on a regular basis would 
ensure that it was of continued benefit in policing efforts.
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Chapter four: Overall summary 
The findings from all four stages are summarised in the following sections.
Stage one: Key informant interviews (law enforcement)
Market characteristics
Firstly, in order to explore these issues, 13 law enforcement KI from Melbourne localities were 
interviewed about their experiences in policing around prescription drug issues. Most informants 
believed that pharmaceutical drug use was dependent on heroin trends, the former increasing in 
response to reductions in the latter. 
Diversion
It was believed that prescription drugs were diverted to the black market via burglaries and 
pharmacy thefts, prescription forgeries, doctor-shopping, and on-selling by users. There had 
reportedly been 720 pharmacies burgled in the previous year in Melbourne, with pharmaceutical 
drugs targeted in many instances.
Links to crime
Most of the KI believed that heroin and methamphetamines were in fact much more likely to be 
associated with crime, in particular burglaries and robberies, than were pharmaceutical opioids or 
benzodiazepines. 
Implications for police and other frontline workers
Illicit use of prescription drugs such as opioids and benzodiazepines was seen as difficult to 
police, as the drugs themselves were legal when prescribed, with the difficulty being in assessing 
whether an individual should have them in their possession. Policing issues for both forms of drugs 
were seen as similar, and identified mainly as a police inability to control the supply of the drugs, 
drug-driving, care of children by intoxicated people, and management of intoxicated people when 
they were apprehended. 
Interventions 
It was considered by most KI that there had not been any substantial programs implemented to 
reduce the use or diversion of pharmaceutical drugs, with the exception of the HIC regulation of 
10mg temazepam gel capsules in 2002. However, it was reported that the drug diversion desk 
of the Major Drug Investigation Division of Victoria Police would be implementing a notification 
scheme in partnership with the HIC in order to reduce the illicit use of prescription drugs.
Stage two: Survey of people who inject drugs
The sample were predominantly poly drug users, whose 'drug of choice' was heroin.
Market characteristics
All participants had used benzodiazepines in the six months prior to the survey, and 45% reported 
they had injected the drugs, mainly temazepam (but also alprazolam and diazepam) in that 
time. Temazepam gel capsules were preferred for injection as they may be heated and liquefied, 
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they also metabolise and enter the brain quickly, resulting in a fast (and long-lasting) effect, and 
increase the effects of heroin. Almost all participants (91%) had also acquired the drug illicitly, 
mostly as a 'gift' from a friend or other user, although almost one-third each had bought them 
from a dealer or a friend. Temazepam gel capsules were reportedly readily available in some areas 
of Melbourne, selling between $5 and $30 each depending on size. The majority of participants 
believed that suppliers of benzodiazepines were users selling their own drugs or small-time 
dealers, but many reported that dealers sold other drugs such as heroin, methamphetamine, 
morphine and cannabis.
Almost all participants had used opioids within the same time frame, and 85% had injected 
them. A large proportion (37%) had been in buprenorphine treatment, and 29% had undergone 
methadone maintenance treatment in the previous six months, and this was reflected by the fact 
that most respondents reporting opioids use reported it was obtained licitly (60% of the sample), 
with six percent reporting they had feigned symptoms to receive opioids. However, 61% reported 
they received opioids as a gift from a friend or other user, and 36% reported buying the drugs from 
a friend or a dealer. 
Most (78%) of the sample had also used morphine, and 77% had injected it, with the most 
frequently used brands Kapanol and MS Contin. Morphine was preferred as it most closely 
approximates the effects of heroin, and was injected by boiling down and filtering the tablets/
capsules. Almost all morphine users (97.5%) had acquired the drug illicitly. More than half the 
sample (57%) had acquired it as a 'gift' from a friend or other user, although around one-third 
each had bought them from a dealer or a friend. Morphine, in particular Kapanol capsules and 
MS Contin tablets, was reportedly readily available in most surveyed areas of Melbourne, selling 
between $10 and $100 each depending on size. The majority of participants believed that 
suppliers of morphine were users selling their own drugs or small-time dealers, but many reported 
that dealers sold other drugs such as methamphetamine and cannabis.
Forty-one percent of the sample had also injected buprenorphine, and 32% of the sample had 
used illicit buprenorphine. Almost half (45%) reported they had been prescribed the drug in the 
previous six months, while 11% said they had received it as a gift, but no-one had bought it from 
a dealer. Buprenorphine was reportedly readily available on the street in most surveyed areas 
of Melbourne for around $5 a dose. The majority of participants believed that suppliers of the 
drug were users sharing their own doses, but many reported that dealers sold other drugs such as 
methamphetamine and cannabis. Nine percent had injected methadone syrup, and 20% of the 
sample had used illicit methadone. A quarter of the sample had been prescribed methadone syrup, 
nine percent reported receiving it as a gift, and three said they had bought it from dealer (for about 
one dollar per ml). The majority of participants believed that suppliers of methadone were users 
sharing their own take-away doses, but many reported that dealers sold other drugs such as heroin, 
methamphetamine and cannabis. Fifteen percent of the sample had injected other opioids (such 
as oxycodone, Panadeine forte and tramadol), with 20% of the sample reporting they had used 
illicitly acquired drugs, and one-quarter reporting they had been prescribed the drugs.
There was a significant relationship between both heroin use and methamphetamines use and 
illicit benzodiazepine injecting in the previous six months. Substantial proportions of participants 
who reported injecting benzodiazepines had also injected illicit buprenorphine, methadone and 
morphine in the same time period, and almost one-quarter of heroin users indicated that if heroin 
were not available they would substitute benzodiazepines for it. There was also a significant 
relationship between both heroin use and methamphetamines use and illicit morphine injecting in 
the previous six months. In addition, substantial proportions of participants who reported injecting 
morphine had also injected illicit buprenorphine, methadone and benzodiazepines in the same 
time period, and six heroin users indicated that if heroin were not available they would substitute 
morphine for it.
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Diversion
Eighty percent of participants had received the drugs via prescription in that time, with 13% 
reporting they had faked symptoms to obtain them, and 85% reported visiting a number of doctors 
(up to 20) to acquire a prescription. Almost 10% had recently stolen benzodiazepines, and six 
percent had forged prescriptions (in both cases temazepam was the drug most likely to be the 
target, but alprazolam and diazepam were also nominated). Six participants reported injecting 
benzodiazepines they had stolen.
Six percent of the sample reported they had feigned symptoms to receive opioids. Three percent 
reported they had recently stolen opioids (mainly MS Contin tablets), all of whom injected them. 
Thirty percent of participants had received morphine via prescription in that time, with four 
percent reporting they had faked symptoms to obtain them, and many reporting visiting a number 
of doctors to acquire a prescription (up to 50). The majority of participants believed that suppliers 
of methadone and buprenorphine were users sharing their prescribed doses.
Links to crime
Two-thirds of the sample reported they had been arrested in the previous year, with charges 
relating mainly to property crimes (37%), fraud (14%), violence (11%), possession (6%), and 
intoxicated driving (6%). A high proportion of the criminal behaviour was attributed to drug use, 
frequently benzodiazepines, and to a lesser extent to methadone. Eleven percent of the sample 
reported recent contact with the police resulting from benzodiazepine use, while 24% reported 
having arguments, and benzodiazepines were blamed for aggressive behaviour (20%), getting into 
fights (13%), getting into criminal trouble (14%) mainly property-related. These issues applied to 
a lesser extent to morphine. Thirty-nine percent of participants reported they had driven a vehicle 
while under the influence of prescription drugs in the previous month, and more than one-quarter 
reported they had done so five or more times (up to 120 times).
Fourteen percent of those using benzodiazepines reported the effects of the drugs had caused them 
to commit a crime, while 12% reported that withdrawal from the drugs had resulted in criminal 
behaviour. Four morphine users blamed effects of the drug for causing them to commit crime, 
and the same number attributed withdrawal from the drug for criminal behaviour. Other opioids 
were blamed by very few participants for criminal behaviour. Statistically, the main predictors of 
criminal involvement were age, frequency of heroin use, and frequency of illicit benzodiazepines 
use. Dependence on methadone (according to the SDS) predicted a significantly lower likelihood 
of being involved in criminal behaviour. Higher dependence scores for benzodiazepines 
and morphine were related to committing crimes while intoxicated on the drugs, and higher 
dependence scores for benzodiazepines were related to committing crimes while withdrawing 
from them. More than one-quarter of participants (29%) reported stealing pharmaceutical 
drugs or prescriptions in the previous month, with 9% stealing drugs from a doctor’s surgery 
(mainly temazepam and MS Contin), and 3% from a pharmacy, with opportunism, or wanting 
the particular drug, the main reasons cited for the behaviour. Seven participants reported they 
had forged a prescription in the previous month, mostly temazepam. More than one-third of the 
sample reported having their prescriptions or pharmaceuticals (temazepam and diazepam) stolen 
from them.
Implications for police and other frontline workers
Most participants had experienced some kind of injecting harms in the previous six months, 
mainly effects of a dirty hit, prominent scarring or bruising, and difficulty injecting, with many 
attributing their problems to having injected prescription drugs in that time. Nine percent reported 
they had experienced at least one overdose, with most of the occurrences attributed to heroin. 
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Application of the SDS suggests that most participants may be dependent on benzodiazepines, 
morphine, methadone and/or buprenorphine. More than one-third of the sample reported 
experiencing memory loss or a blackout associated with benzodiazepines in the previous month, 
with several participants also attributing these symptoms to buprenorphine or methadone. 
A substantial number of participants had experienced social problems, such as relationship 
difficulties, anxiety, lack of motivation, or irritability in the previous month, which they attributed 
to pharmaceutical drugs
Interventions
There were conflicting reports about police activity targeting prescriptions drugs, with 38% of 
PWID reporting it had increased in the previous 12 months. Police activities included checking 
legitimacy of drugs on their person, and being arrested for having illicit prescription drugs. Five 
reported a higher police presence around chemists. Most (68%) did not consider that police 
activity had made it more difficult to access prescription drugs, but 16% thought it had. Other 
activities, such as GP or HIC crackdowns on prescribing practices and doctor-shopping, were 
considered to have impacted on access to pharmaceuticals.
These findings suggest that reducing supply of prescription drugs may have the effect of increasing 
heroin, methamphetamine or alternative pharmaceutical use. They also suggest that supply 
reduction may result in a situation where increased efforts are made to access regular supply of 
other less common drugs such as cocaine. The findings suggest that supply reduction may also 
result in: increased doctor-shopping, the involvement of large-scale dealing, criminal behaviour 
resulting from withdrawal syndrome and efforts to generate income to purchase drugs that were 
harder to obtain.
Stage three: Secondary indicator data
Market characteristics
Prescribing of both benzodiazepines and morphine decreased in recent years in Australia as a 
whole, and in Victoria specifically, according to PBS/RPBS data. Lifetime and recent use of both 
drug classes also declined in the general population between 1998 and 2001 across the state and 
the country as a whole according to the National Drug Strategy Household Surveys (Australian 
Institute of Health and Welfare 1998, 2001). Available PBS/RPBS unpublished data provided for 
2003 also show that prescribed doses of methadone have decreased, especially in Victoria, where 
buprenorphine treatment (and prescribing trends) for drug dependence has seen high acceptance. 
In 2002, Victorian prescriptions for buprenorphine represented 48% of all prescriptions issued in 
Australia under the PBS/RPBS.
The 2003 IDRS found that 80% of the sample had used benzodiazepines in the previous six 
months. The survey also found that 15% had injected them, a large decrease on the previous 
two years, at 21% in 2002 and 40% in 2001. Overall, 69% reported they had injected 
benzodiazepines at some time. The most commonly used forms were diazepam, oxazepam, 
and temazepam. Almost half, at 45%, had obtained the drugs illicitly, and they were reportedly 
obtained through doctor-shopping or blackmarket street selling. Thirty-nine percent of the 2003 
IDRS sample had injected morphine, compared with 51% in 2002 and 32% in 2001, and 83% 
reported they had used the drug at some time. Over 39% of the sample reported they had injected 
buprenorphine in the previous six months (Jenkinson, Miller & Fry 2004). 
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Diversion
The majority of forged prescriptions in Victoria up until 2001, before regulation of the 10mg 
capsules, were for temazepam gel capsules, or for alterations from temazepam tablets to capsules 
(Dobbin 2001). 
Links to crime
Total pharmacy-related crime in Victoria showed a dramatic increase between 1998/99 and 
2001/02, from 805 incidents in 1998/99 to 2,410 in 2001/02, according to Guild Insurance 
Limited (2003) data, with the increase corresponding to the time around the HIC regulation of 
10mg temazepam capsules. 
The number of people arrested for heroin-related offences fell in 2000/01 compared with 1999/00, 
whilst arrests for amphetamines and stimulant-related offences increased, probably reflecting the 
heroin drought. However, in areas identified as Melbourne’s street-based heroin markets, violent 
and property-related offences increased between 2000 and 2001 (Victorian Department of Human 
Services, 2002) following the drought. The Melbourne arm of the 2003 IDRS (Jenkinson, Miller 
& Fry 2004) found that 59% of the injecting drug using participants reported involvement in 
some kind of criminal activity, and 47% had been arrested in the 12 months prior to the survey, 
with 55% of arrests for property crime, 18% for violent offences, 22% for possession, and 14% 
for trafficking/dealing. The overall figures were similar to the 2002 IDRS (Jenkinson, Fry & Miller 
2003), which saw substantial increases in self-reported criminal behaviour from 2000, especially 
in property and violent crimes.
Implications for police and other frontline workers
There was a general trend for decreases also in ambulance attendances at non-fatal 
benzodiazepine-related cases attended by ambulance in Melbourne in recent years, with 2,896 
recorded in the 2001/02 year, dropping to 1,711 in 2002/03, and with 678 recorded between 
July and September 2003. They remain at over 200 attendances per month, however. The number 
of attendances at non-fatal morphine overdoses fluctuated in recent years; after peaking at 18 in 
October 2001, they showed a decrease at the end of the 2001/02 year (to n = 7), then increased 
to a peak again at 19 in March 2003, before declining dramatically towards the second half of the 
year (Data obtained from Melbourne Metropolitan Ambulance Service and compiled by Turning 
Point Alcohol & Drug Centre, Inc, 2004).
Benzodiazepines were the most common drug identified in contributing, or incidental to, heroin-
related deaths at 71% in 2000, and 55% of all deaths between 1997-2001. Morphine-related cases 
remained constant between 1997 and 2001, peaking at 22% in 1999; however, morphine plus 
benzodiazepines comprised more than half of all deaths in recent years, reaching a high in 2001 
(Wallington, Gerostamoulos & Drummer 2003). The number of temazepam-specific incidents 
increased from 6.4% in 1999 to 7.9% in 2000, to 20% in 2001 (Dobbin 2001).
Stage four: Survey of people who inject drugs
The sample was equivalent to the PWID sample from Stage two, with 68% male, a mean age of 32 
years and 88% unemployed. The sample identified that government benefits were the main source 
of income (mean = $361 per fortnight), followed by drug dealing (mean = $214) and begging/
charity (mean = $160). Half the sample was not in current drug treatment, while 10% were in 
current MMT and 36% were in the buprenorphine program. A couple of notable differences from 
the first sample were a smaller proportion with a prison history (42%), and the second sample had 
spent on average a substantially longer period of time in drug treatment programs (mean = 14.7 
months). 
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Market characteristics
Almost all (96%) of the sample had used heroin in the six months prior to the survey, while 
90% had used benzodiazepines orally and 58% had injected them (which was 13% higher 
than Stage two). The most common forms used were temazepam, diazepam, oxazepam and 
nitrazepam. Temazepam was the most commonly injected drug, but diazepam, alprazolam and 
oxazepam were injected also. Three-quarters (74%) reported they had used legally acquired 
benzodiazepines in the previous six months (20% less than Stage two), and 78% reported using 
illicit benzodiazepines. The pattern of illicit benzodiazepines was not dissimilar to Stage two, with 
most obtained as a 'gift' (92% of all illicits), followed by buying from a friend (44%, higher than 
Stage two), and buying from a dealer (31%). The drugs were swapped for other drugs by 12% of 
the sample (n = 6). Gel capsules were reportedly easier to acquire on the street than from a doctor, 
with 16% reporting they were easy or very easy to obtain that way, although tablets were easier, 
with 38%, reporting they were easy or very easy to obtain. PWID reported their benzodiazepines 
dealer was mainly a friend selling their own prescription (24%), or a friend giving their prescription 
away (12%), or a user selling the drugs to fund their own use (12%). Just one reported buying 
the drugs from a small-time dealer or a dealer swapping drugs. Other drugs reportedly sold by 
benzodiazepine dealers included heroin (24%), cannabis (18%), methamphetamines (12%), and 
other benzodiazepines (20%). 
Seventy percent of the Stage four sample had used morphine in the previous six months, which 
was similar to Stage two, with 16% taking it orally, and 64% of the sample having injected it. 
MS Contin tablets and Kapanol capsules were the most frequently used forms (in Stage four, 
more PWID had used MS Contin than Kapanol the opposite of the Stage two finding). Similar to 
Stage two, 62% of the sample had used illicitly acquired morphine. As with benzodiazepines, 
the most common method of obtaining morphine illicitly was as a gift (84% of illicit morphine 
users), then buying them from a friend (64.5%), or buying from a dealer (45%), and 16% reported 
swapping other drugs for them. A quarter of the sample reported morphine was easy or very easy 
to obtain on the street, but about the same proportion considered it was difficult or very difficult. 
As in Stage two, most suppliers of morphine were friends selling their prescription (30% of the 
sample), or a friend giving away their drugs (10%), or a friend selling to fund their own use (6%). 
Only two reported buying morphine from a small-time dealer. Other drugs reportedly sold by 
dealers of morphine were heroin and cannabis (14% each of the sample), other morphine types or 
amphetamines (10% each), and benzodiazepines (4%). 
Over half the participants had used prescribed pharmacotherapies in the previous six months, 
with 38% reporting they had used them illicitly – these findings were similar to Stage two. 
Buprenorphine was the most commonly used, either licitly or illicitly (by 50% of the sample), 
prescribed to 36%. Methadone syrup had been used by 22% of the sample, all but two of who 
had a prescription. Almost half (40%) reported injecting pharmacotherapies, the same proportion 
had injected buprenorphine, and 6% had injected methadone syrup. Illicit and prescribed 
buprenorphine were both injected by 26% of the sample. For methadone syrup injectors, two were 
prescribed the drug and one obtained it illicitly. When pharmacotherapies were illicit, they were 
mostly a gift (67% of these users), otherwise they were bought from a friend (n = 3), or a dealer 
(n = 3). Methadone was reportedly around one dollar per ml on the street, while buprenorphine 
tablets were between $5 and $20 each. 
Other opioids had been used by 46% of these PWID – namely oxycodone, tramadol, codeine 
phosphate, and Panadeine forte. More than half (56.5%) had been prescribed them (tramadol 
and Panadeine forte), and 61% had obtained them illicitly (oxycodone and codeine phosphate). 
Almost 30% of the sample had injected the drugs, mainly oxycodone (Oxycontin tablets), but 
also tramadol and codeine phosphate. The use of oxycodone was much more frequent with this 
sample than the first sample. Where the drugs were acquired on the street, it was mostly as a gift 
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(64% of illicit opioids users), then from buying from a friend (36%), and from a dealer (21%). One 
reported forging a prescription. Eighteen percent of the sample reported opioids to be easy or very 
easy to obtain on the street, while 10% said it was difficult or very difficult. Two participants each 
reported their opioid dealers also sold heroin, amphetamines, and morphine, and one said they 
also sold benzodiazepines, and again most illicit users received the drugs from friends selling their 
prescription (29%) or a friend giving away their prescription (14%). One participant each received 
the drugs from a dealer swapping other drugs for them, or from a small-time dealer selling them.
Diversion
Forty percent of the sample reported they had feigned symptoms to obtain a prescription for 
benzodiazepines, substantially more than Stage two, and reports of doctor-shopping were 
frequent, with up to 15 doctors approached in the previous six months. Most respondents reported 
that gel capsules were too difficult to obtain medically, but tablets were reportedly mostly easy 
or very easy to obtain. Few PWID reported stealing them (n = 2), or forging prescriptions (n = 1). 
Ten percent of the sample had obtained prescriptions for morphine in the previous six months, 
but most participants had not attempted to obtain morphine medically in that time, considering 
it too difficult. However, two had faked symptoms in an attempt to gain a prescription, and 
16% of respondents had tried doctor-shopping, approaching up to 15 doctors for a prescription. 
No participants reported stealing the drugs or forging prescriptions. Overwhelmingly, 
pharmacotherapeutic opioids were reportedly obtained from other users giving away or selling 
their 'take-away' dose. Four participants (8%) had feigned symptoms to obtain other opioids in the 
previous six months, and 28% altogether had attempted to obtain a prescription in that time. Some 
doctor-shopping was apparent, with up to 15 doctors approached for the drugs.
Links to crime
In terms of self-reported crime in the previous month in this sample, there were differences from 
Stage two that suggest the majority of property crimes committed by these PWID may be related 
to shoplifting. Because property crimes were broken down into distinct behaviours, fewer of these 
participants reported it, at 10%, whereas 36% reported shoplifting – 61% once a week or more 
often (the two offences combined are similar to the responses to property crime overall in Stage 
two). Of those that reported committing property crime, two each said that taking drugs made it 
more likely they would commit such offences, and that they needed the money. Reasons given for 
shoplifting were to obtain essential items, such as food for themselves or their family (14% of all 
participants), having no inhibitions while on drugs (10%), taking items to sell to acquire money for 
drugs (4%), and 'liking the challenge' (2%).
Twelve percent of participants reported having committed a crime involving violence in the 
previous month, with all reporting they had done so less often than once a week; the prevalence 
is less than Stage two, but the frequency is higher. Most of these respondents (67%) indicated they 
had been intoxicated at the time of the offence, and the others reported they had been aggressive 
and started a fight. Offences included committing an assault during a bag-snatch, assaulting 
someone at the pub for no reason, assaulting a partner while on Valium, threatening someone to 
obtain temazepam from them, and attacking an ambulance officer and a police officer during a 
'schizophrenic' attack.
More than half of the sample (52%) reported dealing drugs in the previous month, slightly more 
than in Stage two; about a third of these (31%) reported they did so less than once a week and 
70% reported dealing once a week or more. Forty-two percent of those dealing drugs reported 
they did so for money, while 11.5% said they dealt to help friends, and 8% said they enjoyed 
selling drugs. 
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Twelve percent of participants reported they committed some form of fraud in the previous month, 
although 34% also reported having 'rorted' to obtain drugs (rorting was defined as obtaining 
money or goods dishonestly but not through theft, e.g. 'ripping people off', begging, asking 
charities for money, faking symptoms to obtain prescriptions, telling lies), and over one-quarter 
also reported they had 'scammed' to obtain drugs (scamming was defined as similar to rorting).
More than one-third of the sample (36%) reported they had driven while under the influence of 
illicitly used drugs in the month prior to the survey. Most of these respondents (56%) did so less 
than once a week, but 44% reported they did so once a week or more frequently. 
In addition, 8% of the sample believed that changes in benzodiazepines availability had caused 
an increase in crime by motivating stealing in order to pay for the drugs, by directly influencing 
behaviour (by increasing confidence and risk-taking), and by increasing violence.
Implications for police and other frontline workers
Seventy percent of the sample reported they had behaved 'uncharacteristically' because of 
intoxication on drugs, and mostly blamed heroin (38%), benzodiazepines (66%), or a combination 
of the two (24% of the sample), and benzodiazepines combined with other drugs were blamed 
as well. Morphine (MS Contin and Kapanol) and buprenorphine were each blamed by 8% of the 
sample, and methadone syrup was also blamed by 8%. Three participants taking benzodiazepines 
had also been using morphine, as had half of those taking buprenorphine. The benzodiazepines 
held responsible for the behaviour were temazepam, diazepam, oxazepam, and alprazolam. The 
behaviours described as uncharacteristic and drug-induced were 'aggressive/abuse/violent' (23% 
of those reporting such behaviour), 'criminal' (20%), and 'high/silly/energetic' (20%).
Two participants reported experiencing hallucinations while on benzodiazepines, and five 
reported blacking out or forgetting incidents they had been involved in whilst intoxicated on the 
drugs, such as car thefts, shoplifting, robbery, or aggressive behaviour. Six respondents believed 
that the drugs made it more likely they would commit criminal offences, by lowering their 
inhibitions and increasing their confidence and feelings of 'invincibility'. In addition, 8% of the 
sample believed that changes in the availability of the drugs had affected users’ relationships, 
because of aggression, fighting, and family breakdowns, as well as affecting people financially 
with the drugs more expensive on the street.
Interventions
Twenty percent considered that benzodiazepines had become more difficult to obtain on the 
street in the previous 12 months, 18% reported doctors were becoming less willing to prescribe 
them, and 10% reported increasing police activity around the drugs, with police more likely to 
check PWID for them and check prescriptions. Twenty-two percent of the sample believed the 
morphine market had changed substantially in the previous six months, with 8% each reporting it 
had become more difficult to obtain and more expensive; however, the general consensus was that 
there had not been any increase in police activity around morphine or other opioids on the street.
Stage four: In-depth interviews of key informants (health and law 
enforcement)
Market characteristics
Most of the 28 KI interviewed (n = 18 health workers, and n = 10 law enforcement personnel) 
reported heroin was the primary drug of choice for PWID using benzodiazepines and 
pharmaceutical opioids. It was considered benzodiazepines were primarily used by PWID to 
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supplement heroin and increase its effects, rather than as a primary drug of choice. There were 
also reports that use of prescription drugs is fluid, with PWID alternating drugs according to 
availability or their financial or health situation. On the other hand, it was considered by some KI 
that benzodiazepines had become the drug of choice of some PWID as a result of supplementary 
use gradually shifting to primary use over time as a consequence of the relative affordability of the 
drugs, and a perception that at times they offered a longer lasting effect than heroin. In terms of 
opioids use, KI considered there was a combination of primary and supplemental use, with some 
PWID using pharmaceutical opioids, such as buprenorphine exclusively, and others 'topping up' 
with heroin (although it was thought that people were less likely to top up the longer they were 
in the program). According to the KI, the most frequently illicitly used benzodiazepines were 
temazepam and diazepam, while the most common opioids were reportedly buprenorphine, MS 
Contin and Kapanol. 
Law enforcement KI considered that trafficking in pharmaceuticals was more likely to occur in 
Melbourne’s drug 'hot-spots', although they were doubtful about the existence of formal trafficking 
in buprenorphine, with the drug more likely to be a prescribed dose shared by a patient. On the 
other hand, some KI reported a brisk street trade in buprenorphine. Similarly, some KI reported 
that the trade in benzodiazepines was reduced currently due to decreases in prescribing by 
doctors, but others disagreed with this. The lack of agreement about drug markets seemed related 
to geographical areas, with Frankston and Footscray named as having bigger street markets. The 
general agreement seemed to be that dealing, rather than undertaken as a money-making activity, 
was more likely to be an informal network at street-level, comprising a disorganized system of 
trading, selling or sharing as part of a 'drug-using culture'. Most KI agreed there was no organized 
crime element or organized black market in prescription drugs, with the possible exception of 
morphine as it is more difficult to obtain and therefore more valuable. This was because most KI 
did not consider the financial rewards of selling prescription drugs to be great. 
Diversion
KI considered that most of the prescription drugs available emanated from prescribing doctors, 
although temazepam was considered more likely to be obtained at street level, becoming more 
difficult to acquire medically. Morphine on the other hand was believed to originate from patients 
on pain relief, or friends and family members or others with a legitimate prescription. Doctor-
shopping for both benzodiazepines and pharmaceutical opioids was considered to be rife and its 
relative ease was generally related to personal qualities of individual doctors (e.g. doctors thinking 
they are doing the right thing, being known as 'easy' or 'soft' by users, being inexperienced or 
'tired'). On the other hand it was considered that temazepam was now more difficult to obtain this 
way because of the regulation of 10mg gel capsules. All agreed that doctor-shopping did not apply 
to methadone and buprenorphine, this being very rare. Thefts from pharmacies or distributors’/
manufacturers’ premises were mentioned as possible sources for the drugs, although it was 
considered these had reduced considerably over the past two years. The Internet was not seen as 
a viable source for prescription drugs, with KI considering that the drugs were too expensive, and 
many PWID were not computer literate or did not have access to the technology.
Links to crime
The common attitude about the relationship between specific drugs and criminal behaviour 
was that the use of benzodiazepines may mean people are more likely to commit crimes they 
had already planned on committing, for instance shoplifting, but with less inhibition. A sense 
of 'invisibility' and 'invincibility' was also associated with the use of benzodiazepines, with KI 
considering they may be a factor in crimes. All law enforcement personnel reported that there was 
a 'definite correlation' between benzodiazepines and pharmaceutical opioid use and crime, with 
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burglary and theft being the crimes that are seen to be specifically related. Included in this were: 
bag snatching; thefts from motor cars; drug users stealing from families; theft of prescription pads; 
robberies; and thefts from pharmacies or doctors’ surgeries.
In addition to thefts, one KI reported that although he couldn’t name specific crimes related to the 
use of benzodiazepines and pharmaceutical opioids, he did think that there was a connection to 
shoplifting in order to then on-sell goods. 'That’s a big one we’re getting now, shoplifting, because 
we’ve got a lot of receivers [of stolen goods] in the community'. A single KI commented that armed 
hold ups committed using a knife or syringe were related to benzodiazepines and pharmaceutical 
opioid use. Another suggested that some crimes of violence, such as male partners assaulting 
women, are related to benzodiazepines and pharmaceutical opioid use. A further KI reported that 
trafficking in benzodiazepines and pharmaceutical opioids was a specifically related crime.
Licit opioids were considered more likely to reduce crime than increase it, taking away the need 
for generating an illicit income to pay for the drug of dependence. Where crimes were seen 
to relate to benzodiazepines and pharmaceutical opioids, the offences were most likely to be 
shoplifting, property crime, and burglaries, as well as pharmacy-related crime, crimes of violence, 
and trafficking in the drugs. There was a perception that the lack of availability of drugs, including 
benzodiazepines and opioids, also may precipitate crime that aimed at attempting to obtain them.
Implications for police and other frontline workers
Health-related KI identified serious health issues resulting from benzodiazepine use; for instance 
vein damage, abscesses, amputations, dependence, poly-drug use, and overdose. On the 
other hand benzodiazepines were considered useful for helping to manage withdrawal in drug 
dependent people. Overall, the responses of the Stage four law enforcement KI were similar to 
those in Stage two; that is, prescription drugs were not really an issue for police, or were seen 
as more or less the same as other drugs, having in themselves a small impact on their work, and 
that there was little point in focussing on them until they become 'huge'. Police did mention 
that diversion of benzodiazepines to the black market because of their desirability caused law 
enforcement problems and they considered that it was more useful to focus on trafficking in 
pharmaceuticals than on users. Police KI mentioned the provision of the Victorian Police manual 
An Investigation Guide to Pharmaceutical Drug Trafficking and Use (Victoria Police 2004) for all 
stations as a great benefit in identifying drugs and laying charges when appropriate. On the whole, 
however, prescription drugs were not seen to be the problem that illicit substances such as heroin 
and amphetamines were, and were not linked with criminal behaviour or organised trafficking 
networks in the same way, thus did not generate the same level of attention. 
Interventions
Many KI suggested that changes to health care would make a prescribers’ role easier regarding 
the limiting of pharmaceutical products. One KI suggested that the reduction of benzodiazepines 
prescribing in general would have an effect on diversion, however, did not think that this was the 
only alternative option. Several KI recommended that a more holistic approach to prescribing 
would reduce the opportunity for the diversion of pharmaceutical products because this approach 
would mean doctors would be less likely to prescribe them in large doses. With regard to 
buprenorphine, one KI suggested that the provision of more prescribing pharmacies where drug 
users are 'welcome' would result in increased vigilance with dispensing and, as a result, less 
opportunity for diversion. In addition, another KI commented that the development of a fizzy 
'Berocca™ like' form of buprenorphine might prevent diversion. Some KI suggested that tracking 
the amount of prescriptions an individual has, taking extra care to secure prescription pads 
and arranging daily pick-ups on a case-by-case basis for benzodiazepines, may limit diversion. 
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Several KI suggested that if an injectable form of pharmaceutical opioid was to be introduced 
via pharmacies, the motivation for diversion would be removed. Law Enforcement KI agreed 
that ensuring that buprenorphine tablets are crushed and ingested on the spot would help with 
diversion. One law enforcement KI suggested that the sharing of information and strategies 
amongst doctors would ensure that all doctors were aware of which drugs are targeted for 
diversion, and as a result could reduce the amount they prescribe. KI from the health sector do not 
want to see restricted access to benzodiazepines or pharmaceutical opioids, but more responsible 
prescribing and dispensing.
Most KI did not think that police activity had any effect on the use of benzodiazepines and 
pharmaceutical opioids. Police presence was seen as more influential in terms of illicit drug use. 
Several KI commented that the displacement of illicit drug trafficking to another area as a result 
of policing leads to an increase in benzodiazepine use if illicit drugs are more difficult to obtain. 
This was seen by one KI as contributing to the number of overdoses occurring. One KI thought 
that police activity might result in benzodiazepine use becoming more discreet, and also that, as 
a result of pharmacists calling police when scripts seemed suspicious, people might also be more 
wary of presenting forged scripts to pharmacies. One KI mentioned that people in possession of 
benzodiazepines without a script were being charged. Police activity was seen as having little or 
no effect on corrupt prescribing of benzodiazepines or pharmaceutical opioids.
KI commented that police cautioning and diversion programs were having an impact on various 
forms of drug use. As well, several KI reported that police activity in areas like shopping malls 
was having an influence on drug use by making access more difficult and in turn reducing 
crime in those areas. However, two KI also suggested that police activity around trafficking has 
caused trafficking to become more covert. Finally, one KI suggested that increased co-operation 
between police and pharmacies had the potential to influence the use of benzodiazepines and 
pharmaceutical opioids.
In terms of the historical benefits and problems of policing in regard to pharmaceutical opioid 
misuse, law enforcement KI reported a variety of benefits. Policing efforts had reduced the use 
of pharmaceuticals and hence the incidence of crime, as reflected in crime statistics. Another 
benefit of policing in regards to pharmaceutical misuse was seen to be the changing approach 
of police towards drug users. With the diversion of drug users into cautioning programs, police 
are more able to focus their efforts on the trafficking of pharmaceuticals. The production of the 
guide An Investigation Guide to Pharmaceutical Drug Trafficking and Use (Victoria Police 2004) 
for all stations is also seen to benefit policing efforts, in that it allows officers to correctly identify 
pharmaceuticals and to lay charges where applicable.
In response to the question of what would make their policing role easier, law enforcement KI 
made a range of suggestions. Restricting the source of benzodiazepines and pharmaceutical 
opioids as well as dispensing them from a 24 hour clinic would be of assistance, as would 
establishing pharmacies in a wider range of areas to prevent people from flocking to 'hot-spots'. 
One KI also suggested that there be a system to track batches of benzodiazepines as they come out 
of the factory in conjunction with a national database of dispensing. Another KI remarked that the 
provision of information to police around emerging problems would make policing easier. Finally, 
KI reinforced the positive impact of An Investigation Guide to Pharmaceutical Drug Trafficking and 
Use (Victoria Police 2004) and suggested that the updating of the guide on a regular basis would 
ensure that it was of continued benefit in policing efforts.
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The primary aims of the research were to: gain a greater understanding of illicit benzodiazepine 
and pharmaceutical opioid market-place dimensions and characteristics; investigate the 
hypothesised relationship between benzodiazepine and pharmaceutical opioid misuse and 
crime; explore the implications for emergency services staff of emergent illicit markets for 
benzodiazepines and pharmaceutical opioids; and consider appropriate interventions to address 
both the law enforcement and health impacts of benzodiazepine and pharmaceutical opioids 
misuse. The original 25 research questions relating to these broad aims (Appendix A) were 
further analysed by the research team, resulting in a final total of 33 questions pertaining to the 
key themes of links to crime, implications for frontline workers, diversion, market dimensions 
and characteristics and interventions. The prioritisation exercise with Victorian law enforcement 
personnel (n = 13) revealed that this group expressed a wide interest in the questions and issues 
presented to them around benzodiazepines and pharmaceutical opioids, and how these relate to 
the key themes of links to crime, implications for frontline workers, diversion, market dimensions 
and characteristics and interventions. The average priority ranking of 32 of the 33 issues and 
questions presented was rated as 4 ('very important') for law enforcement, with no clear preference 
or higher priority indicated for different themes. See Appendix B. The main findings from the 
Victorian study are discussed in regards to these themes.
Market characteristics
The IDRS (Fry & Miller 2002) found an emergent trend towards the illicit use and injecting of 
benzodiazepines and pharmaceutical opioids among PWID in Australia and Victoria following 
the heroin drought at the end of 2000, with such use of benzodiazepines appearing to decline 
again in 2003, and morphine and buprenorphine injecting remaining stable (Jenkinson, Miller & 
Fry 2004). This current study specifically sampled PWID who used illicit benzodiazepines and/
or pharmaceutical opioids. The findings, in the main, confirmed most 2003 IDRS findings, with 
similar prevalence of recent injecting of morphine and buprenorphine, and a higher prevalence 
of recent benzodiazepine injection found among the current sample. It must be kept in mind that 
sampling of the PWID participants targeted those who misuse any/all of these types of drugs, and 
therefore the findings cannot be generalised to broader PWID populations. Nevertheless, clearly 
there exists a demand for diverted prescription drugs. These findings accord with past research 
by others such as Miller, Fry and Dietze (2001), Fry and Miller (2002), and Dobbin (2002). The 
current findings show that whilst temazepam is preferred by PWID for injecting because of its 
fast and long-lasting effect, and the way it increases the effects of heroin, other benzodiazepines 
such as diazepam and alprazolam were also injected. The findings also show that morphine and 
buprenorphine injecting are also an established practice. There were substantial overlaps in drug 
usage, with most PWID being polydrug users.
Changes to the PBS prescribing practices for 10mg temazepam gel capsules in 2001, and re-
emergence of heroin onto the market in 2002 were expected to result in decreases in the misuse of 
prescription drugs (ACC 2003; Breen et al. 2002). The IDRS (Jenkinson, Miller & Fry 2004) found 
that injecting of benzodiazepines did subsequently decline, however, it also found that injection 
of buprenorphine and morphine remained high; findings reflected here. And whilst temazepam 
has reportedly become more difficult to acquire, with most PWID considering it too difficult to 
obtain from a doctor, acquisition and use of the drug still continues, at least amongst some groups 
of PWID in some geographical locations around Melbourne. These findings strongly suggest that 
temazepam, morphine, and to a lesser extent buprenorphine, appear to have become firmly 
established on the black market in Melbourne, and, reportedly, not difficult to obtain, especially 
in the inner-city suburb of Footscray in the case of temazepam, and most areas for morphine and 
buprenorphine. 
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It has generally been considered that prescription drugs are used by PWID to increase the 
pharmacological effects of heroin, or as substitutes for heroin (e.g. Marshall & Longnecker 1992; 
Rall 1992), as they are considered to be of a consistent quality, reasonably priced and easy to 
acquire (see Breen et al. 2002; Dobbin 2002). Most KI from the health sector, and all KI from law 
enforcement, agreed with past reports, asserting that benzodiazepines are used to supplement 
a primary drug of choice rather than being a drug of choice, contending that benzodiazepines 
are used to increase the effects of heroin use, to ease symptoms of withdrawal, or to deal with 
sleeplessness or anxiety. However, these findings suggest that this may not necessarily always 
be the case, and that prescription drugs may in fact be the primary drug for some PWID. There 
were reports that benzodiazepines are used as a primary drug of choice by some PWID, with 
suggestions that temazepam in particular was used in preference to other drugs as a consequence 
of its relative affordability, and the perception that it may offer a longer lasting effect than heroin. 
In addition, the use of benzodiazepines was reported to be quite fluid, with PWID alternating 
between substances according to availability, health and financial situation. With regard to 
pharmaceutical opioids, KI suggested there was a blend of primary and supplemental use. 
The findings suggested that the prescription drugs market in Melbourne, with the possible 
exception of morphine which was more expensive and less easy to acquire than benzodiazepines 
and buprenorphine, did not at this stage appear to be large-scale. The market seemed to be 
dominated by small-time dealers, users selling to fund their own use, and a diffuse network of 
users sharing their own prescription drugs, and swapping drugs amongst themselves. There were 
reports of prescription/prescription drugs thefts and attempts at doctor-shopping for all drugs, 
and benzodiazepines were reportedly acquired by these PWID mainly via friends and medical 
prescriptions, and through small-time dealers. PWID also tended to inject buprenorphine they 
were prescribed, or shared others’ doses. Tablets reportedly sold for as little as one dollar, and 
gel capsules for between $5 and $30 each, although morphine tended to be acquired through 
friends or dealers for around $50 for 100mg. Respondents generally reported that dealers of all 
prescription drugs were other users with a prescription for sale, or were 'small-time', although 
there were frequent reports that many dealers sold other illicit drugs as well. These reported 
patterns of dealing and use suggest an opportunistic way that polydrug using PWID might adapt 
to and manipulate available drugs for maximum effect, according to the availability, price, and 
consistency of illicit drugs on the market at any given time, balanced against the widespread 
availability and relatively low price, as well as the predictable quality, of prescription drugs. 
While PWID were clear that use of prescription drugs have become established among PWID, 
and offer another selection of choices in the dealers’ menu of drugs – apparently reasonably 
easily available and widely used – comments by law enforcement KI seemed to reflect a feeling 
that such use was not entrenched or problematic. These KI generally considered that heroin and 
amphetamines were the main drugs of choice, and represented the main drugs market, with the 
use of benzodiazepines only supplemental, or in place of heroin, if it was not available, and that 
there was not a notable market in benzodiazepines and other prescription drugs. PWID and KI, 
however, did seem to agree about the make-up of dealing networks. KI argued that the majority 
of pharmaceutical drugs originated from medical prescriptions, with the possible exception of 
temazepam, which reportedly had become increasingly difficult to obtain, and was considered 
to be more likely to be purchased on the street. This tended to agree with PWID reports for most 
drugs, except morphine, which seemed particularly difficult to obtain medically (as well as 
temazepam gel capsules). KI and PWID agreed that any networks were low-level and disorganised 
with no organised crime involved. However, part of the KI reasoning for this conclusion seemed 
to be based on the opinion that selling pharmaceutical drugs was not financially rewarding. That 
perception was not necessarily borne out by these findings, given that the drugs may potentially be 
obtained for around $4 for an entire prescription and then sold for anywhere from $1 and $100 a 
tablet, and participants reported spending up to $1,000 in two weeks on prescription drugs. 
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The main question about the prescription drugs market in Melbourne that was raised by these 
current findings, as well as past assertions by others such as the Australian Bureau of Criminal 
Intelligence (2002) – that most opioid acquisition was illicit – seemed to be around the original 
sources for morphine and temazepam. Both are restricted drugs, heavily regulated (morphine 
is S8 and temazepam gel capsules are either issued under authority under the PBS or else only 
prescribed privately), and reportedly difficult to obtain medically, yet PWID reported that though 
generally expensive, they were available on the street if 'you know the right people'. Available 
unpublished data from the PBS/RPBS show that temazepam prescriptions, as well as MSContinTM 
and Kapanol (the two most commonly reported forms of morphine used by these PWID), 
declined across Australia in the past five years; yet morphine was used regularly by most of these 
participants, and many had used temazepam gel capsules, and contended they were difficult, 
but not impossible, to obtain on the street. Both PWID and KI reported that users of these drugs 
would not access them on the Internet; however, Australian Customs Service data demonstrated an 
increase in seizures of morphine and of benzodiazepines over the past five years.
Diversion
These findings accord with Dobbin’s (2002) assertion that a strong demand for the drugs was 
driving intense and extensive diversion of licit drugs to illicit markets, and that policing of the 
issue was complicated by the difficulty in identifying where use and/or possession was licit or 
illicit. The current findings suggest that all the surveyed prescribed drugs were frequently diverted 
to the black market. This was achieved by diverting of legitimate prescriptions via PWID who 
either gave them away, swapped them for other drugs or sold them. Diversion was also achieved 
via thefts of the drugs, or forgeries of prescriptions. However, no pharmacy break-ins or hold-ups 
were reported by this sample of PWID. These current reports were contradicted by KI contentions, 
and also seemingly by LEAP data (Victoria Police, 2004). On the other hand, the KI did believe 
such criminal activity had reduced over the past couple of years, a view supported by previously 
reported figures (Dobbin 2001; Guild Insurance Limited 2003).
Most participants in this study had received both prescribed and illicit benzodiazepines, most 
had also received illicit morphine, and the use of both prescribed and diverted buprenorphine 
was widespread as well. Law enforcement KI considered prescribed drugs mostly originated from 
medical prescriptions, but also may have come from pharmacy burglaries and thefts from drug 
distributors, although they reported these incidents had declined in the past 12 months. These 
findings suggest that swapping and sharing of PWID’s own prescriptions is widespread, and 
comments from both PWID and KI suggest that such sharing activity may be a part of drug culture, 
and related to a reciprocity understanding (i.e. one who shares their own drug this week will be 
owed for the future, calling in the debt when it is needed).
The findings accord with Dobbin’s (2001) assertion that that doctor-shopping may be the origin 
of many of the drugs on the illicit market, being a common source of benzodiazepines (although 
most participants considered it was too difficult to obtain temazepam gel capsules that way), and 
a less successful source for morphine. The initiation of the new prescription-shopper database 
(Kamien, 2004) may help clarify the relationship between doctor-shopping and diversion of these 
drugs to the illicit market. The findings also concur with Dobbin et al. (2003) – that prescription 
forgery had been used to source prescribed drugs, in particular benzodiazepines (74% of all 
forgeries). Dobbin et al. (2003) found that the majority of benzodiazepine forgeries (85%) were 
for temazepam gel capsules, which PWID reported to a lesser extent here. The difference would 
presumably be because the increased regulation of these forms of the drug since 2002 has made it 
increasingly difficult to present such forgeries to pharmacists. These PWID did report prescription/
drug theft, especially of benzodiazepines. They reported stealing them, or else having them stolen 
from them. In the case of the former, the activity tended to be opportunistic, although PWID 
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expressed preferences for the drugs that they stole. The current findings further suggest therefore 
that, for this group of PWID at this stage at least, prescription drug acquisition, diversion, and illicit 
use, seems primarily to be operated by a diffuse network of low-level user/dealers. 
Links to crime
The majority of research in Australia to date had found that heroin use was most closely related 
to criminal behaviour (e.g. Makkai 2002), and the current finding was that frequency of heroin 
use was most closely associated with self-reported commission of crimes, with the current sample 
predominantly heroin users. However, these findings do suggest that prescription drugs may be 
related to crime in several ways. Eleven percent of the first sample reported they had experienced 
contact with police because of their benzodiazepines use, and a high proportion of both samples 
of participants reported involvement in criminal activity, especially shoplifting, other property 
crimes, drug dealing, intoxicated driving, and to a lesser extent violence, and most blamed drugs 
for their offences. However, they were also, in the main, reportedly polydrug users, and previous 
research, while linking drugs and crime (e.g. Makkai 2002), has been unable to pinpoint how 
specific drugs relate to specific crimes (e.g. Makkai 2002; Weatherburn et al. 2002). Other findings 
suggest that sometimes drugs may be used purposefully to reduce fear of committing a crime 
(Makkai 2002). When considering theories of drugs and crime, these findings are thus ambiguous, 
suggesting either PWID who are dependent may need to increase their income through crime 
in order to pay for the drugs, which would accord with the 'enslavement' model forwarded by 
Makkai (2002), the PWID may be part of a 'deviant' lifestyle involving both drug use and crime 
('criminality model'), or else the psychopharmacological effects of the drugs may increase criminal 
behaviour ('psychopharmacological model') (Makkai 2002).
On the one hand, these findings accord with previous research, such as Bonn and Bonn’s 
(1998), Rall’s (1992) and the ACC’s (2003), that has found that prescription drugs, especially 
benzodiazepines, may exert a psychopharmacological effect on users that increases 
uncharacteristic, aggressive, disinhibited and/or criminal behaviour. PWID reported they were 
more likely to commit criminal offences when they were intoxicated by, and withdrawing from, 
prescription drugs, especially benzodiazepines and to a lesser extent morphine. Research has 
suggested that benzodiazepines may cause personality changes, disinhibition, and bizarre 
behaviour, as well as precipitating feelings of over-confidence and invincibility (e.g. Bonn & 
Bonn 1998; Dobbin 2001; Rall 1992). These participants frequently reported feeling 'invisible', 
'invincible' and more confident than usual, believing they could get away with behaviours 
they would not normally undertake. A high proportion of these participants directly attributed 
such behaviour as aggression, shoplifting and thefts, to benzodiazepines – either alone or in 
combination with other drugs. Some PWID also reported they had experienced hallucinations and 
black-outs while intoxicated by benzodiazepines, with reports of participants committing offences 
whilst intoxicated, but having no memory of the events the following day. 
It was found that the frequency of use of illicit benzodiazepines was related to the number of 
different kinds of criminal behaviours that respondents reported being involved in, and the degree 
of dependence on benzodiazepines was also related to whether a crime had been committed 
whilst intoxicated by, or withdrawing from, benzodiazepines. A relationship was also found 
for dependence on morphine and committing crime whilst intoxicated on the drug, which is 
problematic for the psychopharmacological model, but more supportive of the enslavement  
model (morphine is generally acquired illicitly and is expensive) or criminality model. The 
finding that dependence on methadone for these PWID tended to reduce involvement in criminal 
behaviour also supported a psychopharmacological relationship for methadone and crime (Makkai 
2002); however, MMT was far less expensive than illicit drugs, thus may not precipitate the need 
to commit crime to increase income in the same way (Makkai 2002). The current finding was that 
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KI considered that when a PWID was undertaking a maintenance program such as buprenorphine, 
the regular expenditure could be such that it becomes prohibitive, and that may be a catalyst for 
crime, which may also support the enslavement model (Makkai 2002). A high proportion of these 
respondents also reported dealing drugs, with a substantial proportion of their average income 
attributed to the activity, which means that many may be involved in a cycle of drugs use and 
criminal activity that is related to an entrenched lifestyle. If that was indeed the case, possibly 
they are more likely to offend, or to offend more frequently, than if they were not using drugs. This 
might accord with the 'criminality' model of drugs and crime discussed by Makkai (2002). 
Law enforcement KI were of the opinion generally that prescription drugs were not a major cause 
of crime in Melbourne. The first sample of KI reported the main policing problem associated with 
the drugs was in the care and management of intoxicated people in custody, and intoxicated 
driving. The second sample, though, indicated that while they were of the belief that problems 
associated with prescription drug use were not 'huge', benzodiazepines were related to bag 
snatches, burglaries, robberies, armed robberies, property crimes and thefts. KI did consider 
that prescription drugs might disinhibit behaviour, and thus make it more likely that a crime 
already planned may take place, which is in agreement with PWID accounts about the effects 
of benzodiazepines on their behaviour. It seems possible, however, that KI assessments of the 
impacts of these drugs on behaviour may be underestimated when compared with PWID reports. 
When considered in their entirety, these findings do suggest a link between the use of prescription 
drugs and criminal behaviour, through changes in behaviour, self-reported offences attributed to 
the drugs by these PWID, and the consideration that where dependency on a drug exists there 
is a need to maintain supply (Makkai 2002). Further, many of the drugs, particularly morphine 
and temazepam, are difficult to obtain and may be expensive and not affordable on a legitimate 
income (especially as the vast majority of the PWID gain most of their income from government 
benefits, begging and charity). Past research suggests that more serious and financially rewarding 
crimes tend to be committed by the heaviest drug users (SACACWG, 2002), and these participants 
tend to use a wide range of drugs frequently. These findings accord with contentions by Makkai 
(2003) and Makkai, McGregor & Wei (2003), that the relationship between drugs and crime is 
complex, with the phenomena varying according to types of offenders and drug users, and a 
number of environmental, situational and psychological factors.
Implications for police and other frontline workers
The main harms attributed to prescription drugs by both previous research – such as the 
IDRS (Jenkinson, Fry & Miller 2003), and Dobbin (2001) – and these current findings, have 
been injecting harms such as vein damage, thrombosis, 'dirty hits', scarring and infections. 
Almost two-thirds of these PWID participants reported experiencing injection-related harms, 
and benzodiazepines and morphine were frequently blamed. Injecting harms apply to all 
the prescription drugs commonly used by these PWID, especially temazepam, morphine 
and buprenorphine, as they are manufactured for oral use, and injection is only possible by 
heating and liquefying the tablets/capsules. The resultant liquid hardens once it is injected and 
reaches body temperature, potentially causing severe health effects, including the need for 
amputation. High proportions of these participants agreed there were negative consequences 
of using prescription drugs, such as: physical/health effects, volatile behaviour, overdose, and 
addiction (benzodiazepines); overdose/death, physical/health effects, and addiction (morphine); 
addiction and physical/health effects (methadone); and injecting/health effects and addiction 
(buprenorphine). Prescription drugs intoxication and withdrawal were also blamed for social and 
relationship problems, anxiety, lack of motivation, and irritability by the PWID. Health KI reported 
that the habit-forming nature of benzodiazepines, as well as injection-related damage, were a 
potential negative consequence of their prescription. They also contended prescription drugs 
overdose was a problem, especially with benzodiazepines when used with other drugs, and with 
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methadone. KI reported a relatively high incidence of sharing between partners, and there were 
reports that female drug users were sometimes coerced into undertaking sex work in order to make 
money to procure drugs for themselves and their partners.
Dependence and overdose (especially when the drugs were combined with other drugs and/or 
alcohol) were cited by PWID as two of the biggest disadvantages to using prescription drugs. 
Two-thirds of these PWID recorded scores on the SDS that suggested they may be dependent 
on benzodiazepines, morphine, buprenorphine, and/or methadone. In addition, data from the 
Melbourne Ambulance Service (analysed by Turning Point) confirmed that most heroin-related 
deaths in the past ten years have involved benzodiazepines and/other opioids. In addition, law 
enforcement KI considered the desirability of benzodiazepines on the black market and the abuse 
of benzodiazepines, especially when used in conjunction with other drugs, to be problematic, 
driving diversion of the drugs. The use of pharmaceutical opioids and other drugs (such as heroin) 
in combination were considered to be one of the main drawbacks of prescribing the drugs to 
PWID, and some law enforcement KI considered the provision of pharmaceutical opioids as a 
bandaid solution that did not address drug use. Law enforcement KI argued that the diversion of 
buprenorphine was a negative aspect of prescribing, and health KI suggested that inconsistencies 
in the dispensing of buprenorphine, such as not crushing the tablet on the spot, were a problem, 
allowing the drug to be diverted or injected. 
On the other hand, there were suggestions that lack of supply of prescription drugs could force 
both dependent and non-dependent benzodiazepine users to seek a more harmful replacement, 
thus causing health and law enforcement problems. There was general agreement that prescribing 
of pharmacological drug treatments were essential for the health and quality of life of drug users, 
and for the reduction of crime, although several KI argued that the sometimes prohibitive cost 
of ongoing treatment may result in less access to treatment, reduced improvement in the health 
and wellbeing of drug users, and an increase in crime for some people as they are compelled to 
commit crime to pay for their dose. This contention was supported by the finding that some PWID 
who are on the buprenorphine program had spent up to $50 in the previous fortnight on the drug.
Interventions 
This study found that police activity generally was not considered by PWID to have impacted 
on the availability of prescription drugs on the illicit markets, and this may be supported by the 
finding that many law enforcement KI found it difficult to police the illicit use of prescriptions 
drugs. In accord with this, most KI did not consider that police activity had any effect on the use 
of prescription drugs by PWID, impacting more on illicit drugs. However, a few law enforcement 
KI did not agree, arguing that police cautioning and diversion programs were having an impact 
on all drug use, and that police activity in shopping malls was making access to drugs (including 
pharmaceuticals) more difficult, and reducing crime in those areas. Law enforcement KI reported 
that policing efforts had reduced the use of pharmaceuticals, and hence the incidence of 
crime, and this was reflected in crime statistics. They also considered this kind of visible police 
activity may reduce the incidence of forged prescriptions being presented. A further suggestion 
of these findings was that another benefit of policing in regards to pharmaceutical misuse may 
be a changing approach of police towards drug users. With the diversion of drug users into 
cautioning programs, police contended they were more able to focus their efforts on the trafficking 
of pharmaceuticals. The production of the Victoria Police manual An Investigation Guide to 
Pharmaceutical Drug Trafficking and Use (Victoria Police 2004) for all stations was also seen to 
benefit policing efforts, in that it allows officers to correctly identify pharmaceuticals and to lay 
charges where applicable, suggesting that wider distribution of this or a similar publication may 
be useful. Provision of information to police about emerging problems and regular updating of the 
manual are therefore suggested by these findings.
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The current findings suggest that potential consequences of police 'crackdowns' – resulting in 
more 'underground' activity and use of pharmaceutical drugs – should be considered when 
planning such programs. It was considered by other KI that police crackdowns on illicit drugs leads 
to displacement of illicit drug trafficking to other areas (moving the problem but not solving it), 
or may result in drug trafficking becoming more covert in response, and/or an increase in the use 
of benzodiazepines, as illicit drugs become more difficult to obtain. Another side effect of police 
activity cited that may result from crackdowns is PWID sharing injecting equipment, injecting 'on 
the run' and in unsanitary conditions, thus increasing injecting harms considerably, as well as the 
risk of overdose. Injecting harms were considered to be the major problem by health KI, and they 
prioritized the development of harm reduction practices around injecting pharmaceutical drugs. 
It was also mentioned that, where people in possession of benzodiazepines without a prescription 
had been charged, it often resulted in prescription drug use becoming more covert. 
Overwhelmingly, this study found that pharmacological drug treatments were considered to be 
of the utmost importance in reducing both health and law enforcement problems associated with 
prescription drugs use, and health KI considered that targeted and monitored benzodiazepines 
could be useful in a withdrawal treatment regime. Treatments were attributed with significantly 
improving the health and well being of drug users, with flow on effects to employment and 
housing, thereby leading to continuing stability for individuals. It was considered that provision 
of these treatments reduced crime as they reduced the need for substantial amounts of money 
for financing a habit. On the other hand, some consideration may need to be given to the costs 
of these programs, as KI contended that the cost of regular treatment (up to $5 per day) for those 
on low incomes could become prohibitive, and may in fact precipitate criminal behaviour (law 
enforcement KI agreed that pharmacotherapy treatments were worthwhile, and considered that 
their availability could disengage PWID from street supplies of heroin). Some KI thus suggested 
that the cost should be reduced or waived because of this. The findings suggest that diversion and 
maintenance of PWID into such (affordable) treatment programs may have a positive effect on both 
health and law enforcement outcomes. Further to this, police considered that strategies that would 
assist them in policing pharmaceutical drug misuse include dispensing pharmacotherapies from 
24-hour clinics and establishing pharmacies in a wider area than currently to reduce the numbers 
of people flocking to 'hot-spots'.
The findings suggest that interventions from health authorities, rather than law enforcement, 
may have a greater impact on the use of prescription drugs. For instance, temazepam injecting 
appears to have declined since the HIC regulated prescribing of the 10mg gel capsules under 
the PBS/RPBS in 2001. The cessation of production of all gel capsules that has now occurred in 
Australia may be expected to have a further impact. Several other interventions in prescribing 
practices were suggested by these findings. KI tended to agree that medical interventions may be 
useful in reducing prescription drug misuse. For instance, KI considered that limiting prescribing 
of some drugs, such as benzodiazepines (for example by prescribing daily pick-up of enough of 
the drug to maintain a person for only the next 24 hours), may reduce diversion. In support of this, 
PWID often reported that when they received a prescription, they kept a proportion for their own 
use and sold or gave away the rest, suggesting that if they had less of the drug they may be less 
inclined to share it. Furthermore, PWID reported that GP and HIC crackdowns on prescribing and 
doctor-shopping were the activities most likely to have made the drugs more difficult to obtain 
both medically and on the street. Findings from the current study – that temazepam and morphine 
were very difficult to acquire medically, and there was no point in trying to get them this way 
– further suggest that prescribing practices have reduced access to the drugs, and have most likely 
discouraged doctor-shopping for them. 
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Somehow restricting the sources of benzodiazepines and pharmaceutical opioids, tracking the 
prescriptions an individual has, as well as the development of a system that tracks batches of 
benzodiazepines as they are produced, cross-matched with data on dispensing, may help reduce 
diversion of prescription drugs. Many doctors (e.g. Kamien 2004) are also looking forward to 
availability of the HIC prescription shopper’s data base, replacing the doctor-shopper hot-line 
as a way of enabling better control of over-prescribing and doctor-shopping. There were some 
suggestions that that it would be helpful for data collected by pharmacists on 'doctor-shopping' to 
be fed back to doctors and A&E departments at hospitals, and that access to different sorts of data 
sets, for example law enforcement data, may be of use. Law enforcement KI agreed that access to 
cross-matched data could be of use. Privacy is obviously an issue with these suggestions. PWID 
reports suggest these strategies may have some effects, as PWID reported that when they believed 
they were on a doctor-shoppers database they did not bother to attempt to obtain prescriptions for 
drugs. Other strategies suggested for reducing diversion included better vigilance with prescription 
pads, pharmacists calling police where forged prescriptions are presented (which often does 
not currently happen), crushing of buprenorphine in the pharmacy before administration (or 
administering a 'fizzy' form similar to Berocca), injectable buprenorphine delivered in the 
pharmacy, and more sharing of information between doctors and police about drugs preferred for 
diversion. 
Methodological considerations
The PWID samples surveyed in this study were convenience samples and therefore caution is 
necessary in generalizing these findings to a broader population of PWID. A further consideration 
for external validity is that the samples utilized were targeted specifically for their prescription 
drugs misuse, with all participants selected and surveyed because of their reported pharmaceutical 
drug use; therefore, the patterns of drug use for these samples cannot be generalized to any 
population. Although the sampling targeted users of prescription drugs, because the drugs have 
many categories within them (e.g. specific benzodiazepines, specific morphine etc.), when 
these participants’ use patterns were broken down into these categories and then examined 
for associated behaviours, the numbers were too small to enable meaningful analyses to be 
conducted, which meant that validly answering some research questions was problematic. 
For instance, there were only four PWID who reported being intoxicated on morphine whilst 
committing any kind of crime, and a similar number reported they used temazepam and 
committed criminal offences. Therefore, inferential findings should be treated with extreme caution 
where the statistical test does not examine the entire group or large sub-samples, and the findings 
can only be applied to these samples and not generalized to any other groups or populations.
Directions for future research
Several directions for future research are suggested by these findings. Since Sigma pharmaceutical 
company has now discontinued the production of temazepam gel capsules, which completely 
removes the gelcap formulation from Australia, it will be interesting to monitor use trends of the 
drug in the PWID community. An examination of sources of morphine and temazepam would be 
of value, as the current findings raise the question of the origin of these drugs, given the difficulties 
in obtaining prescriptions for them, and the reluctance of participants to attempt to obtain them 
medically. Australian Customs Service data show that seizures of morphine shipments have 
increased substantially in recent years, and international findings show that the Internet is a source 
for prescribed drugs – it may be they are links in the chain maintaining supply of these drugs.
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A study examining supply sources and diversion of prescription drugs that utilises a comparison of 
non-PWID participants may also enable closer investigation of the issue of where the drugs initially 
originate. Several participants in this study commented that they received morphine, in particular, 
from patients with pain medication or cancer treatments, and that these people sold their 
medication to raise money. It would be informative to examine this further to determine whether 
this is a significant contributor to the diversion of prescription drugs onto the black market.
Further, research that enables a closer examination of the issues explored in the current study 
should be implemented. A problem with this study was that, where participants reported using 
specific forms of prescription drugs (e.g. temazepam) and also reported being involved in criminal 
activity, the numbers were too small to enable a meaningful analysis to be conducted. By 
purposely sampling users of such specific drugs, who also report undertaking criminal activities, 
it may be possible to determine more specifically the links between specific drug use and specific 
crimes.
Summary
The current research found clearly that misuse and injecting of benzodiazepines and 
pharmaceutical opioids, especially morphine and buprenorphine, has become entrenched among 
some groups of PWID in Melbourne. The findings suggest that the drugs are diverted to the black 
market and sold for considerable profit. The drugs may be diverted from legitimate prescriptions 
and prescribed doses, via doctor-shopping, or from forged prescriptions or stolen drugs. 
Prescription drugs appear to be relatively easy to obtain on the street, and the findings suggest they 
are available from a diffuse network of users, friends of users, dealers and suppliers, some of who 
also sell all kinds of illicit drugs. The findings suggest criminal behaviour may be related to the 
dependence on, and the use of, prescription drugs: for instance shoplifting, property crime, drug 
dealing, violence and intoxicated driving; and disinhibited, aggressive, and bizarre behaviour, as 
well as feelings of invincibility, were attributed to the drugs, in particular benzodiazepines. On the 
other hand, dependence on methadone may mitigate against the commission of crime. Besides 
criminal behaviour, other negative consequences of prescription drugs use were considered to 
be injecting harms, dependence and overdose, as well as social impacts such as relationship 
breakdown, effects on mood, anxiety and irritability. There were several potential interventions 
put forward for consideration, for instance decreasing the costs of drug treatments, a more holistic 
approach to prescribing of drugs, close monitoring of PWID who are prescribed benzodiazepines, 
development of alternative forms of buprenorphine that cannot be diverted, keeping police up to 
date with prescribed drugs that are likely to be diverted, and education of doctors and pharmacists 
about diversion of the drugs, and encouraging sharing of information between different bodies that 
produce data.
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Appendix A: NDLERF pool of research questions from RFT   
04/02
Key Theme Research Questions
Links to crime 1. Is benzodiazepine/pharmaceutical opioid use amongst illicit drug users 
related to the commission of particular crimes (either to obtain these drugs 
and/or while under their influence)?
2. What effect does being under the influence of/withdrawing from these 
drugs have on the types of crimes committed and the behaviour of those 
committing the crimes?
3. Which drugs from the benzodiazepine group and the pharmaceutical 
opioid group are most likely to be associated with crime (which is 
committed to obtain the drugs and/or while under their influence)?
4. Do those drug users who steal benzodiazepines and pharmaceutical 
opioids exclusively or primarily inject them?
5. Are injecting benzodiazepine/pharmaceutical opioid users more likely 
than non-injecting users of these drugs to commit crime; to commit higher 
rates of crime; or different profiles of crime?
6. Are there particular localities more likely to be targeted for the 
commission of benzodiazepine/pharmaceutical opioid-related crimes (either 
to obtain these drugs and/or committed while under their influence, i.e. 
urban, regional etc)?
7. Are there groups other than illicit drug users who are committing 
benzodiazepine/pharmaceutical opioid-related crimes (either to obtain these 
drugs and/or committed while under their influence)?
Implications for 
frontline workers
8. What are the implications of this for police and other frontline workers 
such as accident and emergency staff, ambulance officers and health/youth 
workers?
Diversion of 
drugs
9. Are there particular types of benzodiazepines/pharmaceutical opioids that 
are more likely to be targeted by those wishing to steal them and if so why? 
Market 
dimensions/ 
characteristics
10. Are illicit benzodiazepines and pharmaceutical opioids sold by sellers of 
other illicit drugs?
11. What is their cost?
12. Do shifts in other parts of the illicit drug market affect rates of 
benzodiazepine/pharmaceutical opioid use? If so, which drug markets or 
drug types have most effect?
13. Is there a correlation between the use of benzodiazepines/ 
pharmaceutical opioids and other drugs; for example, methadone?
14. How are benzodiazepines and pharmaceutical opioids obtained on the 
illicit market?
15. To what extent is doctor-shopping used to obtain benzodiazepines and 
pharmaceutical opioids and how easy is it to obtain these drugs by this 
method?
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Appendix A continued
Key Theme Research Questions
Interventions 16. What action is currently in place to identify individuals engaged in 
doctor-shopping?
17. What are the limitations of existing Health Insurance Commission (HIC) 
processes and what, if any, changes should be considered?
18. What impact does the scheduling by the Pharmaceutical Benefits 
Scheme of benzodiazepines have on their misuse and impact on crime (e.g. 
what is the impact of the rescheduling of Temazepam capsules)?
19. How can the information held by the HIC on individuals identified 
as actual or suspected doctor-shoppers be shared with law enforcement 
agencies? If impediments exist, e.g. privacy provisions under National 
Health Act, what action can be taken to enhance the sharing of information?
20. What opportunities does this present the law enforcement and health 
sectors in terms of having the maximum impact on reducing the supply 
of illicit benzodiazepines and pharmaceutical opioids, such as the 
rescheduling of some of these drugs, the removal from the market of certain 
formulations of these drugs, or education of GPs?
21. Where inappropriate prescribing is identified, what are the underlying 
factors contributing to this practice (e.g. fear, intimidation, lack of 
knowledge, criminality, lack of case management of patients)?
22. What impact would an increase in benzodiazepine/pharmaceutical 
opioid use have on the rates of benzodiazepine/pharmaceutical opioid-
related crime in particular and on profile of crime in general?
23. What would be the potential/likely implications of more effective supply 
reduction of benzodiazepines and pharmaceutical opioids in terms of crime, 
offending and/or creating an environment that is more conducive to the 
establishment of a heroin/cocaine market and an environment in which the 
overall level of harm may actually be increased?
24. What existing data systems can be better used to enhance 
the understanding of the nature of the illicit benzodiazepine and 
pharmaceutical opioid market and its impact on crime?
25. What other collection sets/processes could be instituted in the future to 
understand these issues?
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